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Abstract
This thesis explores the perspectives and related behavioural shifts of the heterogeneous Kenyan
scientific community in the development and subsequent implementation of biosafety
regulations. Kenya's biotechnology innovation system has been driven largely by the
contradictory framing of biotechnology as a scientific tool for innovation and international
competitiveness on the one hand, and as a technology that has adverse effects on the
environment on the other. A transition towards an integrated regulatory system over the last one
and half decades had entailed unprecedented institutional configurations and changes in
behavioural patterns of the scientific community.
To analyse the role of the scientific community in shaping the regulatory process and
instruments in the evolving biotechnology innovation system, the thesis draws on interviews,
documentary analysis and observation data collected from a wide range of scientist and non
scientist actors. It finds that, as scientists adapt to institutional changes necessitated by the
biotechnology innovation transition, they have been reconstituting themselves consciously and
unconsciously around different linear and non linear modes of knowledge production. In the
process, learning has occurred, knowledge has been produced and diffused impacting on both
technological innovation and emergence of a regulatory regime. The latter is however bounded
up in the former. The thesis further finds that the capacity to influence the regulatory process
and instruments was spurred not only by the individualised scientific expertise, but also by the
relationships and coalitions built around the different regulatory phases. Knowledge produced in
this regulatory context challenges the application of knowledge theories in the light of its
potential to influence scientific practice and regulatory policy instruments. From lessons and
insights drawn from theories of knowledge, the emerging policies and practices are skewed
towards a narrow, linear form of technical and scientific expertise, thus ignoring many
underpinning factors that are important for emergence of socially desirable processes and
policies. The study recommends reconceptualisation of both scientific practice and policy-
making in reflexive and systemic ways that encourage incremental learning.
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Chapter 1
1 Introduction
It has taken Kenya about one and half decades to develop and implement a functional
biosafety system in spite of all the available technical capacity and promises from new
biotechnologies. This scenario presents an excellent opportunity to investigate the role
of the scientific community in the delayed biosafety regulatory process.
Many policy reports seem to support the view that modem biotechnology or genetic
engineering technology (GE)' will have a positive impact on economic development as
it has the potential of improving agricultural production, particularly in developing
countries (cf RoK, 2006a in Kenyan context; Juma and Serageldin, 2007 in regional
context). Efforts towards this goal are hampered by controversies related to safety of its
application. As a result it is highly regulated through biosafety regulations' which are
instruments for meeting an acceptable level of governance. At the global level, this
regulation is provided through the Cartagena Protocol on Biosafety to the Convention
on Biological Diversity (Cartagena Protocol, 2000).
Development of requisite biosafety regulations involves intensive input of expertise
because of the technical nature ofbiosafety. Consequently, the scientific community has
been called upon to resolve these technical and high profile controversies, thus getting
entangled in the process as experts in biosafety policy (Scoones, 2002) and policy
targets in biotechnology development (Chataway et al., 2006).
IThe application of in vitro nucleic acid techniques, including recombinant
deoxyribonucleic acid (DNA) and direct injection of nucleic acid into cells or organelles, that overcome natural
physiological reproductive or recombination barriers and that are not techniques used in traditional breeding and
selection (Cartagena Protocol, 2000). It is used interchangeably with genetic modification (GM).
2 Biosafety is the avoidance of risk to human health and safety, and the conservation of the environment as a result of
the use of products ofGE [Biosafety Act, 2009 (RoK, 2009)].
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This thesis therefore examines how biological scientists in Kenya perceive the biosafety
regulations related to modern biotechnology and how these perceptions shape the
implementation of regulations. The study in particular explores how these perceptions
are constructed around the regulatory process in relation to GE technology and the
perceptions related to scientific and regulatory roles and behaviour. Further, the study
aims to understand how the perceptions around regulations and regulatory practice
shaped the regulatory instruments and what the implications this might have for the
broader biotechnology innovation system in terms of knowledge use for economic
development.
The purpose of this chapter is to demonstrate the importance of researching the
implementation of regulations, and why the scientific community is a key target group
to focus on. It presents the background to the study, its aim, research questions, the
study approach, the findings and some key definitions.
1.1 Background
1.1.1 Kenya's biotechnology innovation at a glance
Kenya's Science and Technology (S & T) policies emphasize the importance of
agriculture in economic development. The recently launched Kenya Vision 2030 (RoK,
2007b) and the Science and Technology Innovation Policy and Strategy (RoK, 2007a)
attest to this. However, in the agricultural sector, the post green-revolution era has been
characterised by poor performance due to various biotic and abiotic production
constraints (RoK, 2005a; De Groote et al., 2005 in their reference to maize). Advanced
technological tools are poised to address some of these constraints like pests, diseases,
weeds control and drought (Kelemu et al., 2003). Modern biotechnology has been
earmarked as one of the tools to address these challenges [(Strategy for Revitalisation of
Agriculture (SRA) (RoK, 2005a)].
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As will be shown in Chapter two, endeavours to introduce GE technology started in the
early 1990's, with a hope of producing products such as transgenic sweet potato,
towards addressing food security challenges. Developing a GE product takes a long
time particularly at the laboratory stage because GE involves gene manipulation.
However, in Kenya like in many developing countries, scientists did not have to re-
invent the wheel as most of the activities being undertaken have been provided already
transformed in developed laboratories in technologically advanced countries like USA
(see AATF at www.aatf-africa.org).This being the case, deploying the technology for
economic competitiveness and use by farmers was expected to take a shorter duration.
This has not been the case and almost 20 years down the line, there are no
commercialised products available.
Many factors are attributed to this, one being the regulatory requirements imposed on
the technology world-over that originate from the fear and uncertainties about claimed
benefits and risks (Bananuka, 2007; Paarlberg, 2001; Nang'ayo, 2007). Regulation
therefore is hampered by competing value-laden perceptions, aggravating technology
deployment. Consequently, governments have been faced with a difficult task of
balancing the perceived beneficial claims and perceived risks as citizens adopt different
views. The biosafety regulation is therefore intended to serve a dual purpose - to address
these ambivalences as well as facilitate the deployment of biotechnology for economic
use (RoK. 1998; RoK, 2006a). This is where Kenya finds herself and the process of
establishing a sustainable biosafety regulatory system has been a challenging task.
Further to this, the political economy of Kenya's biotechnology is such that Kenyan
scientists depend on foreign institutions for research support partly because of the
reduced government funding for public research (Beintema et al., 2003; Odame et al.,
2003).
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1.1.2 Role of the heterogeneous scientific community in this study
The scientific community is one group of Kenyan citizens that has been widely
mentioned in connection with the regulatory process (Harsh. 2008; Sander. 2007). The
community considered in this study comprises of mainly biological and a few non
biological scientists. but heterogeneous in various respects; profession, organisation
(employer) and discipline. Moreover, they are spread out in different sectors that deal
with biosafety regulations as policy makers, regulators, practitioners, industry, Non
Governmental Organisations (NGOs) in civil society and pro-biotechnology
organisations. and academic institutions among others. To simplify the diversity and
enhance analysis of perceptions, they are categorised into three non homogeneous
groups as follows:
• GE Practitioners (GP) are those scientists who are (or have previously) engaged
in contained and confined research involving genetically modified crops and
vaccines. Some claimed to be passionate about GE work.
• Policy Scientists (PS) are either senior government officials and biological
scientists in the National Biosafety Committee (NBC) and/or Institutional
Biosafety Committees (lBCs) and regulatory institutions. The senior government
officers are (or have been heads of government institutions or ministries). The
scientists in the NBC and IBCs are generally from public academic institutions,
regulatory agencies and one international research organisation. Some of them
are affiliated to other professionally related institutions. Participants in this
group identify with GE research in one way or another.
• Non State Scientists (NSS) belong to non-governmental organisations (NGOs)
that have a stake in biotechnology activities. They support biotechnology
activities in various ways like funding or awareness creation. They are backed
up by their biological science background.
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Besides the scientists, another category of non biological scientists was considered in
this study. They are spread out in civil society, lawyers, journalists, biotechnology
industry and funding organisations, and include social scientists.
The Kenyan scientific community has been associated with implementation of biosafety
regulations in three significant ways: Firstly as individuals or within knowledge-based
groups, they comprise of proactive actors in the development of a purportedly effective
biosafety system (Harsh, 2005; Sander, 2007; Odame et al., 2003 and Appendix 9).
Secondly, products of GE technology (in form of research) have been at confinement
stage and have not been exposed to the public. This may imply that most of what is
being debated has been at the hands of the scientific community. Thirdly, the group had
expressed concerns regarding regulations implementation in the light of their dual role
in implementation as policy targets and policy developers. This is in relation to
decision-making processes pertaining to research trials and policies on the one hand;
and executing, managing, enforcing and monitoring the trials on the other (pilot study
carried out between Dec 2006 and Jan 2007; Paarlberg, 2001; Mugo et al., 2005).
This puts scientists in an awkward and compromising position, that of developing
regulations and that of enforcing them. Their contribution to the biotechnology
development is undoubtedly key to the eventual deployment of the technology for
economic gain. In addition, their role in the construction of requisite regulatory
instruments cannot be underestimated because they are interested parties.
1.1.3 The technological, institutional and individual actor dynamics
Fig (1) below illustrates the issues raised in this section highlighting how the regulatory
process has been bound up in the broader biotechnology innovation system. It also
defines the scope of the study by situating the scientific community within the
multiplicity of actors involved in the biotechnology innovation process. The framework
illustrates technological, institutional, individual actors and linkages between them that
interplay significantly as components to influence the multifaceted dynamics in the
overall innovation process, including regulatory process.
1. S & Technology trajectory
·Sclence (events .cqulsltlon,
nesotl.tlon, Implement.tlon of
tn.ls In I.bonltory, greenhouse,
field te.tlns).
-Product development (the
National Performance Trials
(NPTs), seed crop & release.
-Farmers (seed level).
-Consumers of various products
(fanners, urban dwellers, traders).
2. Regulatory process
Regulatory policy domain
-Institutional (NBC, Institutional
Biosafety Committees (IBCs),
government departments, academic
&research institutions, regulatory
agenciesJ.
-Policy instruments (e.g RoJ(, 1998,
2009; research application forms;
standard operating procedures;
inspection manuals etc).
-Private sector (providing resources).
3. Actors
-Scientlsts, policy makers,
regulators.
- Communities of practice &
epistemic communities.
-Users (farmers, consumers)
-Organisational actors (pro &
anti biotechnology NGOs,
government, donors,
biotechnology industry,
professional groups etc).
Note: The bold & highlighted
aspects define the scope of this
study within the broader
biotechnology innovation and
governance. The two-way arrows
denote the iterativeness with
components in each ofthe three
circles influencing and impacting
each other considerably.
Figure 1: A non-linear, iterative illustration of a complex interrelationship between
components in governance of biotechnology in Kenya.
1.2 Research problem
This study set out to achieve a number of objectives. Firstly, to look at the factors that
impact upon the way biosafety regulations are implemented in practice. Secondly, to
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situate the role of different actors and in particular those in the biotechnology science
and biosafety arena, in policymaking and the systemic issues that determine the way
these roles are articulated. Thirdly, illuminate actors framing of issues around the first
two considerations (implementation of regulations and role of scientists in regulatory
policy-making) and the motivations behind the emerging discourses. Fourthly, by
weaving these discourses together, establish how the scientific community impact upon
or influence regulatory instruments in terms of context and content as this would have
implications for broader innovation policies and eventual biotechnology deployment.
1.2.1 Rationale and research questions
Development of an effective regulatory system for management of biotechnology
innovation has been an important institutional innovation. This has been debated under
the broader decision-making processes linked to governance of the new life sciences (cf
Tait et al., 2009a). Actors have had to adjust to accommodate the unprecedented and
requisite institutional and organizational revolutions that have accompanied these new
innovations. Despite this dynamism, the knowledge being produced by both the
institutions and the individual social actors in the process of adaptation has not been
given enough consideration. In particular, the knowledge being produced in the
regulatory process seems to collide with other linear and non linear forms of
technological knowledge impacting upon the behaviour of actors. This thesis argues that
articulation of regulatory knowledge in policy-making may open up a new way of
studying scientific practice and knowledge production dynamics. Arguably, literature
around knowledge production dynamics involving experts and policy-making (Gibbons
et al., 1994; Nowotny et al., 2001; Haas, 1992,2004) has not articulated the regulatory
context under which knowledge in the new life sciences is generated. This knowledge
tends to be political and value laden as asserted by Jasanoff (1990) and Murphy and
Chataway (2005).
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The institutional changes that characterise new knowledge production terrain as
described by proponents of Mode 2 tend to underplay the corresponding adaptation that
social actors have to undergo in the process (Gibbons et al., 1994)_3This thesis argues
that this adaptation is embedded in existing and evolving cultural practices" that
influence the nature and form of knowledge produced, and how it is used. Drawing
insights from two strands of literature, sociology of science scholarship on the one hand
and innovation systems on the other, provides a new framework for investigating
regulatory processes in practice and the role of actors. This consequently informs the
context for governance of the new life sciences like agricultural biotechnology based on
empirical evidence.
These arguments rest on the understanding that the actors involved in policy
formulation or implementation need to be aware of the different types of knowledge
produced for the purposes of policy-making in areas that are knowledge intensive like
biotechnology. Scientific knowledge is only one type of knowledge and can originate
from different sources (e.g. individual or institutional/organisational). More important is
the way these forms of knowledge are utilised for policy-making to legitimise the
process on the part of the policy makers, those being regulated like researchers and the
broader public. In the Kenyan context, as the scientific community engages with
biotechnology institutions which they are part of (research, non-research, regulatory
instruments etc), knowledge is produced and diffused in the process, perceptions are
constructed and coalitions emerge. The technological and political nature of the Kenyan
regulatory policy process also has an impact. All these factors put together impact on
3 Mode 2 describes the changing nature of knowledge production in contemporary research but from the broader
institutional context (Gibbons et al., 1994).
4 Culture with respect to development refers to creative abilities of man expressed through re-organisation of social
existence via a set of institutions, regulations and values but may vary based on purpose and individual (Mabawonku,
2003:118). Mabawonku further notes that a particular group's cultural practice can be conceptualised in terms of
incidence or preference of behaviours or the actions of this group. See also section 1.5 of this chapter for a detailed
definition ofthe term culture as applied in this thesis.
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the regulatory process and instruments, and the broader innovation policies and
implementation.
In order to empirically explore the above arguments, research questions were designed
to elicit views from a heterogeneous group of the scientific community (Appendix 1)
regarding their experiences in the implementation of biosafety regulations. These
questions were:
1. What are the perspectives of scientists on implementation of biosafety
regulations and why might they be holding these views?
2. Have the practices of scientists related to implementation of biosafety
regulations shaped the evolution of the regulatory process, and if so how?
3. What is the implication of the scientific practice on the biotechnology
innovation policies and knowledge use?
1.2.2 Motivation of the study
The focus of this study as explored in this section is important for biotechnology
governance and its impact on deployment of biotechnology products for economic
usefulness in Kenya. The literature briefly analysed below and further in Chapter two
(see section 2.5) suggests a compelling argument that biotechnology and biosafety
systems have co-evolved, and that multiple actors have been involved.
A study by Odame et al. (2002, 2003) yielded general statements on the role of the
scientists in the policy-making process and the possible outcome. Other studies have
presented positive statements pointing towards engagement of scientists in the
biotechnology regulatory policy process (Sander, 2007; Harsh, 2005, 2008). Harsh and
Sander in particular seem to have come closer to the phenomenon under consideration
in this thesis; the governance of modern biotechnology. Their work focused on
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perceptions and regulatory practice involving scientists in various ways but within their
broader institutional settings (e.g. NGOs and research institutions). An institutional
approach seemed to be yielding useful data but it was masking the role of scientists in
biotechnology governance either as individual entities or within institutionalised
settings.
This study specifically looks at scientists as social actors bound up in their institutional
settings (as opposed to the institutional focus applied by previous scholars). Taking this
path has various implications. It made me focus on the role of scientific community as
a social institution in the regulatory policy-making process and meant that I did not
focus directly on controversies relating to biotechnology. This approach does not
however take for granted the role of the broader public in policy-making. Instead, I
focused on a better understanding of role of the scientific community in public policy-
making and the implications of their practices for the wider public policy. Previous
studies, perhaps because of the technological and broader institutional approach, tended
to mask specific innovations (like policy or regulatory) which are important for the
overall functioning of the biotechnology innovation process in the risk governance
context.
Analysis of the empirical data focuses on the research stage since at the time of field
work, biotechnology research had not gone beyond field trials. Thus, it is more oriented
towards particular innovations (e.g. regulations) and the context under which they have
evolved. The concentration on modem biotechnology in agricultural innovation presents
a good opportunity to investigate the dynamics involved in policy and institutional
innovations, particularly in the context of the controversies associated with governance
of the new life sciences in Africa.
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Another justification for this study relates to my professional background (see Chapter
four, section 4.2). During my 8 years working as a regulator and interacting with
biological scientists (myself being one), I observed technical and policy related tensions
that can occur between the scientists interested in GE technology on the one hand and
scientists in the policy and regulatory arena on the other. This drove me into asking
hypothetical questions related to this technology on the one hand and regulations on the
other. For instance, I asked myself what is so special about GE technology and what
made practitioners frustrated during implementation of regulations? Reflecting on these
probing issues, I could see a disconnect between different categories of scientists (those
with policy orientation and those involved in practice) and a gap between regulatory
instruments and what they are meant to achieve (facilitation and regulation according to
RoK, 1998). This observation seemed to suggest that a lot of the tension around
regulation implementation was to do with perceptions and consequent actions (practice).
This again points towards the importance of focussing on the scientific community
which has already been identified in the preceding sections as active players in
biotechnology and biosafety arena.
1.3 Research methodology
Chapter four presents in detail how the above research questions were tackled. Kenya
was considered as a particular study area where the above-mentioned phenomenon
could be examined. There were many advantages for choosing Kenya as justified in
Chapter two and further detailed in Chapter four. As the research questions indicate, the
study has both components of perceptions of regulations and perceptions of practice (in
the process of implementing the regulations). The methodology employed in this study
therefore focussed on eliciting these different perspectives. The complex factors that
confront the biosafety regulation arena as described in the background section were kept
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in mind during the entire research process. An interdisciplinary approach was adopted
that incorporated both empirical and theoretical research approaches.
To generate rich empirical data, a qualitative approach was adopted that resulted in use
of engaging methods - semi-structured interviews complemented by observations and
documentary research as sources of data and/or way of corroborating the accounts of the
interviewees. This yielded detailed understanding around the dynamics that shape the
process of policy-making in biotechnology innovation. The non-scientist interviewees
served a dual purpose in this research: firstly, they corroborated certain specific issues
related to views of scientists and regulatory practices and secondly, as source of data on
certain aspects of this research such as nature of regulations and regulatory process.
Validity was checked in various ways through different sources of data and different
methods.
Data generated via these methods were coded and analysed deductively and inductively.
As this process was data led, it enhanced further validation and led to the emergence of
interesting themes that form the substance of the empirical chapters. Since the
relationship between perceptions and regulatory practice is key in this study, cognitive
mapping was used as a tool to display visually the thoughts of scientists about
regulations and related actions taken towards articulating these thoughts (influence).
This is important because visual maps are amenable to analysis for policy actions and
recommendations (Eden, 2004). This tool enhanced tackling of the third research
question which is policy-oriented.
Several conceptual and theoretical approaches were considered to complete the
investigation process by grounding the empirical data in theoretically sound concepts.
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1.4 Summary of findings and implications
Findings emanating from analysis of the rich empirical data generated from this study
suggest the following;
• The heterogeneous scientific community has contrasting views of regulations and
regulatory process built around the prospects of biotechnology in addressing food
production constraints on the one hand, and risk perception, on the other. Unlike
other related studies, this study has empirically exposed complex technical and
social factors (capacities, values, beliefs, interests, globalisation and reduced
funding of public research among others) that collectively shaped the evolving
perceptions of scientists of regulatory process and practice.
• Different values exhibited by the scientific community reflected cultures of different
social knowledge groups and coalitions that they belong to (academic disciplines, .
professional and policy groups). This scenario presents a different way of
interrogating knowledge use, departing from the way it has been researched by
various scholars (Gibbons et al., 1994; Nowotny et al., 2001; Haas, 2004). It has
also opened up a new way of looking at knowledge flow and relationships building,
augmenting the interactions and cumulative learning emphasised in innovation
systems and policy networks literature.
• The scientific community engages in various ways in regulatory and scientific
activities which is consistent with Mode 2 integrated practice. The context under
which these activities are articulated has informed better understanding of specific
concepts that speak about knowledge and knowledge production dynamics. For
instance, knowledge production and use in a regulatory context is complex and
value laden which tends to challenge application of Mode 2 principles.
• The Mode 2 research environment impacts scientific behaviour which ultimately
affect how knowledge is eventually used in regulatory decision-making processes
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based on the underpinning complex context. This calls for rethinking of role of
knowledge and scientific practice in the regulation of biotechnology contributing
conceptually to the growing scholarship around governance of the new life sciences.
• The institutional shortcomings that were revealed in the process of regulations
implementation suggest a need for policy makers to reconceptualise governance
approaches to regulation of biotechnology research towards regulatory models that
are pro-innovation.
1.5 Definitions
A number of concepts which have been used extensively in the thesis are explained
briefly:
Modern biotech nology/ genetic engineering (G£): manipulation ofliving organisms to
produce goods and services useful to human also referred to as genetic engineering
(GE). It is distinguished from traditional (or conventional) in that it is a modem or
transgenic approach that develops products (such as seed varieties) through insertion of
genetic material from different species into a host plant. It can also be defined as the
application of in-vitro nucleic acid techniques, including recombinant deoxyribonucleic
acid (rDNA) and direct injection of nucleic acid into cells or organelles (Cartagena
Protocol, 2000). The products derived using these techniques are commonly referred to
as Genetically Modified Organisms (GMOs).
Biosafety: the avoidance of risk to human health and safety, and the conservation of the
environment as a result of the use of products ofGE [Biosafety Act, 2009 (RoK, 2009)].
In broader terms, it encompasses the regulatory mechanisms that the government has
put in place for the governance of GE activities in order to balance the views between
perceived technological benefits and safety (Cartagena Protocol, 2000).
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Regulation: The term has many meanings such as "assignment of authority to a
decision-making body" (Dworkin, 1996 cited in Andanda, 2006:1362). In the case of
biosafety which is the focus of this study, the definition by Braithwaite et al. (2007), is
more appropriate as it argues that governments and governance are about providing,
distributing and regulating. It encompasses both those regulating and those being
regulated, bringing to the fore important components of regulatory practice:
"Regulation can be conceived as that large subset of governance that is about
steering the flow of events and behaviour, as opposed to providing and
distributing. " (Braithwaite et al., 2007:3)
Regulations implementation: This concept is used interchangeably with regulatory
process. According to UNEP-GEF, biosafety implementation is encapsulated in the
term regulatory regime that "comprises all those legal instruments (laws, acts,
regulations, decrees, orders, guidelines etc) that are relevant to the regulation of GMOs
activities including the institutional arrangements for implementing those regulations"
(UNEP-GEF, 2004). The concept is used in this thesis to denote two main aspects:
firstly, activities related to risk assessment (RA), risk management (RM) and risk
communication (RC) in execution of GE trials and secondly, the formulation of
regulatory instruments. Based on these two aspects, regulatory practice refers to the
role played by scientists in the implementation of regulations, including the institutional
context under which they articulate this role.
Culture: From innovation systems perspective, culture is conceptualised as institutions
or habits and customs that define patterns of behaviour and shape human interactions
(Coriat and Weinstein, 2002:279). Huzair (2008:219) referring to the scientific
community and biotechnology research further argues that culture [and the related
cultural practices] underpins networks and learning associated with this community.
Ultimately, this culture gives "this community distinct characteristics and behaviours
which evolve over time to cope with the changing context" (Ibid). Cultural practice in
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this research in Kenya therefore refers to the behaviour of the scientific community in
the implementation of biosafety regulations in the context described in Chapter two.
Actors: Based on Ayele's (2007a) description, actors in biotechnology and biosafety
arena encompass those parties concerned with, and affected by decision-making
processes. They share values and interests, and have the power to thwart a decision
through various means like formation of coalitions. The term is used in this thesis to
refer to individual social actors like scientists and the affiliated
organisations/institutions. These organisations (as demonstrated in Chapter two) are
nodes of knowledge production in the context of biotechnology innovation system and
regulatory process. The scientific actors who participated in this study were selected
from these diverse knowledge nodes.
Scientific community: is a subset of actors used in this research to refer to scientists in
research, academia, NGOs and policy arena. This group is engaged in biotechnology
activities or debate but with background training in mainly biological sciences
(Appendix 1). A scientist is considered to have various scientific and regulatory roles
in biosafety regulations implementation process - reviewer of GMOs applications, risk
assessor, risk manager in an effort to comply with biosafety standards and inspection or
monitoring manuals and protocols, researcher in his respective professions and provider
of advisory service in biosafety committees for policy decisions (Jasanoff, 1987, 1990;
Newell, 2002; Maclean et al., 2002). He also plays an expert role in the science policy
deliberations like in formulation of environmental policies or factual public education
(Haas, 1992,2004; Weingart, 1999; Sense about Science report, 2009).
Boundary organizations: These are sites of simultaneous production of knowledge and
social order facilitating collaboration between scientists and non scientists (Guston,
2001). They create a combined scientific and social order through the generation of
boundary objects (e.g. regulations) and standardised packages. In the Kenyan context,
the National Biosafety Committee (NBC) and regulatory agencies can be considered to
be boundary organisations and the biosafety bill/Act (or biosafety regulations) may be
perceived to be boundary objects.
1.6 Overview of the thesis structure
The rest of this thesis is structured as follows: Chapter two presents a detailed
description of the Kenyan context in relation to modern biotechnology and regulatory
instruments evolution since 1990's when biotechnology programme was initiated in
Kenya. Emphasis is given to the role of scientists who are the focus of this thesis and
their interaction or involvement in the implementation of biosafety regulations and
regulatory policies. This brings to the fore the context within which they implement the
biosafety regulations and the contextual factors that interplay in the construction of a
purportedly effective biosafety system, for the governance of modern biotechnology.
Chapter three reviews relevant literature related to knowledge production and use,
biotechnology governance with a focus on biosafety regulation and the role of scientific
actors in controversial policymaking. Key theoretical concepts and approaches are
reviewed to situate the study within the broader science and technology studies and
policy-making. In Chapter four methodological approaches and instruments employed
to undertake this study are discussed. These include both the empirical and theoretical
approaches that guided the data generation, analysis and interpretation. In Chapter five
and six empirical data generated is presented. In Chapter seven there is further analysis
and discussion of the data, weaving together the empirical data and the theoretical
concepts. Chapter eight summarises and concludes the thesis.
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Chapter Two
2 The Co-Evolution of Biotechnology and Biosafety
Institutions in Kenya
2.1 Introduction
Building on some of the studies on biotechnology governance in Kenya (discussed
further on), this chapter calls attention to the importance of the various aspects of
technological, regulatory and social local contexts in which the scientific community,
related actors (e.g. organisations) and regulatory process are embedded. It seeks to
provide the regulatory context for the subsequent chapters as well as situate the
scientific community as actors engaged in biotechnology research and development (R
& D) for the last two decades within the process of regulation implementation. By doing
this, the chapter exposes the motivations and opportunities for the scientists in their
engagement with biosafety regulatory process and formulation of regulatory
instruments, and the institutional challenges and strengths related to modern
biotechnology governance. This prepares the requisite background needed to respond to
the research questions stated in Chapter one.
The content of this chapter is drawn from empirical data gathered from the interviews,
complemented with secondary data (such as literature and relevant Kenyan documents)
and observation data. It sets the scene for the more data oriented empirical chapters that
follow. In what follows, the next section provides the current status of science and
technology policies situation in Kenya, followed by a discussion of biotechnology
development and biosafety regulation evolution both in general terms and in the context
of the role of the involved multiple actors. The chapter concludes with a critical analysis
of the evolutionary trend of the different phases of the regulatory system trajectory and
a brief review of literature around governance of biotechnology in Kenya.
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2.2 Science and Technology (S&T) policies
Agriculture is the cornerstone of Kenyan economic development although performance
has often been poor due to various production constraints (RoK, 2005c; RoK, 2005a).
Biotechnology is seen as one way through which the production constraints can be
addressed (RoK, 2005a; RoK, 2006a). Until recently, none of the S & T policies had
incorporated biotechnology. However, there have been significant milestones towards
addressing the policy vacuum reported widely by many scholars with regard to
biotechnology research and development (R & D) as well as biotechnology innovation
(Odame et al., 2002; Harsh, 2005, 2008).
A biotechnology policy was approved in 2006 (RoK, 2006a), while the Biosafety Act
was approved in 2009 (RoK, 2009). Alongside these developments, other significant
policy changes have occurred. For instance, the launch of Kenya Vision 2030 (RoK,
2007b), the development and implementation of the Strategy for Revitalisation of
Agriculture (SRA) (RoK, 2005a), the development and launch of the draft Science,
Technology Innovation (STI) Policy and strategy (RoK, 2007a) and the recently
launched National Biotechnology Awareness Strategy (BioWARE) (RoK, 2008b). The
SRA operationalises the Economic Recovery Strategy for Wealth Creation (ERS) (RoK,
2003a) and gives priority to the agriculture sector (RoK, 2005b: 54). The STI policy and
strategy operationalises the Kenyan Vision 2030.
These recent initiatives outline vividly the role of agricultural research and some
specifically identify biotechnology as one of the new science and technologies that need
to be supported for the anticipated robust agricultural system (RoK, 2005a; RoK, 2006a;
RoK, 2007a). However, it largely remains unclear how this is going to be advanced
within the knowledge intensive biotechnology sector towards meeting the Millennium
Development Goals (MDGs) as well as benefiting the resource poor farmers as one of
the overall goals of most of these policies (cf RoK, 2005b).
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2.3 Evolution of modern biotechnology and biosafety regulatory
regime
Modern biotechnology has revolutionised many sectors including agriculture and
embraces a wide range of applications including tissue culture, markers assisted
selection and genetic engineering (GE). All these are being applied in Kenya, but the
latter is the focus of this study. Just like many African countries, GE is relatively new,
but GE products have been handled indirectly through trade in form of food aid
(Kagundu, 2008).
Agricultural research and development (R&D) has long been recognised as central to
knowledge creation, technology development and innovation. During the pre-
independence period, the R&D agenda was set by the British colonial government,
which recognised the importance of S & T in agricultural production (Ochieng, 2007). It
is not until early 1990's that biotechnology innovations in form of tissue culture
received considerable attention (Wambugu, 2001). Actual work involving advanced GE
commenced in 1991 when Kenyan scientists went to USA and in collaboration with
scientists there, engineered a virus resistant sweet potato (Odame et al., 2002, 2003).
Thereafter in 1998, the transformed plants required regulatory approval for this research
to continue in Kenya. Actual process of regulatory process and implementation had
commenced prior to 1998 (see Appendix 6).
To date, six GE R&D initiatives have been evaluated in public institutions in
conjunction with local and international partners (Table 1 & Box 1). As these
tabulations show, all these trials have been implemented under containment either in the
laboratory, greenhouse or open confined field trials (CFTs)s under quarantine. The crop
activities include Bt maize and Bt cotton engineered for resistance to insect pests,
S This is a field trial of GM plants not approved for general release in which measures for reproductive isolation and
material confinement are enforced in order to confine the experimental plant material and genes to the trial site
(Halsey.2006:4)'
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cassava for resistance to viruses and sorghum for resistance to striga weed. The
recombinant rinderpest vaccine initiative targeted control of rinderpest disease in cattle
and other viruses in small ruminants. Other initiatives are in the pipeline for example
the sorghum fortified with nutrients funded by the Bills and Melinda gates foundation
through the Africa Harvest Biotechnology Foundation International (see
www.africaharvest.org). Since the approval of the first transgenic crop- the sweet potato
in 1998, no product has reached the farmers and the furthest the biotechnology activities
have gone towards a product is the Cf'Ts (see Box 1).
These research activities are however under government control through the interim
governance that has existed since early 1990's. In addition, although this was not clearly
provided for in the regulatory instruments prior to the Biosafety Act, all interested
investors/persons needed to partner with a government research or academic institute,"
The Biosafety Act 2009 (RoK, 2009) however removes this restriction and recognises
an applicant as "a person submitting an application" and does not state whether this
person should do this collaboratively or not. It can be said that the partnering
requirement ensuring government control has been implemented effectively, since all
the six research trials were licensed through the Kenya Agricultural Research Institute
(KARl)' and Kenyatta University (KU), and the principal investigators have been
scientists from public institutions.
6 Interviews with ARp-PS2 and ATBp-PSS.
7 KARl is the main public agricultural research institute in Kenya and is mandated to conduct relevant agricultural
research. Five of the six GM trials (and all the field trials) have been conducted at approved biotechnology confined
quarantine facilities within KARl.
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Table 1: Modern crop biotechnology innovations in Kenya (as of Dec 2008)
GE Activity Initiative trigger/trait Status Collaborators
Sweet potato engineered -The virus coat protein gene Contained laboratory KARl, Monsanto, ABSP,
for disease resistance- availability from Monsanto. &CFTs ISAAA, Michigan state
Feathery mottle virus. -Diseases attack causing low university, Kenyan
yields. universities.
Bt maize-IRMA project -Bt technology availability from Contained laboratory, KARl, CIMMYT.
engineered for resistance Syngenta. greenhouse & CFTs Syngenta, Rockefeller
to insects-African maize -Pests infestation in particular Foundation. USAID,
stem borers. Maize stalk borers. Kenyan universities &
Monsanto.!
Cassava engineered for -Disease infestation in particular -Contained KARl, Danforth center-
Cassava Mosaic Disease the CMD reducing yields laboratory & USA, USAID, Cornell
(CMD) resistance- significantly. screenhouse University-USA. ISAAA,
African cassava Mosaic -The coat protein gene availability -Application has been Kenyan universities.
virus & East African from Monsanto. pending for a CFT.
cassava mosaic virus.
Bt cotton engineered for -Declining production Contained KARl, Delta-pine South
Insect resistance-cotton performance. greenhouse & Africa, Monsanto, KIRDI,
bollworms (Bollgard I & -Bt Technology availability from CFTs ISAAA.
II). Monsanto.
-Pests infestation in particular
African boll worms.
Transgenic sorghum for -The availability of a -Contained Kenyatta University
resistance to striga collaborative research grant. laboratory & screen (Kenya), University of
parasitic weed. -The persistence of parasitic striga house. California Davis (USA).
weed in cereals growing areas in -Proof of consent,"
Kenva.
Source: Compiled from primary and various secondary sources. See abbreviations on pages ix-x.
Box 1: Field trials discussed by the NBC or conducted in Kenya as of Dec 2008
• Bt Maize
Several field trials have been conducted successfully. The results have shown resistance to Chilo parte/us, a
stem borer prevalent in the lower maize growing zones and less protection over the Busseola fusca prevalent in
the major maize growing zones. Efforts are being made to address this problem using event MON 89034 from
Monsanto. perceived to be effective against this pest.
• Bt Cotton (Bol/gard I & II)
Three field trials have successfully been conducted. The first one used Bollgard I while the subsequent ones
have been testing Bollgard II which is perceived to be superior in terms of controlling boll worms.
• Transgenic sweet potato
KARl scientists transformed initial varieties in USA. The trial was purportedly a flop, which is blamed on the
wrong choice of varieties (interviews with RSIn-GP9, TAN-NSS2 and PRp-PS4). Research still continues at a
slow pace under containment in the laboratory. Other scientists and partners have since joined in the
implementation of the project.
• Transgenic cassava
The trial was approved for containment in the greenhouse. An application for a CFT was discussed in several
NBC meetings but was denied approval after the applicant failed to provide non-target environmental data
(interview with ATp-PS3; NBC minutes).
• The recombinant rinderpen vaccine
Successful on-farm trials were carried out in 2002-2004, at KARl Kiboko research station. They were to test
the efficacy against rinderpest disease and safety of the vaccine in the African cattle. The trial still continues
under laboratory confinement in a small scale (interview with RSPu-GP7).
• Monsanto is the recent entrant into IRMA project through provision of events MON 810 & 89034. The latter has
two genes perceived to be effective against stem borer prevalent in the main maize growing zones (personal
communication with KARl scientists).
9 This project was for proof of consent as part of a PhD student's research work and had no immediate plan for
commercialisation (interview with RSAc-GP5).
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2.3.1 Biosafety regulation in Kenya
2.3.1.1 Regulatory mechanism
Many interviewees perceived the biosafety regulatory regime to be the only way of
balancing the opposing and diverse views held by both proponents and opponents of the
GE technology (see Chapter five). Biosafety therefore encompasses the regulatory
mechanisms that the government has put in place for the governance of GE activities.
Kenya signed and ratified the Cartagena Protocol in May 2000 and January 2002
respectively. This further obligated the government to put up regulatory structures to
operationalise it. Article (16) of the Protocol and Article (8g) of the Convention on
Biological Biodiversity (CBD) provide for establishment of appropriate mechanisms to
regulate, manage and control risks associated with Living Modified Organisms (LMOs).
The protocol emphasises on risk assessment (RA) and risk management, and provides
guidelines to achieve this (Annex III). There are several ways in which risk identified
during RA can be managed, e.g. confinement, restricted use, provision of guidance,
technical advice and record keeping (Halsey. 2006).
As in many other countries, a "sound science" or "science-based" approach to decisions
pertaining to modem biotechnology regulation is the "official approach" to regulation in
Kenya. This is illuminated in the various obligations, official and non-official policy
documents that guide the regulatory process (see Table 2). The legal authority
associated with each instrument qualifies it as binding or non-binding. The binding
instruments are based on the obligations that each confers in terms of implementation
and legal administration. They include those international agreements that Kenya has
signed and statutes of parliament that incorporate general regulatory issues like plant
protection or environmental monitoring. The statutes however fall under mandates of
different regulatory agencies. The unofficial or supporting guidelines can be termed as
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non binding as there is no legal power bestowed upon implementation. It can be said
that they were drafted to facilitate the regulatory process including trials management.
Table 2: Binding & non-binding instruments for biotechnology regulation relevant
to environmental safety
Policy instrument (see Relevance
abbreviations on pages ix-x]
International and binding
CSD (1992) Governs the conservation of biological diversity & the sustainable use
of its components.
WTO-SPS (1994) Provides guidelines for regulation of products in relation to sanitary and
phytosanitary concerns that can affect trade.
FAO-IPPC (1997) & ISPM No. 11 Provide common and effective action to prevent the spread and
(FAO,2006b) introduction of pests of plants and products, and to promote measures
for their control. ISPM No. 11 in particular deals with pest risk analysis
for quarantine pests, including analysis of environmental risks
quarantine and LMOs.
The Cartagena Protocol to the CSD Provides guidelines for "ensuring an adequate level of protection during
(Cartagena Protocol, 2000) the transboundary handling of LMOs that may have adverse effects on
environment and human health" (Article 1).
Codex and OECD guidelines:" Used sparingly during risk assessment audit of GE applications as
reference on food safety and substantial equivalence aspects
respectively.
Local and binding
The Science & Technology Act of It provides for establishment of the NCST "to advice upon all matters
1980 (RoK, 1980) relating to the scientific and technological activities and research." This
provided NCST the early legal mandate to coordinate drafting of
regulations of 1998.
The Plant Protection Act (Cap 324) Provides for "prevention of the introduction & spread of diseases
of 1962 (revised in 1979) destructive to plants." Enforced through KEPHIS.
The Seeds and Plants Variety Act Confers power to regulate transactions of seeds (import & performance
(Cap 326) of 1977 (revised 1991) evaluation) including granting of proprietary rights to breeders.
Enforced through KEPHIS.
Environmental Management and Provides for management of environmental policies through
Coordination (EMCA) Act of 1999 establishment ofNEMA for enforcement purposes.
The Environmental (Impact & Provides guidelines for EIA of all projects likely to have a negative
Audit) Regulations (EIA), 2003 environmental impact (Article 3) under the EMCA Act.
Biosafety Act 2009 (RoK, 2009) Provides for regulation of activities in GMOs through establishment of
theNBA.
Local and non binding
The Monitoring and Inspection Provides broad monitoring & inspection guidelines for both animals and
manual (NCST, 2006a) plants.
The draft regulations for conduct of Provide for specific management measures of a CFT, including
CFTs for GE crops (KEPHIS, confinement measures for selected crops and is accompanied by
2004a) standard operating procedures (SOPs) for inspectors and trials managers
(KEPHIS,2004b). Enforced through KEPHIS.
Guidelines for handling requests A resource manual for guiding the NBA in handling & evaluation of
involving GMOs in Kenya (NCST, GMOs applications. It provided for the NSA even before the Biosafety
2006b) Act that establishes the NBA was enacted.
Source: Various secondary sources that include the mentioned statutes and guidelines.
10 OECD and Codex guidelines stress on science based risk assessment protocols in line with the substantial
equivalence (OECD, 2007; Codex, 2003).
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At the early stages of biotechnology research activities, Kenya opted to use the existing
infrastructure, the Science & Technology Act (RoK, 1980) to institute regulatory
mechanisms through the drafting and adoption of the Regulations and Guidelines for
Biosafety in Biotechnology in Kenya (RoK, 1998; and the revised version, RoK, 2003b).
There have been concerns that these regulations came long before the biotechnology
policy and have not been legally binding as required by the law. I I In an effort to legalise
the regulations as well as the biotechnology activities, the National Biotechnology
Development Policy was drafted and later approved in 2006 (RoK, 2006a). This was
followed by different versions of the biosafety bill which became law in Feb. 2009
(RoK, 2009). These three policy instruments are the heart of this thesis as the major
policy outcomes of the evolution of the regulatory process discussed substantively
further below. But first, these biosafety instruments are discussed briefly and revisited
later in Chapter five.
Regulations and Guidelines for Biosafety in Biotechnology in Kenya (1998) and the
revised version (2003): These regulations have since been implemented in regulation of
the biotechnology activities to date. They served a dual purpose, promotion of
biotechnology science and protection of citizens concerns about risk associated with use
of the science. In other words, they intended to enhance safe application of
biotechnology while facilitating advancement of technological innovations initiated
then through Kenya Agricultural Research Institute (KARl):
"Regulations and guidelines should be effective in encouraging the use of new
products, and for ensuring human health and environmental safety are
intended to ensure that Kenya benefits from the products of biotechnology with
minimum risks to public health and environment. " (RoK, 2003b: 24)
11 In a normal situation, a policy should precede a law. Consequently, regulations and guidelines are appended to the
law as implementing instruments (interviews with LABp-NS8 and LAEp-NS9).
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Both 1998 and 2003 versions are concerned with SCIence transfer as opposed to
technology transfer. The major provision is the administrative management of the GM
activities through the establishment of the Institutional Biosafety Committees (IBCs)
and the National Biosafety Committee (NBC). The regulations require that all
institutions intending to engage in GM work must establish an IBC. Its role is to advise
the respective institution in drawing up proposals that meet the biosafety measures to
the satisfaction of the NBC. In addition, it is to advise the respective institution on any
technical issue that should be brought to the attention of the NBC. Following the
approval of these regulations, KARl IBC was formed and later ICIPE IBC (Traynor and
Macharia, 2003). However, other IBCs have since been established (e.g. ILRI, Kenyatta
University and KEMRI).
The National Biotechnology Development Policy (2006): The policy was the first legal
attempt by the government to charter a roadmap for biotechnology development in
Kenya. It was adopted in 2006 without any public resistance, although it was felt that it
should have come before the regulations as this is the routine with other policies.V It
paved way for the creation of an administrative and legal framework for biotechnology
development and use. Some of the key objectives of this policy relevant to this study
are:
• creation of enabling administrative and legal frameworks for biotechnology
development and commercialisation environment.
• support the development and retention of human resources in science,
innovation and biotechnology.
• stimulate collaboration among public, private sectors and international agencies
in order to advance biotechnology both locally and internationally.
• promote public understanding of the potential benefits of biotechnology.
12 Interview with TRTp-NSS3; see also Sander (2007).
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The policy emphasises the importance of biotechnology application in addressing major
challenges that hamper realisation of full economic potential in agriculture sector. It
recognises that technological developments must be translated into innovations for the
country's national benefits through conducive policy strategies. It further acknowledges
the multi-sectoral nature of biotechnology in terms of institutions that promote,
implement and regulate biotechnology, which calls for continuous re-alignment of
existing policy instruments to accommodate the new science. One noticeable point
regarding this policy that is also evident in the regulations and guidelines is the
emphasis on precaution in the adoption of biotechnology. The policy therefore provides
a roadmap for the biotechnology activities but based on the identified need to regulate
them.
The Biosafety Act (2009): This Act seeks to operationalise the Cartagena Protocol. The
scope and other provisions are discussed in Chapter five. The controversial
developments surrounding its formulation over the years are at the centre of this thesis.
Harsh (2005) reports similar controversies but up to 2005, however, the current study
shows that these controversies escalated after 2005. Appendices 7 and 9 capture some of
the main developments, revealing the dynamics that include the engaged different actors
and the nature of engagement, and details the different forms of public and policy
makers' engagement between 2002 and 2009. Within this period, various versions of
the biosafety bill were drafted and discussed before the final version (RoK, 2008a) was
approved to become an Act. Meanwhile, regulations to be appended to the Act are being
drafted under the Program for Biosafety System (PBS) support.V
2.3.1.2 Conclusion with respect to the regulatory mechanism
The overall regulatory mechanism discussed here portrays a picture that suggests that
the regulatory process has relied upon existing legislation for implementation (for
13 www.isaaa.org/kc/cropbiotechnologyupdate accessed on 12 Dec. 2008.
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example the binding local instruments in Table 2). This perhaps contradicts what has
widely been reported by some scholars regarding how the existing biotechnology
research activities were advanced under a legal vacuum (cf Wakhungu and Wafula,
2004).14The main instruments analysed here (and in details in Chapter five) however
give further context to the thesis in various ways. For instance learning, knowledge
production and use amongst actors that characterised the regulatory phases discussed
further on is embedded in these statutes. It is also important to note that, although the
biotechnology policy is not considered to be a regulatory instrument in this thesis, it
legally established a foundation upon which regulatory instruments prior to the
Biosafety Act and the Act itself are anchored.
2.3.1.3 The interim structure for GMOs governance (as of Dec 2008)
i. Multi-sectoral mode of governance
Prior to the approval of the Biosafety Act 2009, the governance of modem
biotechnology in Kenya had adopted a multi-sectoral approach involving many
institutions and sectors. These actors include different ministries and different
regulatory agencies (see Table 3). This study focused on environmental biosafety and
therefore the highlighted institutions and policy instruments have been instrumental
in the regulation and management of the GE trials. However, beyond confinement, and
with the approval of the Biosafety Act, 2009, it is anticipated that the other regulatory
institutions will get engaged in a greater magnitude.
As indicated in the table, all the respective government departments or institutions have
their respective mandates that touch on biotechnology or GE products in various ways.
KEPHIS for instance has been very instrumental in directing the five crop related
regulatory activities empowered by a number of legal and supporting regulatory
14This contradiction is revisited in Chapter five, section 5.3.1.
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instruments. It is therefore not surprising that many interviewees linked some regulatory
challenges discussed below to the enforcement style of KEPHIS.1S The department of
veterinary services is responsible for regulation of animal related activities including
recombinant vaccines and was instrumental in the regulatory approval and
implementation of the recombinant rinderpest vaccine. The Agricultural Sector
Coordinating Unit (ASCU) under the ministry of Agriculture was instrumental in
coordination of two key activities: the drafting of the Strategy for Revitalisation of
Agriculture (RoK, 2005a) mentioned in section 2.2, and the public awareness tool, the
National Biotechnology Awareness Strategy (BioAWARE) discussed in Chapter six,
section 6.3.2.
Currently, all the involved government actors and other non governmental players
involved in GMOs governance" are brought together as a Committee (NBC) under the
umbrella and coordination of the National Council for Science and Technology
(NCST)17, which serves as a secretariat to this committee. This coordination role will be
taken over by the proposed National Biosafety Authority (NBA). It is currently not
clear how the NBA will operate and this remains to be seen during the actual
implementation of the Biosafety Act, 2009.
15 Interviews with RSPu-GPl, RSIn-GP2, RSPu-GP4, RSAc-GPS, ATBp-PSS, RSPu-GP8, TAN-NSS2, TAR-NSSl,
TRTp-NSS3 and ATp-PS3.
16 Since the initiation of a biosafety system in 1998, the constitution of the NBC has been changing (see Appendix 8).
Several reasons may be attributed to this, for instance the changing regulatory terrain discussed in section 2.4.
17 NCST was established by the Science and Technology Act (Cap 250) of the Laws of Kenya (RoK, 1980) to "be the
national reference centre for policy and advisory services in the scientific and technology services" Its coordination
mandate is spelt out in Article 4.
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Table 3: Government institutions with relevant mandates in agricultural GMOs
governance
Ministryll Agency ILegislation/Policy
Ministry of Higher NeST RoK, (1980); NeST, (2006a, 2006b)
Education, Science NBC RoK, (1998, 2003b)
Technology Proposed RoK, (2009)
(MOHE,ST) NBA
Ministry of KEPHIS PPA, SPVA, Legal Notice No. 305, ISPM No. 11
Agriculture (MOA) of IPpe (FAO, 2006b) and KEPHIS, (2004a,
2004b, 2005).
ASCU· RoK, (2005a); RoK, (2008b)
Research &
Extension
group
PCPS PCPA ofl982
Ministry of Environment NEMA EMCA Act 1999; The Environment (Impact & Audit)
& Natural resources Regulations,2003.
Ministry of Trade and KESS Standard Act of 1974; FDCSA Act of 1965; Draft Code
Industry of Practice for handling GMOs; Codex guidelines on
GMOs.
KIPI Industrial Property Act of2001
Ministry of Public Health Department of FDCSA Act of 1965
& Sanitation (MOPHS) Public Health
Ministry of livestock DVS Animal Disease Act of 1965
Source: Adapted from Harsh (2005) with modifications.
ii, The NBC interim governance as a boundary organisation
The NBC has been acting as a boundary organisation overseeing the implementation of
the biosafety regulations (boundary objects) that govern the conduct of all actors,
including scientists and institutions involved in GM R&D work in Kenya. As a
boundary organisation, it has been articulating two major roles:
• Assessment (including risk assessment) and decision-making processes
pertaining to GE activities.
• Coordination of development of the regulatory instruments.
Assessment and decision-making
The major role of the NBC has been to receive, discuss and review GM applications
with a view of making science-policy oriented decisions. This process has been
18 Other acronymsused in this table: FDCSA-Food,Drugs& Chemical SubstancesAct; PPA-Plant Protection Act;
SPVA-Seeds& PlantVarieties Act; PCPA -Pest Control ProductsAct (see other abbreviations on pages ix-x),
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coordinated through NCST as the secretariat to the committee. Figure 2 below gives an
overview of how this process is articulated. As illustrated by this diagrammatical
presentation of the process, key regulatory agencies and Institutional Biosafety
Committees (IBCs) are enlisted to enhance the regulatory approval process in various
ways. Preliminary risk assessment (RA) commences at the compilation of the regulatory
dossier by the applicant (responsible scientist) which is further vetted by respective
IBCs before submission to the NBC for rigorous RA audit.
At the NBC, the actual RA and decision-making process takes into consideration the
suitability of containment facilities to undertake GE work and requisite RA audit
conducted by NBC members, and sometimes experts from regulatory agencies and
subject specialists from academic institutions.V Decision is communicated by NCST to
the respective regulatory agency for action in relation to further administrative matters
[like discussion of application by other ministerial committees like Kenya Standing
Technical Committee for Imports and Export (KSTCIE) and issuance of permits]. One
issue to note from this diagram is the presence of the KSTCIE, a committee chaired by
the Director of Agriculture with all its other deliberations being coordinated through
KEPHIS. This tends to confuse what would be an "official, all biotechnology activities"
approval process as purported, and a question arises as to whether this standing
committee serves all institutions and all biotechnology applications, and whether this
would generate institutional tensions.
It seems from this diagram that players in the regulatory arena conceptualise
biotechnology narrowly through crop agricultural innovations and perhaps the reason
why KEPHIS and related institutional arms dominate the interim process. It may
therefore not be surprising that many interviewees perceived the decision-making
191nterviews with ATp-PS3, Blp-PSI and PRp-PSIO.
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processes implemented under the interim governance to be characterised by both
shortcomings and positive attributes discussed in details in Chapter five.
The Applicant (Researcher, Importer or Exporter)
Institutional Biosafety
Committee (IBC)
Independent
applicant who has
nolBC
Independent
consultant
Relevant
regulatory agent
consulted
(KEPHIS. KEBS.
DVS. NEMA)
Regulatory
agency
(KEPHIS)- ....~f---J
issues import
permits for
NCST/NBC
Applicant & KSTCIE
chair informed
officially of
regulatory decision
Figure 2: Interim approval process of biotechnology activities (Source: Handbook for Policy
Makers, 2007). See abbreviations on pages ix-x,
Coordination of the development of regulatory instruments
The other role of the NBC is to coordinate development of regulatory instruments under
the guidance of the NCST (RoK, 1998). Members of the various technical taskforces
involved in the drafting of the regulatory instruments were drawn from the NBC
members or from the scientific and legal fraternity. Those outside the NBC had to
undergo vetting and commendation from the committee.i" The role of scientists in the
formulation of regulatory instruments forms a substantive analytical part of the entire
thesis and in particular Chapter six.
20 Interviews with ATp-PS3, Blp-PS I, ATBp-PS5, ARp-PS9 and minutes of various NBC meetings.
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2.3.2 Challenges confronting the evolving agricultural research and modern
biotechnology governance terrain
2.3.2.1 Contract research
It is widely argued that biotechnology is a key tool for 21st century sustainable
development (cf Bananuka, 2007). However, most people agree that this may remain a
dream unless certain challenges are addressed that include political support through
provision of incentives for research and regulation (cf Ibid,:30; Echeverria and
Beintema, 2009). In Kenya, government support for S & T including biotechnology R
& D has been minimal (Beintema et al., 2003; Odame et al., 2003). However, the
government has reiterated the importance of agriculture in economic growth (see
section 2.2) and with the new reforms, it has pledged to increase funding for agricultural
R&D within the research institutions by 2% of the national Gross Domestic Product
(GDP) through the Ministry of Agriculture by year 2010 (RoK, 2006b:66; RoK,
2005a:6). This is however interpreted as a mere statement of intent and previous
commitments have not been honoured. For instance at the time of the field work, the
Executive Secretary to the NeST lamented that the government committed to increase
its budgetary provisions for research to 1% of the GDP in 1982/83 but never honoured
• • 21ItScommitment.
The dwindling research funds and other policy reforms have encouraged collaborative
research, technology development and deployment (RoK, 2005a; KARl, 2005; RoK,
2007a). Although the government continues to fund public agricultural research, a
significant support comes from donor organisations (Beintema, et al., 2003:5). Kenya
Agricultural Research Institute (KARl) being the major research institute involved in
modern biotechnology research (and the only one undertaking open field trials) has
undergone significant restructuring in response to these reforms and challenges. KARl
21 Interview with Blp.PS13.
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had to revise its strategic plan first published in 2000 to accommodate the collaborators
needs:
"KARl's collaborating partners within CGIAR system have revised their
strategies, indicating areas offuture collaboration with NARS" (KARl, 2005: 1-
2).
These changes have contributed to a rise in contract research characterised by increased
donor funding (Beintema, et al., 2003:5; Frempong, 1999). For instance all the
agricultural GM trials are being undertaken through Public Private Partnerships (PPPs)
arrangement (Ayele et al., 2006).
Collaborative or contract research has a historical link and is not new in KARl. In late
1980's KARl was already involved through signing of Memorandums of Understanding
(MOUs) in contract research in maize breeding with Kenya Seed Company (KSC),
tissue culture flower production with Oserian Development Company, and in sugar
research with Kenya Sugar Authority (now Kenya Sugar Research Foundation-
KESREF) (Beintema, et al., 2003:5). A lot has also been documented regarding the
tissue culture bananas contract research (cf Smith, 2004). As the current study suggests,
in the case of modern biotechnology, the nature of contractual research is still under-
researched and is undergoing changes at unprecedented rate due to the evolving
institutional and regulatory contextual issues that are discussed throughout the thesis.
What seems to lack is information on how scientific social actors have been responding
to the institutional changes associated with regulation of biotechnology science.
2.3.2.2 Biotechnology and biosafety capacity
According to Bananuka (2007), the need for regulatory capacity evolves alongside an
operational biotechnology sector, and this has been the case in Kenya. Since the
biotechnology programme was initiated in early 1990's, capacity in both modern
biotechnology techniques and biosafety (human, infrastructural and institutional) has
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been built over the years. For instance, a modem biosafety Level II greenhouse has been
put up at the KARl biotechnology centre and two open quarantine facilities have been in
operation for over five years in KARl, at Mwea and Kiboko. According to a report
prepared for policy makers (Handbook for Policy Makers, 2007), the number of
scientists trained in biotechnology countrywide has gone up, with 45% of those trained
being actively engaged in GE work. In addition, capacity in regulatory institutions like
KEPHIS, KEBS, DVS and DPH has been strengthened and as argued in this report,
these institutions are in a state to oversee the implementation of biosafety regulations (if
the biosafety bill, 2008 was to become a law).
These rhetorical claims were advanced by GMOs proponents, in their endeavour to
lobby for the enactment of the bill (see Chapter six, section 6.3.2). However, these
capacity building and biopolicy developmental efforts have been collaborative.f
Despite these milestones, both infrastructural and human capacity remains far from
being adequate. This is attributed to several factors among them inadequate government
support for research discussed above and lack of regulatory policy environment to spur
development (Wafula et al., 2007), that would further encourage and favour capacity
building efforts. The increased cross-over of trained scientists from public institutes to
international organisations locally and abroad has also contributed to the unsustainable
capacity building efforts," a trend which is prevalent in the African region as a whole
(Hastings,2009).
2.3.2.3 Conclusion with respect to challenges and institutional role of actors in the
interim GMOs governance
The interim governance of GMOs activities described in the previous section had
empowered the NCST and the NBC to handle all GMOs matters through a multi-
22 See Appendix S for description of the multiple actors and their various roles.
23 Interviews with TAD-NSS6 and TAN-NSS2.
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sectoral representation. Theoretically, this interim governance seems to have worked if
approval of six GE trials is anything to go by. However, interviews with different
stakeholders revealed a different picture based on experiences of scientists in biosafety
regulations implementation as discussed in details in Chapters five and six.
From the foregoing analysis, it is emerging that various challenges have hampered the
evolution of the twin processes - biotechnology innovation and regulatory regime.
These relate to partly the technical and institutional capacities, but this analysis does not
address an important question related to how the actors (individuals, organisations and
related links) deal with the analysed challenges. Further, the implications in terms of
how challenges are dealt with are important in informing the dynamics around
knowledge use and regulatory policy-making. What would lead us to a better
understanding of these questions is investigation of activities and relationships built
around the evolution of the twin processes (biotechnology research and regulatory
regime). Relationships touch on actors and interactions among them, and are central to
this thesis. In addition, it is noteworthy pointing out that involvement of scientists (and
other related actors) in the related relationships building dynamics is historically linked
to the way both processes were initiated in Kenya (Sander, 2007). This is the subject of
the next section.
2.4 Actors and relationships dynamics in the evolution of
biotechnology and biosafety regime
.
In the co-evolution of biotechnology and biosafety developments since early 1990's,
four significant phases of the regulatory process can be identified based on the
dynamics between actors on the one hand, and the biotechnology and institutional
innovations on the other. In this section this co-evolution process is discussed, seeking
to illustrate how iterative and non-linear the involvement of scientific community in the
regulatory process has been.
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This description serves four main purposes. Firstly, it situates the scientific actors in the
co-evolution process. Secondly, it makes a case for the important role the scientific
community plays, not only in the innovation process but also in the policy process.
Thirdly, it highlights the contextual factors that make Kenya unique as a tool for
investigating perceptions and practices of scientists and fourthly, it justifies why
particular scientific actors were selected for the fieldwork. The last two factors further
reinforce the justification of the methodology adopted in this study (see Chapter four,
section 4.5).
The argument advanced in this section is that, scientists have been articulating various
roles in the regulatory process, but more important is how this is achieved within the
diverse knowledge nodes that they directly or indirectly engage with. The complex
interactions involved are illustrated in Figure 1 (Chapter one). The different regulatory
phases under which the different types of relationships have been built and different
roles played out within this setting are discussed below in detail.
2.4.1 Phase 1(1990-1998)
This phase is simply the planning and initiation phase of the regulatory process that
commenced with the early biotechnology research agenda. Various actors are involved.
The National Advisory Committee on Biotechnology Advances and their Applications
(NACBAA) was formed in early 1991 by the Ministry for Research, Science and
Technology under the NCST to advice on matters pertaining to national priority setting
on biotechnology applications that "could resolve productivity constrains of
conventional agricultural methodologies" (Sander, 2007:23). The committee
emphasised the need to cooperate to enhance effective biotechnology deployment
(Olembo et al., 1995, cited in Sander, 2007:24-25). This implies that it was conceived
early as recommended by this committee that biotechnology could only achieve its
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objective if actors worked corporately and collaboratively. This therefore marked the
beginning of the external funding euphoria and donor dependency that was to
characterise future biotechnology activities and regulatory instruments formulation
endeavours. NCST was to offer the requisite coordination of the many actors and has
continued to do so. This is how NCST became an active focal point on matters of
biotechnology and later biosafety policy (Thitai et al., 1996).
In the spirit of collaboration, capacity for biotechnology was enhanced and the role of
scientists came to the fore. Through the USAID- Agricultural Biotechnology Support
Programme (ABSP), KARl scientists started a collaborative venture on tissue culture.
Later this was upgraded to modem biotechnology where two projects were initiated (the
rinderpest vaccine and the transgenic sweet potato). The former has not been
controversial as the latter although both were initiated at the same time (Sander, 2007).
Some interviewees expressed concern that the way biotechnology was popularised by
the "early scientists" as a panacea to food security could have aggravated the crop
biotechnology controversy. 24
Analysis of reports of workshops proceedings held within this phase to discuss the draft
regulations suggests that, early scientists who got the opportunity to be involved in the
modem biotechnology initiation made a case for biotechnology during these workshops
(Wambugu, 1996). However, other scientists outside the biotechnology programme
argued for capacity building and safe deployment of biotechnology hence made a case
for biosafety policy (cf Mbaratha, 1998; Ekirapa, 1996).
Scientists in this phase can be seen to be articulating two roles; as scientific or technical
advisors and as policy advisors unified by one goal, to develop a regulatory structure for
R&D research. However, the objective was not to enhance safety in application of
24 Interviews with RSIn-GP9, RSPu-PS7, RSPu-PS8, TAN-NSS2 and NGOco-NS4.
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biotechnology products but to enhance scientific opportunities for both KARl and the
government (NCST) (Sander, 2007:42). This implies that KARl interests were not in
conflict with the government interests, while the interests of non state partners were not
directly regulatory policy related.
The Dutch government (Europe) through the Directorate General International
Cooperation (DGIS) funded the drafting of the first regulations. This support was later
criticized by analysts from US, arguing that Europe involvement led to a precautionary
approach to biosafety regulations and practice in Kenya (Paarlberg, 2001, 2007, 2008).
What is not immediately clear is how this influence may have occurred, considering that
USA through USAID later became intensely involved in the biosafety policy process
(see phase 3). According to the empirical data from this study, this accusation may be
linked to the failure of the first regulations to incorporate technology transfer aspects in
favour of research or science transfer (under confinement), and which is interpreted in
various ways by scientist interviewees (see Chapters five and seven).
Despite these contentions about role of actors and impacts, it is argued that the
collaborative effort of DGIS, NACBAA and USAID contributed to learning that
resulted into shift of NCST developmental policy agenda to biosafety policy (Sander,
2007; interviews with Blp-PSII and RSIn-GP9).
2.4.2 Phase 2 (1998-2005)
Actual controversies surrounding governance of biotechnology innovation commenced
during this phase. It is characterised by actual implementation of regulatory instruments
prior to the Biosafety Act which many actors found inadequate as regulatory
benchmarks (see Table 8). Consequently, challenges encountered during this phase
energised the scientific community to become proactive in the regulatory policy
process.
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There was one aspect which was not disputed by all the interviewees; that the existing
regulations were not legalised as would be expected (see also similar claim by Odame et
al., 2003). This may be linked to many factors. First, the circumstances under which the
biosafety regulations were found necessary points towards science side pushing the
government side (see phase 1). This may imply that the legal implications pertaining to
implementation may not have been given critical thought" Second, NCST became the
focal point for biotechnology and biosafety but questions have been raised as to whether
this is the right institution given that other institutes hold a mandate with regards to
agriculture and environmental policy matters'" (see also Table 3).
The subsequent entering into force of the Cartagena Protocol in September 2003
signalled major policy initiatives (see Appendix 7). However, the ratification of the
protocol came after 1998 and the subsequent obligation to operationalise it pointed
towards revision of the existing regulations. This became another key motivation for
many actors (individuals, organisations and donors) to get involved in the regulatory
process.
Three main players are actively involved in this phase but are linked to multiple actors
through complex interactions:
1. The Eastern African Research Network on Biotechnology and Biosafety (BID-
EARN) project funded by the Swedish Developmental Agency (SIDA)
commenced in 1998 with main focus being human and infrastructural capacity
building in biotechnology R&D. Consequently, biosafety and biotechnology
policy-making were identified as key challenges towards achieving this goal.
2S Interviews with LABp-NS8 and LAEp-NS9.
26 For instance NEMA is mandated by EMCA Act to regulate environmental matters, KEPHIS is mandated to
oversee implementation ofthe National policy on biotechnology (Legal Notice, No. 305 establishing KEPHIS under
the State and Corporations Act) as well as regulate introduction of crops that may cause injurious harm to the
environment.
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Thus, the programme sponsored awareness workshops for scientists, policy
makers and private sector aimed at stimulating collaborations (Mugoya, 2007: 9)
and other initiatives that resulted into policy materials (cf BID-EARN, 2003-
resource book for biosafety implementation in East Africa). One key factor to note
is that activities under BID-EARN largely involved natural scientists in academic
and policy arena, while the information resources materials were intended to
impact policy change:
"The main goal of the resource book is to provide a tool for regional guidelines
in biosafety implementation to scientist and national biosafety assessors. " (BIO-
EARN, 2003: i-ii)
It is however claimed that BIO-EARN did not directly impact policy change and the
only tangible output is training of PhD students from academic and research institutes
(Sander, 2007).
11. The UNEP-GEF Biosafety Enabling Activity project: Kenya was one of the 18
countries that benefited from this project which had two phases. Phase I
commenced in 1997 and Phase II in 2002. The latter aimed at securing adoption of
a national policy and a law through establishment of a regulatory regime (Traynor
and Macharia, 2003). It supported the development of an institutional and legal
national biosafety framework (NBF) with the goal of establishing a sustainable
and effective biosafety management system, and strengthening the capacity and
national infrastructure for handling GMO's in the country. A National
Coordinating Committee (NCC) was formed and launched in September 2002 to
support the implementation of this latter phase. The NCC consequently formed
various working groups and task forces among them the legal taskforce which
came up with drafts of the following policy documents; the Revised Regulations
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and Guidelines on Biotechnology and Biosafety, 2003; National Biotechnology
Development policy and the biosafety bill, 2005.
Sander (2007) claims that, the NCC minimised the role of research scientists in the
policy process because its members were drawn from the NBC. Contrasting this view,
the findings of this thesis suggest that, in the external activities outside the NCC and the
internal activities within the NBC and IBCs, the research scientists were actively
involved as policy and scientific experts. Indeed, most interviewees admitted being
involved in various ways (e.g. within IBCs, NBC or during public awareness and
biosafety workshops).
iii. The Program for Biosafety System (PBS) was a renewed initiative launched in
2003 by USAID to support the national biosafety policy and institutional capacity
development (see www.pbs.org). It was meant to address the pocket gaps left by
the UNEP-GEF project, particularly capacity building of the key regulatory
agencies'" (see also www.ifprLorg). Early PBS activities were coordinated
through NCST and focused mainly on building KEPHIS capacity to enhance the
regulation of field trials and training of IBC and NBC members. PBS also engaged
consultants to backstop the review of the supposedly cumbersome old GMOs
application form that resulted into a revised application for Confined Field Trials
(CFTs)_28 These capacity building efforts were aimed at enhancing transparent.
proportionate risk based-reviews and efficient regulatory approval process (Jaffe,
2006; Maclean et al., 2002). Some interviewees supporting the role of PBS
claimed that, tension between regulatory agencies and research institutes tended to
slow the regulatory approvals and hence PBS was stepping in to harmonise the
27 Interviews with Blp-PSI, TAD-NSS6 and TAD-NSI1.
28 Interviews with RSIn-GP9, PRp-PS I0 and SIp-PS I.
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regulatory operationsr" PBS was later to get involved aggressively in biosafety
policy process and in lobbying for the enactment of the biosafety bill (see phase
3).
A critical analysis of dynamics under this phase suggests that the increased activities of
actors including donors focused on regulatory policy, a reverse of what occurred in
phase one. Financial support, learning and knowledge use in phase one targeted
technology development while in this phase, these endeavours were oriented towards
policy learning and influence. Consequently, the corresponding scientific activities
seem to be heavily masked by the policy hype, with majority of scientist actors
assuming policy roles.
2.4.3 Phase 3 (2005-2009)
This phase constitutes the climax of controversies surrounding the legalisation of
biotechnology research and the interim biosafety regime through the public and
parliamentary debate of the biosafety bill versions 2005, 2007 and 2008 (see Appendix
7). It was characterised by proliferation of pro and anti groups (NGOs) who adopted
opposing stances demonstrating dynamic activism (see Appendix 6). Two main actors
are worthy mentioning at this point. The Kenya GMO Concern Group (KEGCO) that
evolved to Kenya Biodiversity Coalition (KBioC) after its membership increased from
12 (as ofSep 2004) to over 30 (as of2008).1t comprises ofNGOs from the civil society
who were opposed to the biosafety bill (and some against GMOs). The other group is
the Kenya Biosafety Coalition (sometimes referred to as Kenya Biotechnology
Coalition) discussed in Chapter six, section 6.3.2.3. The latter articulated its goals and
interests through wide range of institutionalised policy and scientific networks [e.g. The
29 Interviews with TAR-NSSI, TAN·NSS2, ATBp·PS5, RSPu-GPI and TAD·NSII.
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Open Forum for on Agricultural Biotechnology in Africa (OFAB) and the NBC], while
the former was more proactive through public and media avenues.
The USAJD through the Program for Biosafety System (PBS) and International Food
Policy Research Institute (IFPRI) is a key actor in this phase. Its activities unlike in the
second phase are coordinated through two organisations - NCST and ISAAA-
Africenter. PBS in collaboration with NCST is involved in a programme intended to
harmonise the regulatory institutions operations in Kenya, thereby streamlining and
enhancing their capacity for efficient deployment of GMOs in Kenya including GMOs
food (see www.biosafety.ke). On the other hand, ISAAA-Africenter collaborates with
IFPRI in coordinating the communication component of PBS in Kenya. Under this
component, the policy makers, regulators and media, were actively sensitized to make a
case for biotechnology, while emphasising the need for a biosafety law.3o One
significant difference between this phase and the others is the increased utilisation of
resources, notably information and finances, for the counter and rhetorical activities
articulated tactfully to influence policy learning and trajectory (see Chapter six, section
6.3.2).
Another key thing to note is the division among parliamentarians between pro and anti-
groups. The pro-group aligned itself with the biotechnology proponents while the anti-
group with opponents. The media became the sphere for expression of opposing
standpoints as analysed in Appendix 9. Just like phase 2, it seems like activities in this
phase were highly politicised with a temporary merger between science and politics on
the one hand, and public and politics on the other.
30 For instance, journalist interviewed in this study admitted receiving training and exposure to GM fields locally and
abroad through ISAAA and ABSF; see also Handbook for Policy Makers, (2007) and Wafula et al., (2007).
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The most significant outcome of this phase is the approval of the bill to become an Act,
ushering in the era of technology transfer through commercialisation of GMOs, and
perhaps more controversies. A parallel counter biotechnology and biosafety bill 2008
was also presented to the parliament for consideration by the civil society but was
however rejected in one of the parliamentary sessions. This parallel bill was
accompanied by a comparative analysis of the government fronted bill and the civil
society preferred alternative counter bill.
The different conflicting outcomes of learning through different and diverse interactions
tend to question the nature of influence of the regulatory process. This is investigated
further in the empirical chapters.
2.4.4 Phase 4 (beyond 2009, post enactment of Biosafety Act, 2009)
This phase may be perceived to have commenced after the biosafety bill, 2008 received
presidential assent in Feb. 2009, laying the regulatory structure for GM trials approval,
risk assessment (RA) and eventual deliberate release of products of GE technology into
the environment. Not so much can be said about this phase for it is still early, however,
it is anticipated that the public will be watching to establish the truth of the claims
related to GE technology (benefits and risk potential). The Act provides for public
education, RA and mechanisms for enforcing deterrent measures, but it remains unclear
how these provisions will be implemented. More controversies are envisaged during
implementation based on the weaknesses inherent in the approved Act which were
identified by interviewees (see Chapter five, section 5.6.2).
2.4.5 Conclusion with respect to evolution of regulatory phases
Critical analysis of the different phases of the regulatory path since early 1990's
suggests dynamism of actors in relation to cumulative learning, knowledge production
and use, and the impact of this knowledge on technological and regulatory innovations.
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Understanding this dynamism is important and provides a context for supporting the
argument advanced in the entire thesis related to scientific practice, including the
cultural shifts and the role of knowledge in influencing the regulatory process.
To conclude the chapter, a number of empirical studies that further provide a context for
this thesis with regards to knowledge gap are explored before engaging with the more
broad literature review in the next chapter.
2.5 Empirical studies on modern biotechnology governance in Kenya
From a developing country context, a number of studies have been undertaken to
establish how different countries are dealing with the challenges inherent in
biotechnology regulation." These studies are however fragmented and do not address
the core aspect of how the scientific practice is indeed shaping or being shaped by
learning and knowledge production dynamics that occur individually or within
networks.
A number of scholars have previously investigated controversies surrounding
governance of modem biotechnology in developing countries context. Clark et al.
(2002) demonstrate that governance as opposed to capacity issues has considerably
shaped the science and technology (S & T) policy debates in developing countries.
Among the things they recommend in order to revolutionalise the debates is dialogue
amongst all players in terms of understanding policy implications associated with
biotechnology innovation. They suggest that developing countries need to provide their
scientists (natural scientists) with an understanding of the social and economic contexts
31 C Researchers from the Institute for Development Studies (IDS) based at Sussex have extensively looked at how
these issues arc being confronted in developing countries (see www.ids.org).
C Researchers at Innogen ERSC centre, UK have brought to the limelight how biotechnology is being governed in
developing countries (cf Ayele, 2007a & 2007b; Ayele et al., 2006; Mugwagwa, 2008 among others-
www.innogen.ac.uk).
c'Ihese studies can be compared to the extensive studies carried out in EU and USA related to biotechnology
regulation (See Chapter three, section 3.6.3).
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within which biotechnology is likely to develop. This may imply that scientists lack
understanding of the social factors that influence their research work but to what extent
this may be the case is not clear. This reveals a gap that seems to point towards
empirical research related to perceptions of scientists on their related scientific activities
like regulatory practice.
Ayele et al. (2006) exemplify the fact that Kenyan crop biotechnology activities are
public private partnerships (PPPs) originating from outside the public sector. Although
this work does not directly concern individual scientists, it sheds some light on the
contextual factors under which scientists operate as researchers. The PPPs arrangements
put the Kenyan scientists at the centre of the debate in that, one, they are perceived to be
initiators of some of these projects and two; they are bound by the rules that cement
these partnerships. These PPPs are therefore pivotal in influencing the direction and
ultimate performance of expected or desired policy innovations through the choices
scientists make, and subsequent behaviour and implications.
The current study may be seen as a continuation of the work of several other scholars
who empirically endeavoured to understand the governance issues related to modern
biotechnology in the Kenyan context. Odame et al. (2002, 2003) attempted to
operationalise the innovation system concept by exploring the biotechnology innovation
and how it impacts social, political and institutional change. They revealed weaknesses
related to biotechnology governance at its initiation stage and demonstrated dynamism
of biotechnology innovation process, citing evidence of influence of the process by
technology developers (mainly scientists and their allies). They show how the
introduction of modem biotechnology presents an excellent arena through which the
practices of actors and in particular behaviour of scientists can be analysed as they
manage GE trials and consequently adapt to the regulatory demands. However, how the
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different institutional and policy dynamics might have impacted the current regulatory
practice at both the individual and institutional level is not clear. In addition, how this
may have influenced the existing regulatory instruments is also unclear.
Harsh (2005, 2008) identifies informal and formal governance of biotechnology where
non state actors (NGOs) take up the space of the government in policy deliberations. He
empirically demonstrates the diverse and multiple roles played by NGOs in both
biotechnology and biosafety development. Thus, his work offers some insights in
understanding the technological and political environment under which scientists
operate as individuals or within knowledge networks. However, the role of the scientific
community who make up most of these NGOs in the biotechnology and biosafety arena
either in their individual and/or institutional capacities is not clear. Moreover, NGOs are
rich sources of policy related knowledge but how it is utilised and disseminated is
equally important, an aspect that he has not articulated effectively. Further, it is not
clear from his work how the NGOs shape scientific practice in a regulatory context.
Building on Harsh research, the relevance of time, space and policy subsystem, in
relation to the construction of the biosafety bill provides an opportunity through which
GE technology governance and evolution of governance mechanisms over time may be
understood. Consequently, the revealed dynamics may inform reconceptualisation of
policy and practice by relevant actors including scientists.
Sander (2007) looks at the construction of biosafety regulations and guidelines, giving
prominence to the role of international donor agencies in this process. Using the actor
network theory, his study documents how the activities carried out by different
institutional actors influenced, and shaped the context and content of the biosafety
regulations that existed before the Biosafety Act, 2009. He reveals the complex
interrelationship between the network of actors involved in the construction of biosafety
48
regulatory instruments. Sander's application of the term actors is more general and
although he recognises the importance of science, he does not give scientists
prominence in his analysis. Scientists make up most of the institutions and organisations
he describes, but a key question that he does not address is how they gain or negotiate
authority to become key actors in the policy arena.
2.6 Chapter conclusion and summary
The complex dynamics associated with controversies inherent in the Kenyan
biotechnology and biosafety process as the two twin processes co-evolved for almost
two decades point towards different roles of scientific actors in the regulatory process.
As this analysis suggests, different contextual factors directed the different roles and
different styles adopted by multiple actors in articulating these roles. It is however
implicit from this snapshot how the involved dynamics interplayed to influence the
regulatory path.
The empirical studies reviewed in this chapter also fall short of exposing vividly the
role and behaviour of scientists in the regulatory process, perhaps because of the
organisational and institutional approach adopted in the analysis of biotechnology
governance. Despite these limitations, these empirical studies provide useful insights
which the current study builds on to explore empirically learning and dynamics in
knowledge production and use, in the context of a complex interrelationship between
scientists (in the midst of multiple actors), biotechnology science and regulatory process
(see Fig. 1).Meanwhile, Table (4) below presents a summary of issues identified in this
chapter and their limitations, and how they relate to this thesis. These issues are the ones
taken up in the next chapters, starting with exploration of relevant literature discussed
next.
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Table 4: Summary of issues identified in the analysis of the Kenyan context and
limitations
CHAPTER SUMMARY
Issue literature/other secondary Findings and limitations for current
sources research study
S & Tpolicy -Many other S & T policy initiatives -Prior to the Biosafety Act, only few policies
initiatives and exist to support overall agricultural addressed regulation of modern biotechnology.
evolution economic development.
-Biotechnology & biosafety regime -Biosafety regime evolution is submerged
evolving in tandem. within the broader biotechnology innovation
system.
-It is implicit from analysis how the co-
evolution process shaped behaviour of scientific
community and vice versa.
-Biosafety regulation through interim -Lack of clarity on role of NBC as a boundary
and multi-sectoral structure. organisation under the interim structure.
-There are multiple international and -Lack of clarity on different legality claims
national policy instruments guiding considering the many legal and non binding
biosafety regulation. instruments used in environmental regulation.
-Multiple challenges confront both -Not clear how actors negotiate through these
technology and biosafety regime challenges and implications.
evolution.
Different sources of resources (e.g. There is lack of clarity on how the resources
donors) playing a key role in the influence learning ad the overall regulatory
process. trajectory & policy.
Actors -The evolution process is multi- -The interrelationship between biotechnology
dynamics & actors driven by incremental learning innovation, actors and regulatory process is
evolution of through distinct regulatory phases. complex.
regulatory -Individual actors' roles submerged -The underpinning learning and knowledge
phases within institutional and dynamics in relation to actors' roles in
organisational set ups. regulatory process and nature of relationship
between scientific actors and the organisations
they are linked to is implicit.
-It is unclear to what extent learning occurs, and
how knowledge production influences
regulatory innovations.
Empirical -Most adopt an organisational and -There is a knowledge gap linked to scientific
studies on institutional approach masking role practice in the governance or regulatory context.
biotechnology of social actors.
governance
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Chapter Three
3 Regulation Implementation and Scientific Practice
in the Changing Knowledge Landscape
3.1 Introduction
Deployment of agricultural biotechnology as a new life science is associated with
increased institutional changes which are far removed from the normative and
traditional setting under which traditional science & technologies take place. The body
of literature discussed here seeks to understand the dynamics associated with these
changes in the context of institutional innovations and scientific practice. Using insights
drawn from innovation systems, theories of knowledge production, science policy and
policy networks literature, this chapter scrutinises how the views and practices of the
scientific community are being impacted upon by these institutional changes as they
implement biosafety regulations. The analysis is done on the premise that there are
some unexplained gaps that are associated with implementation of regulations linked to
the knowledge intensive biotechnology innovation and its governance. The overall goal
is to explore how responsible governance may be enhanced.
The chapter is organised as follows: Firstly, governance of the new life sciences which
is the main concern of this research is discussed. This paves way for the more specific
two strands of literature, sociology of science and innovation systems, discussed in the
context of knowledge and scientific practice as the main analytical concepts. Secondly,
the changing role of science in society is explored. Thirdly, the emerging new modes of
knowledge production and the factors impacting change are scrutinized. Fourthly,
theoretical concepts that speak about knowledge dynamics and the renewed role of the
contemporary scientific community are reviewed. Fifthly, empirical studies related to
scientific practice and related knowledge use are presented. Lastly, biotechnology
innovation is explored in the context of the changing knowledge production terrain.
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3.2 Governance in the new life sciences
The different applications of the term governance have been contested both in theory
and practice. In this section, this concept is analysed based on how it is applied in the
regulatory processes linked to the new life sciences and in particular agricultural
biotechnologies. Levidow (2007:22) notes that governance provides "cooperative means
to deal with common problems" associated with biotechnology acceptance in Europe.
Governance has also been applied in public policy-making to reconcile the role of
multiple actors in debating, defining and achieving policy goals. In this respect, the role
of the respective governments (albeit theoretically) becomes that of coordinating and
steering (Lyall et al., 2009b: 4). Indeed in the new life sciences, there is a clear call to
engage a wide range of stakeholders in regulatory policy-making (Tait et al., 2006).
Analysis of governance is thus heavily anchored in the decision-making approaches that
broadly define governance based on the rules, institutions, practices and power that
shape the behaviour of different actors (Harsh and Smith, 2007:252).
3.2.1 Challenges in governance of the new life sciences
Despite this clear understanding of what governance entails, there are challenges that
confound how decision-making processes are articulated in the new life sciences which
include:
• Dynamic growth of the sectors involved that is faster than the requisite
institutional structures to support regulatory and policy processes (Tait et al.,
2006).
• Strategies for dealing with the tensions emanating from the diverse views of
different governance actors, while upholding transparency and accountability
(Lyall et al., 2009b).
• Strategies for reconciling the diverse and sometimes conflicting belief systems
and interests (Laurie et al., 2009).
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• The increasing necessity for scientific and social evidence to guide the decision-
making processes (Lyall et al., 2009b), challenging the traditional scientific
approach.
These governance challenges notwithstanding, the government control of many aspects
of the decision-making processes is still evident (cf. Mugwagwa, 2009, with respect to
Africa). This form of government control is particularly manifested in enforcement of
safety standards linked to products of new technologies on the one hand and regulatory
standards on the other (Tait et al., 2006). Thus, the conflict in reconciling the
governance agenda and government control places respective sectors and actors at
different points within a government-governance continuum (Lyall, 2007b).
Considering its importance, how then can the governance agenda be advanced in the
backdrop of the still much needed government control?
With regards to developing countries, governance approaches have been complicated by
a number of contextual factors that are social, technical and political in nature,
questioning the way governance principles are generally understood (Smith, 2009). The
governance agenda in Africa is further challenged by the capacities and the political
environment which direct who gets involved in policy processes and how they are
engaged (Harsh, 2009; Mugwagwa, 2009). Harsh in particular challenges the role of
non-governmental organisations (NOOs) in enhancing the governance agenda, arguing
that there are limits that tend to thwart the expected democratic outcome.
In Kenya which is the focus of this thesis, the subject of biotechnologies and
governance presents a scenario that deserves critical analysis. This is because
transparency and accountability in decision making associated with good governance
have been constrained by lack of proper legislation to guide governance actors
(Wakhungu and Wafula, 2004; Harsh, 2005). Further, the role of the state in enhancing
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effective decision making is particularly challenged by the different power relations
among the many stakeholders (Harsh, 2005). This legitimises an empirical analysis of
the role of different stakeholders in relation to specific governance role/so
Globally, a number of approaches have been suggested to enhance the governance
principles for policy processes which are inherently political in nature. These include
policy networks and advocacy coalitions (see section 3.4.4). The former is understood
as "flexible and dynamic alliances" in which the different stakeholders get involved
actively in the policy process through various acceptable means (Lyall et al., 2009b; 4;
Lyall, 2007b). Coalitions on the other hand are established within policy subsystems
that advance the political interests of actors based on their belief systems (Sabatier and
Weible, 2007). Integration has also been proposed by various scholars as a way of
enhancing governance in the new life sciences (cf Tait et al., 2006; Lyall and Tait,
2005). Primarily, integration attempts to deal with uncertainties and the complex
decision-making process while addressing confusion and inefficiencies in dealing with
those targeted by regulations. Arguably, this proposal seems to be generally targeting
the various affected groups or stakeholders but there are disparities exposed when
analysis focuses on specific group of actors and different sectors (cf Chataway et al.,
2006).
Lyall et al. (2009c) have also offered policy recommendations pertinent for a balanced
governance approach, considering the important role of all actors in a government-
governance continuum. These include:
• Realisation that governance is a dynamic process that should evolve in a manner
that captures this dynamism. This is arguably a difficult task.
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• Governance is context dependent and should be evaluated from this perspective.
This allows the emerging strengths, weaknesses and challenges to inform the
decision-making process.
To operationalise and implement the foregoing approaches and recommendations, it
would be pertinent to consider the diversity brought about by different contexts linked
to politics that vary across regions (Smith, 2009a). For instance, the introduction of
agricultural biotechnologies in African countries to purportedly address food insecurity
has not been without high level local and international mediated politics. This has had
an impact on governance based on strategic approaches adopted by different actors
within respective countries, places and locations of decision making (Harsh and Smith,
2007).
Another difficulty that may impact the operationalisation of the different proposals is
the nascent and evolving nature of the two related processes, biotechnology
development and regulatory policies, characteristic of many African countries
(Mugwagwa, 2008). In Kenya for example, the two processes have been co-evolving
(see Chapter two). This presents a challenge in terms of how different social actors
should behave and be concerned about the integration of governance principles in the
evolution process. In the new life sciences, regulatory practice and the role of actors
form a significant component of the "joined-up" governance-based decision-making
processes (Lyall and Tait, 2005:3-17). Despite this understanding, these scholars seem
to be speaking to policy makers and actors purportedly targeted by governance policies
in a bid to address policy and practice institutionally more generally. Less attention is
given to the scientific communities yet they control the requisite institutional or
organisational actions. This is an area that needs to be addressed empirically to inform
how they should be brought to bear on productive and socially robust decision-making
processes.
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Perhaps a more important aspect to consider is the form of governance that is
experienced and exhibited within networks or coalitions. In the context of developing
countries, these high level and interconnected relationships generate knowledge that
may influence governance approaches based on the way knowledge is articulated
(Harsh and Smith, 2007:256). Looking at knowledge generation and use in the context
of biotechnologies regulation would therefore generate useful insights around the role of
different actors towards responsible governance. This thesis takes cognizance of the fact
that the contemporary scientific community plays a crucial role in directing the
development agenda of the science and technologies as discussed in the subsequent
sections of this chapter. It thus looks at dynamics of knowledge application through the
lens of a heterogeneous scientific community and their interaction with biotechnology
development on the one hand, and biotechnology regulation on the other. This
consequently enables a more nuanced understanding of the multifaceted interactions and
the consequent learning, and suggests how a productive regulatory practice might be
better informed.
3.2.2 Challenging role of scientist actors in the governance agenda
Considering the challenges and limits to governance in the new life sciences, the role of
scientific evidence (alongside other forms of evidence) has been put to the test (Tait, et
01.,2006: 381-382: Tait and Lyall, 2005:180). How then should experts who constitute
a significant part of the scientific community behave towards these unprecedented
challenges as they engage in the new life sciences in various ways? Despite clear
demonstration of institutional and organisational disruptions that accompany the new
technologies (Tait et al., 2006), the strain that individual social actors undergo tends to
be taken for granted. This is an issue that has not been given adequate attention in the
governance literature alluded to above, which tends to pay more attention to the
principles of governance more generally.
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Analysis of the context under which actors, such as different groups of the scientific
communities, negotiate their way around the complex governance scenario is crucial.
This is because in the new life sciences, decision making seems to be occurring at
different multiple layers (Lyall, 2007a) with highly interconnected network of actors
influenced significantly by the local context (Harsh and Smith, 2007). Further,
regulatory practice and related social and institutional accountability as part of the
broader governance are embedded in the behaviour of the scientists in the various
institutional arenas.
Evidence-based, context-bound practice would go a long way in informing a reflexive
regulatory practice that is called for by the multifaceted and multi-actor life science
innovations. It would in addition enrich the understanding of the appropriate role of the
scientific community vis a vis that of other stakeholders in the government-governance
continuum and the overall biosciences policy debates. This is crucial for the institutional
and social reforms needed to make the new technologies, particularly agricultural
biotechnologies, contribute to meaningful development especially in developing
countries (Smith, 2009b; Odame et al., 2003).
3.3 Changing role of science in society
The principles that guided the production of knowledge in the old basic or applied
science show science as being constructed in technical, social and cultural realms
(Calion, 1995). These principles are however delinked from a practical societal setting
and are described as localised and individualised where quality of knowledge is judged
through peer review (Gibbons et al., 1994). Thus, there is increased call for
reconceptualisation of the relevance of science to the needs of society (Nowotny et al.,
2001, 2003). This has opened new ways of investigating how knowledge is actually
produced and used in different settings, in relation to different goals that relate to the
broader functioning of the society (Jasanoff, 2003). This has changed the simplistic way
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of conceptualising knowledge as science based and instead views other social actors as
sources of policy usable or relevant knowledge in a situation where "science and society
are becoming more porous" and knowledge socially distributed (Nowotny et al.,
2001 :53). Knowledge produced in this context, unlike disciplinary based knowledge,
has been tested by the social, political, economic and cultural context under which it is
generated and applied:
"Socially robust knowledge has three interrelated aspects: it is tested for
validity outside as well as inside the laboratory; it is most likely to be achieved
by involving an extended group of experts; it results from having been
repeatedly tested, expanded and modified. "(Nowotny, 2003: 155)
These discussions reflect a shift in knowledge production dynamics triggered by
complex factors discussed in the subsequent section.
3.3.1 Factors influencing change in knowledge production dynamics
It is apparent that the new institutional and knowledge production dynamics that have
spurred the new role of science in society are seemingly complex and are driven by
many factors some of which are explored in this section.
3.3.1.1 Changing knowledge economy and integrated practice
New forms of technological innovations are viewed in terms of globalised knowledge
economy in a process of "globalisation of the scientific and teclmological communities"
(Fukuda-Parr, 2006:2). This type of globalised integration is viewed in the context of
collaborations in many aspects. But as Russell et al. (2008) argue, this integration is
driven by knowledge economy where commercial goal is given a lot of space. This
stems to some extent from the changing practice where research is oriented towards the
"customer" (Waterton, 2005). This narrow view of "knowledge user" has implications:
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• Use of knowledge as something that can be traded implies that knowledge is
defined by knowledge consumers and partners (narrowly defined) as the
knowledge may have ownership restrictions.
• Evaluation of what constitute "good knowledge" is contested because it is
largely directed towards meeting the different clients' demands.
This creates conflicts and tension as relates knowledge use for public good and imposes
certain behaviour on the part of scientists:
"The blurring of public and private science -science for knowledge
advancement and science for commercial gain- has many important
ramifications for the contexts for scientific endeavour and, in turn, how
scientists must engage with the policy and regulatory process" (Scoones,
2002:6).
A commercial driven approach defies the problem-focused and integrated approach
implied by transdisciplinarity principle as advanced by proponents of Mode 2 (this
concept describes a renewed form of practice prompted by the trans-disciplinary
setting). However, transdisciplinary practice still remains relevant when addressing
complex issues that have societal, economic and environmental concerns.
3.3.1.2 Environmental concerns
Social concerns for environmental have increased and largely relate to management of
uncertainty and increased demand for accountability associated with environmental
imperatives. For instance, the United Nations Environmental Programme (UNEP)
articulation of these issues through the Global Environment Facility (GEF) fund attests
to the global and urgent nature of these issues. Moreover, Cartagena Protocol is one
convention that is driven by environmental protection agenda. Thus, environmental and
risk knowledge is not only local but also transnational in nature (Russell et al., 2008).
Environmental concerns have enhanced transdisciplinarity, calling for integration of
many disciplines. This has been seen as one way of bringing knowledge created from
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various disciplines (natural and social) together in order to confront these problems
head on in a systemic way (Miller, 2004). Despite the efforts to standardise ways of
dealing with environmental uncertainties, risk assessment and public participation in
decision making pertaining to environmental management are contested. These
challenges plead for a new way of integration that involves addressing actors' practices:
"Finding solutions to environmental problems requires not only understanding
of environment and threats to it; it also involves influencing the actions and
behaviours of multiple societal actors. "(Russell et al., 2008:464)
Application of Mode 2 thinking in environmental sciences may be challenged because
of the political context under which the science policy terrain is advanced. This is an
area that may present new ways of looking at dynamics related to changing knowledge
production terrain in a contemporary setting.
3.3.1.3 Informed society
Knowledge has become fluid and socially distributed triggered by improved exchange
of information from the increased knowledge nodes, facilitated by the advanced
technological development and the growing venues for information exchange (Nowotny
et al., 2001; Gibbons et al., 1994). Consequently, information that is not necessarily
knowledge is being generated and diffused. What becomes legitimate knowledge is
determined by what the broader society including policy makers consider scientific and
policy relevant. This has implications as sometimes the values of science in providing
scientific solutions to complex and social problems conflict with some basic social
values (JasanofT, 2003). This calls for new ways of society engagement to uphold best
practice guided by evidence-based approaches (social and scientific) as Tait and Lyall
(2005) contend.
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3.3.2 Emerging linear & non linear modes of know/edge production
Gibbons and Nowotny using Mode 1 and Mode 2 concepts have described how the
traditional basic scientific practice is being replaced by a more integrated practice.
Mode 1 practice mimics linear, individualised and localised characteristics common in
research institutes or universities where knowledge is eventually taken up by
government or industry. Mode 2 practice on the other hand is transdisciplinary in
nature:
"Mode 2 takes on transient and temporary forms, exhibits fluid contours and
provisional norms, and occupies temporary institutional spaces which can
accommodate knowledge producers with many different institutional affiliations,
either simultaneously or sequentially. " (Gibbons et al., 1994:33)
The debates about Mode 2 in research have revolutionalised discussions around
knowledge production depending on the way certain features discussed below are
operationalised. These features have provided new ways of investigating societal issues
in which many individuals are stakeholders and include:
• Role of "experts" or "specialists" who have acquired different or multiple roles
under the principles of "transdisciplinarity" and knowledge produced under
"context of application" (Gibbons et al., 1994:148). This relates to research and
scientific practice.
• Disciplines and social identities (Gibbons et al., 1994: 148-150). The demand
for different types of knowledge (e.g. policy, technical, academic, project and
public) has placed the scientific community in a compromising position.
• Learning process and the ultimate way knowledge is used for policy innovations
(Sabatier and Weible, 2007).
Transdisciplinarity: This principle is a response to a new and integrated way of doing
things (e.g. research, policy-making) that promotes trans-disciplinary approach in terms
of disciplines, institutions, individual researchers and boundaries. New methods evolve
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through an iterative and reflexive process in line with the problem at hand and increased
collaboration between players with interest in that particular problem (Russell et al.,
2008). The emerging collaborations are perceived to be flexible, fluid and transitory
(Gibbons et al., 1994), consultative, socially robust, contextualised, systems-based and
adaptable (Nowotny et al., 2001):
"Mode 2 creates a novel environment in which knowledge flows more easily
across disciplinary boundaries, human resources and more mobile, and the
organisation of research more open and flexible. " (Gibbons et aI., 1994:20)
The knowledge generated in this context can be said to be problem focused, relevant
and easily transferable to stakeholders outside the traditional knowledge nodes like
research institutions or universities. It may also be transferable to other non technical
organisations like public associations as stakeholders. According to Russell et al.
(2008), transdisciplinarity at all levels (institutional or individual) is a practice, hence
amenable to analysis and change. However, the way Gibbons, Nowotny and their
colleagues approach transdisciplinarity is open to criticism because they restrict their
approach to mainly technological research activities. They tend to generalise underlying
issues that underpin technological practice. For instance, the new life sciences are linked
to complex governance issues that may complicate the transdiciplinarity practice
because of the context specific institutional structures and policy requirements (Lyall
and Tait, 2005; Lyall et al., 2009a). These issues which have been overlooked need to
be expounded to give a new perspective and more substance to the concept.
Know/edge generated in the context of application: The way Gibbons, Nowotny and
their colleagues debate this feature relates to partnering of both knowledge users and
developers in knowledge production for a socially desirable outcome. The site of
knowledge generation and the site of eventual use are purportedly tightly linked which
seems to be an oversimplification because "context" can be framed or interpreted in
different ways. There are many factors that may influence the way a desirable outcome
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may be achieved. Uncertainty, politics, values and interests for instance confound
endeavours to deal with decision-making processes in the new life sciences (Newell,
2002; Laurie et al., 2009). Thus, knowledge produced in this context cannot
automatically be perceived to be legitimately "applied" or desirable. In view of this,
knowledge generated in the context of regulations implementation that occurs in tandem
with technological developments is also critical since it has implications for socially
desirable regulatory practice.
Reflexivity and changing identities: The increased integration and collaboration under
Mode 2 practice challenge certain behavioural aspects related to knowledge
management. Integration calls for reflexivity where the innovation communities as
knowledge suppliers are expected to agree with users. This may be problematic because
reflexivity in a trans-disciplinary setting may be constrained by capacities and beliefs
(Gibbons et al., 1994:139), individual capabilities and influence by communities of
practice" as they interact and promote learning (Johnson and Thomas, 2007:46-47).
Again the ability to balance and promote both scientific and socially related identities
depends on the nature of research, problems at hand and organizational context
(Gibbons et al., 1994:139; Waterton, 2005). In the context of regulations
implementation particularly in policy formulation, certain social and technical values
may constrain reflexive practice (Jasanoff, 2003; Murphy and Chataway, 2005).
Knowledge flow and increased communication: This feature is embedded in the other
features discussed above and as demonstrated by Gibbons et al. and Nowotny et al. it
may occur in two ways. Firstly, in the case of the scientific fraternity, codified and tacit
knowledge-flow facilitate transdisciplinarity through mobility (in various forms like
scientific fora, networks, emails, direct contact etc), changed priorities setting amongst
32 Communities of practice are groups of people who have a common interest and are engaged in a shared enterprise,
through which they both have, and further develop, a repertoire of knowledge, skills and practices (Wenger, 1998,
cited in Johnson, 2007).
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scientists and competition and cooperation among scientists as they deal with research
related issues.
Secondly, in the case of society, communication of technological knowledge from
scientific fraternity to society has been necessitated by the increased societal demand for
accountability. What is not clear from these scholars' narrative is how complexities and
challenges associated with the two-way knowledge-flow may be dealt with in different
contexts like a regulatory context. Scholars who have pursued governance issues in the
new life sciences have empirically shown how cumbersome desirable policy
instruments for communication and integration have become (cfLyall et al., 2009a).
Quality control: This is one of the implications of the changing knowledge landscape
which presents itself as a knowledge management challenge due to varying
accountabilities demanded by multiple actors involved (Nowotny et al., 2001, 2003:
Waterton, 2005). In Mode 1 research, quality control is upheld through peer review but
with Mode 2 research, standardising quality control is problematic as this transcends
science and non-science arenas. There has been for instance an increased demand for
non-scientific knowledge to legitimise risk assessment process in controversial and
contested sciences (Jasonoff, 2003; Levidow, 2007). This is perhaps because the public
is losing faith in authority of science to provide convincing solutions to societal
problems (Russell et al., 2008; Jasanoff, 1987). This feature presents a new way of
investigating behavioural changes related to management of knowledge that is policy
relevant like regulatory science.
3.4 Understanding knowledge dynamics and actors' practice
The interdisciplinary approach adopted in review of literature for this study permits
exploration of approaches that give a clear and different perspective of scientific
practice in the backdrop of the complex factors, and linear and non linear modes of
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knowledge production discussed in the preceding sections. This section looks at
scientific practice and knowledge dynamics in light of how this has been debated under
different key theoretical approaches, exposing the underpinning factors that qualify
practice.
3.4.1 Innovation systems: institutions and social actors
Two interrelated key concepts that have been widely debated under Innovation Systems
(IS) literature are learning and knowledge. As Johnson and Wilson (2006:748) contend,
learning is the process of knowledge attainment and generation. The two concepts are
important in understanding the role of actors in the processes of innovation or
development and social change more generally (Johnson, 2007:277). Indeed the IS
approach as a framework provides a way of understanding the dynamism of knowledge
production (which is both informational and institutional) and its implication for the
innovation system (Clark, 2002). A lot of information is generated in a dynamic system
such that it becomes important to "identify what is relevant to any specific activity and
organise it in a productive way" (lbid,:360). This brings in the social context that
qualifies information as knowledge. Oyelaran-Oyeyinka (2005:14-15) further contends
that in a dynamic system, there is increased learning characterised by co-evolution of
technology and institutions (informal and informal). Consequently, what is co-produced
between actors is "usable knowledge'Y' that links knowledge nodes (e.g. research
institutions) to "action" nodes (policy makers, farmers and other users) outside the
codified forms of knowledge (Kristjanson. 2008:2).
Knowledge and learning are however conceptualised better in an institutional context.
But this can be problematic because application of the term "institution" is confusing
linked to different interpretations of the terms "organisation" and "institution" used
33 Usable knowledge is perceived to be accurate knowledge relevant for policy-making but the process of
its production is contested (Haas, 2004).
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interchangeably in most cases (Edquist, 1997; Edquist and Johnson, 1997). As Edquist
and Johnson (1997) note, organisations diffuse and manage scientific and technical
knowledge while institutions direct this knowledge:
"Institutions are sets of common habits, routines, established practices,
rules or laws that regulate the relations and interactions between
individuals or groups." (Edquist and Johnson, 1997:46)
This definition presents a clear distinction between formal and informal institutions.
The formal rules are statute law, common law and regulations while informal
institutions comprise of social norms, habits, routines and practices (Oyelaran-
Oyeyinka, 2005:7, expounding the definition by North, 1990). This definition brings the
"social context" in the whole institutional picture that guides the way agents behave or
operate (Coriat and Weinstein, 2002; Nelson and Nelson, 2002). Thus, social actors are
key components in the innovation process through the practices they engage in but
usually masked by the firm or organizational view.
The IS approach explains how institutions in their organizational forms are the nodes
through which social actors engage in knowledge generation and dissemination
activities. However it is implicit about how social and institutional elements interplay to
shape the innovation process. Indeed such studies in a multifaceted and globalised
innovation like biotechnology are few. One such recent study involving Hungarian
scientific community shows how learning and knowledge-flow are highly integrated in
such a system (Huzair, 2009). Huzair introduces the concept "culture" that enriches the
operationalisation of the innovation system concept in a biotechnology innovation
context. She argues that culture acquired and institutionalised in the advent of
challenges through learning by epistemic communities'" tends to concretise a system.
Cultural dynamics are part and parcel of an evolving innovation system. This may
34 Members of an epistemic community belong to knowledge-based groups and share principled and causal beliefs
(Haas 1992: 35). As like-minded scientists, they are transmission belts by which new knowledge is developed and
transmitted as usable knowledge (Haas, 2004:587).
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explain why particular groups of actors may exhibit commonalities in the way they
articulate particular issues or activities. Nelson and Nelson (2002) reinforce this
argument in their claim that there is a "set of understandings or beliefs" reflected in
particular routines. Paying attention to routines or cultural dynamics opens a different
way of understanding human/institution interface that has been given less attention in IS
literature (Coriat and Weinstein, 2002).
Based on social context, learning and knowledge production can occur in different
ways. For instance according to Johnson (2007:277), this can happen as communities of
practice engage in capacity building activities through shared learning. The same is
likely to occur as epistemic communities engage in policy processes (Haas, 2004). What
seems to be lacking in these debates is clarity about social actors' practices and social
change that promote learning and knowledge production dynamics. There is also lack of
reference to policy developments in transformative technologies like biotechnologies
considering their political and value laden context under which learning & knowledge
production occurs (Philips, 2007). Exploring this further would enrich empirical and
productive operationalisation of IS concept from a regulatory context as well as from an
informal institution perspective which has not been adequately articulated (Edquist,
1997:27-29).
Application of the IS framework in agricultural development by recent scholars has
illuminated various features that are relevant to this thesis as highlighted below:
Actors' roles and activities: The IS framework recognises the diverse and important
roles played by individual actors. In the World Bank report (2007: 19), actors can
acquire multiple roles and as they learn, roles can evolve and their relative importance
can change during the innovation process. Hall (2005: 615-616) also share similar views
and describe actors as stakeholders.
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Attitudes and practices of actors: These are institutions conceptualised as learned
behaviours that shape the innovation process. Attitudes and practices determine how
organisations respond to innovation triggers like changing policies or technology. They
differ across organisations, countries, regions and sectors (World Bank report, 2007:20).
Patterns of interaction: The World Bank report (2007) and Hall (2005) suggest that
collaborations and linkages when analysed in their historical and contemporary context
may offer insights on their role in strengthening the innovation capacity. It is however
unclear whether the same is true with regards to strengthening the policy instruments
like regulations that shape innovative behaviour and consequently innovation capacity.
Other forms of interactions that promote learning in innovation systems have been
debated. Kristjanson et al. (2008:20) for instance emphasise the importance of
interactions that promote "learning" rather than "knowing" which is an important
approach especially in the contemporary science & technologies and the overall
complex institutional setting in which they are embedded.
Enabling environment that comprises of policies and appropriate institutional
framework: The World Bank report (2007) and Hall (2005) contend that policies shape
behaviour thereby interacting with attitudes and practices. Essegbey and Puplampu
(2007) note that conducive and enabling policy environment is particularly important
for biotechnology because of the social controversies and complexities associated with
its governance. This therefore makes research on behavioural patterns important and
compels a researcher to ask for instance, which changes in practice would suggest how
actors adapt to particular policies?
3.4.1.1 Context for research in actors' practice from an innovation system
perspective
Institutional change, which is closely connected to learnt practices and habits, is
inevitable for any dynamic innovation system (Hall; 2005; Clark, 1995). Evidence-
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based research has come up with suggestions on how practice may be improved through
revitalized interactions (cf Essegbey and Puplampu, 2007; Hanlin, 2006; Kristjanson et
al., 2008). However these recent endeavours still focus on technological innovations
and technical change mainly at the micro level and fail to make explicit how
knowledge, particularly scientific and regulatory, may be directed (consciously or
unconsciously) towards impacting policy innovations. This thesis seeks to explore this
area by adopting a systemic view of the Kenya biotechnology innovation system. The
scientific community as social actors spur the dynamic changes in knowledge
production and institutional learning within and across the system as they operate within
institutions and knowledge based groups (e.g. epistemic communities and communities
of practice) to which they belong.
3.4.2 Scientific practice and Mode 2 research
The well-founded IS literature discussed above has pointed towards institutionalised
practice that stems from actors' learning but not the intricacies that arise thereof. This
section looks at how scientific practice is impacted upon during utilisation of the
technical knowledge (codified or tacit) generated from a dynamic and contemporary
setting.
The working environments under which the new life sciences like agricultural
biotechnology take place have tremendously been transformed towards a trans-
disciplinary setting characterised by shifting institutional knowledge landscape (Russell
et al., 2008; Lenhard et al., 2006; Gibbons et al., 1994; Nowotny et al., 2001).35 This
shift has also involved social and cultural changes which these scholars do not seem to
explicitly expose. Gibbons, Nowotny and their colleagues have convincingly (although
not empirically) offered explanation of how the behaviour of social actors alongside
35 This shift is purportedly complex, contentious and contradictory. For instance, scientific knowledge is becoming
more important yet its authority has been put to test as discussed previously, knowledge is becoming more socially
distributed while science faces complex problems that have social and political interests.
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related institutional changes has been effected. They claim that what scientific actors
have been experiencing is a paradigm shift from Mode 1 to Mode 2:
"Old paradigm of scientific discovery (Mode 1) characterised by the hegemony
of theoretical or experimental science, by internally-driven taxonomy of
disciplines, and by the autonomy of scientists and their host institutions - was
being superseded by a new paradigm of knowledge production (Mode 2) which
was socially distributed, application oriented, trans-disciplinary, and subject to
multiple accountabilities" (Nowotny, et al., 2003: 179).
Transdisciplinary concept is perhaps the main principle which has been challenged and
is closely linked to this shift. Since it is a practice (Russell et al., 2008), it instils in
actors the need to cooperate in a complementary way. Actors are required to adapt and
in the process they assume multiple social identities (Gibbons et al., 1994:139). The
challenge for scientists is the management of disciplinary and social identities in this
setting. It calls for diverse capacities to manage the complexities involved. Gibbons et
al. (1994) describe how strenuous this is for scientific actors arguing that radical
changes in behavioural practice are needed to adapt to the strains that confront
individual researchers:
"The transformations are sources of stress. Researchers will be faced by an
overload as demands generated by Mode 2 knowledge production are added to
those produced by traditional forms of discipline-based enquiry. Professional
identities are loosened and broadened, scientific careers become more
precarious and mobility adds to strains already inherent in any scientific
career. "(Gibbons et al., 1994: 146-147)
In the process of increased integration and collaborations, the scientific community
acquires a status that Gibbons et al. call "new hybrid communities" that comprise of:
" ....people who have been socialised in different subsystems, disciplines or
working environments, but who subsequently learn different styles of thought,
modes of behaviour, knowledge and social competence that originally they did
not possess" (Gibbons et al., 1994:37).
They argue that articulating this hybrid role may require researchers to "evolve a wide
range of strategies for survival" (Gibbons et al., 1994:23). The authors attribute this
shift in behaviour to dwindling research funding and increased competition for the
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limited resources. They further argue that for specialists acquiring ability to work within
and across internal and external environments, what is important is the ability to move
back and forth between these environments (Gibbons et al., 1994:150). But this may not
be easy as implied. Lenhard et al. (2006:345) in their empirical research on structural
change in disciplines found that "old loyalties are fiercely maintained while new
identities are created". But perhaps what is important is the question about implications
of these identities shifts for practice. Moreover, the form of shift impacted by the
changing knowledge economy may result in positive or negative change.
The description of the shift in behavioural practice as presented by Mode 2 proponents
perhaps does not look critically at how knowledge use can significantly be influenced
by social and economic differences that have been found to influence contentious policy
processes (Murphy and Chataway, 2005). This actually opens up a new perspective of
reconceptualising transdisciplinarity and contextualised practice. For instance, it would
be important to establish how actors like scientists conceptualise changes in the new
cultures of science prompted by particularly the regulatory demands (as opposed to
competition for research funds) and how this thinking is linked to the regulatory or
scientific practice; and further still what the implications this may have for the
knowledge production and use. It is also not clear how different researchers at different
research settings may exhibit these changes especially where motivations and context
may be different. Itmay be also important to understand how reflexivity would relate to
behavioural change. For instance, is it possible for experts to be reflexive to
accommodate opposing interests as is the case with controversial policies? In this
regard, a Mode 2 working environment presents underlying tensions and conflict that
may not be evident from the surface, even among the scientific community. This is what
may need to be exposed empirically, thus opening different ways of re-thinking policy
process and practice.
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3.4.3 Scientific practice in the science policy boundaries
The role of scientific evidence in policies regulating new sciences is acknowledged
(Scoones, 2002; Lyall et al., 2009a). In environmental policies, science is used by
policy makers to legitimate policy actions (Weingart, 1999). In biosafety policy, science
is relied upon to legitimise the process for instance in risk assessment (Scoones, 2002;
Levidow et al., 2005; Jasanoff, 1990; Cartagena Protocol, 2000: Annex Ill). This
implies that scientific experts are key players in these processes as they seek to explain
the uncertainties associated with GE technology and its regulation. But more important
is the way they articulate this role in science policy boundaries or boundary
organisations which in their institutional form play a mediation role between science
and politics (Guston, 2001).
Boundary work as like in science policy boundaries is meant to facilitate social
desirability of evidence-based knowledge by demonstrating social accountability,
relevance and legitimacy through co-production by actors (Kristjanson et al., 2008: 2).
But what it does to science and scientific actors is pose serious challenges and strains
that concern social and science identities (Jasanoff, 1987). Ideally, contemporary
scientists continue to explore new cultural spaces for science (Gieryn, 1995: 416) in
order to uphold their own identities as scientists as empirically argued by Waterton
(2005). Boundary work and boundary organisations when viewed from this science
policy context tend to underplay the important role played by other forms of boundary
organisations like professional groups or lobby groups as knowledge intermediaries.
This thesis considers these forms of neglected knowledge nodes as key avenues of
relevant science policy knowledge.
Because of their perceived objectivity and neutrality, scientists are entrusted to control
the boundary between policy and science without bias (Keeley and Scoones, 1999:7).
This has however been challenged by the political nature of science policies (Weingart,
72
1999) and the value related social factors. Studies have reported unwillingness of
scientists to acknowledge that scientific knowledge is socially constructed and therefore
value-laden (Jasanoff, 1987; van Zwanenberg and Millstone 2000; Weingart, 1999;
Garvin, 2001). The reason behind this may not be clear but Jasanoff(1990) argues that
they do this in order to protect their scientific status in society and their role as policy
advisors. Perhaps more important is the capacity of scientists to influence regulation
which "relates to their ability to frame problems in a particular way and to suggest
solutions and appropriate regulatory paths" (Haas, 1990 cited in Newell, 2002: 15). This
process is subject to manipulation based on interests, values and different disciplines
alluded to elsewhere.
Controversies in science policy debates complicate the process of reconceptualisation
advanced by Nowotny et al. (2001) towards a socially desirable practice. The challenge
is how scientists can construct their views and adjust their scientific practices in relation
to the regulatory issues. This is in the light of their ability and freedom to play multiple
roles or shift identities in a changing knowledge production terrain. This has
implications now more than ever before because of the increased uncertainties about
risk, suspicion between players and increased demand for accountability in
environmental sciences. For example the increasing commercialisation of science policy
orientation of science has raised questions about the kinds of knowledge able to be
produced and judged to be relevant in certain specific contexts (Waterton, 2005;
Levidow, 2007). However as Nowotny (2003) asserts, it is not the reliability of
scientific knowledge that is being questioned, but rather the context of validation and
use that bears Mode 1 individualised and localised characteristics.
Conflicts and tensions related to regulation may be perceived to be unproductive with
far-reaching implications threatening and challenging the linear and traditional culture
of science in many and significant ways. The immediate result of this as asserted by
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certain scholars is the threat posed to the scientific cognitive authority and legitimacy in
informing policy decisions (Nowotny, et al., 2001; Weingart, 1999; Jasanoff, 1987).
This being the case, there is a clear need for institutional reforms (policy and cultural) to
accompany the requisite technological, regulatory and policy change. Such reforms
would enhance innovative or economic potential, and how science and scientists can
contribute effectively to regulatory policy debates.
3.4.4 Scientific practice in policy coalitions
Many scholars have tried to illuminate the complex, messy, interactive and political
nature of policy process in practice (cf Considine, 2005; Hajer, 2003; Sabatier, 2007;
Keeley and Scoones, 1999). Clearly, there are complex dynamics involved that relate to
different actors, generation of different knowledge, sharing of knowledge and resources,
power dynamics and competences among others. Consequently knowledge generated
may impact policy change.
Analysis of learning from a policy process perspective is important for young
innovation systems that are still evolving. This is because the focus shifts from analysis
of incremental learning that leads to technological change, to analysis of learning
(sometimes short lived) that targets policy change. The former is linked to innovation
systems and policy networks (Lyall, 2007a) while the latter is linked to policy coalitions
(Sabatier, 2007; Hajer, 1995). In addition, the science-policy interface discussed in the
preceding section where scientific actors get entangled in controversial regulatory
processes makes exploration of dynamics in policy coalitions worth pursuing. This is
because public policy controversies particularly environmental policies are driven more
by politics and values rather than technical issues (Mazur, 1981 quoted in Weible,
2007:95).
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Sabatier's advocacy coalition framework (ACF) and Hajer's discourse coalition
concepts have been applied to explain the dynamics of policy change in a political
context. They have both strengths and weaknesses that are highlighted below in relation
to this thesis. The Advocacy Coalitions (AC) concept is given more weight due to a
number of unique features which are relevant to this research.
3.4.4.1 Advocacy Coalition Framework (ACF)
To get a good grasp of a political dispute, a theoretical framework that focuses on a
holistic view of a broader policy subsystem would be appealing. This is because it
would take cognisance of the complex and interactive factors that underpin the
functioning of such a system. ACF has the potential to explain actors' behaviour and
policy outcomes in intense political conflicts over periods of a decade or more (Sabatier,
1993; Sabatier and Weible, 2007). It offers an alternative approach to understanding
behaviour of policy actors in a manner that complements other theoretical approaches
applied in this thesis.
Advocacy Coalition (AC) concept stems from Sabatier's conception of a policy
subsystem which is an "interaction of actors from different institutions who seek to
influence governmental decisions in a policy area" (Sabatier 1993: 16; Sabatier and
Weible, 2007:192). Actors who constitute a policy subsystem aggregate into "advocacy
coalitions" which are amenable to analysis based on their "belief systems". A belief
system is "a set of basic values, causal assumptions, and problem perceptions" (Sabatier
1993: 25) while a coalition is "people from a variety of positions who share a particular
belief system and who show a non trivial degree of coordinated activity over time"
(lbid). Coalitions seek to manipulate institutional rules and actors in order to achieve
certain policy goals.
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The dynamism of a coalition is dependent upon resources which include money,
expertise, technical information, number of supporters and legal authority with the latter
being embedded in institutions (lbid,:29). The way these resources are used IS
important. Technical information for instance is used by actors as they "seek to
convince other actors of the soundness of their position concerning the problem and the
consequences of one or more policy options" (Jenkins-Smith and Sabatier, 1993: 45).
Shared beliefs rather than interests direct the behaviour of individuals within coalitions
providing "principal glue of politics" (Sabatier 1993: 27). Sabatier argues that beliefs
are more inclusive and more verifiable than interests and that belief systems models are
flexible thus able to incorporate individual and institutional interests (lbid,:28). This
argument tends to underplay the role of interests and values that drive players in the
new life sciences decision-making processes (Laurie et al., 2009).
Unlike policy networks which focus on institutionls like government or public for
analysis of policy or institutional change (cf Lyall, 2007a), a policy subsystem is the
principal unit for understanding policy change. To assess the influence of actors on a
particular policy system, a policy change must be evident. Based on AC approach, a
policy change occurs as a result of various factors. One, non-cognitive factors external
to a policy subsystem may change components of policy core beliefs. Two, "policy
oriented learning" over long periods of time may result from incremental accumulation
of information or increased experience of actors. Learning therefore affects the beliefs
of actors within the policy subsystem which can lead to major policy change (Jenkins-
Smith and Sabatier, 1993: 42). Three, a hurting stalemate which is a situation in which
all parties involved in dispute view continuation of the status quo as unacceptable and
run out of options and venues to achieve their objectives.
As a theoretical framework, AC is appealing for analysing policy change because it
accounts for mobility of specific individuals within institutions or a subsystem and
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variation in behaviour exhibited by individuals (Sabatier 1993 :25). It creates an
environment for players with similar beliefs (regarding a particular problem) to interact
cooperatively as opposed to partnering with those of different beliefs. They tend to
distrust those with dissimilar policy core beliefs (Weible, 2005).
ACF's unique focus on a particular subsystem opens up additional ways of
understanding the knowledge dynamics in a policy process like biosafety regulation. It
offers a way of understanding value related factors linked to actors in a political system
thus developing a good understanding of the underlying tensions. This way, it is
possible to grasp the political context of the problem being analysed (Weible, 2007: 96).
Understanding the policy process requires knowledge of the goals and perceptions of
actors "over a period when these actors are actively seeking to propagate their specific
spin on events" (Sabatier, 2007:4). Policy outcome would then be interpreted as the
victory of a certain belief system. These features make the subsystem concept very
relevant to the study of Kenyan regulatory policy subsystem. This is because it has been
co-evolving alongside the technological developments for more than a decade. It has
also involved many players who may be perceived to hold diverse belief systems
amenable to analysis (Chapter two). The analysis consequently enhances provision of
policy recommendations or actions that are commensurate with the political problem
(Weible, 2007). Despite these appealing features, it has shortcomings one being that it
has not been tested widely empirically especially in a developing country context.
3.4.4.2 Discourse coalitions
This concept emanates from Hajer (1995) in his study "the politics of environmental
discourse" in which he explores the dynamics in environmental policy-making. Hajer's
main argument is based on the fact that the social construction of environmental
problems drives developments in environmental politics. The framing of issues
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consequently impacts on the behaviour, organisations, institutional arrangements and
the emerging policies. This approach exemplifies the way issues are talked about
regarding a certain policy area. This gives rise to relationships or discourse coalitions
that reflect particular strategies or consensual paths. Discourse analysis can therefore be
used to identify coalitions that gather around or interpret a particular storyline. This can
further be linked to a specific social practice and policy change.
This concept can be used in understanding how the Kenyan scientists construct their
views around the regulatory process, which may enhance in-depth understanding of the
scientific and regulatory practice. Indeed it was applied by Harsh (2008) to investigate
the role ofNGOs in governance of GMOs in Kenya. However, as others have noted (cf
Jasanoff, 2004c), it gives a lot of attention to language which may limit its analytical
potential. Discourse analysis as a methodology was not considered in this thesis which
may limit its constructive operationalisation. Secondly, as empirically shown by
Boschert (2005), the concept takes beliefs, interests and values as given, elevating
discourse above these factors that have been found to be key in controversial science-
policy debates.
3.5 Empirical studies on scientific practice in new knowledge terrain
Despite the diverse roles scientists play in science policy arenas, empirical research on
their role in boundary work (or policy relevant activities meant to create scientific and
social order) and how these boundaries impact on their construction of perceptions and
knowledge dynamics has not been given a lot of attention. In a study involving UK
scientists, Waterton et al. (2001) and Waterton (2005) attempted to understand in
practice how contemporary scientists undertake boundary work:
"Contemporary scientists are both experiencing, in increasing intensity,
science-policy boundaries of various kinds, and have the ability to sit back and
reflect on their own involvement in this boundary work. ,. (Waterton, 2005:436)
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Waterton (2005) observes that natural scientists undergo a pragmatic shift from
contemporary science practice to Mode 2 practice. This is consistent with the argument
advanced by proponents of Mode 2, but in this empirical case, there were major impacts
on scientific behaviour influenced by many unreported underpinning factors. Some of
the characteristics demonstrated by scientists in the articulation of boundary work
include:
a) Forging of science-policy alliances or contracts which Waterton claims shape the
types of knowledge constructed through negotiations:
"The variations in co-construction of science-policy boundary in which
scientists play a part means that research questions, resulting knowledge and
anticipated outputs are always calibrated together with policy questions, policy
knowledge and policy understanding of what constitute acceptable outputs."
(Waterton 2005: 439)
Waterton further asserts that there are other different kinds of relationships that are
inevitable but somewhat "counter productive" e.g. regulators. These "non-commercial"
relationships have not been given proper attention in literature in view of their impact
on scientific practice.
b) Scientists have the ability to "reframe science in such a way as to enjoy policy
funding and influence" prompted by reduced funding and increased competition
among scientists who target same financiers.
c) Scientists demonstrate shifting identities (though not very conspicuous) as they try
to accommodate and satisfy the different relationships. As Waterton puts it, there is
inconsistency and some level of awareness in the way this identity shift is played
out.
"In describing this communication (whether with fellow scientist, policy maker
or sponsor), this scientist seems to be experimenting with his own identity as a
scientist as much as he is experimenting with the organism he is researching. "
(Waterton 2005: 442)
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In addition to other impacts, these different identities present communication problems
due to different expectations. She however notes that contemporary scientists are
actually self-conscious of the many compromises and adaptations that they have to deal
with under Mode 2 research.
The changing research practice has not been confined to natural scientists only. Recent
research conducted to explore the relationship between Mode 1 and Mode 2 research
terrain for social scientists in Malawi showed that, they engage in consultancies outside
their disciplines, and are reflexive enough to accommodate demands of patrons usually
for economic gains (Holland, 2009). Reports emanating from these consultancies
largely reflect the patrons' terms of references.
These two empirical cases seem to suggest that dynamics surrounding behaviour of
scientists in the changing knowledge economy is complex than explained by the
commercial imperatives or "knowledge commodification" (Russell et al., 2008). It has
something to do with endogenous individual interests and gains, rather than the
commonly assumed influence by exogenous factors like multinationals, perceived to
have trade interests (Middlendorf et al., 2000 cited in Magnan, 2006).
Further insights have been debated under Mode 2 innovation in an effort to capture the
developments in the innovations paradigm shifts (Clark et al., 2009). Recently, scholars
in innovation and development studies have operationalised different features of Mode
2 in different contexts." They have opened up different and productive ways of
analysing learning, knowledge use and actors' practices from an innovation perspective.
36 See for example Chataway and Hanlin (2008) in application of knowledge-flow and capacity building through
networks and partnerships in health innovations; Chataway and Smith (2006) in operationalisation of communication
and partnerships concepts in health innovations; Clark et al. (2009) in operationalisation of Mode 2 innovation and
Below Radar Innovations (BRIs) in the dynamic Asian drivers economies.
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3.6 Biotechnology innovation in the new knowledge production
landscape
The iotechnology innovation system provides a platform for analysis of unprecedented
changes in institutional infrastructure and knowledge production terrain that have
confronted the scientific community in recent years. The drivers of learning and
institutional and social change discussed in section 3.3.1 have been operationalised in
biotechnology innovation context, and have formed a reflexive debate in this area. This
section explores some of the discourses around biotechnology innovation and in
particular those that relate to implementation of biosafety regulations which is the main
focus of this thesis.
3.6.1 Framing ofGE technology as a unique branch of science & technology
Recent developments in life sciences advanced through recombinant DNA techniques
have improved the conventional biological science in various fields like
pharmaceuticals, agriculture and the environment (Paarlberg, 2001: 1-3: ICTSD report,
2007: 1-12; Kelemu et al., 2003:396). As these scholarly materials seem to point out,
GE technology may be perceived to be different from other sciences. They allude to the
fact that it is precise involving careful, strategic and selective manipulation of genes
undertaken in highly regulated laboratory setting. This precision is used by GE
proponents (mainly scientists) to strengthen their positive position for GE technology.
Consequently, subsequent understanding and framings about this subject are based on
scientific activities undertaken in such a disciplinary based and confined research
environment (Mode 1 practice as conceptualised by Gibbons et al., 1994). This setting
is different from a normal environment under which this science is supposed to perform
for its usefulness to be realised, e.g. in the farmers' fields or in the market by consumers
(Scoones, 2002:4). In view of this, it can be said that the debate has been framed from
the "prospects perspective" towards solving complex technical problems, rather than the
"innovative perspective" that would encompass broader economic and social issues
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(Hisano, 2005). The latter, purportedly normal and ideal environment would be
perceived to be socially desirable in line with Nowotny et al. (2001) argument.
The view that biotechnology holds a key towards addressing major challenges in
agricultural production especially in developing countries has been globalised and
advanced at international arenas (Hisano, 2005). FAD (2004) for instance affirms and
endorses agricultural biotechnology as having "potential to address the needs of the
world's poor and the food insecure". Others have found these discourses to be
misleading and sometimes confusing the debate (cfKelemu et al., 2003; Hisano, 2005).
This discourse is similar to what has been described as biotechnology determinism (cf
Levidow, 2007). These debates although influencing learning and knowledge
production terrain in an unprecedented way have not received critical attention in the
context of how knowledge and learning impact the scientific practice and related
biosafety regulatory instruments.
3.6.2 Biotechnology in the evolving global knowledge economy and multiple
players
Factors that impact modem biotechnology development and deployment for economic
usefulness stem from globalisation reflected in the dynamic knowledge economy
(Fukuda-Parr, 2006) and dynamic technological changes (Tait et al., 2006). This has
come with some form of reorganisation of operations. Although sometimes not very
obvious to the scientist actors themselves, the hitherto localised, discipline based
boundaries and operations have slowly been disorganised (Gibbons et al., 1994) and
replaced by increased collaborations. This integration is evident in form of public-
private research not only in developed countries (Waterton et al., 2001; Waterton, 2005;
Scott, 2005:12-16) but also in developing countries (Ayele, et al., 2006; Odame et al.,
2003). Clearly there has been a revolution with different disciplines integrating in a way
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that seems to portray biotechnology as a unique and different form of S & T as
mentioned in the preceding section?'
One factor that has contributed to these institutional changes relates to the fact that the
infrastructure and the large investments involved in biotechnology transfer are beyond
the capacity of individual scientists or the public research institutes. However, these
inevitable collaborations have elicited conflicts, suspicion and tension amongst
proponents, opponents and governments, some seeing this as positive and others wary
of potential exploitation by some who may have vested interests; an indication of
varying perceptions.
Biotechnology deployment is also shaped by many other actors at both national and
international levels. These include multinational corporations who own the intellectual
property, farmers, research scientists, anti-globalisation and environmental NODs
(Fukuda-Parr, 2006). All these actors are perceived to have diverse interests. For
instance, players dominating the OMOs arena have been linked to large corporations
with business agenda or exhibiting the economic culture (Middlendorf et al., 2000 cited
in Magnan, 2006).
Other factors that have shaped biotechnology innovation are regulatory in nature and
include trade and markets (national priorities) and rules (biosafety at national and
international level and IPRs) (Fukuda-Parr, 2006). Biosafety regulation which is the
heart of this thesis is discussed exhaustively in the next section.
3.6.3 Biosafety regulation
Application of modern biotechnology is poised to have varying environmental concerns
and therefore attracts varying perceptions related to risk and uncertainties. This being
the case, its transfer and consequent realisation of economic potential must go hand-in-
37 Biotechnology science is multi-disciplinary and cuts across various disciplines like molecular biology, genetics.
ecology, pathology, toxicology etc.
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hand with policy and regulatory innovations. This is in an effort to balance economic
gains and safety (Kameri-Mbote, 2002; ICTSD report, 2007:14-57; FAO, 2006a).
Regulations therefore attain a unique importance as a boundary object (Guston, 2001) in
technology governance (Braithwaite et al., 2007).
Globally, several legal and non-binding instruments have been put in place to regulate
environmental biosafety. Most of these legal instruments have been formulated with
risk and safety (precaution) as the guiding factor (Paarlberg, 2001: Scoones, 2002). The
Cartagena Protocol (CP) is an example of how risk regulation has been framed in an
international context. The African Model Law adopts the same approach (www.africa-
union.orglbiosafety) and some argue that it has taken a more cautious stance than the
CP (Mayet, 2000, cited in Andanda, 2006:1364). These instruments mimic
characteristics of process based, product based and precautionary principle approaches
described extensively in risk regulation literature (cf Tait and Levidow, 1992; Tait,
2001; Marchant, 2001; Levidow, et al., 1999; Dunlop, 2000).
These approaches have been interrogated and criticised in different contexts. Murphy et
al. (2006) for instance claim that the "precautionary principle" concept has been used to
attach meaning to conflicts surrounding regulations of GMOs. Paarlberg (2001) makes
similar claims when analysing the regulatory approaches in different developing
countries' contexts. He identifies among others, the promotional approach that mirrors
USA permissive approach, and preventive regulation similar to the EU precautionary
approach. These approaches culminate into what Tait and Levidow (1992) refer to as
reactive and proactive approaches that stem from actors' perception of risk (Chataway,
1992:210). The reactive approach is process-based and those who favour it tend to be
more sceptical, while the proactive approach is product-based and those who favour it
tend to argue for substantial equivalence in assessment ofGMOs risk (Marchant, 2001).
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This reflects a polemic, polarised and political debate based on framing of regulations
from risk and uncertainty perspectives (Newell, 2002).
In line with the above arguments, regulatory debates from the African context have been
rife and contested. For instance, Mugwagwa (2008) exposes several regulatory
approaches adopted by the Southern African countries prompted by several factors,
some of which are related to safety. He however brings out other approaches that have
non-safety orientation. He alludes to the proactive approach where countries embrace
biotechnology as national developmental goal (developmental approach), opportunistic
approach where countries engage in policy process due to available foreign funds, and
the "joining the band wagon" approach where countries engage in regulatory policy
process because other countries are doing so. These approaches depart from the
common risk based approaches discussed above that have an origin in USA and Europe.
The "risk approach" to regulation may be perceived to be narrow from an African
perspective. This is because Africa is perceived to be confronted with chronic, poverty
related challenges and cannot feed its ever-increasing populace (Kelemu et al., 2003;
Wafula et al., 2007). Proponents of biotechnology see this as an opportunity to address
some of these chronic problems by tapping on the potential benefits of GE technology
(Hisano, 2005), hence the need to embrace a benefit approach to regulatory approaches
(Karembu et al., 2008; Paarlberg, 2001, 2008). There have been recent initiatives by the
scientific community to popularize this benefit concept."
These approaches show how contested biosafety regulation is, partly because of the
global, political and economic nature associated with biotechnology discussed above.
This notwithstanding, these approaches have had an implication for regulatory policy
trajectories being discussed or adopted in developing countries (Newell, 2002;
38 See Appendix 9; Open Forum on Agricultural Biotechnology in Africa (OFAB) at www.ofabafrica.orglcountry and
the Handbook for Policy Makers (2007).
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Paarlberg, 2001, 2008; Scoones, 2002). Further, apart from international regulatory
approaches influences, Africa has regional and transnational bodies that are promoting
certain regulatory approaches.t''
Despite these contested approaches to biosafety regulation, African governments have
recognised the need to embrace modern biotechnology in addressing some of the
agricultural production constraints (Juma and Serageldin, 2007). Further, they have
understood the nature of biotechnology as a double-edged sword; as beneficial as well
as risky (related to its application). This is evidenced by the numerous motivations and
initiatives to engage in development of effective regulatory mechanisms (Mugwagwa,
2008; Nang'ayo, 2007; UNEP-GEF, 1995; FAO, 2006a; AATF, 2006; Sengooba et al.,
2005). Most emerging frameworks aim at building biosafety institutional capacity for
responsible implementation of GE activities. Actually, in Africa, it was conceived early
that benefiting from modern biotechnology depended on parallel development of
biosafety regulations and biosafety capacity for implementation (Mugoya et al., 2002;
Mugoya, 2007). It is however not clear how this parallel model of technology
development alongside regulatory regime may impact regulatory practice and policy
instruments, as well as the broader innovation process.
3.7 Chapter conclusion and summary
A critical analysis of the foregoing literature seems to indicate that scientific practice is
impacted by, not only institutional factors that are complex, but also by social and
culturally embedded factors which most theoretical approaches in knowledge dynamics
fail to capture vividly. The changing institutional terrain for agricultural biotechnology
innovation and the unstable role of scientists in science policy boundaries suggest that
scientists get entangled in the regulatory policy debates in diverse ways. Despite this,
39 EAC, AU, COMESA; see also attempts by PBS towards harmonisation of confined field standards within East
Africa [Sengooba et al., (2005); Linacre and Cohen (2006)] and in harmonisation of regulatory policy efforts within
Africa (Mugwagwa, 2008).
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role of scientists in science policy deliberations as epistemic communities on the one
hand, and as innovation drivers within communities of practice on the other, continues
to be valuable (Haas, 1992, 2004; Weingart, 1999; Johnson, 2007). But productive
engagement is threatened by the changing linear and non linear modes of knowledge
production that cause strains at individual, institutional and organisational levels. This
causes confusion in terms of the way scientists and policy experts are expected to
behave.
Although cultural and behavioural shifts in scientific practice related to pressure of
funding has been acknowledged in boundary work (Waterton, 2005), literature has not
explicitly articulated the shifts or behavioural patterns impacted upon actors by the
inevitable paradigm shift from the basic research practice to the integrated practice
called for by biotechnology innovation and related biosafety regulation. Overall, in a
bid to deal with the difficulties that constrain learning and knowledge production,
scientists tum to different integration strategies that include among others enlisting of
relationships like policy coalitions. This new and integrated policy working
environment is further confounded by the contentious governance issues linked to
biotechnology as a new life science. Consequently, this complex scenario evokes
different social identities reflected in different behavioural shifts.
Meanwhile, Table (5) below presents a summary of issues and theoretical approaches
explored in this chapter, and the missing gaps that the narrative presented in subsequent
chapters attempts to address.
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Table 5: Summary of literature and limitation for this research
CHAPTER SUMMARY
Issue Literature Findings/what Is lacking for this research
Governance This has been debated Less attention is given to articulation of
of new life from the context of multiple forms of evidence (knowledge) that
sciences participative decision- should guide legitimate policy processes.
making processes. Focus This may imply that individual social actors
has been the overall who are knowledge producers and drivers are
institutional and policy masked by this generalised approach.
change. Attention is given
to evidence-based
decision-making
processes.
Science and Changing role of science This is scattered within various bodies of
society in society prompted by literature that are complementary when
changing knowledge analysed from knowledge perspective.
economy, environmental
imperatives and informed
society.
Scientific Innovation systems -Less attention given to learning of social
practice concept explains learning actors in regulatory policy related
and knowledge dynamics interactions and networks. Social actors play
within a dynamic a key role in knowledge dynamics.
innovation system. -There is need to understand the dynamics
behind regulatory policy innovations where
the context of knowledge use may be
different, process short lived, relationships
informal and sometimes end product is
definite (e.g. development ofa regulatory
instrument).
Mode 2 concept carefully -Operationalisation of contextualised practice
explains the changing is limited to technological research and gives
knowledge dynamics in less attention to policy innovations like
new sciences in relation to regulations. This opens a new avenue for
actors'transformed investigating scientific practice.
practice. -Trans-disciplinary practice somewhat
different in implementation of regulations
suggesting further investigation in the context
of policy innovation rather than the
traditional technological focus.
Policy coalitions explain -This concept complements Mode 2
policy knowledge principles.
dynamics within networks -There is no empirical application of this
in policy processes. concept in the biosafety regulatory processes.
-Concept underplays certain factors like
interests, influence and relationships that are
identified as key in science policy and
innovation systems literature.
Biosafety Most approaches to -Context specific literature scanty
regulation regulation are risk or particularly with regards to empirical studies
promises based, that seem in developing countries.
to situate scientist actors as -Perceptions of regulations and factors
having a narrow view of influencing these perceptions are not clear
innovation. from the empirically grounded literature.
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The gaps summarised in this section therefore legitimise a study that would illuminate
empirically how scientists get entangled and how they navigate their way through the
challenging knowledge production terrain, while upholding their scientific ethos and
disciplinary identities. Such a study may be important because of the trans-disciplinary
nature of biotechnology, which may imply that certain regulatory behaviour may be
reinforced by different cultures colliding in this setting. It would also bring insights in
the way scientists use policy relevant knowledge to impact policy change the new life
sciences. In addition, the governance of biotechnology has called for new ways of doing
things towards governance agenda rather than the controlled government approach (Tait
et al., 2006). It is again empirically unclear how governance approach to regulation,
particularly at a micro or local level might affect the scientific and related regulatory
practice.
Since one of the objectives of this thesis is to offer suggestions on better ways of
governing biotechnology, the insights generated from this literature review, although
from a global and general context inform this endeavour. But first the methodology
applied to generate empirical data to support the subsequent discussion is presented in
the next chapter.
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Chapter Four
4 Methodology
4.1 Introduction
This research is about the perspectives of the scientific community regarding
implementation of biosafety regulations and the role of this community in shaping the
regulatory process and instruments. The approach to this study assumed the existence of
diverse perspectives and practices dictated by the controversies and contextual factors
driving the debate in governance of the new life sciences. These aspects had a bearing
on the integrated research design adopted that provided flexibility for the scientists'
views to come through despite these factors. However, guided by the research
questions, I had to steer clear of the controversies inherent in GMOs debate.
This chapter presents the resulting research design detailing the research methods used
after introduction of two important aspects that shaped the overall methodology: firstly,
my professional background that was a motivation for this study and secondly, an
overview of the adopted line of enquiry. Following this, subsequent sections describe
the process of data generation and analysis. It is important to point out that, the research
stages were not as clear-cut as presented here. This is because the methods were
iterative and evolved as data generation, analysis and writing progressed.
How the issues of researcher's bias, ethics, data validity and reliability were dealt with
is also covered explicitly across the sections, against the challenges and opportunities
encountered during the research process.
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4.2 Personal background
Trained as a biological scientist, I got involved in the plant protection (quarantine)
regulatory work in 1999 as a practitioner employed by Kenya Plant Health Inspectorate
Service (KEPHIS). When the biotechnology activities commenced in Kenya in the
1990's, KEPHIS became the main government institution enforcing the monitoring and
inspection aspects guided by the interim biosafety regulations published in 1998 (RoK,
1998). Capacity in both biotechnology and biosafety was a challenge for the
government and the organisations involved. This resulted into both national and
organisational collaborative efforts to build the requisite capacity. I was one of those
people who benefited from this early and subsequent capacity building efforts, receiving
training in modern biotechnology techniques as well as biosafety. KEPHIS later became
a key player in the biosafety regulatory instruments formulation, and consequently I
became actively involved as a regulator, interacting extensively with biological
scientists in the biotechnology arena. This may therefore imply that I have brought,
though not deliberately, my own understanding of issues influenced by my previous
traditional disciplines, into the social science methodological approaches.t"
Rather than assume or ignore this academic and professional background and
experience, I adopted a heuristic form of enquiry, prompted by this self-reflective
question:
"What is my experience of this phenomenon and the essential experience of
others who also experience this phenomenon intensely?" (Patton, 2002: 107)
Heuristic research is not detached from researcher's personal experiences, reflections
and insights. It endeavours to disclose the truth through understanding of tacit
knowledge. These attributes are enhanced through its two basic principles: first, the
researcher must have a personal experience with, and intense interest in the
40 This may have both advantages and disadvantages that are discussed further on in the chapter.
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phenomenon under study and two, others who are part of the study (e.g. scientific
community interviewees) must share an intensity of experience with the phenomenon
(Patton, 2002: 107). Consequently, the eight years I worked as a regulator while
interacting with the biological scientists (myself being one), prompted me to adopt an
interdisciplinary approach to the research design and other methodological approaches
used in this research. The purpose was generally to enhance the interpretation of the
empirical data in the best way possible rather than test any existing social science theory
or approach.
4.3 Qualitative approach
The subjective views of the scientific community related to implementation of
regulations, the reasons why they hold these perspectives and their behaviour related to
regulatory process were the topic for interpretation in this study. What was important
therefore was the scientists' worldview, solicited through a qualitative approach. This
approach is different from the quantitative approach that adopts tests, surveys and
experiments in data generation (Glatthorn, 1998: 34). Creswell (2007:3) argues that,
there is no antagonism in choosing either a qualitative or quantitative approach as they
represent "different ends of a continuum". However, it was understood that statistical
methods could yield a lot of quantitative data, but to generate rich data embedded in the
accounts of those who make regulations and those affected by these rules, a qualitative
approach was found to be promising. As Silverman (2005) observes, qualitative
research sacrifices scope for detail. Thus, engaging qualitative methods were used
which entailed in-depth semi-structured interviews complemented with observations
and documentary research.
This research is therefore "grounded" in the interpretations of the interviewees which is
the ultimate aim of qualitative research - that of generating ideas or concepts that
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illuminate the issues under investigation (Hammersley, et al., 2001). In this study the
issues being illuminated were scientists' perceptions surrounding regulations and
regulatory practice. Consequently, the emerging themes are supported by examples
while considering the context under which the research was carried out (Rubin and
Rubin, 2005). Context was an important aspect in this research because of the different
contextual circumstances involved. For example, the different interviewees' academic,
professional or institutional backgrounds may imply that divergent perspectives could
emerge under these different circumstances.
Because of the heuristic inquiry adopted, this research was explicitly reflexive. Most
qualitative approaches exemplify the importance of reflexivity (cf Etherington, 2004;
Bryman, 2004:500; Robson, 2002). Robson defines reflexivity as "awareness of the
ways in which the researcher as an individual with a particular social identity and
background has an impact on the research process" since s/he is not detached from the
social world s/he is researching (Robson, 2002: 172). This position is also shared by
Gillham (2000) who asserts that it is common for researchers to carry their prior
conceptualisations and prejudices into the fieldwork based on their background and
experiences. Consequently, he recommends that the researcher should be conscious of
this, acknowledge the prejudices upfront, and aspire to maintain an open mind. This
implies that through reflexivity, a researcher is able to put aside personal preconceived
ideas as well as acknowledge the preconceived perceptions related to himlher, held by
the participants. This is achieved through critical reflection on the practice, the process
of research and the role of the researcher (Litchman, 2006).
Adopting a reflexive and heuristic approach made me approach the data collection with
an open mind, hence navigated this process reflexively (see for instance section 4.6.4
detailing how interviewing was approached). I was aware that I had some preconceived
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perceptions of scientists and the Kenyan regulatory process (having been part of it for
eight years), but I sought to keep these out of the research process, endeavouring instead
to learn from the field.
It is important to note at this point that throughout the research process, varIOUS
components co-evolved: the theoretical perspectives informing this study, the field work
and data generation, and writing to eventually come up with the final thesis. The
process of data collection, review and analysis continued even during the writing
process. For instance, during the final stages of writing up, I continued to gather and
review additional data based on identified gaps and new insights, which were integrated
into the research analysis. Further, the writing process continued to be informed by
controversies surrounding the biosafety bill, which intensified after the fieldwork."
4.4 Review of methods used in studies concerning perceptions and
practices of scientists
The contested context that confronts any research related to controversial technologies
like biotechnology has already been mentioned elsewhere. This section looks at specific
previous work related to scientists' attitudes and practice towards biotechnology
innovation with a focus on subjects relevant to this study. In general, there are very few
empirical studies in these areas (scientists' perceptions and practice). Some are
discussed here with a view of locating the strengths and weaknesses, which informed
the methods selected for this study.
Previous work has shown that scientists differ in their perceptions related to risks and
biotechnology (see Chapter three, sections 3.4.3 & 3.6.3). Several reasons have been
attributed to this ranging across organisational affiliations, public perception of science,
political and scientific values and the different meanings attached to the framing of risk
41 The biosafety bill development process continued to receive a lot of attention from the public front even after
fieldwork (see Appendces 7 & 9).
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and benefits of GE science. The methods applied in these empirical studies have ranged
from questionnaires and surveys (Lynn, 1986; Rabino, 1991, 1994), as well as
interviews (Lynn, 1986; Scott, 2005; Cohen et al., 2001; Harsh, 2008). It is not very
clear though how the methods adopted in these studies could have influenced the
reported findings. However, in depth interviewing has been proved to be a useful
instrument in the study of scientists' belief systems when compared to the other
methods due to its ability to elicit detailed views of interviewees (Scott, 2005).
Regarding scientific practice, very few empirical studies have been conducted in this
regard. Some relate to scientists' experiences as they adapt to new working
environments demanded by the new sciences as well as the changing research-funding
scenario (Waterton, 2001, 2005; Cohen et al., 2001). Both these studies involved UK
scientists but no such research has been conducted in the African context. Even more
important but neglected aspect is the scientists' practice in the regulatory policy-
making. From the Kenyan context, Harsh (2008) through interviews demonstrates how
and why NGOs scientists get entangled in the politics of biotechnology and biosafety
policy-making.
Even with inadequate empirical studies on this subject (scientists' perceptions and
practice), it is now clear that developing countries have limiting contextual issues like
the relative different roles of actors and institutions (government and non government)
that drive biotechnology policy processes (Harsh, 2009; Mugwagwa, 2009; Smith,
2009; Newell, 2002; Scoones, 2002). Despite this knowledge. it is not clear how these
contextual issues may be factored into the methodology. This notwithstanding, the
empirical studies reported here used interviews, which yielded important data related to
perceptions and practice of actors. Consequently, the in-depth, semi-structured
interviewing (among other methods) was considered to be an important method for
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studying the perceptions and practice of Kenyan scientists related to the biosafety
regulations and implementation.
4.5 The context of the study
The preceding sections outlined the basic approaches that informed the research design
and the line of enquiry and in so doing tried to locate this research in the broad
qualitative research approaches. The personal background reinforced these approaches
thus justifying the interdisciplinary and integrated approach adopted in this study. This
section describes the process of data generation starting with the rationale for selection
of the study context. This is followed by the methods employed to generate these data.
4.5.1 Choice of tile study context
To generate rich data pertaining to scientific community's real experiences in the
implementation of regulations related to biotechnology as a new science, there was need
to target a setting that would enhance this. Maxwell (2005) emphasises the importance
of focusing on aspects that are data rich in qualitative research. The "biosafety
regulations implementation" was perceived to be an invaluable process through which
rich data could be generated. In addition, it was important to select participants who had
a stake in this process. Based on this, the rationale for selecting Kenya as a study area
and biological scientists as main participants was based on several factors:
i. There is a significant body of literature on the Kenyan regulatory policy
process that informed the problem statement. This literature reveals that the
establishment of the Kenyan biosafety regulatory regime had become
controversial (Sander, 2007; Harsh, 2005, 2008).
11. Prior to and during the field work, the selected participants were actively
engaged in this process in various ways (pilot study undertaken in Dec 2006 to
Jan 2007; mass media reportage).
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lll. Kenya is perceived to have advanced both in tenus of OE research and
development (R & D), and progress made towards establishment of a biosafety
regulatory regime (Nang'ayo, 2007). This factor further strengthened the
rationale for preferring scientific community because at the period of this
study, no GE product had gone beyond research stage implying that the other
stakeholders (like fanners or consumers) had marginally been involved in its
deployment.
iv, Kenya is host to many non-state organisations (NOOs) perceived to be pro-
biotechnology (Harsh, 2005, 2008; Sander, 2007). This factor made it possible
to further expand the scope of interviewees to include scientists fromNOOs.
v. Familiarity with the research terrain (see section 4.2) was perceived to be an
advantage in tenus of access.
Having selected Kenya as the study area (and biological scientists chosen as main
participants discussed further below), the fieldwork was carried out from 1st October
2007 to 15th April 2008.
It is important to report that the fieldwork coincided with the general elections in late
2007 and there were incidents of extreme political skirmishes, sparked by disputed
elections results. This caused a minimum delay in the data generation process.
4.5.2 Participants selection
This study relates to how the scientific community view the biosafety regulations
implementation and how they behave or react towards this process. In this regard,
representativeness was paramount [the representativeness of the process (biosafety
regulations implementation) and of individuals likely to be articulating or heavily
involved in this process at that particular point in time (R & D stage of biotechnology
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activities and the formulation of biosafety regulatory instruments)]. Consequently,
selective sampling was preferred (Maxwell, 2005) since random sampling would not
have acquired this objective. For instance, only a small proportion of academic, policy
and NGOs scientists are involved in GE research and biosafety regulatory work. In
addition, heterogeneity within the scientific community as well as establishment of
possible comparisons or divergences amongst them was important.
Interviewees were therefore purposefully selected ranging across practitioners, policy
makers, academics and civil society. Snowball sampling also happened later during
fieldwork after previous interviewees recommended other participants. In addition, the
fieldwork coincided with a period when the public was debating the biosafety bill. Thus,
statements issued through media provided a link to interviewees who seemed to be
opposing the process. Consequently a total of 42 participants, who have been involved
in biotechnology research and biosafety policy-making in their various capacities as
biological scientists and as non-scientists were selected (Table 6). They were also
affiliated to organisations that have (or claim to have) a stake in modern biotechnology
and biosafety arena. They include key senior officials in the NGOs circles, public
research and academic institutions, regulatory organisations and government ministries,
and biotechnology R&D coordinators and principle investigators (see Appendix I for
the detailed list that captures the institutional affiliations and professional backgrounds).
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Table 6: Research participants
Categories of participants Participant code Institutes/org No.
1 GE Practitioners (GP) are (or have previously)
engaged in GE activities. Some in the
interviews claimed to be passionate about GE
work. The professional profile information
supports this claim as well as institutional
documents.
RSPu-GPl, RSln-GP2,
RSln-GP3, RSPu-GP4,
RSAc-GP5, RSPo-GP6,
RSPu-GP7, RSPu-GP8,
RSln-GP9
Public research,
public universities
and international
organisations.
9
2 Policy Scientists (PS) are either senior
government officials, biological scientists in the
NBC andlor IBC and regulatory institutions.
The senior government officers are (or have
been heads of government institutions or
ministries). The scientists in the NBC and IBC
are generally from public academic institutions,
regulatory agencies and one international
research organisation. Some of them are
affiliated to other professionally related
institutions. Participants in this group are all
connected to GE research in one way or
another.
BIp-PS I, ARp-PS2,
ATp-PS3, PRp-PS4,
ATBp-PS5, RSIn-
PS6, RSPu-PS7,
RSPu-PS8, ARp-PS9,
PRp-PSIO, BIp-
PSI I, FSp-PSI2,
BIp-PS 13, ABp.
PSI4, ENp·PSI5,
ARBp·PSI6
Government
ministries, public
universities,
international research
institutes, regulatory
agencies and public
universities.
16
3 Non State Scientists (NSS or NGOs) belong to
non-governmental organisations with a stake in
biotechnology activities. They are backed up by
their biological science background.
TAR·NSS1, TAN·
NSS2, TRTp-NSS3,
TAN-NSS4, EPA·
NSS5, TAD-NSS6
International &
regional
organisations, NGOs
& donor agencies.
6
4 Non-Biologists Scientists & Non-Scientists
(NS). Participants in this category are spread
out in civil society, lawyers, journalists,
biotechnology industry and funding
organisations and include social scientists.
Total
NGOf-NSl, NGOf·
NS2, NGOcs·NS3,
NGOco·NS4,
NGOco·NS5, JO-
NS6, JO-NS7,
LABp-NS8, LAEp·
NS9, TAI-NSlO,
TAD-NSll
Government legal
arm, civil society,
farmers & consumer
associations, media,
industry and donor
agency.
11
42
By and large, prior interaction with majority of the participants facilitated access to
individual interviewees and detailed information about the scientists and their working
environment. Maxwell (2005) argues that this sort of familiarity with research
environment may be both advantageous and disadvantageous to any qualitative
research. I acknowledged early at the design of the project that this prior relationship
with participants could have a negative impact on the research findings, resulting in
critical reflection, while paying attention to the potential "researcher's bias" or
"interviewees' reactivity" that could have affected the reliability of the findings
(Maxwell, 2005:}08-}09). Maxwell further notes that this reflection and resultant
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flexibility can be productive since emerging insights can be used to revise research
design or generate different types of data (Ibid, :81).
This study required me on the one hand to have a unique relationship with the
participants, different from the regulator-scientist "policing" relationship. On the other
hand it required me to understand the perspectives of the participants without bias, as
well as encourage an environment that would enhance trust and minimise suspicion.
This was accomplished through; one, explaining the purpose of the research; and two,
establishing a "researcher-respondent partner" kind of relationship (Maxwell, 2005). I
emphasized that it was important for them as respondents to be candid about their
experiences as co-partners in this research study (see section 4.2). In addition,
triangulation enhanced validity of research process and findings as discussed next.
4.6 Data generation and triangulation
This study focused on both the perspectives and behaviour of interviewees related to
regulations implementation. The "what" "why" "how" and the "so what" nature of the
three research questions had to be tackled (Chapter one, section 1.2.1). Subsequent
methods were therefore selected based on this. In view of this, the research approach
considered a variety of sources and methods, endeavouring to gain broader and more
secure insights of the participants and their experiences as well as experiences of others
in the biotechnology and biosafety arena. It was important therefore to adopt methods
that could allow views of participants to come through explicitly by applying
triangulation in form of both data generation instruments and data sources. According to
Denzin and Lincoln (2005), triangulation adds rigour, breadth, complexity, richness and
depth to an inquiry. In this study, different methods and instruments were applied to
reveal diversities and similarities in perceptions hence increasing trustworthiness and
enhancing in-depth understanding of perspectives of participants.
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4.6.1 Data generation
Various sources of data were used (three categories of scientists; non scientists; field
notes). The four categories of participants therefore enhanced validation of accounts
across these groups in order to expose areas of agreements and disagreements. Field
notes were captured through informal and formal gatherings, informal observations and
casual conservations, organisational documents, mass media reportage, policy
documents, correspondences between ministries and government departments, and
statements from policy makers.
In addition, the data were also collected using multiple data generation instruments.
For instance, data from participants was collected through formal interviewing
alongside other informal activities that included, attending scientific and policy fora,
reviewing scientific and policy related publications, and review of presentations made
by scientists and policy makers during various local conferences. By participating in
formal and informal gatherings organised by the scientific community, I engaged in
casual conversations and sometimes incidental observations. This way, I made
descriptive field notes that provided crucial contextual information.
Multiple methods and multiple sources of data further enhanced credibility and
accuracy of the findings, minimising potential limitations likely to emerge while using
one method (Maxwell, 2005:94).
4.6.2 Observations
Formal or informal observations offer a direct contact with the participants and the
settings in which the research is being undertaken (Patton, 2002). Patton further argues
that this has various advantages ranging from encounter with the real setting,
understanding the order of interactions, noticing the taken for granted things, learning
things that are concealed during interviews, and the researcher forming personal
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impressions that enhance reflection during the data analysis (Ibid, :261-264).
Hammersley and Atkinson (2007) further reinforce this argument by noting that even
studies that use interviews as the main method still employ observational methods to
note the body language and other gestures that are consequently linked to what the
interviewee is saying. Further as Angrosino observes, observation in social science is
perceived to be "a convincing form of verification" (Angrosino, 2005:730).
There are different types of observations. Yin (2003) for instance talks of direct and
formal observation. Although in a formal observation (or participant observationj.V one
is expected to have a long-term involvement with the participant, this study
concentrated on direct observation during a fieldwork period that lasted about six
months. Thus, the direct observation involved focussing on specific activities
undertaken by the scientific community related to the regulatory process.
I participated in several biotechnology and biosafety fora and institutional meetings that
I was invited to attend." This opened up opportunities for observing the participants
face to face and in their active environment (practice). Consequently, I made notes of
the undertakings related to; who, when, and where, including the context under which a
particular behaviour was being exhibited (Angrosino, 2005). For instance, a breakfast
meeting I attended involving pro-biotechnology NGOs scientists, policy scientists,
industry and practising scientists (most happened to be target participants) discussed
rhetorical strategies that could be adopted in engaging the government and the
parliamentarians towards the enactment of the controversial biosafety bill.
42 Although this is discussed in the context of case studies, Yin (2003:86, 92-96) gives a distinction between direct
observation and participant observation. For the former, opportunities for observation tend to be informal as one
visits the "site" while in the latter case, the researcher assumes an active role within the case being studied. Both have
strengths related to "covering reality in real time" and are "contextual."
43 For instance, Codex meeting on labelling ofGMOs on IS Nov. 2007 at KEBS headquarters, Nairobi; Various
OFAB meetings between Oct, 2007 & Mar, 2008, in Nairobi; BiotechnologylBiosafety Consortium Meeting of 5
Dec. 2007 held at MOA headquarters, Nairobi; BiotechnologylBiosafety Consortium meeting of3 Apr. 2008
organised by ABSF at Panafric Hotel; KEPHIS & KEBS GMOs meeting on 22 Nov. 2007 at KEBs headquarters,
Nairobi.
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Consequently, personal observations captured how the scientific community engage in
negotiations related to policies that are of interest to them, their motivations as well as
gaining of understanding about the practical Kenyan biosafety legislative process.
Differences between the different groups of participants were noted in a way that could
be linked to previous or subsequent interviews involving some of them. Sometimes
subsequent interview questions were guided by the impressions and information
obtained from prior observations. Permission to be part of these fora was a good sign
that the participants had no suspicion related to my being present.
Direct observations were also undertaken during interviews, basically paying attention
to the details of the interview setting and consequently recording this. This was actually
provided for in the interview guide (see Part 1 of Appendix 2).
Patton (2002: 274) notes that the duration of observations largely depends on the time
and resources available to the researcher. Time was a limiting factor in this study and
therefore actual, long term participant observation could not be achieved. This was
further complicated by the fact that all the participants were spread out across different
organisations, thus difficult to get one suitable case study representing the different
categories of scientists.
4.6.3 Documents
Documents are important sources of data (Bryman, 2004:381-397). Yin (2003:86-87)
argues that documents can be used to validate and complement evidence from other
sources. In this study, various documents were used at various levels, either before
fieldwork, during field work or after fieldwork. They augmented observations and
interview data with regards to the dynamics of biotechnology and biosafety process in
Kenya. The documents were bringing out interesting insights related to the behaviour of
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scientists, their role and other actors' role in the regulatory process. They were therefore
serving the complementary, validation and corroboration purposes.
This research is also about implementation of biosafety regulations. In view of this,
several documents that charter and direct this process through the guidance they give to
policy targets, policy makers and regulators were extensively consulted and reviewed.
These include: the regulations and guidelines of 1998 & 2003, the biosafety bill, 2008
including a counter parallel bill (the biotechnology and biosafety bill, 2008) originating
from the civil society, the biotechnology policy, 2006, the manual for inspection and
monitoring of GMOs in Kenya, the draft regulations for conduct of field trials among
other policy instruments (see Table 8 & section 5.2 in Chapter five). Other documents
included media reports (see Appendix 9 for a summary of key reports), other relevant
Acts of parliament like EMCA Act, 1999, official reports and proceedings of
government and public deliberations, correspondences between institutions, publicly
available scientific reports or testimonies, parliamentary debates on biosafety bill,
organisations or government departments brochures, newsletters and profiles. Some of
these reports are available from various websites while others were obtained during
fieldwork from various sources including the participants themselves. Caution was
taken to establish confidentiality status in order to guide their subsequent use.
Emphasis was given to the quality of the documents in order to address the issue of
credibility and potential bias related to the source (Bryman, 2004). The issue of
authenticity was taken seriously and during the interviews, certain documentary
evidence was discussed with key participants as a way of validation. However, it was
understood that documents would not provide objective accounts of the status quo and
therefore they were analysed in the context of other sources of data.
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4.6.4 Interviews
Interviews were conducted in Nairobi, and a few in the outskirts of Nairobi between
October 2007 and March 2008. The fieldwork coincided with a period when the
biosafety bill was being debated in parliament and there were increased media reports
from both the anti and pro groups related to the bill and its formulation process (see
Appendix 9). This became a key subject that was passionately discussed by all
participants during the interviews.
4.6.4.1 Ethical considerations
Prior to fieldwork, the Open University Ethics committee approved this research.l" It
also received approval from the Ministry of Education, Science and Technology in
Nairobi, Kerrya." The first approval required that interviewees consented to being
interviewed and recorded in addition to making the purpose of the research known prior
to the interviews. Participants were provided with the option to withdraw at any point in
the interview process or to decline to comment. This was provided for in the consent
forms and letters of introduction sent to them prior to the fieldwork (see Appendix 3).
All the interviews consented to being interviewed and being recorded, however, only 37
signed the consent form. In the consent form there was a provision for anonymity. Most
interviewees preferred their identity to be concealed during report writing, unless where
they would be given an opportunity to approve the content before hand. Some
categorically expressed their wish to have the organisations they worked for not linked
to their expressed views. A few interviewees requested either the audio recorder to be
switched off at some point, expressing their wish to have certain opinions not being
made public. In reporting the findings, the identity of the interviewees has been kept
confidential but I cannot eliminate the risk of forming an opinion about the interviewees
44 Ethical approval reference HPMEC/07/#339/1 dated 26 Sep. 2007.
4S Research Penn it No. MoEST13/001l37C 728 dated 26 Oct. 2007.
105
as a result of the findings (partly because of my previous professional status as a
regulator).
4.6.4.2 Interviewing process
Interviews are of many types ranging from structured, semi-structured and open-ended
(Rubin and Rubin, 2005). They may also take the form of face-to-face verbal
exchanges or one-to-one telephone conversations. One-to-one, in-depth semi-structured
interview approach was employed in this study. As some authors have noted, in-depth
interview provide a flexible and adaptive approach to situations and context of
participants, checking against the researcher's pre-conceived biased ideas (Gubrium and
Holstein, 2001; Rubin and Rubin, 2005; Robson, 2002). This strength differentiates in-
depth interviews from other data generation methods. This has many advantages that
include increased reliability and validity. Semi-structured interviews begin with a pre-
determined set of questions, but allowing flexibility as interviewing progresses.
A theoretically informed interview guide was prepared prior to the fieldwork, tailored to
each group of participants (GE practitioners, scientists in the policy & regulatory arena,
NGOs and biotechnology industry, and the civil society). This interview guide as much
as possible captured the main thematic areas surrounding the biosafety implementation
process. These thematic areas included (and not limited to) perceptions of the following:
GE technology, regulatory policy and approval process, biosafety risk related to field
trials, scientists' role in the policy process and stakeholders' engagement in the policy
process (see details in Appendix 2; part 2). Adjusting of the themes was possible
because of the semi-structured nature of the questions (Rubin and Rubin, 2005:129-
151). Consequently, the interview guide was later adjusted reflexively to accommodate
each individual, after adequate information related to them or their affiliated
organisations was gathered.
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Forty-two participants were involved in this study. Consequently, forty-two interviews
were conducted at venues that interviewees found convenient that ranged from offices,
restaurants and in one case, inside the car. They were all recorded using a digital audio
recorder. During the interviews, flexibility was enhanced through allowing the
interviewee to guide the process in what Gubrium and Holstein (2001: 111) describe as
"moving with the flow" which permits eliciting of productive and sometimes
unexpected information. I only came in to confine the process to the anticipated scope
to avoid potential deviation from the study focus.
The interview guide provided the guidance needed, but follow-up questions and probes
were asked. Follow-up questions were guided by comments made by the interviewee
while probes were to request for clarifications or emphasis of what was said regarding a
particular issue. This enhances "depth, detail, vividness, richness and nuance" (Rubin
and Rubin, 2005:129). As Rubin and Rubin further assert, interviewing skills are very
important in achieving this depth. The pilot study conducted in Dec 2006 to Jan 2007
was essential and enhanced the interviewing techniques applied in this study.
Interview sessions lasted between 30 minutes to two hours mainly based on the
interviewees' availability.i" Prior to the interview or immediately after each interview,
observational notes were made, detailing the interview setting.47
To further enhance reliability and credibility of each account, prior to each interview
session, it was made very clear that the research was being undertaken as part of a
doctoral project and that it had nothing to do with KEPHIS. This was to reinforce the
emphasis made in the invitation/information letters (see Appendix 3, third letter) sent to
interviewees prior to fieldwork.
46lnterviews with the GE practitioners and policy scientists took longer than the interviews with the other groups of
interviewees. This is because there were practice-related questions that were pertinent only to them. By and large. the
~uestions tried to elucidate the perceptions of the interviewees regarding the interview themes.
4 The notes included the perceived response and reaction to the questions where appropriate.
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Although this resulted into relaxation, some interviewees had a lot of expectation from
this research. This is because majority of the pro-biotechnology scientists have been
critical of the regulatory process (revealed through literature and pilot study) and
therefore welcomed the study with a hope of the findings informing and consequently
impacting the process in tenus of efficiency. One interviewee who plans to put up an
application for GE sorghum remarked:
"We want you to evolve [change} in terms of regulating us [those interested in
GE research in Kenya} ........please I will ask you to advise KEPHIS to please
build the regulatory capacity for sorghum." (TAR-NSSI, researcher &
technology advocacy, international NGO, Feb. 2008)
Despite the measures taken to enhance reliability, assumptions were not made regarding
any potential bias. As Robson (2002: 173) notes, even if biases are acknowledged, they
are culturally embedded and may not be done away with easily. In view of this, this
research gave careful attention to the data generation, triangulation and analysis process.
In this regard, my being a biological scientist and having been a regulator as well as
having interacted with interviewees previously, was therefore not a validity threat to
findings and conclusions of this thesis.
4.7 Data analysis
This far the chapter has described the general methodological approaches and how
particular methods were selected and operationalised to eventually generate the data.
This section now turns to the process of data analysis, discussed in details to
demonstrate how this study is grounded in the participants' accounts of their worldview
(inductive).
The data analysis adopted a thematic approach. As Braun and Clarke (2006) observe,
thematic analysis is a method of identifying, analysing and reporting patterns within
data. Fereday and Muir-Cochrane (2006: 4) hold similar views, arguing that it involves
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"careful reading and re-reading of the data, a form of pattern recognition within the data
where emerging themes become the categories for analysis". This process is described
and elaborated further below in section 4.7.2.
Cognitive mapping was also used as a data organisation and analysis tool thereby
presenting the views and actions of participants in a form that is amenable to analysis
for potential implications related to practice and possible policy recommendations.
4.7.1 Deductive and inductive process
The literature review prior to fieldwork and the prior knowledge of the study context
enhanced the development of a theoretical framework and scope for this study that
comprised of particular objectives and research questions (see Chapter one). In other
words, this framework provided a boundary within which the data generation and
analysis was confined. It can therefore be said that this initial literature and the context-
led framework building adopted a deductive process. Further, insights that informed the
conceptualisation of data during fieldwork constituted the beginning of data analysis
and formed part of the record of field experience (Patton, 2002: 436). For instance, all
the interviews were concluded with an analytical section referred to as "observational
notes" that described the interview setting. This implies that data analysis commenced
early, adopting an iterative practice with early decisions being informed by the research
design, while the later analysis stages consequently being informed by data (Maxwell,
2005: 95).
As illustrated further below, coding adopted both inductive and deductive approach.
Indeed, the entire data analysis process was both deductive and inductive as
recommended by some scholars who favour this approach. Patton (2002: 437) for
instance suggests that analysis should be guided by research question on the one hand
and insights and interpretations that emerge during data collection on the other. Foss
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and Waters (2007) also recommend a similar approach, but they caution against
interpretation of the approach as theory-led as opposed to a way of organising the data
analysis process.
4.7.2 Thematic coding
All the audio recorded interviews and conversations were transcribed verbatim. The
field notes and selected documents were re-read and organised such that sections of text
concerning themes of interest related to implementation of biosafety regulations and
practices of scientists were identified. At the early point of listening to the recorded
interviews with the help of the digital voice editor 2, and the reading and re-reading of
the notes or transcripts, notes were made for future reference in later data analyses.
These notes consisted of early thoughts of what the data was revealing. These early
activities signalled the commencement of the thematic analysis by reading and listing
the patterns from transcribed data and the texts from field notes or documents.
Because the data generated were large, I devised a way of coding, bearing in mind that
the objective was to organise the data in a form that is amenable to categorisation based
on commonalities, differences or relationships (Patton, 2002). This was achieved
through the help of the NVivo 8 software.t'' Transcripts from interviews and texts from
documents and field notes were entered as "sources" in the internals of this programme.
These "sources" aided in the initial organization and management of the data based on
the different groups of participants (organizational categories). With the data coded and
refined based on participants categories (see Appendix 4), the 1st level (open) coding
was inductively undertaken, guided by issues that participants were critical about and
why. These were closely linked to the units of analysis derived from the research
questions (e.g. perceptions of regulations). Various distinct categories (or labels) were
48 NVivo 8 (2007) provided by QSR International apart from aiding in data organisation also facilitated retrieval and
easy access to the large data coded from all the sources. With this software it was possible to play around with
excerpts by importing or merging. based on commonalities or disparities.
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identified from this open coding and because they were very many, further revision of
the first framework was done leading to merging of categories/labels based on the
descriptions that unified them. Consequently, the labels given to specific codes reflected
the characteristics they shared. This approach is similar to that described by Foss and
Waters (2007: 185-215).
Further coalescing of the labels was done using insights drawn from Patton (2002:439),
who emphasises the importance of "processes" as an organising principle. This study is
about processes; "implementing regulations", so processes became a data organizing
principle. Through this approach, processes-related themes were generated. For
instance, the label/category that organised codes that described "policy process and
implementation" revealed processes like "participating or engaging in the policy
process." From these processes-related themes, a 2nd level advanced coding resulted
into data-led themes following the thematic coding approach applied by Fereday and
Muir-Cochrane (2006). This advanced coding generated sub-themes that succinctly
described the scientists' perceptions, revealing the issues they were concerned about
regarding implementation of biosafety regulations, and reflected the language used by
interviewees. At this stage, it was possible to establish commonalities or shared
perspectives as well as relationships and linkages between the codes, labels and
categories; both within and across interviewees' groups. This enhanced further
generation of main themes that formed the basis for data presentation. Appendix 4 is an
illustration of how this interconnection was achieved using only one sub-theme
(perceptions of regulations) as an example.
Although the categories identified in the first level open coding were critical in
subsequent analysis, care was taken to ensure that the coding process continued to be
guided by data. This being the case, constant reference was made to the raw data, the
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excerpts attached to these labels and at times re-listening to selected interviews.
Excerpts from data that clearly explained the meaning behind the main themes were
recorded and used in creating an explanatory schema guided by insights from Foss and
Waters (2007: 196-215).
4.7.3 Cognitive mapping
Cognitive mapping technique was used in a limited way as an additional analytical tool
to achieve two aims. One, in generating visual aids (maps) thus illustrating
commonalities and differences on how ideas (concepts) were interpreted by the
scientific community. Two, it facilitated the establishment of relationships (visual)
between scientists' perspectives about the regulatory process and practice. The concepts
obtained from coding of the empirical data were used to visually display how
participants interpreted different regulatory issues and the actions they took towards
dealing with them. The Decision Explorer software'" aided the generation of the maps
(see the generated maps in Chapter six, section 6.4).
Cognitive mapping describes the method of representing ideas as well as relationships
between them in a visual form and the process can be applied to individuals as well as
groups (Huff, 1990 cited in Scott, 2005). This concept originated from Kelly's theory of
personal construct, which argues that "we make sense of the world in order to predict
how the world will be in the future, and to decide how we might act or intervene in
order to achieve what we prefer within that world" (Kelly, 1955 cited in Eden and
Ackermann, 2004:616). This implies that the individual actors, inspired by their belief
systems, expertise and values can take control in the way they perceive, construct, or
make decisions about what kind of action to take regarding a particular problem (Swan,
1997: 185). Consequently the way individuals think about a particular issue is the focus
49 This tool enhances management of the maps associated with complexity of handling many concepts (see
www.banxia.com).
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of the mapping techniques and can be achieved through interviews or analysis of
documents (Eden and Ackermann, 2004:616).
According to Eden (2004), the visual maps generated through this technique represent
the subjective world of the actors and because they are amenable to analysis, they have
a policy orientation. This means that they can inform further work on the problem at
hand since they are not only visual diagrams of the actors' description of their
worldview, but "interpretations of what is meant by the interviewee" (Eden, 2004:675).
Eden and Ackermann (2004) further reinforce this policy analysis claim, arguing that it
is possible to pose the question "so what" which can result to possible policy options
and in turn, devise or suggest strategies for addressing these policy options. What is not
immediately clear from the visual maps generated in this study is whether the actions
the participants took are positive or negative for the overall goal (moving GE
technology forward from research stage to products). It is however possible to pursue
the implications of their action towards policy recommendations in the light of
controversies linked to GE technology (see Chapter eight).
Although this technique is popular in management research, use of cognitive mapping
tool in this study was inspired by work of other researchers in the field of technology
innovations. Swan (1997) applied the tool to demonstrate importance of cognitions in
decisions about technological innovation in information technology. Through this tool,
the nature of an innovation process in relation to knowledge structuring and decision-
making could be established. She emphasises that a distinction ought to be made
between cognitive maps and the output of cognitive mapping technique. The latter
"describes a set of techniques that are used to try and identify subjective beliefs and to
portray these externally" while the former is the outcome of the mapping technique
(Fiol and Huff, 1992 cited in Swan, 1997). Levidow et al. (1999) applied the tool to
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reveal cognitive elements from interviews undertaken with people involved in GM
regulation in Britain. Chataway (1992) and Chataway and Tait (1993) applied the
technique for data collection, analysis and presentation in a study looking at managers'
strategic options in management of biotechnology firms. Scott (2005) used the
technique to analyse the contrasting views of UK scientists regarding GM debate.
4.8 Validation and reflections during data generation and analysis
The previous sections have covered explicitly all the methodological aspects related to
data generation and analysis. However, there are clear challenges that confront this type
of research. These include issues of validity, reliability and generalisation of data. These
challenges were tackled in various ways but the objective was to enhance credibility of
the research findings. This section summarises certain issues that I reflexively reflected
on, related to the data generation and analysis process in the context under which this
research was being undertaken.
As interview process proceeded, adjustments were made to enhance capturing of
emerging issues in the subsequent interviews. The interview guide was previously
tailored to each category of interviewees based on their affiliate organisations (or
employer) and background information obtained beforehand. This was found
unsustainable and was revised as interviews progressed. Gubrium and Holstein
(2001: 113) argue that deviation from the original research plan is an important attribute
of a skilled interviewer and it reveals new information that may have been taken for
granted. The final categorisation of interviewees presented in Appendix 1 was therefore
shaped by the progressive outcome of the data.so
so See for example RSln-GP9 working for an international NGO and fitted earlier as an NGO scientist but regards
himself as a GP practitioner and responded to questions as a researcher. ARBp-PS 16 who was initially categorised as
GP scientist for being an active plant breeder responded to questions as a policy scientist, backed by her position as a
member of both an IBC and the NBC.
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The overall objective of this study was to generate a portrait of the regulatory policy
process and the role of scientists from the perspectives and accounts of the scientific
community. The meanings they attach to the process and the ensuing action may seem
as given, but trying to make a connection between the views and action is difficult. This
is because there are contextual factors that were at the heart of data interpretation
process. For instance, we cannot rule out the influence of the organisations that the
participants work for, on opinions they expressed. Mostly, the interviewees made
explicit the distinctions between their views and those of their respective employers. So
it became important to cross-reference their views with the mandates of the
organisations they worked for. To further ground this research in the interviewees'
worldview, the in-depth semi-structured interviewing combined with observations,
documentary research and validation from selected non-scientists enhanced reliable
conclusions on the nature of the regulatory process and the role of the scientific
community in this process.
As would be expected, there were methodological limitations linked to time constraint.
For instance, validation of research process by having other players (e.g. other
researchers and participants) commenting on the themes or visual maps emanating from
the data was not done. However to ensure that the interviewees were aware of
interpretations emanating from analysis of data, three presentations were made at
conferences in Kenya which allowed opportunities for further comments by the
scientific community.t' Other data dissemination channels are being explored.
SI aAgricultural biotechnology Innovations Policy in Kenya. KARl Biennial Science Conference and 3rd Agricultural
Forum: "demand-driven agricultural technologies for sustained production", 10-14 Nov. 2008, Nairobi, Kenya.
olowards a smart regulation: the case of Kenya. l" All African Congress on Biotechnology; Harnessing the
Potential for Biotechnology for Food Security and Social-Economic Development in Africa", 22-26 Sep. 2008,
Nairobi, Kenya.
aCan horticultural scientists do things differently in the changing knowledge production terrain? Lessons from
biotechnology innovation system. )It all Africa horticulture congress "grown under the sun", 3) Aug. - 3 Sep. 2009,
Nairobi, Kenya.
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Overall, the contextual Issues underpinning the aspects of this study (biosafety
regulatory process and the scientific community as knowledge and innovation
communities) therefore called for a reflexive and interdisciplinary research approach.
Care was exercised as described in the chapter to ensure that the methodology meets the
accepted rigor and credibility expected of this kind of qualitative research.
4.9 Concluding remarks: linking data to theory
The preceding sections discussed in detail the process of data generation and
preliminary analysis. This early process enhanced presentation of an explanatory
schema, which is the substantive subject of the chapters that follow. However, data
analysis is incomplete until data is situated in the appropriate more abstract theoretical
disciplines relative to the study's research questions (Bryman, 2004:497). Theoretical
insights discussed explicitly in Chapter three have largely contributed to the emerging
storyline presented in the next theory-building chapters of the thesis.
Meanwhile, Table (7) below presents a summary of methodology adopted in this thesis
to study perspectives and practices of the scientific community in Kenya related to the
implementation of biosafety regulations. It summarises insights drawn from literature
and their limitations for this research.
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Table 7: Summary of previous knowledge insights and their limitation for this
research
CHAPTER SUMMARY
Issue Previous knowledge Input for Limitations for this research
this study
Previous -There are limited empirical studies -Available cases expose methodological challenges in
knowledge on scientists' belief systems and that they have used survey, questionnaires and
regulatory practice in agricultural interviews methods for data generation in an implicit
biotechnology sector. way (not collectively).
-A wide body of literature in -These studies are not specific to regulatory policy-
science & technology studies and making hence limited knowledge on best and
governance of new sciences appropriate methods.
provided early insights and lessons -They are also not clear on how controversies in
that shaped the research process. biotechnology regulatory policy process impact
methodology.
Methodological Qualitative, reflexivity and heuristic -To operationalise these concepts encouraged
approaches concepts useful in qualitative interdisplinary approach which presented challenges.
research. Thus, to remain focussed, only basic and few features
in qualitative approaches were used.
Methods & Multiple methods of data collection -None stand out alone to be able to withstand validity,
sources of data (e.g. in-depth interviews, reliability and generalisability.
documents and observations) & -This thesis required a principled mixture of many
multiple sources of data (e.g. methods.
scientists, non-scientists and field Large data were obtained from secondary
notes) increase reliability and interviewees (non scientists) that mainly served a
validity of data based on their validation purpose.
strengths.
Data generation This process requires skills and The process was influenced by unplanned prevailing
careful planning. circumstances and previous plans had to be re-
adjusted. For example, the biosafety bill was being
discussed then, which became a key theme in the
analysis thus perhaps masking other regulatory
themes.
Data analysis -Deductive and inductive thematic -Large data were generated resulting into time
analysis enhances a focused and consuming and data management challenges.
data led process. -Thematic coding is a rigorous process and there was
-Computer assisted coding helps in a limit to the use of the NVivo software.
data management and organisation. Consequently, merging of categories was done
manually for the process to remain manageable,
focused and productive.
The limitations exposed in this table and how they were tackled are factored in the
entire thesis. To commence the journey involving the blending of empirical data and
theory, the chapters that follow take us to the presentation of results obtained through
the methods and knowledge described in this chapter.
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Chapter Five
5 Perspectives of Scientists on Regulations and
Regulatory Practice
5.1 Introduction
This chapter presents the research findings that address the first research question: the
perspectives of scientists about regulations implementation and explanations supporting
these views. The chapter is organised around the dominant themes that emerged from
data coding and analysis. It is structured as follows: Firstly, the main regulatory
instruments used as a benchmark in this thesis are reviewed. Following this, views
regarding the nature of regulations are explored. Thirdly, the identified approaches to
decision-making process pertaining to the regulatory process and related challenges are
discussed. Lastly, the dynamics surrounding the formulation of the biosafety bill as a
desired regulatory instrument are analysed.
5.2 Review of biosafety regulatory instruments
Regulation is a component of governance that is about steering the flow of events and
behaviour (Braithwaite et al., 2007). Regulatory instruments on the other hand empower
decision making bodies in order to guide the steering process (Andanda, 2006).
Biosafety regulations prior to the enactment of Biosafety Act 2009 (RoK, 1998 and the
revised version RoK, 2003b) and the Act (RoK, 2009) are the official regulatory
instruments used in the biosafety decision making matters and evoke some form of
authority. However, there were other supporting instruments which were widely
referred to by the interviewees in view of the concerns they elicited during
implementation. All these regulatory instruments put together serve as benchmarks in
interpreting the accounts of the interviewees related to regulations and regulatory
practice. They are therefore analysed in the next subsections based on data-led
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organising themes identified during coding which include the scope in terms of
regulatory aim, approaches to risk assessment (RA) and decision-making processes.
5.2.1 Cartagenaprotocol
This is an international legally binding instrument providing guidance for cross-border
handling of Living Modified Organisms (LMOs). As alluded to in Chapter two, it is the
main motivation for most of the national efforts to establish a biosafety regulatory
regime as an implementation obligation, Kenya being a signatory.
The protocol focuses on risk assessment (RA), risk management (RM) and risk
communication (RC). RA refers to identification of potential environmental adverse
effects or hazards; and determining when a hazard is identified, the probability of it
occurring. RM refers to mitigation measures instituted to minimise the potential hazards
identified using science based RA protocols.
The decision-making process pertaining to LMOs is based on an Advanced Informed
Agreement (AlA) notification procedure, accompanied by a rigorous RA process.
Annex III of the protocol details the RA procedure which is presumably science based
but with precautionary elements and vague provisions for socio-economic
considerations. Decision making period by respective member states includes 90 days
acknowledgement of the AlA notification and 270 days for actual decision making after
RA audit.
It is important to note that, the protocol came into force after Kenya had already
initiated a regulatory regime in 1998 through the drafting of the first regulations
discussed below. Consequently, the revised version (RoK, 2003b) was the first attempt
to incorporate the provisions of the protocol, while subsequent efforts were geared
towards legalising the already initiated biotechnology activities and regulatory
instruments through an enforceable Act of parliament.
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5.2.2 Regulations of 199812003 and Blosafety Act 2009
In relation to implementation, these instruments were intensely referred to by many
interviewees. Thus, they are analysed and compared in Table (8) below based on
different issues relevant to data presentation in this chapter. Key aspects that the
analysis brings to the fore are weaknesses related to lack of clarity on different aspects
of risk assessment (RA) guidelines and overall regulatory decision-making processes
pertaining to trials approval and implementation. These weaknesses are particularly
prominent with the instruments prior to the legalised Biosafety Act and form a
substantive part of this chapter.
Table 8: Tabulated review of key regulatory instruments
Issue RoK,1998/2003b RoK,2009
Scope Research trials under containment. Containment & deliberate release.
Legal status Lack legal authority. LegalIy binding.
Decision- Notification through NBC but lack welI Clearly defined notification process through
making defined standards. NBA.
procedure Guided by RA. Guided by RA.
RA procedures Based on available scientific information but Based on technical & scientific information
& decision with precautionary approach. and uncertainty is handled through more
making information and appropriate RM measures.
RA information obtained through responding RA information obtained from applicant,
to RA based questions in application form. regulatory agency reports and relevant social
economic concerns from the public.
RA audit risk-based but questions are broad -RA audit is risk based but specific to type of
(human & ecological safety). RA standards are application (contained/deliberate release).
minimum commensurate with level of risk -Regulations to define specific standards are
(Biosafety Levels I-I V) but inadequate being developed to be appended to the Act.
standards for field trials.
Decision period Not specified. 30 days after notification & 90-150 days for
RA & decision-makinK~ocess.
RM & -Measures imposed after RA and self -RM measures imposed after RA audit.
reporting regulation is emphasised. -Enforcement is through monitoring by
-NBC relies on regulatory agencies for biosafety officers from NBA & regulatory
enforcement. agencies.
-No reporting guidelines during trial
execution.
Public Emphasised but entrusted to NBC, emphasis is -Provided for during decision-making process
participation & on prudence and openness with regards to pertaining to regulatory approval.
transparency information disclosure. -Public comments are to inform RA and
decision-making process.
Implementation This has been achieved through mcs & NBC. Full responsibility of legally empowered
of the NBA.
instrument -Mernbership of these institutions not Constitution ofNBA membership-majority
specified but broadly qualified as private and will be institutional representatives but with
public. technical knowledge on biosafety and
-Mcrnbers qualifications not specified. biotechnology.
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In addition to the above major instruments, there were some supporting instruments
reviewed next, that some interviewees in practice identified with. They augment the
discussion advanced in this chapter.
5.2.3 Application form for contained research of genetically modified crops
RoK (1998) has provisions for an application form (referred to in the thesis as old
form), detailing RA questions that applicants would use to prepare a RA dossier for
regulatory approval. This form is also appended to the manual for handling requests
involving GMOs (NCST, 2006b). The scope entails both containment and
environmental risk assessment related questions. Many GP interviewees found certain
requirements of this form cumbersome to implement due to seemingly irrelevant and
repeated questions, which some found to be very technical and scientific.V Challenges
encountered by users during implementation led to its review.
5.2.4 Application form for confined field trial of genetically modified plants
According to some scientist interviewees, this instrument arose out of a need to simplify
the regulatory process for confined field trials (CFTs). The form entails RA questions
related to a crop and purpose of application which relate to type of confinement
measures required to minimise potential spread of the crop genetically modified (GM)
material. Categorisation of confinement measures as either "genetic" or "material"
distinguishes the type of questions asked and the corresponding RA information
solicited. Genetic confinement serves to inhibit gene flow and the researcher or
applicant is only required to provide physical and biological measures that restrict or
contain gene flow like removal of floral parts (part 3). Material confinement serves to
keep GM material out of food and feed pathways e.g. through fencing of trial site and
proper packaging of GM material during handling (part 4). Part five consists of
52 Interviews with RSln-GP9, RSPu-GP4, RSln-GP2, RSPu-GPI, TAN-NSS2, ATBp-PS5 and TAI-NSIO.
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contingency plans on measures that are to be undertaken in case of unplanned or
accidental release ofGM material like spillage.
5.2.5 KEPIlIS monitoring and inspection documents for field trials
These documents were developed by KEPHIS to enhance management of field trials.
The draft regulations for conduct of field trials of Genetically Modified Plants (GMPs)
in Kenya (KEPHIS, 2004a) outlines detailed regulation and enforcement procedures at
all stages of handling GM material. The Standard Operating Procedures (SOPs) &
inspection manuals for conduct of field trials of GMPs in Kenya (KEPHIS, 2004b) are
put together as a guidance document for inspectors and trial managers. KEPHIS (2004b)
was being used by the trial managers for trials management in line with terms and
conditions of approval by the National Biosafety Committee (NBC). It was also being
used by inspectors for recording purposes whenever they went for inspection.
These KEPHIS documents seem to enhance understanding of all the minor details
needed for implementation of the biosafety regulations and are specific for maize and
cotton, reflecting the biology of each crop. They may therefore be interpreted to be
technical documents, facilitating compliance with regulations and monitoring of trials.
5.2.6 Conclusion with respect to review of instruments
Critical review of the regulatory instruments in line with accounts of the interviewees
suggests certain unclear general weaknesses that include (among others) inadequacies of
institutional mechanisms responsible for regulations implementation. To further
understand these emerging issues and the underpinning factors, the subsequent
discussion is based on these instruments as benchmarks. Thus, the next section is
presented thematically based on how and why interviewees defined and perceived the
regulatory instruments vis a vis the regulatory process.
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5.3 Regulatory purpose defining nature of regulations
Many scientists described regulations from an "evolving" perspective based on the
purpose they expected the regulations to achieve. They expected regulations to evolve
in terms of formulation in tandem with science (technology) development, but in their
view, the latter was progressing faster. To describe this irregular trend, one NSS
interviewee commented: "regulations are not evolving with science" (TAR-NSS 1,
researcher & technology advocacy, international NOO, Feb. 2008). Reinforcing this
view, another scientist noted:
"Scientists have been doing biotechnology research for quite some time without
the [regulatory] policy and the guidelines." (TRTp-NSS3, research & trade
policy advisor, association of seed traders, Nov. 2007)
The expected evolution vis a vis the status quo was interpreted differently in line with
different regulatory purposes as presented next.
5.3.1 Legality
Simultaneous evolution of OE research and the biosafety system would enhance legality
of research activities and regulatory process. A number of interviewees observed that
regulations prior to the Act lacked legal backing or deterrent measures, a view shared by
both scientists and non-scientists. S3 Civil society groups however, argued legality issues
in terms of the perceived exploitation whereby the proponents of biotechnology would
take advantage of the legal vacuum to advance their trade interests illegally, purportedly
through research path:s4
"That is why I am saying that we are almost operating in a vacuum. We have
laws which we refer to and these laws are not doing us any good. When we say
about the science going ahead, people can just bring it and get it into the
market. This is the kind of mix-up that we are in. " (NOOco-NS4, consumers'
rights advocacy, NOO, Jan. 2008)
53 Interviews with RSln-GP9, Blp-PSI, ATBp-PSS, LABp-NS8 and NGOco-NS4.
5. Interviews with NGOf-NS I and NGOco-NS4.
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Legalising research activities was perceived to have many other advantages. It would
set up and sustain a credible regulatory system hence enhance public trust.ss It would
also provide a legal basis for the existing regulations and guidelines:
"The J998 regulations, it is out of good will that we have said let science go on.
But if lawyers took it up to challenge it, you would be told that there is no legal
basis for these regulations." (LABp-NS8, parliamentary counsel, Attorney
General's chambers, Jan. 2008)
Some policy scientist interviewees however claimed that the legality aspect especially
of the crop based trials had all along been addressed by supportive pieces of legislation
that have been quarantine in nature. S6 This seemed to contradict the seemingly legal
vacuum that other interviewees claimed existed.
5.3.2 Promotion of investment and good image
If regulations were to evolve as anticipated, they would provide security for
biotechnology investment. 57 A policy scientist supporting this view commented:
"No strong investor can invest in a place where there is no legal framework If
the biosafety law is in place, those people who are interested in investing in
biotechnology will look at the biosafety law and they will invest as per the law.
But now no investor can come here and invest on biotechnology because he does
not know how the law is." (BIp-PS1, biosafety policy advisor, government
agency,Jan.2008)
While a NSS interviewee remarked:
"Already a lot of people are waiting to bring in a lot of things like soybeanfeeds
for pigs. Investors want these products brought but without the bill nothing [no
investment] can happen. " (TAN-NSS4, technology advocacy, regional NGO,
Oct. 2007)
Corroborating this view, an interviewee from the industry commented:
"If the biosafety bill passes in the next one or two years to come, then the
science that is in the pipeline will come auf onto the market ..... the bill shows you
55 Interviews with TAR-NSSI, Blp-PSI and ATBp-PSS.
56 Interviews with PRp-PSIO, ATp-PS3, PRp-PS4 and Blp-PSI1.
57 Interviews with RSln-GP2, Blp-PSI, BIp-PSI3, TAN-NSS2, TAN-NSS4, TAD-NSS6 and TRTp-NSS3.
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the route to market. " (TAI-NS 10, technology advocacy, biotechnology industry,
Jan.2008)
Evolution of regulations development alongside the research trials as many interested
players would have wished to happen was also seen as a way of promoting Kenya's
good image in terms of biotechnology advancement, hence setting a good precedence
locally and regionally.P
5.3.3 En/lancing confidence through safety considerations
Some PS interviewees argued that regulations would enhance safety in addition to
building confidence of scientists, motivating them and other technology developers to
be innovative. 59 Inclusion of safety elements in the regulations was also seen as a way
of promoting public confidence through addressing public concerns for safety:6o
"Without the bill, the scientists and all those who may want to use the
biotechnology are still hindered because we do not have measures in place to
give Kenyans the confidence that somebody is looking at what those people are
doing and regulating to make sure they are safe .... the bill has to be enacted for
the policy to take root and give Kenya that direction to enhance development. "
(ARp-PS9, regulator, zoo sanitary regulatory agency, Oct. 2007)
These views expressed by some policy scientists relating to regulation and safety
mirrored those of non-scientist interviewees from the civil society. The only difference
is that, the former seemed to balance their opinions about safety and benefits that could
be attained through GE application as the above comment seems to indicate.
5.3.4 Enhancing government control
Regulations development alongside technology development was one way of ensuring
that the government remained in control of the contested biotechnology research as
claimed by many scientists and some non scientists." Control was to be achieved in
58 Interviews with RSPu-PS8, ATBp-PSS and ABp-PS14.
59 Interviews with BIp-PS 13, RSPu-PS7 and ARp-PS9.
60 Interviews with ABp-PSt4 and ARp-PS9.
61 Interviews with PRp-PSIO, BIp-PS13, ABp-PS14, PRp-PS4, TAN-NSS2, FSp-PS12, NGOcs-NS3 and NGOco-
NS4.
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various ways. A senior government official (BIp-PS13) emphasised the need for this
control to safeguard against technological imperialism which is nevertheless not a
biosafety issue. Viewing regulations as instruments through which government may
gain regulatory control is perhaps the reason why some policy scientists were careful in
the way they approached regulations, which may have contributed to the slow evolution
process. Corroborating this view, one senior policy interviewee emphasised the need for
a cautious approach to regulating biotechnology research trials in order to deal with
uncertainty:
"If you want to have effective regulations, they should be precautionary. You
are approaching the unknown and you must ensure that certain things are in
place. Then if they do not work right, really you did everything possible. " (PRp-
PS4, regulator & policy advisor, regulatory agency, Feb. 2008)
Scientists referred to in this section were in agreement that regulations if they evolved
to a legal status, would further promote government control and institutional harmony in
terms of regulations implementation and enforcement. Some non-scientists
corroborating this view were confident that this was the only way institutional or
regulatory operations would be streamlined, through government gaining control of the
regulatory process.62 A non-scientist supporting this view and emphasising the
importance of a legal framework commented:
"We are not against the technology but things cannot be done in a state of
anarchy, there has to be order. We really want [government} to regulate imports
of GMOs that come to the country and the handling aspects. If it is something
that is meant for an enclosed environment, then it should be confined and not
released into the environment like it is being done now. We highly suspect that
GM materials have been released to the open environment but the authorities do
not want to accept." (NGOcs-NS3, civil society's rights advocacy,
environmental NGO, Jan. 2008)
This analysis suggests that, regulations have a very important role to play in managing
concerns linked to application of GE technology, especially with regards to institution
of some form of control, confidence and trust.
62 Interviews with LABp·NS8 and TAI·NS 10.
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5.3.5 Concluding notes with respect to regulatory purpose defining the nature
of regulations
Regulatory purpose as a way of interpreting the regulations seemingly presents a need
for some sort of protection, authority and space for economic progression in form of
effective regulations, informed by incrementalleaming. The following section further
explores another purpose-related view of regulations.
5.4 Narrow versus broad nature of regulations
As analysed in Table (8), the scope of the regulations prior to the Act was narrow,
covering only provisions for contained GM research, with very limited elaboration on
open field trials. This was not a deliberate omission and was pre-determined. According
to some interviewees who were involved in the early regulatory phase, there was
already a consensus amongst the taskforce members drafting the regulations on what
was expected - to facilitate scientific research only (and not commercialisatiom/"
Despite this understanding, there were varying standards used to classify regulations
prior to Biosafety Act as narrow or broad, and in most cases these analogies were used
in reference to the draft bill (RoK, 2008a) that was under formulation during field work.
In the following sub sections, the defining themes that qualified regulations as narrow
or broad are analysed.
5.4.1 Research stage and research aim
Many scientists perceived the regulations to be adequate for confined research (science)
but inadequate to move science beyond research. These sentiments were corroborated
by a number of non scientists. One GP interviewee noted:
"So Jar at least they [regulations] allow us [researchers] to perform confined
trials within the research centres. But now when you want to go to the next step.
we cannot complete the research process. " (RSPu-GPl, research scientist, PRI,
Jan.2008)
61 Interviews with TAN-NSS4, ATBp-PSS, PRp-PS4 and BIp-PSII.
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While a PS interviewee reinforcing the same concern remarked:
"Those regulations were developed in 1998 and so far they have served us as
far as research is concerned. But unfortunately those regulations cannot take us
further than the field trials. " (Blp-PS 1, biosafety policy advisor, government
agency,Jan.2008)
A non scientist supporting views of scientists argued that RoK (1998) regulatory
instrument impacted negatively on: "research development by hindering potential
researchers with an eye on commercialisation" (DW-NSI2). A senior policy
interviewee further considered the existing regulations to be "blunt" and narrow in focus
lacking innovative emphasis, stopping at science for knowledge (human resource
capacity building), rather than science for economic use:
"We have been talking about science and technology for development since
1977 and we have left out innovation ...... if you develop a new plant, how are you
going to use it? So we have very powerful human resource but which is not
empowered in terms of policies and regulations. " (Blp-PS 13, policy advisor,
government agency, Oct. 2007)
These interpretations suggest that many interviewees longed for broad or all
encompassing regulations to enhance continuity of research for economic gains.
5.4.2 Cumbersomeness in enforcement
Both practitioners and policy scientists reported frustrations related to the enforcement
of the regulations prior to the Act. Challenges were encountered during risk assessment
(RA) and decision-making processes, trials management and monitoring. Thus,
regulations were perceived to be undefined and therefore broad in focus. The old
application form was supposed to guide applicants in RA requirements prior to
submission of regulatory dossier for approval by the NBC. However, GP interviewees
seeking trials approval found the application form very broad, asking what they
perceived to be unnecessary questions for the intended confined research." One of them
described the process of completing a research application for regulatory approval as
64 Interviews with RSln-GP9, RSPu-GPI, RSPu-GP4, RSAc-GPS and RSln-GP2.
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similar to [defending a PhD thesis] (RSIn-GP9). Another scientist interviewee
explaining the broad nature of the regulations remarked:
"1 think these regulations are even more than adequate ....we are actually
implementing quarantine measures which more than adequately address the
risks [and] are supposed to even deal with more serious organisms than
GMOs. "(RSPu-GPl, research scientist, PRI, Jan. 2008)
These regulations implementation challenges were corroborated by other non-researcher
interviewees." One of them, a policy scientist, expressed his frustration with the old,
cumbersome and purportedly broad application form that he felt was "too scientific"
limiting his ability as a policy and regulatory advisor to guide applicants and researchers
adequately (BIp-PSI).
The GP interviewees further perceived the supporting regulations from KEPHIS
(2004a, 2004b) to be restrictive, limiting their freedom to manage field trials. A trial
manager referring to the KEPHIS (2004b) regulatory instrument commented:
"You do not have the freedom to manage the trial the way you want. If only
some things can be made easier, management can be easy" (RSPu-GP8,
research scientist, PRJ, Dec. 2007).
Because of challenges encountered in implementing various aspects of the regulations
prior to the Act, a number of both GP and PS interviewees suggested that revision
should incorporate user experiences. The revised application for confined field trials
was one of the outputs of this recommendation."
5.4.3 Uncertainty and safety
Interviewees' interpretation of caution and safety seemed to define the focus of
regulations. As mentioned elsewhere, a number of PS interviewees admitted that the
existing regulations adopted a precautionary approach. Consequently, some
interviewees felt that, in this safety conscious form, regulations were restricting
65 Interviews with TAN-NSS2, BIp-PSI and TAI-NSIO.
66 Interviews with PRp-PS 10, RSIn-GP9 and BIp-PS 1.
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research." From this point of view, regulations based on uncertainty were narrow in
focus for failing to capture science transfer through commercialisation:
"I have no problem with anybody advocating for precautionary principle. But
you do not want to be careful to the point of death. You can be so careful that
you do nothing [fail to progress in research). Caution yes, but reasonable
caution. "(RSPu-PS7, researcher & policy advisor, PRI, Nov. 2008)
Some non-scientist interviewees linked to pro-biotechnology organisation echoed
similar sentiments with one describing regulations as overly cautious and narrow in
focus (TAI-NS 10). He linked this to uncertainty and negative perception that the public
and policy makers seemed to have about GMOs. Interviewees from the civil society
were sceptical about safety and social economic aspects of GM technology and hence
found the regulations to be narrow in focus for failing to address these aspects.t''
5.4.4 Conclusion with respect to narrow & broad view of regulations
Narrow and broad concepts in defining nature of regulations seem to suggest value and
interest based perceptions, shaped by the prevailing circumstances or experiences
related to the regulatory process. To explore these emerging aspects further, the next
section turns to interviewees' views and interpretations around the regulatory process.
5.5 Approaches to risk assessment (RA) and decision making
The regulatory instruments discussed in Table (8) seem to emphasize science based RA
procedures towards what would be perceived to be an objective decision-making
process. In practice however, many interviewees noted that the overall trials approval
process, decision-making process and subsequent implementation of decisions have
been highly ineffective, attributed to different factors discussed below. One thing they
seemed to agree is that the decision-making process was initially slow at the initiation
of GM activities but improved considerably due to technological and policy learning
67 Interviews with RSln·GP2. RSPu·PS7 and RSPu·GP4.
68 cFor instance patenting of seeds, loss of biodiversity and allergenicity (interviews with NGOcs·NS3, TAD.NS 11
and NGOf·NS 1).
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linked to improved capacity, familiarity and experience. The claims of inefficiencies
and reasons behind these claims were however described in different ways as discussed
in the following subsections.
5.5.1 Risk perception and RA in decision-making processes
Interviewees were in agreement that GE research presents potential risks and hence RA
and consequent decision-making process should be based on the nature of risk. There
were however differences amongst interviewees on how RA should be approached,
reflecting different understandings of risk and how "unknown" risk should be
quantified. To some, risk associated with GE technology is "perceived", arguing that it
is not substantially different from any other risk (for instance risk posed by non-GE
crops).69 Thus, RA should be assessed with this consideration in mind. They felt that
failure to make a distinction between perceived and actual or quantifiable risk enhances
fear in minds of people, which further confounds decision-making processes.
Some argued that risk associated with GE technology is not easy to quantify, whereas
benefits can be assessed and quantified, and thus were of the opinion that evaluation of
risk based on product rather than process of obtaining that product was predictable: 70
"If you have not been able to quantify that risk ...you will still be talking about
the possible or potential risk. I think the benefits are usually more obvious when
it comes to the products that have been approved than trying to tell the people
about the process itself" (TAN-NSS2, technology advocacy, international
NGO, Jan. 2008)
A number of policy scientists were however sceptical about reaching an amicable
decision based on RA driven by the "unknown" risks. Perhaps this is why they needed
to exercise caution during the formulation of regulations and in evaluating applications
for regulatory approval:
69 Interviews with RSPu-GPI, RSln-GP3, RSln-GP2, TRTp-NSS3 and TAN-NSS2.
70 Interviews with RSPu-GPI and TAN-NSS2.
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"Maximum caution must be given to all the process of introduction and research
to ensure that we are within safe limit as far as the risk is concerned. There is a
lot and there is no doubt about it that we really do not know and nobody wants
to make any serious mistakes now. We really have no information on the
repercussions if something seriously went wrong. " (ARp-PS2, regulatory and
policy advisor, MOA, Jan. 2008)
This comment exposes an element of uncertainty which triggered some fear among
policy makers, a factor that seemed to guide RA and consequent decisions around GM
activities and management. Fear of the unknown among some PS interviewees could be
aligned with views of the civil society interviewees about risk associated with GE
technology. However, there were differences in the way risk posed by this technology
was interpreted. Without specific reference to GE science, some non-scientists
interpreted risk in a broad way and some had the following to say:
"When you are dealing with anything new ...you try to think about the possible
risks that you may be putting yourself to" (NGOco-NS5, local NGO); HI
perceive risk as something that I am not quite sure of, and that is how the
ordinary Kenyan sees it" (JO-NS7, journalist, local daily).
In contrast, some scientists could relate risk to the nature of research particularly field
trials. Thus, risk in this context relates mainly to escape of transgenes from a confined
area to an unintended area and the consequent harm that may arise thereof.71 They
argued that this type of risk can be addressed through appropriate, technically sound
risk management (RM) measures imposed on field trials.
Some policy scientist interviewees had a problem with RA that seemed to emphasise
negatives (risks) more as opposed to the open and balanced view that takes cognisance
of both risks and benefits.72 This imbalance may explain why the regulatory instruments
discussed earlier have been formulated with risk and safety in mind as continned by the
following remark from a senior regulatory scientist:
71 Interviews with RSPu·GP4, RSln·GP3 and RSPu·GPI.
72 Interviews with PRp·PS4, ARp·PS9, ABp·PSI4, ARp-PS2 and ATBp-PS5.
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"Most of our policies and regulations are actually based on risks but risk on the
negatives. You do not say that I am coming up with these regulations tofacilitate
fast moving of GM-adoption of GM products in the country. You say, I am
coming up with these regulations to guard against a, b, c, d. Most of the policies
we have adopted the view, glass is half empty ...... You always have to have
caution....the question is that you are approaching the unknown." (PRp-PS4,
regulator & policy advisor, regulatory agency, Feb. 2008)
The pro-biotechnology non-scientist interviewees shared this same opinion as many
scientists, arguing that existing approaches to RA and decision-making process adopted
a risk prevention approach.P
Approach to RA from risk and safety perspective seems to have been reinforced in most
policy documents discussed at the beginning of this chapter. The regulations and
guidelines (RoK, 1998, 2003b) have repeatedly stated that biotechnology development
and use may pose risk to human health and environment. Further, the biotechnology
policy outlines the cautious guiding principle for biotechnology development. It states:
"The precautionary approach contained in Principle 15 of the Rio declaration
on environment and developmentforms the basisfor biotechnology development
[in Kenya]." (RoK, 2006a:9)
Consequently, this risk principle and associated perceptions seem to have guided the
drafting of the Biosafety Act74 as emphasised by one member of the drafting team:
"But I think thefocus of the bill is and should be biosafety, will Kenyans be safe
even as research on biotechnology continues?....to ensure all plants, Kenyans
themselves and the environment are safe regardless of the type of work going
on. " (ARp-PS9, regulator, zoo sanitary regulatory agency, Oct. 2007)
Risk perception in defining the RA audits and decision-making processes hints at
contested ways of judging risk. It however calls to mind non-technical factors like fear
that influence the judgement. These aspects that seem to exacerbate approaches to
objective decision-making processes are kept in mind for further investigation in
Chapter seven.
731nterviews with TAD-NSII and TAI-NSIO.
7. Biosafety is defined in the Biosafety Act 2009 as "the avoidance of risk to human health and safety, and the
conservation of the environment, as a result of the use ofGMOs."
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5.5.2 Challenges in RA, decision-making processes and trials management
Interviewees identified several challenges directly linked to how the regulatory process
was advanced. Among other factors, one major challenge was lack of guidelines and/or
clear procedures to guide both decision makers and researchers, and is given more space
in this section. Tensions emanating from this challenge as different groups of scientists
engaged in different regulatory processes and activities are analysed thematically, while
expounding reasons behind the expressed opinions.
5.5.2.1 Regulations and procedures lacking clarity
Under normal circumstances, clear rules are meant to offer benchmarks for procedural
RA evaluation and decision-making processes thereof. This would consequently
enhance consensus in trials approval process, reflecting a science-based decision-
making process that would be interpreted as objective and effective as the regulatory
instruments seem to indicate. Accounts of interviewees reflected a seemingly different
picture with many complaining of unwarranted regulatory delays that caused tensions
and frustrations." One principal investigator lamented: "we had to amend the whole
contract because of the delays which are still there" (RSPu-GP7, animal research
scientist, PRJ, Jan. 2008). Meanwhile, an NBC member explaining the reason for the
delays commented:
"The application process was partly delayed because the scientists did not get
clear guidelines from the NBC. " (TRTp-NSS3, research & trade policy advisor,
association of seed traders, Nov. 2007)
One interviewee from the biotechnology industry in relation to impacts of the delays
commented: "a big frustration has been the time delay. Companies look at time as
money." (TAI-NSIO, Jan. 2008)
75 Interviews with RSln-GP2. RSPu-GPl. RSAc-GPS. RSPu-GP7. RSPu-GP4. RSln-GP9. RSln-PS6. ATBp-PSS.
TRTp-NSS3. TAN-NSS2. ARBp-PSI6. PRp-PSIO. NGOco-NSS. LABp-NS8 and TAI-NSlO.
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The repercussions and tensions linked to lack of clarity of regulations pertaining to
different aspects of decision-making processes are presented below.
Unclear institutional mandates: Some regulatory delays were blamed on institutional
bureaucracies and unclear institutional mandates, causing regulatory tensions." A GP
interviewee lamented: "l feel that sometimes we are not clear about the roles of the IEC
and NBC, and who is supposed to do what and when" (RSPu-GP7, animal research
scientist, PRJ, Jan. 2008). Emphasising this further, some PS and NSS interviewees
noted that unclear guidelines aggravated institutional frictions, suspicion and
misunderstandings amongst scientists in different institutions regarding how RA should
be advanced. This hampered the decision-making process particularly at the early
regulatory phases: 77
"There is in-fighting between people representing certain institutions which I
have to regulate as the chair [of KARl-Institutional Biosafety Committee).
Attempt to impose more stringent regulations on the other party [research
institution] always brings some [institutional] frictions. These disagreements
became highlypersonal. " (ATBp-PS5, technological & biosafety policy advisor,
public university, Nov. 2007)
According to Table (8) and RoK (1998), operations of the NBC were designed to be
institutional in nature, but analysis presented here suggests inability of this form of
design to deliver the intended regulatory guidance and institutional harmony.
Contested NBC representation: Clear regulations are also meant to provide legally
binding guidelines on nature of membership of the NBC committee and attendance of
meetings. These important requirements are lacking in the regulatory instruments. To a
number of interviewees, this caused tensions, constraining the decision-making process
even further: 78
76 Interviews with RSPu-GPI, RSIn-GP2, RSIn-PS6, PRp-PSIO and RSPu-GP7.
77 Interviews with ATBp-PSS, ATp-PS3, TAN-NSS2 and ARBp-PSI6.
78 Interviews with ATp-PS3, Blp-PSI, ARBp-PSI6 and PRp-PSIO.
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"NBC members are not employees of the government [NCST}, They are all
coming from different organizations and sometimes to get people to a meeting
can be quite tricky. There are times the NBC had to cancel meetings due to
unavailability of members." (PRp-PS 10, regulator, phytosanitary regulatory
agency,Jan.2008)
Unclear guidelines were observed to be the cause of undefined NBC membership,
making it quite large." The issue of contested representation was corroborated by some
non-NBC interviewees from the civil society.t" One observed:
"There are so many research scientists [at the NBC] who are on the science but
others like the social scientists are not well represented ....we only have one
farmer and one consumer representative." (NGOcs-NS3, civil society's rights
advocacy, environmental NGO, Jan. 2008)
What seemed to be emerging is the assumed view that non-scientific community like
farmers or consumers should only be represented by social scientists. However,
institutional representation at the NBC was paramount as a democratic right, allowing a
wide range of views'" as the then NBC chair seemed to reinforce: "as it is right now,
NBC ref/ects the diversity of the interests groups whose interests must be properly
represented" (ATp-PS3, Nov. 2007). How these different interests should be
legitimately represented was nevertheless contested as discussed next.
Unanimity as democratic decision-making process: Democracy was equated to
unanimity and was the decision-making style of NBC in practice, as described by the
then NBC chair:
"NBC is a very heterogeneous committee. If there is a voice that says no [to a
particular RA issue], then you may have to suspend that [application] until we
all come to an agreement" (ATp-PS3, technological & biosafety policy advisor,
public university, Nov. 2007).
This style of decision-making process was confirmed by a GP researcher who has been
an applicant, with vast experience in the Kenyan regulatory approval process:
79 Interviews with TAR·NSSI, TRTp·NSS3 and TAN·NSS2.
80 Interviews with EPA·NSSS and NGOcs·NS3.
81 Interview with Blp·PSI, ATp-PS3 and documents of NBC meetings obtained from NCST.
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"The way NBC votes and decisions are made is not right where it has to be
unanimity....lt should be structured in such a way that probably; if three
quarters agree, the rest [disagreeing] quarter are asked to appeal, but not
unanimity. Even the current chairman I saw him doing the same." (RSln-GP2,
research scientist, IRI, Dec. 2007)
Different disadvantages associated with this style of decision making were noted. Some
felt that it made the process prone to interests and value-led judgementr"
"The way decisions are made....it again comes to the risk oj regulator making
the wrong decision. I know when you do not have a structured way oj making
decisions; then the person who talks the roundest, the person who has the most
interest, carries the day." (RSln-GP2, research scientist, IRI, Dec. 2007)
It also made consensus difficult to be achieved on various aspects of the decision-
making process including RA, a view shared by some non-scientist interviewees. One
of them from the industry noted:
"Within the IBC and the NBC, sometimes you get dissenting voices in every
process and this can delay things as people try to develop that consensus. A
better system would be two thirds majority or three quarter majority system in
order that decision making can be more expeditious... (TAI-NS 10, technology
advocacy, biotechnology industry, Jan. 2008)
The analysis presented here brings to mind the contention between democratic decision-
making process and unanimity in an attempt to uphold democracy. This style of
engaging actors in the regulatory process requires further investigation with respect to
balancing diverse interests and achieving legitimacy.
Objectivity & constrained independence of scientists: There was consensus among
many scientist interviewees that the decision-making process advanced by NBC should
be objective and guided by science. However in practice, this was impacted upon by
different exogenous factors (like institutional obligations) that limited neutrality. This
was linked to unclear benchmarks that were perceived by some interviewees to be
exposing the regulatory process to subjective judgements.V
82 Interviews with RSln-GP2, RSPu-GPl and RSln-GP9.
83 Interviews with RSln-PS6, RSln-GP2, BIp-PSll and RSPu-GP4.
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Although NBC is made up of heterogeneous scientists who are relied upon to guide the
process, the academic scientists were perceived to be neutral and fair in their biosafety
related judgements. This was linked to the view that they are teaching/academic
oriented and less research or policy oriented, hence no conflict of interests:
"I think the NBC should have more independent scientists in it, to give very
independent scientific views without representing the views or perceptions of
any institution.....as people who participate in the NBC in their independent
personal capacity as scientists and not representatives from institutions. They
can give their views without fear of redress by their institutions or without being
quoted as having represented the institution view. There are certain things other
[non-academic] scientists will not say because they are sitting in those
committees on behalf of their institutions. Their views may be influenced by the
position that has been taken by their institutions. I think I would trust academic
institutions [& scientists] with independent views a lot more than scientists who
come from other institutions that are research based" (RSln-OP3, research
scientist, IRI, Mar. 2008)
Indeed, one academic scientist who held the position of the NBC chair during field
work was perceived to be fair: "the new chair listens to all stakeholders' views
including applicants, leading to fair and balanced decisions" (RSPu-OP4, Nov. 2007).
This comment reaffirms the above observation.
Perhaps confirming the institutional related conflict of interests, many NBC members
admitted that as they deliberated on biosafety issues at the NBC, they endeavoured to
safeguard interests of their institutions, rather than their own individual views. An
interviewee from civil society confirming this commented: "I attend NBC meetings as a
representative of consumers; I never take my personal interests" (NOOco-NS5, local
NOD, Jan. 2008).
As much as NBC members were perceived to be fronting institutional opinions, there
are others who had observed that decisions at NBC are more individual-based rather
than lnstitutional-based.f" This contradicts the preceding view, but nevertheless reflects
841nterview5 with RSln-PS6 and ATBp-PS5.
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a process that is value laden (institutional or individual based) due to nature of the
subject under deliberation as emphasised by one NBC member:
"Because [ sit at the NBC, [ can say most of the NBC people try to work with
facts and data. But the facts and data available vary ....when it comes to GMOs
it depends on which area somebody subscribes to. NBC uses scientific reasoning
but it is an area of science whereby the scientific reasoning is very varied. Some
people are liberal, some are still conservative. " (RSln-PS6, general health &
safety advisor, IRI, Nov. 2007)
Scientists seemed to prefer separation of scientific issues from social issues, especially
in risk evaluation/" However, some noted that the decision-making approach adopted
by NBC seemed to accommodate social aspects that confuse decision makers and
complicate the regulatory decision-making process:
"I know a number of applicants and applying institutions still feel that the
NBC's practice of [risk] evaluation and eventual [application] approval process
is not fully guided by scientific evidence. Occasionally there are introduction of
other factors outside regulatory - ethical, social and other attitude based issues.
Depending on composition of the NBC, I know applicants have expressed this
feeling that certain NBC members introduce other issues that are not science
based." (ATBp-PS5, technological & biosafety policy advisor, public
university, Nov. 2007)
Confirming this approach, the then NBC chair argued that non-scientific issues are
considered and weighed against scientific facts during regulatory approvals and final
decision making (ATp-PS3, Nov.2007). This attempt to incorporate social issues again
constrains a purportedly objective decision-making process.
Scientific or science-based approach to decision-making process was further
constrained by non-technical aspects like "fear" linked to sensitivity of GE technology,
but which nevertheless affected ability of regulators to make independent judgement."
"The problem with regulations and the regulatory system in Africa which is still
developing, the individual person as the regulator has a problem because you
fear that if [ allow this GE trial and something goes wrong, you will be the one
to be slaughtered. So the fear that you might get cheated and you do the wrong
I' Interviews with RSln-GP9, RSPo-GP6, ATBp-PS5 and TAR-NSSI.
161nterviews with RSln-GP2, RSPu-PS7, PRp-PS4, RSln·GP9, RSAc-GP5 and ARp-PS2.
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thing and you lose your job and your children go hungry is real. " (RSln-GP2,
research scientist, IRI, Dec. 2007)
This observation was corroborated by non-scientist interviewees who sit at the NBC,
but thought that this unwarranted fear could be resolved through legally binding
regulations to guide and protect the decision makers.V
Despite these contestations, many interviewees believed that the overall decision-
making process by the NBC has been fairly objective, guided by science-based risk
assessment audit, where views and interests of all members (institutional or personal)
are considered.V However, there seemed to be different understandings between
democratic-based thinking and the science-based and objective line of argument. The
latter is the cornerstone of the regulatory instruments discussed earlier, replaced by the
former undefined value-laden practice as narrated by interviewees. This disparity is
explored further in Chapter seven.
Lack of clarity in RA procedures and reporting: Some GP interviewees involved in
research trials used the following phrases to describe lack of clarity of RA information
demanded from applicants through the application forms: "unrealistic demands, adhoc,
unclear, strict and not user friendly.,,89 Policy scientists responsible for formulating
regulatory instruments also found some aspects of the regulations prior to the Act too
cumbersome to enforce particularly during RA and decision-making processes. One PS
interviewee referring to the old application form made the following comment:
"I don't know who came up with the first [application} form because it was
complex. Most of the applicants / think were lacking capacity to interpret [those
questions} on the form. Even the NBC members could not interpret them
because they were too scientific." (Blp-PS 1, biosafety policy advisor,
governmentagency,Jan.2008)
87 Interviews with LABp-NS8 and NGOco-NSS.
881nterviews with FSp-PSI2. Blp-PSI, ABp-PSI4, PRp-PSIO, ARBp-PSI6, ATp-PS3, LABp-NS8. NGOco-NSS and
TAI-NSIO.
89 Interviews with RSAe-GPS, RSPu-GP4, RSIn-GP9 and RSln-GP2.
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Some interviewees confirming this anomaly argued that inadequacy of the existing
regulations to guide in RA prompted reliance on RA data generated elsewhere.f"
Perhaps because of the difficulties encountered during RA and decision-making
processes, interviewees reported accounts of attempts to address the regulations
inadequacies. For instance the old application form was found to be inadequate for field
trials (Cf'Ts) and consequently revised "to make it user friendly" (PRp-PS 10, Jan.
2008).
Regulations also lacked clarity on how RA information and field trials reports should be
handled as reported by some GE interviewees and corroborated by some PS
interviewees." This could have an implication for subsequent decisions that were
purportedly supposed to be informed by experiences of previous trials. How then would
continuity be enhanced if trials activities are not reported to the decision makers
accordingly and not properly documented for future reference?
The accounts reported here seem to expose a disconnect between technical or scientific
information (like biology of cotton) that was needed to guide RA process, and
subsequent decision-making processes. This implies that the information solicited for
RA through the old application form did not reflect the practical situation that should be
guided by technical aspects of the regulatory instruments.
Regulatory costs: A number of interviewees mainly practitioners and some policy
scientists considered the regulatory approval process to be costly.92 They associated this
with unclear regulatory guidelines that lacked structured payment fees to guide
researchers and potential applicants:
90 Interviews with RSPu-GP7, RSIn-GP9 and BIp-PSI.
91 Interviews with RSln-GP2, RSPu-GP4, ARp-PS9, BIp-PSI and PRp-PSIO.
92 Interviews with RSPu-GP4, RSIn-GP2, RSAc-GPS, ATp-PS3, PRp-PSIO and TAI-NSlO.
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"There are no guidelines for payments, how much and who should pay and all
that. It should be clear and there must be some information somewhere given to
applicants saying these are the charges from the beginning." (RSPu-GP4,
research scientist, PRI, Nov. 2007)
The costs were linked to undefined and unpredictable cost of paying risk assessors and
decision makers attending the IBC and NBC meetings. For instance and as reported
elsewhere, NBC members had to be enticed to attend meetings through payment of
participation allowances and other allowances like transport costs and RA audits.
Lack of predictable decision making time lines, and the fact that reaching an agreement
was time consuming and challenging implied that unplanned NBC/IBC meetings would
be held. This tended to escalate regulatory costs, a view that was corroborated by a non-
scientist interviewee from the industry (TAI-NSlO, Jan. 2008).
5.5.2.2 Conclusion with respect to unclear regulations & guidelines
From the narrative presented in this section, tensions caused by inadequate or lack of
clarity of regulations qualify the approaches to RA and decision-making processes
adopted by decision makers as inefficient. One thing to note here is that challenges were
experienced among different actors irrespective of whether in policy or practice. This
seems to confirm some aspects of the nature of regulations discussed previously like
enforcement difficulties. What may not be clear from the analysis is the impact of the
reported challenges on the eventual decisions arrived at, in terms of acceptability or
implementation by the wider scientific community (e.g. researchers or regulators). This
is revisited in the next chapter.
Besides these technicalities, it is important to note that values and interests as non-
technical factors confounded the decision-making processes and are explored further in
Chapter seven. Despite this, many interviewees felt that, guidance of an effective
decision-making process depends on clear regulations and guidelines.
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There were other factors which seemed to complicate the RA and decision-making
processes even further as explored in the next subsections.
5.5.2.3 Capacity issues
At the commencement of modem biotechnology activities in early 1990s, inadequate
technical understanding of biotechnology and biosafety is perceived to have contributed
to inefficient and delayed decision-making process. This early capacity challenge was
experienced by individual scientists and institutions responsible for certain aspects of
the decision-making process, both at practice and policy leve1.93
All the six GP interviewees who have been applicants cited incompetence of NBC
members in dealing with biosafety and biotechnology matters. This made some of the
members to ask what was interpreted as embarrassing and non technical questions,
which also reflected lack of seriousness and commitment." This incompetence was also
echoed by some NBC members with one of them noting: "members were not
adequately trained 10 undertake or to clearly make decisions on these highly scientific
applications. "(TRTp-NSS3, Nov. 2007)
Another aspect that was raised by some interviewees was the technical incompetence of
head of institutions involved in regulatory processes which is however a political issue,
since they are government appointees. This was perceived to be another factor affecting
smooth and politics-free decision-making process"
The bureaucratic process that contributed to delayed decision-making process was also
partly linked to inadequate and limited institutional capacity within regulatory agencies
and the Institutional Biosafety Committees (IBCs). IBCs according to RoK (1998) were
93 Interviews with ATp-PS3. PRp-PS4. ARp-PS2. ARBp-PSI6. PRp-PSIO, Blp-PSI, RSln-PS6, ABp-PSI4 and
ATBp-PS5.
9<4 Interviews with RSPu-GP4. PRp-PSIO, BIp-PSI and TAN-NSS2.
9S Interviews with RSAc-GP5 and RSPu-GP4.
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supposed to technically backstop the NBC's decision-making processes, but this was
hampered by inadequate, technically qualified human capacity."
"The lBCs were not thorough enough to have the application technically sieved
and so the NBC would then refer the issues back and this tended to frustrate
some of the scientists." (TRTp-NSS3, research & trade policy advisor,
association of seed traders, Nov. 2007)
Non scientists also felt technically deficient to contribute to the purportedly scientific
decision-making process of the NBC as expressed by a molecular scientist interviewee
from the civil society:
"The representatives of KENFAP and ClN sitting at the NBC are not adequately
informed as such and do not contribute effectively to the debate. In most cases
they are ill-prepared and do not represent the views of stakeholders. The
common perception of scientists is that the issues are too technical for non
scientist to understand. " (EPA-NSS5, environmental protection advocacy, civil
society, Jan. 2008)
Perhaps inadequate capacity may have contributed to what some interviewees referred
to as multi-tasking where the limited number of experts perceived to be technically
competent in biotechnology and biosafety matters assumed multiple roles. For instance,
RSPu-GPl is a practitioner in a research institution; she is also a member of the NBC
and also secretary to one of the Institutional Biosafety Committee. When asked how
these different responsibilities impact her expert's role, she admitted that in a normal
situation she should not be multi-tasking, but lack of capacity within her institution was
causing this. Capacities referred to by this interviewee were biosafety, molecular
science skills and ability to play out these roles in a highly politicised environment.
There were also different scientists multi-tasking as "experts" by the virtue of being
academic scientists and policy makers at the same time. Many interviewees involved in
96lnterviews with MK-PSI4, TRTp-NSS3 and Blp-PSI.
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this study had at one time in their careers held several positions or were holding policy
positions as scientists."
As much as many interviewees understood the importance of attaining certain level of
technical capacities for enhanced and objective decision-making processes especially
biosafety risk assessment, regulatory instruments were expected to give guidance on
expected technical qualifications. Without giving details, some of the regulatory
instruments analysed at the beginning of this chapter emphasise that risk assessors and
those implementing RA decisions should be technically qualified. RoK (1998) in
particular states that, persons and organisations engaging in biotechnology operations
must be:
"...fully familiar with the risks to which biotechnology products expose the
society and the environment in order to make proper judgement on the safety
arrangements that they must put inplace" (RoK, 1998, executive summary).
The regulatory instruments are however either silent or vague about technical
qualifications, an aspect that might perhaps be addressed in the regulations being
drafted to be appended to the approved Act.
5.5.2.4 Attitude
Some policy interviewees argued that some delays experienced in making decisions
pertaining to regulatory approvals of GE applications may have been caused by the
negative attitude adopted by research scientists towards biosafety regulations."
"We [NBC] have had nasty experiences with experienced researchers. But we
tell them you are the ones who set them [regulations] and we do not doubt your
ability as scientists, but this is a statutory requirement that each one of us
[scientists] has tofollow. " (ATp-PS3, technological & biosafety policy advisor,
public university, Nov. 2007)
97 For example, RSIn·GP9 has been a practitioner, regulator and now pro-biotechnology NGO employee. ARp·PS2 is
a trained biologist who once worked with KARl, later joined KEPHIS and now a senior government officer in the
Ministry of Agriculture. ARBp·PS 16 is a plant breeder who worked with KARl and now is a lecturer in a local
university (see also Appendix I).
98 Interviews with ATp·PS3. PRp·PS4 and ARp.PS2.
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On the part of policy scientists, negative attitude towards GE as a new technology
experienced at the initiation of biotechnology programme in Kenya also caused delays
in regulatory deliberations.99 One policy scientist, perhaps justifying this commented:
Of When it comes to biosafety and GMOs, everything was new to the majority and
so, a little bit of caution is acceptable. " (ATBp-PS5, technological & biosafety
policy advisor, public university, Nov. 2007)
As suggested by this analysis, attitude as conceptualised by actors may constrain
decision-making processes and can be linked to values discussed previously, and
interests explored next. These aspects are kept in mind for exploration in later
discussions.
5.5.2.5 Different players and different interests
Some interviewees expressed concerns that the decision-making process pertaining to
regulatory process was being influenced by interests linked to individual scientists and
affiliated institutions.
Research interests: Researchers were perceived to be bringing research interests into
the decision-making process, a view expressed by many scientists and some non-
scientists.IOO
Government interests: The government represented by various policy scientists was
perceived to be interested in ensuring technology deployment, towards attainment of its
vision.1ol In addition, the government through the NeST was perceived to be interested
99 Interviews with ARp-PS2, ATBp-PS5 and ARBp-PS 16.
lOOInterviewswith RSln-GP9, RSPu-PS7, RSPu-PS8, RSIn-GP2, TAR-NSSI, LABp-NS8, NGOf-NSI, NGOf-NS2,
RSln-PS6, ATBp-PS5 and TAI-NSlO.
101 Kenya Vision 2030 is Kenya's new development blueprint based on three pillars one of which is "economic"
pillar (RoK, 2007b). It is the follow up of the Economic Recovery Strategy for Wealth and Employment (ERS) (RoK,
2003a) that has been implemented since 2002.
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in providing a legal framework for biotechnology investment 10 the country in
compliance with international protocols.)02
Trade related interests: Many scientists and some non scientists were concerned that
GE technology is linked to trade interests as opposed to needs of the public.' 03Some
described these trade linked interests as "business" involving money, cementing the
relationship between trade, politics and power. One scientist commented:
"biotechnology is more the money and money is power" (RSPu-GP7, PRJ, Jan. 2008)
while a non scientist interviewee noted: "at the end of the day, I think everything points
towards trade" (LABp-NS8, parliamentary counsel, Jan. 2008). These political factors
are likely to dominate any decision-making process.
The possibility of different interests infiltrating or informing the decision-making
processes is an issue that warrants further investigation in view of the impact this could
have on the regulatory process and instruments. It is therefore taken up elsewhere in
various parts of this thesis.
5.6 Biosafety bill in achieving the desired regulatory purpose
The foregoing analysis suggests various shortcomings related to regulatory instruments
and regulatory practice that resulted into various challenges and tensions as scientific
actors engaged in the regulatory process. The majority was however optimistic that a
biosafety bill would address these shortcomings, enhancing what was expected to be an
efficient regulatory process.i'" In this section, developments, emerging issues and
controversies surrounding the biosafety bill formulation process are discussed (see also
Appendices 7 & 9). The section concludes with an analysis of the approved Act in the
context of the weaknesses linked to the previous draft version (RoK, 2008a).
102Interviews with RSln-PS6, ATBp-PS5, BIp-PSI, JO-NS7, NGOco-NS4 and TAI-NSlO.
1031nterviews with TAD-NSS6, ABp-PSI4, Blp-PSI, Blp-PSI3, TRTp-NSS3, RSln-GP3, RSPo-GP6, RSPu-GP7,
LABp-NS8 and NGOcs-NS3.
104lnterviews with BIp-PSI, PRp-PSIO, RSPu-PS7, RSln-GP9, RSln-GP2, RSPu-GP7, RSln-GP3. BIp-PSI3, ARp-
PS9, Blp-PSI I, ABp-PSI4, ARp-PS2 and FSp-PSI2.
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5.6.1 Contested representation and transparency in billformulation process
Many interviewees expressed their support for inclusion of all stakeholders in
formulation of biosafety policies because of the inherent broader social issues. IDS One
aspect that some thought had been previously ignored during the drafting of the first
regulations was involvement of social scientists and consequently the exclusion of
social aspects. Some scientists however were of the opinion that science issues needed
to be handled separately from social and ethical issues. This being the case, the
scientists drafting the bill were to exclude aspects that were purportedly not science-
based and difficult to regulate. One scientist explaining the reason for this view
commented: "we should not allow social issues that cannot be regulated to block the
science" (TAR-NSS 1, international NGO, Feb. 2008).
Non scientists from civil society on the other hand did not approve of the seemingly
scientific approach and consequently labelled scientists as "scientific" lacking social
perspective.l'" One referring to the drafting of the biosafety bill commented:
"I could read clearly that the bill is scientists' work I do not blame the
scientists because to them they see things that way. They say they want to
improve thefarmer's life and all that, but at the same time I think they are really
not looking at the issues from the farmers' perspective. " (NGOf-NS2, fanners'
rights advocacy, Nov. 2007)
But how social and scientific issues could be balanced and different stakeholders
engaged effectively in the policy process to the satisfaction of all players was a
contested issue. In the section discussed below, two camps (opponents and proponents)
were suspicious of each other revealing conflicts, mistrust, suspicion and lack of
transparency related to engagement of stakeholders in the bill formulation process. The
opponents (perceived to be bringing the social arguments) were viewed as "anti" and
misleading the public and to the scientific community, they were perceived as against
105 Interviews with TAN-NSS4, TAR-NSS I, PRp-PS 10, RSPu-PS7, RSIn-GP9, RSln-GP2, NGOcs-NS3 and NGOf-
NS2.
106 Interviews with NGOcs-NS3, NGOf-NS2 and EPA-NSSS.
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science (biotechnology). On the other hand, civil society interviewees were suspicious
of GE technology and the scientists who they accused of being secretive in formulation
of the bill. One of them reinforcing this view commented: "when someone wants to hide
some things, you make everybody to be suspicious" (NGOf-NS2, Nov. 2007).
How the public should be engaged in the regulatory process has not been explicit until
the Biosafety Act legally provided for public engagement especially in decision-making
processes pertaining to deliberate releases of GMOs (RoK, 2009: Article 29).
5.6.1.1 The proponents and opponents of the bill
The way stakeholders were engaged in the policy process particularly the formulation of
the biosafety bill exposed controversies that placed actors in "pro" or "anti" positions.
On the one hand, the media and anti-GE activists were the opponents perceived to be
either opposing the bill or impacting negatively upon its enactment, while on the other
hand were scientists and their affiliated institutions (pro-biotechnology actors and
government) as proponents. The majority of scientists expressed similar views with
regards to the opponents, citing frustrations caused by their purportedly opposing
actions. GP interviewees were more sceptical about the media when compared to the
other scientists.
Perceptions of media
Many scientists and some pro-biotechnology non scientists perceived the media and
(the anti-GMOs activists discussed below) as having a major influence on public
opinion on GE technology: 107
"Public perceptions on GE technology in Kenya are shaped a lot by the media
and the public is basically skewed on their perception. The media has been
largely influenced by the adversaries of GE technology, especially the Green-
peace and other NGOs. " (RSIn-GP3, research scientist, IRI, Mar. 2008)
107 Interviews with RSln-GP3, RSPu-GP4, RSPu-GPl, FSp-PS12, PRp-PSIO, RSPu-PS7, ATp-PS3. ARBp-PS16,
ABp-PSI4. TRTp-NSS3. TAD-NSll and TAI-NSlO.
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The views presented by most interviewees on media were linked to a media report
regarding an occurrence of a purportedly scientific error at Kiboko open Bt maize field
trial where the experimental Bt maize was erroneously sprayed with an insecticide. lOS
This was viewed by some, including the Director of Agriculture (also referred to as
Agriculture Secretary) as flouting ofbiosafety regulations and protocols:
"The biggest mistake was the Agriculture Secretary going to the media without
thinking about the sensitivity of the technology and the trials and what it was
likely going to do. Now when it was in the media, it was open to all types of
interpretations ...... you could not filter out what was the issue and what was
not ... because when you tell the media you have stopped the trial, they
interpreted that all GM research in Kenya had been stopped." (RSln-GP2,
research scientist, IRI, Dec. 2007)
Some of the scientists felt that, the media report mentioned here worsened the already
negative perception about scientists and GMOs, citing sensitivity of GE technology.l'"
Consequently, the scientist interviewees described media using different phrases like
"ignorant", "disinterested in GE" "out to make stories", "produced sentimental report
for the purpose of selling.,,110
These arguments seemed to portray a hopeless and desperate situation that led to a kind
of self reflection and an urge for behavioural change on the part of scientists as one PS
interviewee pointed out:
"The media is there to make stories ... but otherwise, muzzling the media, has it
ever happened anywhere? Let's be careful with our work We can never be
careful with the media. " (ARBp-PS 16, research scientist & biosafety policy
advisor, public university, Mar. 2008)
This culminated into education of journalists on scientific reporting by pro-
biotechnology NGOs like ISAAA and ABSF. Many interviewees perceived the training
to be a way of enhancing responsible and informed reporting on biotechnology as one
scientist pointed out:
101 "Government halts GM field trials" in the Sunday Nation. 28 Aug. 2005 by the director of agriculture.
109 Interviews with RSIn-GP2 and TRTp-NSS3.
110 Interviews with RSln-GP3. FSp-PSI2. PRp-PSIO. RSPu-PS7. ATp-PS3. ARBp-PSI6 and ABp-PS14.
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"Part of our awareness creation after the Kiboko incident [and the misleading
media report} was to involve the media more and more, and also train them in
responsible reporting. " (ABp-PSI4, technological & biosafety policy advisor,
MOA. Feb. 2008)
The researchers and practitioners' perceptions of media although triggered by this
particular incident seem to be intimately connected to their values about GE science.
Perceptions of anti-GE activists
Scientists expressed varying views regarding those perceived to be against GE
technology. Many perceived them to be "ignorant", "not sincere" and their arguments
"not informed by facts"!!! To some scientists, the activists misunderstand the GE
potential as well as scientists' good economic intentions.112 Several interviewees
claimed that the activists were not interested in the content of the biosafety bill or its
purpose (which was perceived to be addressing their unfounded fears), but rather in
blocking GE technology since they have already formed a negative attitude about
GMOs.!!3
In addition to misinforming and confusing public, some GP interviewees were
concerned that the perceived unscientific proactive tactics used by anti-GE activists to
discredit GE technology seemed to attract public attention (civil society groups
demonstrating in the streets against the biosafety bill using placards was a case in point
referred to by scientists).
Insincerity portrayed by anti-GE activists was associated with their links to
environmental NGOs who were perceived to be funding their activitiesr "
"The most unfortunate thing in Kenya is, the anti-GM groups ... influenced more
with opinions of international NGOs ...who fund them to carry out
III Interviews with TAD-NSS6, TAN-NSS2, TRTp-NSS3, RSPu-GP8, RSPu-GP4, RSIn-GP2, RSIn-GP9, RSPu-
PS8, PRp-PS4 and ARp-PS2.
112Interviews with RSPu-PS8 and TAN-NSS2.
1131nterviews with ARp-PS2, BIp-PS13, BIp-PSII, RSPu-PS8, PRp-PSIO, RSPu-GPI and FSp-PSI2.
114Interviews with ATp-PS3, ATBp-PS5, BIp-PSI3, RSPu-GP4, RSPu-PS8, TAR-NSSI and RSIn-GP2.
151
advocacy .... their major concern is to take a position of denial, a position that
gives an advantage of criticism. " (ATBp-PS5, technological & biosafety policy
advisor, public university, Nov. 2007)
Some NSS interviewees appreciated the role the activists can play in the GE technology
debate through positive criticism but perceive them to have inadequate scientific
capacity to argue about science, and for some when the capacity is there they don't
utilise it in order to "keep their jobs" (TAD-NSS6, Feb. 2008) and satisfy "those
financing their activities" (TAR-NSSI, Feb. 2008).
Other scientists claimed that, opponents do not understand the process of law-making
where details should be left out of the main Act for inclusion in the regulations that are
usually appended to the law. I IS
Contrasting the views of the scientists, the civil society interviewees lamented that they
were not potentially opposed to a biosafety regulatory regime, but rather the way the bill
formulation process was being advanced by scientists, and some particular content of
the bill (exclusion of social aspects). They cited incidences when they presented their
views and concerns to the government for consideration but they were rejected, hence
opted for a more proactive mode of expressing their views (demonstrating in the streets
to attract public and politicians attentionj.U"
In addition to the political nature of the bill formulation process, this analysis suggests
that the proponents get angered by what they perceive to be anti-science tactics, adopted
by opponents to fight GE science. Again this brings to the limelight their science-based
values and interests. Many interviewees however hoped that the bill would reconcile the
social and scientific issues, but were sceptical on how exactly it does that. This doubt
seemed to be reinforced by the many concerns discussed next raised by a number of
115 Interviews with PRp-PS4, ARp-PS9 and RSIn-GP9.
116 Interviews with NGOcs-NS3, NGOf-NS I, NGOf-NS2, NGOco-NS5 and NGOco-NS4.
152
interviewees regarding its shortcomings.
5.6.2 Concerns about biosafety bil12008
The content was highly contested and the final document was seen as a product of
science advanced by scientists, a perception that was echoed by a number of scientists
and non-scientists. To some interviewees, the biosafety bill was a tool to advance GE
science, while others interpreted the bill as narrow, focusing overly on GMOs (and not
biosafety as implied) and inclined more to crops.117 One regional expert reacting in
relation to the content noted:
"The bill the way it has been designed is mostly a bill against crop GMOs. It is
not a real bill on biosafety in general ... When you talk about biosafety; crop
biotechnology is one of them. You should not develop a bill just around crop
GMOs. This should be inclusive in which you have plants, animals, micro
organisms." (RSPo-GP6, biomedical research scientist, regional pro-
biotechnology organisation, Mar. 2008)
While another senior policy interviewee remarked:
"Biosafety should be looked upon beyond the GMOs and that is not properly
addressed in the Act. The draft bill is concentrating more on the GMOs than on
biosafety per see. " (PRp-PS4, regulator & policy advisor, regulatory agency,
Feb.2008)
Despite different perceptions related to use of the term "biosafety," some interviewees
supported the use of the term, claiming that the concerns are about safety:
"I think the focus of the bill is and should be biosafety. Will Kenyan be safe even
as research on biotechnology continues to ensure all plants, Kenyans themselves
and the environment are safe regardless of the type of work going on?" (ARp-
PS9, regulator, zoo sanitary regulatory agency, Oct. 2007)
Some scientists supported the deliberate narrow nature of the bill, arguing that the legal
framework (Act) can be sketchy on the understanding that actual implementation details
are covered in the regulations.l''' Some scientists however were concerned that the bill
117 Interviews with RSPo-GP6. RSPu-GP4. PRp-PS4. RSIn-PS6 and ATp-PS3.
III Interviews with RSIn-GP9. PRp-PS4 and ABp-PS14.
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ignores safety of final products and social aspects, a view which was also shared by
many non scientists from the civil society .119Regarding this concern, one scientist noted:
"We could have missed out the social science bit of it or the consumer bit of
it ....so that at least the bill really speaks also on social economic issues. You
find that the bill is too scientific ...when you talk about gene flow, it is actually
social science, but someone needs to put it at the social science level because,
even if gene flow is scientific, what you are protecting is social bit of it that is to
do with changing and influencing the environment. So you needed someone who
can speak on it from the sociology and economic bit of it, not just the science
bit. " (RSln-PS6, general health & safety advisor, IRI, Nov. 2007)
While a non scientist commented:
"It [bill formulation] was so scientific. It took a very scientific approach without
looking at the social, economic and environmental aspects. " (NGOcs-NS3, civil
society'S rights advocacy, environmental NGO, Jan. 2008)
Other issues that were raised by both scientists and non-scientists relate to inadequate
enforcement mechanisms to enhance implementation of the bill.120 Some of them noted
that the government, although not well endowed in term of resources, should control the
implementation process to enhance ownership (free of influence) and enhance public
trust.
To put these concerns into context, the Biosafety Act is analysed in the next section.
5.6.3 Blosafety Act 2009
The foregoing discussion although political and controversial led to the formulation of
different versions of the biosafety bill that culminated into an Act in February 2009. The
objective of the Act is to regulate activities in GMOs and to establish a predictable and
transparent process of reviewing and making decisions on GMOs and related activities.
It proposes establishment of a National Biosafety Authority (NBA) whose membership
shall comprise of experts from various multi-sectoral representation. Unlike the NBC
119 Interviews with RSPu-GP7, RSln-PS6, RSPo-GP6, NGOco-NS4, NGOco-NSS, NGOf-NS2, NGOcs-NS3 and
NGOf-NSI.
120 Interviews with EPA-NSSS, NGOco-NS4. NGOco-NSS, NGOf-NS2, NGOcs·NS3, LAEp-NS9, NGOf-NSI,
RSln-PS6. RSPu-GPl, ARp-PS2 and RSln-GP3.
154
representation spelt out in previous documents, the Act has a provision for appointment
of 3 experts in biological, environmental and social sciences, and one representative
from the biotechnology industry. This statute seems to have addressed many of the
concerns raised by interviewees in the preceding sections, pointing towards a potential
for it to achieve the regulatory purpose desired by many interviewees. Some aspects still
remain vague and it is anticipated that details will be captured in the regulations
currently being drafted. However, inclusion of social and economic aspects has been
incorporated in the decision-making process under Article 29. Further, the entire Act
emphasises on safety and measures to manage potential risk.
5.7 Concluding remarks and chapter summary
Despite the existence of regulatory instruments and what seems like an established
regulatory structure (through the NBC), evidence in this chapter suggests that activities
of the scientific community and the regulatory process were constrained by multiple
technical and non technical challenges. Overall, regulations prior to enactment of
Biosafety Act were perceived to be inadequate and regulatory practice inefficient in
terms of decision-making processes. This seemed to slow or curtail technological
development and enforcement of regulations. Arguably, this indicates some sort of
institutional weaknesses. However, there were implicit social related issues that need
further exploration in light of their potential to impact learning, knowledge production
and overall scientific behaviour related to the implementation of regulations.
Regulatory practice is one focus of this thesis and the foregoing discussion related to
institutional weaknesses provides an important context for the exploration of scientific
behaviour. Further, tensions exposed in the process of actors' efforts to achieve a
desired regulatory regime and the attitude related factors which are social in nature
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warrant further investigation. As much as these factors impact technological
progression, they seem also to have an impact on regulatory practice and process.
Table (9) below presents a summary of the findings and related emerging issues from
this chapter that are pursued further in the subsequent chapters in order to understand
how knowledge is managed in a regulatory context.
Table 9: Summary of research findings OD perceptions of regulatory process
CHAPTER SUMMARY
Issues Findings/Perceptions
Regulations and perceived -Regulations not evolving with science hence restricting technology
purpose deployment.
-Regulations have narrow focus based on different interpretations.
Nature of regulatory process, -The approach is based on caution and perception of risk associated
approaches to RA and with GE technology.
decision making -In theory the process is science-based guided by technically sound
RA but in practice the process is inefficient hampered by technical and
non-technical challenges some of which stem from unclear regulations
and guidelines and inadequate regulatory capacities. Non technical
aspects include attitude, interests and values.
-Overall the process lack scientific objectivity and is value laden.
Biosafety bill2008 & -Tensions exposed in formulation process linked to unsatisfactory and
formulation process poor public engagement mechanisms, exposing social & scientific
arguments.
-Tension further exposes two counter groups in the regulatory process
(proponent and opponents).
-The bill as an instrument for reconciling the regulatory conflicts was
not contested, but its content and context in terms of achieving this is
contested.
The next chapter endeavours to explore in details some issues raised in this chapter
through a critical analysis of the role and behaviour of scientists in the regulatory
process. This analysis is based on the different forms of knowledge that seem to
emanate from the different activities they engage in, and how it is managed in the light
of its potential to shape the regulatory instruments or the decision-making processes.
This analysis is augmented by findings on perceptions of scientists on the regulatory
practice and other data sources.
156
Chapter Six
6 Role of Scientists in Shaping the Regulatory Process
and Regulatory Instruments
6.1 Introduction
This chapter is a continuation of the previous chapter detailing perceptions of scientists
related to regulatory practice that expose their role in the entire regulatory process. It
should also be read in the context of Chapter two. The chapter addresses the second
research question: how scientists shaped the evolution of the regulatory process and
instruments.
Regulatory practice denotes activities that are relevant to the regulation of GMOs
activities including instituting institutional arrangements for implementing those
regulations (UNEP-GEF, 2004). Thus, the content of the chapter looks at a number of
aspects that constitute regulatory practice: firstly, the activities related to regulations
compliance in the management of GE research trials; secondly, the public
communication and reporting on trials; and thirdly, the activities related to formulation
of the regulatory instruments. In relation to this, scientific/regulatory practice refers to
the role played by scientists in executing these broad regulatory aspects more generally.
The regulatory instruments discussed in Chapter five have provided benchmarks on how
the first two aspects could be analysed. They are however implicit about formulation of
regulatory policies which is broadly bound up within risk assessment procedures (see
Chapter five, section 5.2).
The chapter is presented thematically in three overlapping sections. The first section, in
reporting the dynamics associated with scientific practice identifies different challenges
and shortcomings related to the regulatory practice as well as motivations that drive this
practice. This is followed by a discussion of scientific practice in relation to the
157
potential shaping of the regulatory process and instruments. The last section put into
context the relationship between perceptions and practice, paving the way for further
discussion about the implications of the scientific practice for regulatory policy and
broader innovation process in the next chapters.
6.2 Dynamics associated with practice of scientists in implementation
of regulations
In the implementation of regulations, the scientific community interviewed encountered
various challenges that impact upon the regulatory practice. These are discussed below
after first exploring the reasons behind the motivations for engaging in the regulatory
process.
6.2.1 Motivations: opportunities and interests
A number of scientists observed that the initiation of the biotechnology research in
Kenya caused hype and excitement among research scientists.l" Biotechnology
research therefore provided an incentive for scientists and some seized this opportunity
for various reasons which include pursuit of knowledge and technology transfer as a
national and social responsibility.122 One scientist noted:
"This drive by the scientists is because they have been given an incentive,
motivated since the country needs food [The policy makers] have also seen GE
might be an answer and rely on scientists to help them. [This being the case],
why wouldn't I [as a scientist], want to discover something for the country?"
(ARBp-PS 16, research scientist & biosafety policy advisor, public university,
Mar.2008)
While one senior executive had the following to say:
"Without saying we overstepped, we dared. I believed that it would have been
irresponsible not to be involved in the quest for knowledge... in being part
developers and part partners of understanding the knowledge chain and I had
no intention oj being left behind. It wasn't a personal curiosity. I think it was a
national responsibility. " (RSPu-PS7, researcher & policy advisor, PRJ, Nov.
2008)
121 Interviews with RSln-GP9. PRp-PS4. RSln-PS6. ARBp-PSI6 and RSPu-PS7.
122 Interviews with RSPu-GP7, RSPu-GPl. RSAc-GP5. RSPu-GP8. ARp-PS2. PRp-PSIO, ATp-PS3. RSPu-PS7.
RSPu-PS8 and TAO-NSS6.
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Another practitioner shared similar views and emphasised that her quest for knowledge
on GE technology was a societal responsibility to address their safety concerns and
development related needs:
"Most scientists do it for the scientific papers butfor this [vaccine] trial ...I need
to know the kind of manipulation they have done and the likely events of that
manipulation. I want to know what are the risks involved because I am the
public eye. I feel that is what I can give back to the society to address our
developing world problems ...so there is that [societal] motivation, and
motivation as a scientist to do good science." (RSPu-GP7, animal research
scientist, PRJ, Jan. 2008)
Other factors that inspired scientists include personal gains like professional
advancement, publishing and passion for fame. One scientist remarked: Ha scientist
wants to befamous and recognized. It is not a crime to want to befamous" (RSPu-PS7,
Nov. 2008), while another commented: "Some of them [scientists] they do it
[biotechnology research] as a source of income. " (RSAc-GP5, Dec.2007)
Other interviewees claimed that they engaged in GE work due to the beliefs they hold
regarding its potential, augmented by understanding of how GE technology works:123
"Some are proponents just because they have been involved in one way or
another, but there are a few who really believe in it and a few who really
understand it enough, who have seen what it has done elsewhere. " (RSPu-GP1,
research scientist, PRJ, Jan. 2008)
While others seized the opportunity to become biotechnology advocates:
"For some, their role is simply to debate and say biotechnology is good. Some
just spend their time just doing that. Some of them are not even qualified to
spend time in labs. They are able to understand it and so they can talk about it
convincingly. "(RSAc-GP5, research scientist, public university, Dec. 2007)
Confirming some of the motivation claims by scientists, a number of non-scientist
interviewees identified personal interests triggered by readily available resources (there
123 Interviews with RSPu·GPl, RSPu·GP7, TAR·NSSl, TAN·NSS2, RSAc-GP5 and RSPu·GP4.
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is more money in biotechnology research as compared to basic research) and aspirations
for fame as possible reasons that draw scientists to GE work:124
"Scientists basically they want to do their work in the laboratory and come up
with something. a result out of that research. But some scientists they just want
to make a name and say I developed this. They do not target a bigger group of
users ." (LABp-NS8, parliamentary counsel, Attorney General's chambers, Jan.
2008)
Some civil society interviewees reported that excitement and hype of the purportedly
new science and the anxiety to engage in it contributed to the scientists "pushy"
behaviour, linking this to personal interests and external pressure from their funding
partners:12S
"GE is the in thing ....you really do not want to be left behind. Our scientists are
in a hurry. Some are doing PhDs ...and they want to finish and get their
certificates ....... or they want to prove to whoever is sponsoring them that they
have done something ." (NGOf-NS2, farmers' rights advocacy, Nov. 2007)
Some senior policy executives admitted that there was hype and anxiety to engage in
GE research but argued that this was a way of testing the scientific and regulatory
systems: 126
"Perhaps we were all anxious; perhaps we rushed a bit; keen to resolve some of
the issues. There were questions at the beginning but we wanted to learn the
process ... (RSPu-PS7, researcher & policy advisor, PRI, Nov. 2008)
Another senior policy executive corroborating the view on "hype" was concerned that
scientists overlooked many technical and social factors that entail technology transfer:
"So when we talk about the successes before even you pipette in the laboratory
it becomes difficult. people saying that Africa will get out of hunger because of
GM transformation and nothing had gone to the farm ." (RSPu-PS8, researcher
& policy advisor, PRI, Jan. 2008)
Perhaps because of conflict between different motivations and opportunities presented
by GE research, and the different challenges associated with biosafety regulations and
124 Interviews with JO-NS6, LABp-NS8, LAEp-NS9 and NGOf-NS2.
125 Interviews with NGOf-NS2, NGOf-NSI, NGOco-NS4 and NGOcs-NS3.
126 Interviews with RSPu-PS7, RSln-GP9, ATBp-PS5 and PRp-PS4.
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implementation, the scientific community exposed certain varying behavioural
practices. These relate to compliance with regulations during trials execution and
communicating information emanating from the trials. These practices and the
underpinning factors that qualify them as contested practices are analysed in the next
subsections.
6.2.2 Non-compliance with regulations
'At the time of fieldwork, two field trials: Bt maize engineered to resist stem borers
attack and transgenic sweet potato engineered for resistance to feathery mottle virus
were extensively mentioned by the interviewees in connection with regulations non
compliance (see Table 1 and Box 1 in Chapter one for detail of the context under which
these trials were executed). Different interpretations explored below support
interviewees' claims of a non-compliant behaviour exhibited by mainly the research
scientists involved in these trials.
6.2.2.1 Lack of commitment by researchers
Many scientist interviewees agreed that the scientists responsible for GE trials
management showed lack of commitment by delegating this responsibility to research
assistants, thus flouting the terms and conditions of regulatory approvals.V' Referring to
the transgenic sweet potato field trial, one former principal investigator confirmed that
this delegation actually occurred (RSIn-GP9, Nov. 2007), while another regulatory
scientist had the following to say about the Bt maize mismanagement at the Kiboko
field trial site:J28 "the trial was not handled properly ... it showed some lack of
seriousness on the part of the scientists. " (PRp-PS4, Feb. 2008)
While a non state scientist interviewee referring to the same Bt trial reported:
1271nterviews with ATp-PS3, PRp-PS4, ATBp-PS5, TAD-NSS6, TRTp-NSS3, PRp-PSI0 and TAN-NSS4.
121This refers to an incident in a Bt Maize field trial reported in Chapter five, section 5.6.1.1 & foot note) 3 l.
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"The research scientist would have taken greater precaution; then a mistake
like this could not have occurred. Admittedly there was a flaw. " (TRTp-NSS3,
research & trade policy advisor, seed traders' association, Nov. 2007)
Research scientists' lack of transparency and commitment to trials management was
corroborated by a number of non scientist interviewees.V" One of them referring to the
Bt maize trial remarked:
"It was a gross mistake for {the concerned scientists] failing to follow the laid
down procedures. Somebody looking at it broadly cannot believe on what the
Kenyan scientist is doing if such an incident can take place. They [scientists]
cannot convince us that they are following science-based procedures and
protocols." (TAD-NS11, technology advocacy, donor agency, Mar. 2008)
It was however pointed out by a number of scientists and non scientists that delegation
of responsibilities to junior research assistants was inevitable because of limited
biosafety capacity that leads to multi-tasking.V'' (See also Chapter five, section 5.5.2.3).
"In this country with regard to this technology, we have very few scientists,
that's afact. The same scientist is a manager, he is a boss in his work station, he
is also to represent the country in a scientific meeting in USA, Europe, S. Africa
etc." (ATp-PS3, technological & biosafety policy advisor, public university,
Nov.2007)
When practitioners were asked to comment about the non-compliant incidences related
to the Bt maize and sweet potato trials,'!' they interpreted them as nonnative basic
research experiences which many other scientists interpreted as good learning
experiences.132
129 Interviews with JO-NS6, LABp-NS8, LAEp-NS9 and TAD-NSII.
130 Interviews with RSPu-GPl, ATp-PS3, ATBp-PS5, TAD-NSS6 and TAl-NSlO.
131 The Bt Maize trial was erroneously sprayed with a systemic pesticide masking the effect of the Bt gene while the
sweet potato trial was allowed to flower posing a danger of genes escape through pollination.
132 Interviews with RSln-GP9, RSPu-GPI, RSPu-GP4, ATBp-PS5, ARp-PS2, ABp-PSI4, TAN-NSS4 and TAN-
NSS2.
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6.2.2.2 Scientists credibility and transparency questioned
The conduct of GE trials was perceived to require a substantial level of credibility on
the part of scientists due to sensitivity of GE technology.P' However, research scientists
were perceived by a number of both scientist and non scientist interviewees to be
untrustworthy and dishonest, perhaps leading to the non-compliant regulatory
practice.l'" One senior regulatory executive referring to scientists' failure to promptly
report the Bt maize incident mentioned elsewhere made the following comment:
"If I cheat you once what would stop me from cheating the second time?
Basically scientists concerned knew this is a [transgenic] trial, so how do you
then spray with Furadan? Honestly, which type of scientist would do that? Ifyou
are honest, you will always tell the truth but if you are not, then it becomes very
difficult in terms of regulatory and the science itself." (PRp-PS4, regulator &
policy advisor, regulatory agency, Feb. 2008)
A non scientist expressing similar concern about trials and transparency reported:
"These guys [GE researchers] even with the guidelines given to them, they may
not be following the guidelines and the products that we might get at the end of
the day might have been produced with possible manipulations of one or two of
the guidelines and regulations. Even science requires transparency. It is not
only in politics. " (JO-NS6, journalist, local daily, Apr. 2008)
Perhaps credibility is one other aspect that regulations should be promoting. One senior
policy executive emphasised the need for monitoring of research scientists as they
implement trials claiming that: "scientist ...will do things that you cannot believe it is
possible. " (RSPu-PS7, Nov. 2008)
Credibility was however found to be constrained by institutional obligations and
compromises that both scientists in policy and practice were forced to makeYs For
example a senior policy scientist defending the reason why the sweet potato trial was
approved despite its previously known shortcomings commented:
m Interviews with ATp-PS3, PRp-PS4, ATBp-PS5, TAD-NSS6, TRTp-NSS3, PRp-PSIO, TAN-NSS4, JO-NS6 and
JO-NS7.
134 Interviews with PRp-PS 10, PRp-PS4, RSPu-PS7, RSPu-PS8, TAD-NSS6, TAN-NSS4, NGOf-NS 1, NGOco-NS4,
NGOf-NS2 and JO-NS6.
J3S Interviews with PRp-PSIO, RSPu-PS7, PRp-PS4, RSIn-GP9 and ARBp-PS16.
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"I knew of all these facts but I said we {NBC] let the sweet potato program go
on because it is a guinea pig. It will show us how to manage the {science and
regulatory] system. In retrospect, we knew it was not going to work We allowed
it to test the system. " (PRp-PS4, regulator & policy advisor, regulatory agency,
Feb.2008)
Credible and ethical behaviour related to GE trials execution and in particular the sweet
potato field trial was also compromised as claimed by one molecular scientist from an
academic institution, and confirmed by a molecular scientist from a civil society. Both
argued that, requisite safety tests were not carried out to guide ethical regulatory
decision-making process.!" The academic scientist noted:
"Personally I would not have taken that sweet potato to the field. They
{responsible scientists] probably did not bother because there are basic things
that you can do to tell you that this plant is bioengineered ...I am just saying
sometimes when you are a scientist you have to see it differently from the other
people. "(RSAc-GP5, research scientist, public university, Dec. 2007)
While the civil society scientist interviewee remarked:
"As a scientist I know we left ampicilin resistant genes and a few other very
nasty genes which we should have removed before even releasing for a cow to
eat. " (EPA-NSS5, environmental protection advocacy, civil society, Jan. 2008)
The regulatory instruments prior to the Biosafety Act are unclear about how credibility
as an ethical practice is linked to compliance and monitoring. Further, compromises at
early years of regulatory process can perhaps be linked to lack of clear regulations and
guidelines to guide objective and ethical regulatory practice (see Chapter five, section
5.5). However, the Biosafety Act provides for intensive monitoring through designated
biosafety experts (Articles 43 & 45).
6.2.2.3 Attitude towards regulations and regulators
Many policy scientist interviewees described scientists as having a negative attitude
towards regulations: 137
136 Interviews with RSAc-GPS and EPA-NSSS.
137 Interviews with ATp-PS3, PRp-PS4, RSln-PS6, RSln-GP9, RSln-GP2, RSPu-GPl and RSPu-GP4.
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"The regulatory documents were very clear but strange enough nobody paid
attention, and as usual for scientists, we are not used to these stringent
regulations. All those regulations were set up by the scientists themselves but
when it comes to application, they want to evade them, feeling it is like waste of
time [implementing them]." (ATp-PS3, technological & biosafety policy
advisor, public university, Nov. 2007)
The reasons behind this negative attitude were explained in varying ways by both
scientist and non scientist interviewees. Some attributed it to conflicting motivations
like research interests discussed previously, making scientists view regulations as
"hindrance to science" (LABp-NS8, Jan. 2008). A senior policy maker further
observed:
"As a breeder for example, all you want is your product to get to the market as
soon as possible. And if there is anything to delay the process, then you take a
short cut. We [regulators] are saying that with these [GE] products, taking
shortcuts will not help them. " (ARp-PS2, regulatory and policy advisor, MOA,
Jan.2008)
Others explained that scientists find it difficult to adjust from their normative basic
research behaviour to a supposedly demanding research practice like the one demanded
by GE research. Others thought that, scientists are "narrow minded," have "optimistic
thinking" and are proud; factors which nevertheless make them ignore regulations: 138
"In most cases we tend to think that science is more superior so you have that
temptation of ignoring [regulations] ... the pride of being scientists. " (ATp-PS3,
technological & biosafety policy advisor, public university, Nov. 2007)
The attitude of researchers towards regulators and vice versa promoted suspicions and
misunderstandings amongst them, constraining effective regulatory practice:
"KARl scientists are suspicious of the regulators, that they are too much of a
police than a guide. There has been a feeling that some of the regulators really
just want to punish the scientists .... the mistrust and the fact that at one time they
worked together in an institution. There is that feeling that, now I am the boss,
you cannot do this [GE research] without me." (TAN-NSS2, technology
advocacy, international NGO, Jan. 2008)
ua Interviews with, PRp-PS4, ARBp-PSI6, Blp-PSI, ATp-PS3, ARp-PS2 and PRp-PSIO.
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Some linked this to personality issues. KEPHIS regulators and KARl scientists were
perceived to be suspicious and at times undermining each other, which was attributed to
the fact that most KEPHIS employees were previously KARl research scientists.l'"
6.2.3 Poorpublic communication and biased reporting
This section reports on practice of scientists related to how they disseminate research
information emanating from the GE research trials. The regulatory instruments prior to
the Biosafety Act and the Act itself are implicit about how this reporting process should
be managed. They however emphasise on transparency that should promote public trust.
RoK (1998) in particular recommends "openness" to "safeguard public interest" through
transparent handling of information and adhering to NBC terms and conditions of trial
approval (executive summary). In RoK (2009), NBA is wholly responsible for
information handling and management including consequent public awareness. A
register will also be maintained as a repository for biosafety information. It is however
unclear how interested parties should access it. It is anticipated that details on how this
should be managed will be inputted in the regulations being drafted to be appended to
the Act. The supporting regulatory instrument (KEPHIS, 2004b) is explicit about
reporting of undertakings during crop trials management but other non crops trials are
not covered. In addition, this is not a legally binding instrument.
Accounts of interviewees suggest that scientists have poor communication skills on GE
matters that are meant for the non-scientific community. In addition, when they
communicate (as demanded by the sensitive nature of this technology), there are
weaknesses that are revealed through the reports and the communication strategies they
adopt. However, many interviewees were in agreement that scientists have a very
important role to play in communicating scientific and technical facts to the public
about their GE work. Some perceived this as the only way of demystifying the
1391nterviews with TAR·NSSI, ATBp.PS5, TAN·NSS2 and ATp·PS3.
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prevailing negative publicity around GE technology. There were however perceived
weaknesses and challenges in the articulation of this role which are explored next.
6.2.3.1 Communicating science versus public understanding of science
Some scientist interviewees claimed that research scientists use "scientific jargon" that
need to be "toned down" for lay people to understand.lt'Tbese sentiments were
corroborated by many non-scientists who supported use of simple and unbiased
language that laypeople can understand.'?' One non scientist noted:
"From a non scientist's point of view, the scientists have got to tell those of us
who are not scientists what it is that they are doing. Scientists have to come out
and find a non-scientific way of speaking to the public and make them see both
the good and the bad side of GE science. " (LABp-NS8, parliamentary counsel,
Attorney General's chambers, Jan. 2008)
The use of technical and scientific language was perceived to be an indicator of poor
communication skills that purportedly differentiates pro-GE scientists from anti-GE
activists.142 Onejournalist emphasising this difference had the following to say:
"Scientists talk scientific jargon such that you get so much lost as a journalist.
On the other hand, an NGO activist will explain to you in a language you can
understand...so it is reported in a very simple and distorted manner but that is
what you understand. You tend to take as journalist what you understand They
[scientists] must learn communication skills. " (JO-NS6, journalist, local daily,
Apr.2008)
This discussion seems to point out that scientists have not come to the level of the non
scientists or the public when communicating technical aspects of GE research. This
analysis does not however expose the reasons behind this seemingly uncomfortable
behaviour and repercussions. This is the subject of the next subsections.
140Interviews with RSPu-PS8 and TAN-NSS2.
141Interviews with LABp-NS8, TAI-NSlO, NGOf-NS2, NGOf-NSI, JO-NS6 and NGOco-NS4.
142 Interviews with JO-NS6 and lO-NS7.
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6.2.3.2 Public communication constrained by fear of misinterpretation
Agreeing with the perceived poor communication claims, many OP interviewees and a
number of NSS interviewees argued that they deliberately avoid communicating
scientific findings to the public because of fear of misinterpretation, propaganda and
potential negative impact this may have, for instance on their careers and research
reputation. Debatably, protection of their careers and good reputation through upholding
of good research ethos involves reporting undisputed "good researcb't.!" One scientist
emphasising this communication dilemma argued:
"Scientists are not really public speakers, they fear being misquoted. We would
like to tell the facts out there to the people, but the media always misquote us
and wefind ourselves in very awkward position. That is the constraint that the
scientists are having in communicating science out there to the world and a lot
of them fear because they don't know what impact it may have on their jobs. "
(RSln-GP3, research scientist, IRI, Mar. 2008)
Fear of propaganda was associated with activists, who some claimed unjustifiably fight
GE technology impacting on scientists' reporting behaviour, as one NSS interviewee
explained:
"So they [research scientists] have avoided bringing negative stories and even
when they see them they remove them and instead keep quiet. The reason being
the activists grab that and start using it as tool of propaganda to make people
turn against GE. So why talk about the negatives if they are gonna bring you
problems. Experience has shown that, any negative you bring will be used
against you. So we have to continue in the way I think we are at least less risky. "
(TAR-NSS1, researcher & technology advocacy, international NOD, Feb. 2008)
A number of non scientists agreed with scientists that scientific facts can be
misinterpreted in different contexts.144 One journalist interpreting the tendency of
scientists to refrain from reporting science for public use commented:
"Historically I know that scientists have a tendency of keeping aloof Theyfear
that what they do [research] may be misreported. " (JO-NS7, journalist, local
daily, Mar. 2008)
141lnterviews with TAN·NSS2, TAN·NSS4, ATBp·PSS, PRp·PS4, Blp·PSI, ARp.PS2, RSIn·PS6 and RSln·GP3.
144 Interviews with JO·NS7, NGOf·NS2, NGOco·NSS and LABp·NS8.
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This has implications as many scientists asserted. The fear of reporting non-factual and
unverified or unconfirmed findings constrain effective and timely reporting, leaving
room for misinterpretation by counter groups, as one policy interviewee noted:
"We would like to go to the public with what we are certain about but at the
time we are going there, somebody else has gone to say what we do not know. It
now becomes very difficult to address an issue of what you do not know because
in science it is basically search of the unknown. So when you know something is
when you can talk about it. When you don't know you can't say much. But if
someone is now saying this is what you are not telling us, yet you do not know it;
it becomes very difficult to counter." (PRp-PS4, regulator & policy advisor,
regulatory agency, Feb. 2008)
Arguably from analysis of this section, scientists are held back from freely sharing their
findings with the public by fear of repercussions associated with misinterpretations.
This has implications for practice on the part of the scientists in respect of information
and knowledge management, and how this is interpreted by others. These issues are
reviewed in the next subsection.
6.2.3.3 Communicating the positives and transparency
Many scientists admitted that when scientists communicate about GE science, it is
basically the positive and promotional information that highlights benefits more than
risks. )45 Misinterpretation was affecting the way scientists communicate, compelling
them to talk more of tangible benefits and less on unverified or "unknown" risks.
Several non scientist interviewees corroborated the "biased reporting" linked to
provision of information inclined more to successes. )46 One of them had the following
to say:
"In Kenya, all we are hearing are the positive aspects. We know that no
technology in this world is without risks. So why is the potential risk side [ofGE
technology] silent? That in itselfsends alarm bells to us [civil society]. "(NGOf-
NSl, farmers' rights advocacy, civil society, Nov. 2007)
14SInterviews with RSIn-GP9, PRp-PSIO, ARBp-PSI6, ATBp-PS5, TAN-NSS2 and TAN-NSS4.
146lnterviews with NGOf-NSI, NGOf-NS2, NGOco-NS4, JO-NS6 and JO-NS7.
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Defending this practice, some researchers argued that, the nature of biological science
training encourages them to pursue only facts, compelling them to withhold information
that cannot be validated.147 This was discussed in connection with confidence and
easiness in reporting facts as opposed to unverifiable information like cases of
uncertainty. They further argued that reporting on GE risks may cause panic among the
public if negative non-validated aspects related to scientific "process" are
highlighted.!"
A policy scientist however claimed that, scientists withholding of some information was
linked to "a normative rigid researchpractice" that compels them to vet what they
report (ATp-PS3, Nov. 2007). This was corroborated by a journalist who portrayed
scientists as research minded and rigid:
"Most of them will be willing to give the information and share it with the media
as long as things are going on well for them....he doesn't want to report failure.
He is not looking at the possible aspect of the experiment changing its course
along the way. To him, it is not an open ended research but a closed end
research - get from here to there and if he is not getting there, then he is not
doing what he is supposed to do. That is the way he looks at it. The moment
things [findings] are not going on according to their [research] proposal, they
will not discuss it. " (JO-NS6, journalist, local daily, Apr. 2008)
This analysis seems to portray scientists as self centred, and tends to put to doubt their
previous claims of fear of misinterpretation. Questionably, there is a disconnect between
constrained communication and the unbalanced information consequently disseminated.
These issues are explored briefly in the next section and revisited in the next chapter.
6.2.3.4 Unreliable & biased information and multiple obligations
Exogenous pressures were perceived by a number of scientists and most civil society
interviewees to be limiting the reporting freedom of researchers, prompting them to
147 Interviews with RSPu·GP4 and RSPu·GPI.
141 Interviews with RSln·GP9. RSPu·GP4, RSPu·GPl. ARBp·PS16. TAR·NSSI and TAN·NSS2.
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produce what was referred to as "biased' and "unreliable" information, presumably
manipulated to suit certain interests.l'"
Many felt that, reports emanating from trials were unreliable because of the partnerships
environment under which GE trials are undertaken. This was perceived to be prompting
reporting that favoured multiple obligations commensurate with different interests. For
instance, a policy scientist interviewee commented that institutional expectations
constrain the GE practitioners from reporting certain risk aspects that may be
unacceptable to their employers' developmental agenda:
"Scientists might fail to report something [negative] because they know they
will lose theirjob. Maybe the institute want to make a story out ofit [out of the
breakthrough). They might be scared if they tell something bad about it.
Sometimes scientists might be driven by different factors to take different
[compromising] positions. " (ARBp-PS16, research scientist & biosafety policy
advisor, public university, Mar. 2008)
While another senior policy scientist describing the reporting pressure coming from
donors remarked:
"The donor has been very specific in the areas they would expect information
from, such that the scientists sometimes are limited. II (ARp-PS2, regulatory and
policy advisor, MOA, Jan. 2008)
One civil society representative further noted: "it is difficult to say per se that in the
current [donor] context the informationfrom those researchers would befully reliable II
(NGOco-NS4, consumers' network, Jan. 2008). Despite this scepticism, research
scientists were perceived to be providing purportedly "unreliable information II related
to trials management that is nevertheless supposed to guide further decision-making
processes. ISO Referring to the mismanagement of the Bt maize trial case reported
elsewhere and potential misinformation, one regulatory scientist noted:
"How many of those types of mistakes are being committed and we could be
making decisions based on wrong assessment not only without the knowledge of
149 Interviews with ARp-PS2, PRp-PS4, EPA-NSSS, NGOf-NS2, NGOcs-NS3, JO-NS7, NGOco-NS4 and JO-NS6.
ISO Interviews with PRp-PS4, Blp-PSI. ARp-PS2 and TRTp-NSS3.
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the regulator and even the public who is being given the information?" (PRp-
PS4, regulator & policy advisor, regulatory agency, Feb. 2008)
Perhaps partly explaining the unbalanced reporting cited in the preceding sections, the
exogenous pressures and associated multiple obligations seemed to exacerbate the
communication endeavours. These issues are discussed later in the next chapter in the
light of their potential to impact the regulatory process.
6.2.4 Conclusion with respect to dynamics associated with scientific practice
The preceding analysis suggests that certain technical and non technical factors largely
influenced the behavioural practice exhibited by scientists in the implementation of
regulations. Some factors are associated with opportunities presented by GE science,
while others are linked to challenges that confront scientists as they engage in
biotechnology research and regulatory process. Although the focus of this chapter is the
role of scientists in shaping the regulatory process and instruments, the foregoing
analysis provides a context for critical analysis of this role in the remaining part of the
chapter and the subsequent chapters.
6.3 Scientists shaping of the regulatory process & instruments
Efforts to develop a legal biosafety regulatory system have been running concurrently
alongside the biotechnology activities. Developments related to the regulatory process
have occurred in four distinct regulatory phases and role of scientists in shaping the
process and the policy instruments is debated in this context (see Chapter two, section
2.4).
6.3.1 Scientists early role & behaviour at initiation of the regulatory regime
Scientists played different roles at the early phases of the regulatory process but this
occurred in a backdrop of cumulative learning and knowledge production.
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6.3.1.1 Scientists as experts and advisors
Undisputed early role: Many interviewees were in agreement that the drafting of the
first regulations and guidelines was wholly undertaken by scientists in research,
academic and policy arena. RoK (1998) acknowledges the work of seven drafting
committee taskforce members who are from academic, research and policy institutions.
This scientists' early involvement in drafting and steering the regulatory process was
not disputed because as argued by one member, they had the needed technical capacity
to understand the purportedly technical and complex science:
"The constitution of the first team that wrote the guidelines was predominantly
scientists. It was historical in that capacity of other groups such as consumers
and other groups was limited in understanding the science behind the
development of biotechnology. " (ATBp-PS5, technological & biosafety policy
advisor, public university, Nov. 2007)
KARl research scientists were instrumental in shaping the Kenyan regulatory process
and were widely mentioned by both scientist and non scientist interviewees as having
pushed for the drafting of the first regulations and guidelines.I" Some interviewees
supported this role claiming that KARl scientists were key stakeholders in the
regulatory framework development.Pi
KARl's role actually revolutionized the government operations and priorities.P' The
National Council for Science and Technology (NeST) actually shifted its focus from
general science and technology to the establishment of a regulatory regime in order to
support GE research (Sander, 2007). A GP interviewee explained how this occurred:
"If there was no KARl or research institution trying to push, the priorities of
NeST would have been different because their work is not exclusively GMOs.
What they [KARl scientists] were doing created need for regulations to be
developed It was a need-based initiative. KARl as a research institute was vital
in defining the priorities of NeST with regards to GM research." (RSln-GP9,
research scientist, international intermediary organisation, Nov. 2007)
lSI Interviews with ABp-PSI4, BIp-PSII, ATBp-PSS, TAN-NSS4, FSp-PSI2 and LABp-NSS.
IS2 Interviews with RSPu-PS7, RSPu-PSS, FSp-PS 12 and LABp-NSS.
ISllnterviews with RSln-GP9, TAR-NSSI, BIp-PSI), RSPu-PS7, RSPu-PSS, ATBp-PSS and PRp-PS4.
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Confirming this early active role, one non-scientist commented: "the 1998 regulations
were developed by scientists for scientists without considering the other wider
stakeholder users. II (LABp-NS8, Jan. 2008)
Coordination and advisory role of policy scientists: Two key policy scientists
interviewed in this study claimed that they were relied upon extensively to advise the
Ministry of Agriculture and regulatory agencies on both biotechnology and regulatory
issues. Consequently, this advisory role impacted upon the regulatory process
trajectory.IS4
6.3.1.2 Incremental learning influencing the regulatory trajectory
In the process of drafting the biosafety regulations, there was an element of learning
which enhanced the process. Much of the early learning was supported by donors who
built awareness amongst the scientists involved in drafting the first regulations and the
policy figures involved in implementing the drafting process. ISS For example one policy
actor noted that a regional biosafety workshop held in Harare, Zimbabwe prior to
drafting of the regulations was an eye opener to the Kenyan scientific community who
attended this workshop with regards to the need for biosafety regulations:
"Way back in 1992//993 KARl had received an application for a trial, so when
they came to the Council, they asked to be advised on regulations and advise on
what to do. I could not understand about the regulations because we only knew
about the research permits. It so happened that around 1993/1994, I was invited
for a workshop in Zimbabwe attended by 11persons from Kenya. When we were
now discussing what this biotechnology is all about, I came to understand why
we needed the regulations and straight away I was nominated the chairman of
the Kenyan group to spearhead that activity right there. When I came back to
Kenya I was very aggressive and I started to constitute groups to discuss the
kind of applications that KARl had submitted. We drafted the first draft, and
finally we came up with the regulations. II (Blp-PSll, policy advisor,
governmentagency,Feb.2008)
1S4 Interviews with RSPu·PS7 and PRp·PS4.
ISSIntcrviews with Blp'PS 11, TAN·NSS4 and ATBp·PSS; see also Sander (2007).
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After the workshop referred to here, a taskforce was formed in 1995 comprising of
natural scientists (most of them having been sensitized during this workshop) and one
legal expert to spearhead the drafting of the first regulations that were officially
launched in 1998 (Thitai et al., 1998). This scientific task force also determined the
early constitution of the NBC members.
Subsequent learning obtained through familiarity with biotechnology and biosafety
matters occurred during the execution of the research trials. Consequently, upon
realisation of the regulations inadequacies during implementation, research scientists
took up the active role of pushing for the review of the first draft.156 Confirming this
pioneering regulations review initiative, a regulatory scientist and a member of NBC
noted:
"Indeed it was the [research} scientists who pushed for the revision of the
application form. It is better if you get the revision requirement from the users
than when it is proposed by the NBC. They are the ones who discovered that
some of this risk assessment information is required [in decision-making
process). " (PRp-PS10, regulator, phytosanitary regulatory agency, Jan. 2008)
Research scientists extensively contributed to both policy and technical learning
through biotechnology and biosafety capacity building efforts that targeted policy
makers and implementing scientists. These efforts were enhanced through the various
research projects that they were involved in. This was aimed at influencing decision-
making processes pertaining to various GE projects regulatory approvals and
implementation:I 57
"Kenya like all other countries makes institutions, and then employs people
trained in just general education, and then they are supposed to regulate very
scientific work. So it was very important to expose them to the technology itself
and expose them to other institutions that are practicing it to understand how it
is [regulated}. IJ (RSln-GP2, research scientist, IRI, Dec. 2007)
1S6 Interviews with RSln-GP9. PRp-PS4. BJp-PSI. PRp-PSIO and TAN-NSS4.
1S7 Interviews with RSln-GP9. RSPu-GP4. RSln-GP2 and RSPu-GPl.
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A senior policy scientist confirmed how he was sensitised on biosafety regulation
through efforts initiated by research scientists:
"I was exposed to the biosafety regulatory environment through the scientists'
interest at Michigan State University. The scientists drove the early regulatory
process. " (PRp-PS4, regulator & policy advisor, regulatory agency, Feb. 2008)
The opportunity presented by biotechnology science seems to have also demanded
requisite learning towards technical understanding, and engaging with both the
technology and biosafety. This partly explains the reasons why the two co-evolved since
as presented in this section the majority of actors embraced learning and supported
efforts like capacity building to sustain the co-evolution approach.
6.3.1.3 Conclusion with respect to early role & introducing next section
The roles played by the scientists at this stage directed the regulatory process without
any contestation. Different interpretations may be drawn from this (see Chapter seven).
The increased learning provides a context for, perhaps the positions scientists occupy
and the role they play in the subsequent regulatory phases as an informed group with
regards to familiarity with technological and biosafety aspects.
Despite the availability of scientific knowledge and institutions which seemed to
support technology deployment (e.g. research, government, donors, NGOs, NBC and
IBCs), what is not very clear from the analysis of this early role is the actors'
motivation, and how learning was harnessed and sustained to spur significant policy
change. The situation seems to suddenly change in the subsequent regulatory phases as
actors engage in diverse roles and activities towards legalisation of the regulatory
process and instruments. The important point to note that leads us to the next section is
the radical change in the conceptualisation of the regulatory process and instruments by
both the scientists and non scientists.
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6.3.2 Role & behaviour of scientists in the legalising of regulatory process &
instruments
National efforts to establish a legally binding regulatory regime in compliance with
Cartagena Protocol commenced in Phase 2 of the regulatory process. Many interviewees
argued that biosafety regulations formulation process engaged the scientific community
in various ways which indicates shaping of the regulatory process in terms of direction
and content. In this section, these activities and developments that relate to formulation
of regulations particularly the Biosafety Act 2009 are discussed, while implications are
explored at the end of the section.
6.3.2.1 Activism of scientists masking government role
The National Council for Science and Technology (NCST) coordination role in drafting
of the first regulations to govern modem biotechnology activities was pivotal and
undisputed. Consequently, RoK (1998) as a regulatory instrument provided for an
institutional framework for regulatory process but under the coordination of the NCST
and the National Biosafety Committee (NBC). One of the roles of the NBC according to
RoK (1998) was to draw policies and procedures to govern biotechnology. In this
regard, this gave NBC through the NCST the legal powers to spearhead the policy-
making process. However, NBC coordination role in the biosafety bill formulation
process was perceived to be blurred by the activism of other actors, a view shared by
both scientists and non scientists:158
"It is difficult to know who has been driving this [bill] process but I think the
NBC should be playing a bigger role. " (RSIn-GP3, research scientist, IRI, Mar.
2008)
Arguably, the scientists and their allies became the main drivers of the bill formulation
process. A non-scientist interviewee confirming this role argued:
IS81nterviews with RSln-GP3, RSPu-GPI, RSPo-GP6, PRp-PSIO, FSp-PSI2, ARp-PS9, JO-NS6 and NGOf-NS2.
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"The main players were the biotechnology industry, and the scientists make
much of the industry. The whole thing [bill formulation process] was supposed
to be an initiative of the NeST but the interest was with people from the
biotechnology industry than what we would call the broader section of Kenyan
society. " (JO-NS6, journalist, local daily, Apr. 2008)
The regulatory instruments however do not state how this process should be advanced
and how stakeholders should be engaged. This seemed to leave room for different styles
of actors' engagement in formulation process, and perhaps the reason why the role of
the government could be masked easily.
NBC is also largely made up of scientists representing different organisations with two
representatives from the civil society. This being the case, and with lack of clear
guidelines on how the process should be directed, it can be concluded that scientists and
their affiliated institutions seized this opportunity to influence the process as interested
parties. Without losing hindsight of the learning and familiarity that had since occurred,
the next section turns to how scientists engaged in the formulation of the biosafety bill
and related tensions.
6.3.2.2 Technical backstopping of regulatory process & conflict of interests
Many interviewees perceived the research scientists to have technically backstopped the
regulatory process.IS9 Some of them however argued that, this was a positive influence
which was necessary to ensure a balanced and a scientific process through provision of
technical information:
"The bill was drafted by legal experts guided by scientists. The ideas camefrom
scientists. They set up a framework that ensures decisions that are made are
based on real scientific facts." (ATp-PS3, technological & biosafety policy
advisor, public university, Nov. 2007)
However, this technical support was questioned extensively by some interviewees.
Some observed that scientists are driven by research interests and thus their
IS9 Interviews with PRp-PSIO, PRp-PS4, RSIn-PS6, ATp-PS3, ATBp-PSS, ARp-PS9 and BIp-PSI.
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participation in the regulatory policy process is to push for policies that would promote
biotechnology science.l'" A NSS interviewee confirming this research driven push and
reason behind it commented:
"You find that the scientists have been putting a lot of pressure already. They
have been doing these things [research], then there are no regulations and
procedures to use .... the government arms should be way ahead and not wait
until the scientists are caught up with the technology and then you don't know
what to do with these scientists. " (TRTp-NSS3, research & trade policy advisor,
association of seed traders, Nov. 2007)
This is perhaps the reason why some emphasised that any scientific contribution to the
regulatory process needed to be vetted by the public to ensure balance with non-
scientific aspects.''"
"Whatever they put down, it needed to receive a consultative process to receive
views from different stakeholders to question the content. There is a danger if it
gets to be overwhelmingly driven by scientists, [and] then they will structure it
just to address scientific needs. Science is for the benefit of the society and
society must view itfrom that light. " (RSln-GP9, research scientist, international
intermediary organisation, Nov. 2007)
Admitting that this nature of influence actually occurred, a GP interviewee involved in
the bill formulation explained:
"I could also look at how the bill would affect the scientists who want to do
biotechnology research in the country ..... so / have also to think about how this
[bill] can affect the scientists in future. " (RSPu-GP 1, research scientist, PRI,
Jan.2008)
Scientists sitting at the NBC are also perceived to be interested parties as applicants or
potential applicants, and are likely to influence decisions to favour interests of scientists
through the biased technical information they provide for risk assessment (RA).162 One
scientist and an NBC member commented:
"If the information you are trying to regulate on is coming from the people you
are trying to regulate, then definitely they will frame it in a way that make their
applications to always to go through [get a regulatory approval). They will skew
160 Interviews with RSPu-PS8. RSPu-GPI. RSIn-GP2 and RSIn-GP9.
161 Interviews with RSIn-GP9. TAD-NSS6. NGOf-NS2. LABp-NS8 and NGOf-NSI.
162 Interviews with RSIn-PS6, ARBp-PSI6 and RSIn-GP3.
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it such that even them when they make an application, it will go through. "
(RSln-PS6, general health & safety advisor, IRI, Nov. 2007)
Exogenous and endogenous pressures and related interests discussed previously further
constrained scientists from exercising objectivity in various regulatory undertakings.
Many interviewees reported that scientists have been used as conduit to advance
interests of pro-biotechnology organisations or to achieve national technological
development agenda.l'" A civil society interviewee, explaining how in practice pro-
biotechnology organisations influence the thinking of players in the regulatory process
noted:
"The people at the NBC are the people who are always taken to USA under the
Cochranfellowship. They go to see those big farms that are producing GMOs;
they are given very good per diems. When they come back, their thinking has
already been manoeuvred." (NOOcs-NS3, civil society's rights advocacy,
environmental NOO, Jan. 2008)
Moreover, it was a concern of non-scientists from the civil society that technical
information used in RA and consequent decision making pertaining to OE trials was
solicited by scientists from technology developers who are interested parties.i'"
Despite the potential conflict of interests, scientists were perceived to be key players in
regulatory process as facilitators, and through their active involvement provided a
regulatory mechanism through which NBC and IBC could operate.16S One PS
interviewee in support of the purportedly positive influence had this to say:
"The scientists never drove the process, they were just the initiators. They are
the ones who woke us [NBC] up to want to have those regulations in place. "
(ARBp-PS 16, research scientist & biosafety policy advisor, public university,
Mar.2008)
163 Interviews with ARBp-PSI6, ATBp-PSS, RSPu-GPl. EPA-NSSS. PRp-PS4. RSPu-PS7. TAI-NSlO. NGOf-NSl
and NGOcs-NS3.
164 Interviews with NGOf-NSl. NGOco-NS4. NGOco-NSS. NGOf-NS2 and NGOcs-NS3.
165 Interviews with ARBp-PSl6. ATBp-PSS. RSIn-GP9. BIp-PSll. TAN-NSS4 and PRp-PS4.
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Despite the conflict of interests and the arguments for or against the nature of influence,
role of scientists in the bill formulation process was articulated in different ways,
discussed next.
6.3.2.3 Institutionalised influence of biosafety bill
As discussed in Chapter two, there are many actors involved in the evolution of both
modern biotechnology and the biosafety regulatory regime. This co-evolution scenario
seemed to provide a conducive environment for the scientific community to pursue their
motivations and interests in an integrated way. Thus, activities related to influence of
the regulatory process were articulated within or through institutional nodes and
knowledge networks. From the preceding section, data suggest that scientists impacted
regulatory policy process as regulatory experts and whichever role they played to shape
the regulatory process is perceived to have received blessings from the government
side.166 Interestingly, the government side is also comprised of scientist actors who have
moved from public institutions to become policy makers which may further bring about
conflict of interests (see Appendix 1).
The nature and role of the ensuing relationships formed around the formulation of
regulatory instruments, particularly the bill, were consequently interpreted in different
ways as collaborations, facilitation or activism, spurred by different factors. The nature
and forms of these relationships together with the related influence are discussed next.
L Scientists working within institutions and networks
A number of key professional and knowledge based networks within which scientific
and non scientific communities influenced the regulatory process were identified in data
analysis as follows:
166lnterviews with JO-NS6 and JO-NS7.
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Tire Open Forum on Agricultural Biotechnology in Africa (OFAB): At the height of
debate on regulatory policies (biosafety bill) in Kenya in 2006, OFAB as an early
initiative of ISAAA and AATF was launched. Its formation was claimed to have been
motivated by the regional High-Level African Panel on modern biotechnology set up by
the AU to advice African heads of states on biotechnology and therefore appropriate
policies to support it (Juma and Serageldin, 2007). OFAB was to address the country
level (Kenyan chapter) as there was perceived need for "national scientists and experts
to provide policy makers and the general public with evidence needed to harness such
technologies" (see www.ofabafrica.org/country).
It has two main objectives: First, to popularise biotechnology:
"OFAR is a place where scientists meet and share their views on cutting-edge
science, research and development issues" (some senior scientists at CIMMYT,
quoted in Karembu et al., 2008).
Second, to push for conducive policies to enhance technology transfer:
"Through the forum, the scientists get the much needed chance to impact policy
makers on the need to mainstream science and technology into Africa's
development agenda. "(Karembu et al., 2008:12)
Indeed the promotion of biotechnology and development of permissive regulatory
instruments have been major items of debate during over 24 OFAB meetings held in
about two years (Karembu et al., 2008 and www.ofabafrica.org/country).
The committee members of OFAB, Kenya chapter, comprise 6 scientists and 2 non-
scientists drawn from AATF and ISAAA as the secretariat. The chapter is chaired by a
non state organisation-ISAAA. In contrast, the OFAB Uganda chapter initiated by the
same Kenyan actors is chaired by the Uganda government through the Uganda NCST
and the Government public research institute, the National Agricultural Research
Organisation (NARO) (see www.ofabafrica.org).
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The Kenya Biosafety Consortium (KBC): was formed in 2006, where members were
predominantly pro-biotechnology scientists, with support from government through
NCST, united under one agenda; having a biosafety law to pave the way for
biotechnology deployment: 167
"We got together as different stakeholder in the biotechnology arena in Kenya
and formed what we called the Kenya Biosafety Consortium ..... then ISAAA was
charged with the responsibility of helping with the coordination 0/ the
consortium. We all agreed that one of the major milestones that we can make in
this country if we really have to move with the technology is to have the
biosafety law." (TAN-NSS2, technology advocacy, international NGO, Jan.
2008)
Its operations were strategic and political m nature as insinuated by one policy
interviewee:
"You are a scientist but you have to understand the society. That Biosafety
Consortium was a pressure group to strategize how the biosafety bill would be
discussed and go through. It has hibernated because now there is no biosafety
bill anywhere. But immediately we start the process, they might come out again
as Biosafety Consortium or maybe another name. " (Blp-PS 1, biosafety policy
advisor, government agency, Jan. 2008)
A point to note is that activities of this consortium ceased after the bill was enacted into
law.
The National Biotechnology Awareness Strategy (BioAWARE): is a public awareness
initiative that was conceived by the scientific community and articulated through the
Agricultural Sector Coordinating Unit (ASCU) within the Ministry of Agriculture
(RoK, 2008b). This initiative was launched in 2008 and a key participant (not involved
in the drafting though) was the Kenya Federation of Agricultural Producers (KENFAP,
previously Kenya National Farmers Union). KENF AP was identified as a key player in
reaching out the farmers while the Ministry of Agriculture has an established extension
167 Interview with TAN-NSS2 and analysis of the minutes of several meetings held by this consortium.
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service.l'" Something to note is that the chairman of this initiative is a scientist and also
an executive member of OFAB. This may perhaps explain how important partnering
and collaboration had become to scientists in ensuring that they achieve their goals,
including public awareness.
These partnering initiatives may imply that the Kenyan scientific community cannot be
perceived to be non-partisan and disinterested players in the biotechnology arena and
biosafety regulatory process.
ii. Mutual and resource bound relationships
The relationships established around the regulatory process in the Kenyan context were
mutual in that the participating players expected to benefit. Scientists and the
government were on the one hand receiving financial support from non state actors. For
instance, GP scientists are pursuing biotechnology research projects under Public
Private Partnerships (PPPs) which some scientist interviewees interpreted as
government policy support for GE deployment.l'" On the other hand, the non state
actors have received political and scientific support to advance their interests in
different ways. Some NSS and non scientist interviewees from the biotechnology
industry interviewed in this study admitted to have been articulating facilitation roles in
the policy process indirectly through their scientist partners, arguing that direct
involvement would elicit negative suspicion, citing sensitivity of GMOS.170 One
industry interviewee explained his company's motivation for engaging in regulatory
process through relationships established locally:
"Ifwe get too involved, then of course as an interested party it will raise a lot of
eyebrows and create a lot of resistance against us and our products. So we tend
to support those who have a national interest - the research community and
168 This analysis is supported by recorded speeches of the chief executive of KENF AP, the minister for agriculture
and the director of agriculture during the launch that I attended in Sep. 2008 in Nairobi, Kenya.
169 Interviews with RSPu·GPI. Blp-PSI and Blp·PSI3.
170 Interviews with TAD·NSS6. TAN·NSS2 and TAI·NSto.
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NGOs that are there to push for the farmers' interest. We work with them and
through them. I am honest about this, the reason why we are still engaged in
trials in Kenya is because we have seen fantastic collaboration from the
scientists, very good science, very good reports and it is impossible to turn back.
We have very good partners who are doing great science, are positive and who
are influencing the policy debate. It is about relationships." (TAI-NS 10,
technology advocacy, biotechnology industry, Jan. 2008)
Meanwhile, another NSS interviewee noted how her donor organisation in addition to
funding GE research facilitated eminent scientists to influence the bill through reaching
out to policy makers, regulators and media:
"We have supported scientists doing research, but we have also facilitated
scientists to have the outreach to the Ministry of Science and Technology, who
were looking at how the content of the biosafety bill could be shortened to
ensure it is accurate... ensuring that it facilitates trade, facilitate research and
commercialization." (TAD-NSS6, technology advocacy, donor agency, Feb.
2008)
Some NSS interviewees explained that they created partnerships and relationships to
achieve what they consider to be product deployment.i" The only NSS interviewee
from the civil society, perhaps confirming these mutual and interest-bound relationships
argued that scientists and their partners created a need for regulations, in order to
promote GE products:
"You can't create something from nowhere. Working with a big corporate, we
tried to push these things [GE products] to Kenya and that would force them
[the government] to work on the biosafety bill, policy regulations and all that. "
(EPA-NSS5, environmental protection advocacy, civil society, Jan. 2008)
These relationships and partnerships were perceived by many interviewees to have
positively enhanced the regulatory process, with some arguing that private partners
permitted the requisite space and freedom for the scientists to dictate the regulatory
policy path.172 Further, some of them were in agreement that the government has
inadequate capacity to support the regulatory process, so these other supporting parties
were filling in that gap. In support of this argument, a GP interviewee remarked:
171 Interviews with TAR·NSSI and TAN·NSS2.
172 Interviews with BIp-PSI!, BIp-PSI, RSPu-GP4, RSPu·GPI, PRp·PSIO, RSln-GP3 and ATp-PS3.
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"When we do not have the capacity in Kenya we rely on others. At the moment
the capacity lies with some of these international players and what they
contribute ends up getting into the biosafety bill. So we really do need to develop
the capacityfor Kenyans to participate effectively in issues of biotechnology and
biosafety." (RSIn-GP3, research scientist, IRI, Mar. 2008)
The GP interviewees had their own perceptions of partners from non-state
organisations. They admitted that they play key roles in GE research and the regulatory
process, a role the government is not articulating effectively.m For instance one GP
interviewee perceives some pro-biotechnology NGOs to be providing information on
GE technology and the much needed financial support for regulatory policy
development:
"Being NGOs activists or brokers, they also have a stake because they are the
ones who looked for the money and sometimes they are part and parcel of
sometimes the research aspects. Like now, every OFAB meeting we have to pay
for lunches and hall. The BioAWARE initiative someone had to sponsor it. I
sponsored a number of days, Ministry of agriculture, but Dr. P from NGO Z
sponsored more days than any of us. So she has more influence because she is
the one who is able to contribute more... (RSPu-GP1, research scientist, PRJ,
Jan.2008)
From these accounts, resources and in particular financial support was a key incentive
cementing these relationships. Indeed, activities and operations of the Kenya Biosafety
Coalition (that played a key role in lobbying for the enactment of the bill) were funded
by non state scientists through the pro-biotechnology organisations (BIp-PS 1, Jan.
2008).
iii. Scientists collaboratively lobbying for enactment of the bill
Many interviewees desired a regulatory environment that would enhance deployment of
products ofGE science. Biosafety bill was a gateway towards achieving that goal. There
was resistance from opponents experienced along the way (see Chapter 5, section 5.6.1).
To counter this, scientists in policy, academic and research arena supported by their
affiliated organisations came together to push for the enactment of the bill.
173 Interviews with RSPu-GP4. RSAc-GPS, RSIn-GP3 and RSPu-GPJ.
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Under the umbrella of the Biosafety Consortium, the scientific community, with support
from the government actively lobbied for the enactment of the bill as described by one
policy interviewee who represented the government side in the consortium:
"They [consortium members] were some institutions, those who had an interest
in biotechnology which came together and decided to push the policy makers
and the regulators. They were like brokers for the biosafety bill. I became a
member because they wanted to hear the thinking of the Government for they
thought the Ministry was the one delaying the process. So I was there to update
them on the bill process [from government side]. I have called them a broker. So
these people were between the executive and the parliamentarians. They were
meeting the parliamentarians, they call me to tell me what they are saying, I
ring the Minister ....In fact it was a very good effort which was put together and
we almost won the gold ...and I am quite happy about them." (Blp-PSI,
biosafety policy advisor, government agency, Jan. 2008)
Some NSS interviewees interviewed in this study admitted playing an active role
through the consortium as one noted: "it is true we were quite involved in catalyzing the
enactment of the biosafety bill" (TAN-NSS2, Jan. 2008).
Media reports analysed during field work confirm some activism by the scientific
community and government in support of the biosafety bill.174 This was not received
well by civil society who under the umbrella of the Kenya Biodiversity Coalition
(KBioC) (previously KEGCO) responded proactively by discrediting the bill.17S
iv. Scientists corporately sensitizing key players as a persuasion strategy
Scientists collectively educated policy makers and journalists, sensitizing them on GE
thus making "a casefor biotechnology" as well as persuading them to support it (RSln-
GP2, Dec. 2007). Sensitising public on GE technology is a role that all GE scientists are
expected to be playing under OFAB.176 Policy makers particularly parliamentarians
were targeted in order to convince them in supporting and passing the bill in
174 Scientists in the academic circles publicly supported the bill, while the government through the NBC attempted to
counter the negative publicity by civil society [see Appendix 9 and NCST (2007) in support of this argument].
17S They published a parallel bill titled "the biotechnology and biosafety bill, 2008" and a comparative analysis of the
two parallel bills. See also the article "biosafety bill 2008, Kenyan MPs selling the country" published in the Daily
Nation on 2S Nov 2008 (Appendix 9).
176 Interview with RSln-GP3; www.ofabafrica.org; personal communication with scientists during OFAB forums that
coincided with the field work (Oct 2007-March 2008).
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parliament.l " One policy scientist supporting this endeavour argued:
"...parliamentarians [often don't] go to parliament to talk of a technology which they
have no idea about" (BIp-PSl, Jan. 2008). Journalists were targeted to enhance
responsible reporting as argued by one GE practitioner:
"The most dangerous group was the journalists. They had the means to give
wrong information....We as scientists we have done a lot in educating the
journalists. Today we see very responsible reporting in the newspapers."
(RSPu-GP4, research scientist, PRJ, Nov. 2007)
In an effort to educate and sensitise policy makers on GMOs, a Handbook for Policy
Makers was published in 2007.178 This manuscript has acknowledged contribution of
technical content by various persons who are all scientists. This may imply that the
handbook presents only scientific views. Another notable effort by the non state actors
in sensitising the policy makers has been through the PBSIIFPRJ-ISAAA program.i " In
one of the PBS publication, the following is stated:
"PBS helped prepare the Kenya biosafety bill for enactment by educating
members of parliament and preparing briefing documentsfor policy makers and
media. " (PBS Newsletter: Issue No. 13. www.ifpri.org)
Recently, the scientific community and other actors in the biotechnology arena have
intensified promotion of biotechnology through the media alongside calls for policy
support to achieve this goal.I80 Despite the undisputed and proactive efforts to change
the thinking of certain players regarding biotechnology, some scientist and non scientist
interviewees were concerned that these efforts had a hidden motive.l'" Some argued that
the interested parties who included the industry were effectively pushing for regulatory
177 Interviews with RSPu-GP4, SIp-PSI, TAN-NSS2, TAR-NSSI and RSPu-GP8.
178 The handbook is published by ISAAA and gives an overview of the status of biotechnology in Kenya. It
emphasises on the benefits ofditTerent applications of crop biotechnology & highlights the institutional and human
capacity that exists to harness and consequently adopt biotechnology products. It concludes by recommending that
the biosafety bill need to be enacted by the readers (policy makers) in order to tap the benefits of biotechnology.
179 Through this program a number of policy documents have been produced: "the truth about the biosafety bill";
"GMOs and exports: demystifying concerns in Africa". One ofthe achievements of this program has been listed as
sensitising the policy makers (www.ifuri.org).
180 For instance a recent media report claims that pro-biotechnology reports have increased, fronted by scientific
organisations and funded by biotechnology industry (East African daily of26 May-I June, 2008); The ISAAA
publication, the Crop Biotechnology update, has been highlighting policy developments in Kenya and in particular
developments surrounding the biosafcty bill (www.isaaa.org/kc).
181 Interviews with RSPo-GP6. RSPu-GP7. NGOco-NS4, NGOf-NS 1, NGOf-NS2 and NGOcs-NS3.
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instruments that are permissive in nature. One concerned non government regional
expert and scientist remarked:
"Our impression was that you had some lobbyists and they were pushing very
hard with the Science Council [NeST). Their agenda was to convince the
politicians so that they can give them the go ahead Uor their products]. So the
target for those lobbyists was not science but members of parliament. So no
attention was given to places like [regional organisation B)." (RSPo-GP6,
biomedical research scientist, regional pro-biotechnology organisation, Mar.
2008)
While a non scientist from the civil society complained:
"If they [scientists and government] have nothing really to hide, why choose just
a section of the members of parliament, fifteen of them, majority from Eastern
Ukambani?" (NGOf-NS2, farmers' rights advocacy, Nov. 2007)
Others non scientists (contrasting the views of civil society interviewees) felt that the
sensitisation role was geared towards lobbying for the enactment of the bill but did not
see any hidden agenda in doing this.182 Journalists interviewed in this study admitted
receiving sensitisation training on biotechnology through the non state scientists both
locally and abroad. They further admitted to have worked with the GP scientists with an
objective of ensuring informed scientific reporting on GE technology. They perceived
this to be a positive influence in terms of changing the negative perception of GMOs
advanced through the media, towards informed and positive reporting.l'"
v. Scientists adopting a "seeing is believing" as a tool for persuasion
"Seeing is believing" is a concept extensively used by many interviewees, both
scientists and non scientists.l'" The research scientists in collaboration with the policy
scientists, non state scientists and industry confirmed that they devised a strategy to
have the policy makers visit the biotechnology facilities, particularly the open field
trials locally and abroad:
182 Interviews with TAD-NSll, LABp-NS8, JO-NS6 and TAI-NSlO.
183 Interviews with JO-NS6 and JO-NS7.
184 Interviews with TAN-NSS2, Blp-PSI, RSPu-GP4, RSln-GP2, TAR-NSSI, RSPu-GP8, RSPu-GPI, ABp-PSI4,
LABp-NS8 and TAI-NSlO.
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"We organized for tours with other stakeholders so that policy makers can
appreciate thefacilities and preparedness that we have as a country to manage
and contain this technology." (ABp-PS 14, technological & biosafety policy
advisor, MOA, Feb. 2008)
Many of these interviewees perceived this as a way of convincing policy makers to
identify with real evidence of GE potential locally and abroad. This way, they were
bound to debate positively in parliament (from an informed point of view) after being
persuaded and convinced concerning GE technology. One practitioner commented:
"These outside trips have mainly involved the policy makers particularly the
parliamentarians because these are the people who can move the biosafety bill
in parliament. They had to be convinced first. " (RSPu-GP8, research scientist,
PRJ, Dec. 2007)
One non scientist supporting this approach perceived it to be positive influence:
"Going to the site is good exposure...They may appreciate what they see in a
different way. I do not think it is any form of bribery" (LABp-NS8,
parliamentary counsel, Attorney General's chambers, Jan. 2008).
In contrast, other non scientists from civil society linked this strategy to negative
influence citing potential manipulation of policy makers' thinking, to favour interests of
certain players.
6.3.2.4 Conclusion with respect to scientists role in legalising the regulatory
regime
Biosafety formulation process as a pertinent step in legalising the regulatory regime
engaged the scientific community intensely, using persuasive strategies in an integrated
way. This was however viewed with suspicion by some interviewees, who were
concerned with what they viewed as biotechnology promotional agenda and associated
politics. A non scientist argued that the nature of activism portrayed by the scientific
community in pushing for the enactment of the bill mirrored that of anti-GMOs activists
(JO-NS7, journalist, Mar. 2008). Several documents obtained during field work and
190
personal observations during some of the scientific forums that I participated in during
field work seem to confirm this pro-activeness.i'"
The analysis of the empirical data presented in this subsection suggests that policy
related learning occurred at various nodes, among and across individuals but more
importantly within strategic relationships. Evidence presented here further suggests that,
knowledge produced at these diverse knowledge nodes influenced the regulatory
process. It is however not clear from this conclusion whether the regulatory instruments
in terms of content and the outcome of decision-making processes were influenced in
the process. This is investigated in the next section. This way, the distinction between
influence of the regulatory process and influence of output of the process is clarified.
6.3.3 Influence: safeguards and control checks
There seems to be strong evidence presented in the foregoing analysis that the scientific
community had an influence on the regulatory trajectory. There were however different
interpretations as to whether this impacted the final content of the regulatory
instruments or particular outcomes of the NBC regulatory decisions.
Some interviewees explicitly described how the interests of scientists were inputted
during the drafting of the first regulations whereby the content made provisions for
scientists' subsequent ownership of the biosafety implementation process.l'"
A number of interviewees reported cases of attempts by scientist actors to influence the
regulatory outcome.l'" One of them remarked:
"We still have the challenge of people [applicants, scientists] trying to go
lobbying, looking for who would be influential" (PRp-PSI0, regulator,
phytosanitary regulatory agency, Jan. 2008).
18S The minutes of Biosafety Consortium (BC) and DFAB meetings. During the BC meetings, the subject of
discussion was the flopped biosafety bill and revived strategies to engage the new members of parliament while
addressing the shortcomings of the previous persuasion strategies.
186 Interviews with ATBp-PSS, RSIn-GP2, ARp-PS2 and TAI-NSlO.
187 Interviews with RSPu-GPl, PRp-PS4, TAD-NSS6, TAR-NSSI, ARp-PS2, PRp-PSIO and ATp-PS3.
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Meanwhile, another policy scientist explained how the pro-GE scientists tried to
influence some content of the bill to suit their interests:
"Some people wanted the number of days that the NBC or the proposed
authority takes to make a decision to be reduced from 270 days to 90 days. This
even went up to members of parliament committee who had almost been
convinced. "(ATp-PS3, technological & biosafety policy advisor, public
university, Nov. 2007)
Despite cited attempts to influence the regulatory process, many interviewees were
optimistic that influence of the outcome of the process was unlikely. One senior policy
interviewee made the following remark to support this view:
"There was an attempt to try and influence how we would think about certain
things. I do not believe they {biotechnology proponents] have influenced the
regulatory environment otherwise by now we are supposed to have done things
that really should not be done. They had the interest of getting certain things
through which they have not gotten. It is true they have spent significant
resources to try and get the regulatory process moving but they have not
influenced the content of the final product. They may have influenced the
thinking in delivering the final product. If they had any influence; the draft bill
would be completely different and even the policy." (PRp-PS4, regulator &
policy advisor, regulatory agency, Feb. 2008)
Different explanations were provided by interviewees to show how influence of
outcome was minimised through safeguards and control checks. These are explored next
thematically.
6.3.3.1 Credibility of scientists and capacity
Many interviewees felt that. credibility of scientists curtailed any attempt by interested
players to use them to influence the final regulatory outpUt.188 A regulatory scientist
noted: "I believe the Kenyan scientists still have independent thinking about GE science.
Since 1996, we have not had a GE product." (PRp-PS4, Feb. 2008) While a NSS
interviewee confirming the credibility noted:
188lnterviews with RSln-GP9. RSPu-PS7. PRp-PS4. RSAc-GP5. TAD-NSS6. TAR-NSSI. TAN-NSS4. TRTp-NSS3.
ATp-PS3 and TAN-NSS2.
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"There are quite a number of people within NBC who are quite independent.
They are not necessarily going by what the Americans want. Professor S [NBC
chair] is very clear and open and when some of these things come up [attempts
to influence}, he will say the best thing is this way for this country [and would
suggest] ...we need to go that way, not this way." (TAN-NSS4, technology
advocacy, regional NOO, Oct. 2007)
Further, scientists had learnt and acquired technical understanding of OE issues that
enhanced science-based and independent reasoning as argued by the then chair of the
NBC: "NBC members are now more experienced on how to handle issues. I don't think
anypotential compromise would gofar. " (ATp-PS3, Nov. 2007)
This analysis still leaves some unanswered questions related to the balance between the
credibility of scientists and the potential of exogenous pressures to influence scientific
practice. These issues are revisited in the next chapter.
6.3.3.2 Credible national regulatory checks
As much as interviewees admitted that there is likelihood of OE researchers being
influenced by pro-biotechnology partners through the research projects, they argued that
there were enough regulatory checks to thwart any attempt to influence the outcome of
the regulatory process:189
"Because other regulatory frameworks are in place and because our approvals
are strictly based on scientific risk assessment, compromise will come out quite
clearly. I do not think they [scientists sitting at NBC] can go far in influencing.
The NBC is not made up of scientists alone. If you go there with your vested
interests as a scientist, there are these other scientists from other organizations.
As much you may want to influence, there are these others who represent
different interest groups of Kenyans." (ATp-PS3, technological & biosafety
policy advisor, public university, Nov. 2007)
Confirming the NBC credible approach to decision-making processes, one GE
practitioner who has been an applicant perceived the NBC to be firm in its decisions:
"Ideally the donor would have wanted us to [do things differently] but our
regulator said no, [the vaccine trial] has to be confined. So I am very happy
that we [NBC, research scientists & Kenyan regulators] managed to stand our
'89lnterviews with RSPu-GP7, ATp-PS3, PRp-PS4 and TRTp-NSS3.
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ground and still have the trial confined, although it didn't turn out the way they
[research partners & donors] wanted. " (RSPu-GP7, animal research scientist,
PRJ, Jan. 2008)
Others felt that there were adequate safeguards to enhance a credible process driven by
national interests rather than interests of specific groupS.190 One GP interviewee who
has been in the sub-committee drafting the biosafety bill commented:
"The influence [by pro-GMOs players] is not much because sub-committees are
national teams who are government institutions, so international organisations
are not influencing final content of policy documents. They expressed their
concerns through various channels but the final national team made the
decision. I would say if allowed, NGOs can drive the process. They have other
agendas but national interests should be upheld. ' (RSPu-GP1, research scientist,
PRJ, Jan. 2008)
Two interpretations can be drawn from this analysis. First, this analysis seems to
contradict the earlier presented scenario that government coordination role of regulatory
process was masked by integrated activism of scientists and pro-biotechnology actors.
Second, the analysis seems to point towards the government firm control of the process,
and therefore not a passive actor as portrayed in the earlier discussion. Both these
scenarios have implications for the conclusion drawn in relation to potential influence
of the regulatory process, instruments and outcome of regulatory decisions by scientists
discussed further below (see section 6.3.3.4).
6.3.3.3 Resistance from anti-bill groups
Critical analysis of media reports and accounts of interviewees suggest that the
opponents of the bill consistently campaigned against the bill and hence had an
influence on the process and public opinion. These efforts to discredit the bill, worked
against interests of pro-GE proponents as one journalist explained:
"I pity the GE proponents in Kenya; they are not quite articulate in pushing
their agenda. Something very small sparked off by the opponents tends to have
the ear of the population or to win the hearts of the majority. The proponents
190 Interviews with RSIn-GP3 and RSPu-GPI.
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are usually overwhelmed by the opponents." (JO-NS7, journalist, local daily,
Mar.2008)
Fighting the bill by opponents was one activity that disappointed those who were
pushing for its enactment as discussed in Chapter five, section 5.6.1. One scientist
confirming this lamented:
"But unfortunately they have an upper hand...they went to the streets which the
president considered more than the technical arguments in parliament. But
because of their methods which scientists cannot do; we are not going to carry
placards; it captures the public eye and actually takes the day. They actually
won, whether we want to believe it or not. " (RSln-GP2, research scientist, IRI,
Dec.2007)
Consequently, the government made various attempts to engage the opponents (NCST,
2007; RoK, 2008b). The BioAWARE initiative (RoK, 2008b) championed by the
scientific community in the biotechnology and policy arena was linked to the
controversies surrounding the biosafety bill and GMOs.
6.3.3.4 Conclusionwith respect to safeguards
From the foregoing observations alone, it is difficult to conclude that the different
safeguards curtailed potential influence of regulatory outcome particularly the biosafety
bill in terms of content. This is because two parallel bills with opponents' preferred
content tabled in parliament to counter the government biosafety bill were rejected.i'"
Further, a number of scientist interviewees still felt that the bill was weak to withstand
challenges during implementation (see section Chapter five, section 5.6.2). How then
would the bill be found to be weak by the same scientists whose active role in the
drafting was confirmed by many interviewees? Might this then confirm the government
control of the process in a bid to balance its promotion of biotechnology for economic
competitiveness agenda and its role in safeguarding citizens concerns with regards to
191 A bill tabled in parliament by Mr. Nakitare, a member in the 9th Parliament. In the lO'h parliament, he was not re-
elected. However another bill "the biotechnology and biosafety bill, 2008" was tabled in 2008. Itwas rejected and
consequently overtaken by events when the biosafety bill was approved in Dec. 2008 and consequently enacted into
Law the following year.
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biosafety? These issues warrant further exploration and form a substantive part of the
next two chapters.
The inconclusive nature of this discussion leads to a question related to how influence
should be assessed, perhaps pointing towards the most important aspect of influence -
implications for scientific practice. The next section explores visually how thoughts of
scientists (perceptions) translate into influence (practice), paving way for exploration of
policy recommendations for improved scientific practice in the subsequent chapters.
6.4 Relationship between perceptions of regulations and regulatory
practice
A cognitive mapping technique was used as an analytical tool to organize the
interviewees accounts related to perceptions of regulations, the regulatory process and
consequently linking them to the regulatory practice (see Chapter four, section 4.7.3).
The constructed visual maps explain this interrelationship. Summary of similarities and
differences within and across the three groups of scientists based on perceptions and
related regulatory action were organised and presented in four different maps. Three are
individual group maps (PS, NSS and GP interviewees) while the fourth map brings
together the views of all the scientists based on the commonalities identified amongst
the three categories of scientists. Visual maps are important in linking the thoughts or
perceptions to actions (see more details including how maps were constructed in
methodology chapter, section 4.7.3).
6.4.1 Reading the cognitive map
The short phrases used in the maps refer to ideas or concepts while the arrow links (»
running upwards, from down towards higher level, are read as "may lead to" and
represents intended goal or outcome. The tail of the arrow is representative of a
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triggering event or drivers. The ellipsis ( .... ) where it appears should be read as "rather
than" while an arrow with a negative pole (-) denotes' leads to a negative action' .
Figure 3: Map of Policy Scientist interviewees (PS)
These scientists are working with frameworks that are both process based and product
based (concept 1). They are interested in an effective and facilitative regulatory
framework that would enhance implementation (concept 2). They have views on both
policy process and regulatory decision-making process (left hand side and right hand
side of the map respectively). They also have views on the weaknesses of the decision-
making process (concepts 9, 11, 8) but are able to undertake actions to address these
weaknesses (concepts 11, 12, 18). Regarding policy process, they perceive the
biosafety bill as a gateway to a permissive and facilitative regulatory regime (concept 2)
so are partnering with GE scientists and others to; provide technical backstopping
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(concepts 20, 21), educate (concept 16) and lobby (concepts 14, 13). However they
were conscious of perceived endogenous and exogenous pressures influencing objective
science-based regulatory process (concepts 6, 17, 19) hence initiated controls (concepts
3, 22, 15). Opponents of the bill are perceived to be slowing the policy process (concept
24 & 23) hence enticed to become stakeholders in the process (concepts 22, 15).
1 Technology
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GE science research
& products
2 permtslve ~ 3 Beliefs in GE
regulatory potential to solve/~~j~m~/~7Pro~~
9 Formulating the enactment of bill 4 Collaborating with
blosafety bill ~I GEsupportsl'll as
partnel'll 10Anti-GE Iobbiats
and media slowing
7 Sensitizing • __... process
parliamentsrians and 5 Seeking alliances 121nvolving ~media ~with governmentand stakeholdel'll for an
research scientists all inclusive
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/
8 op~nts fighting
bill
11 Field trials
providing tangible
evidence of GE
potential
These scientists are working with frameworks that are both process and product based
Figure 4: Map of Non State Scientist interviewees (NSS)
(concept 1). They are interested in a permissive regulatory regime (concept 2). They
believe in GE technology and its potential to address agricultural production problems
(concept 3) through deployment of biotechnology products (concept 1). They therefore
support the deployment & regulatory process through enlisting of relationships
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(concepts 4, 5, 7, 12) to establish a permissive regulatory environment (concept 2)
through the bill (concepts 9, 11,6) and counter the opponents (concepts 8, 10).
1 Technology
deployment through
GE research
1
2 Facilitative
regulatory
environment
14 Scientists /"" \backstopping policy --~)o 21 Fonnulatlng the
process blosafety bill! 6 lobbying for.":'"=:--T\~I
7 Sensitization of 8 Soliciting
parliamentarians & political suport7~-
13 Education of
stakeholders to show
case for
\
3Seeklng
relationships with_om~\
4 Delays In decision
process
~
9 Weak Institutional
suppor1for
regulatory process
10 Anti-GE Iobblsts
and media slowing
process •••
supporting
11 FIeld trials
providing tangible
evidence of GE
potential
As practitioners, these scientists may be perceived to be pro-GE technology and process
Figure S: Map ofGE Practitioner interviewees (GP)
based (concept 1). They are working with regulatory frameworks that they perceive to
be constraining their work. They are keen on a facilitative regulatory environment
(concept 2) that they perceive would enhance technology transfer (they believe
biotechnology has a potential-concept 12) and believe biosafety bill is the gateway to
achieving this goal-technology deployment (concept 1). The decision-making process
related to this science is of interest to them (concepts 4, 9). So, they are actively
involved in the regulatory policy process through technical backstopping (concepts 14,
21), lobbying (concept 6), enlisting relationships (concepts 3, 5, 8) and
educating/awareness creation (concepts 7, 11, 13). They also perceive opponents (media
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& GE activists) to have been working against achieving a facilitative regulatory
environment (concept 10) so have actively engaged media in education (concept 13) in
an effort to enhance positive reporting about GE science.
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Figure 6: Scientists shared map
This map shows the commonalities in terms of views and actions. The scientists agree
on a relatively effective regulatory process (concept 2) and are in agreement that
biosafety bill would lead to this (concept 9). Partnerships are enlisted towards
enactment of the bill (concepts 5, 6, 8, 7) and addressing institutional weaknesses
(concepts 3 & 4), while field trials are used as tangible evidence in sensitization of
policy makers (concept 11). The opponents are perceived to be acting against the
process (concept 10) and therefore inevitably brought to the process as stakeholders
(12). Interests that may influence the process negatively (concepts 13, 14) are checked
through controls (concept 15).
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6.4.2 Conclusion with respect to visual illustration of relationship between
perceptions and practice
This graphic representation of views related to regulatory process and instruments
suggest a strong interrelationship between the perceptions held by the Kenyan scientific
community about both biotechnology science and the desired regulatory regime.
Consequently, critical review of the maps points towards a proactive and engaged
nature of both the scientist actors and the regulatory process. The maps complement the
data analysis and interpretation that has informed the empirical chapters and policy
recommendations in Chapter eight. The maps do not however reveal the underlying
factors that underpin this practice, and nature of learning and knowledge produced
through the prominent relationships around the different activities and processes. These
factors are substantively covered in other sections of the empirical chapters.
6.5 Chapter conclusion and summary
The argument advanced in this thesis relate to how scientists impact regulatory process
and instruments through the processes of learning and knowledge production activities
they engage in. Shaping of the regulatory process and instruments is important in
understanding the role of incremental learning and knowledge production dynamics in
scientific practice. Evidence in this chapter suggest that for the scientists to achieve their
desired regulatory goal, cooperation is key and knowledge produced individually must
be augmented by other forms of knowledge to impact policy change. What is however
crucial to note is the nature of influence that is ultimately directed through this interest
driven proactive policy process as graphically presented through the visual maps.
The focus of this thesis is the scientific community, and their role and behaviour related
to implementation of regulations. The exogenous and endogenous pressures and
motivations that confront scientists as they implement regulations cannot be taken for
granted as they are points of reference in terms of the potential to impact behavioural
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change. In addition, the tensions that this process generated relating to regulations non-
compliance, science communication and controversies around the biosafety bill cannot
be ignored as they have implications for implementation of policy instruments and
broader innovation process. Table (l0) below summarises these practice based issues
and the related findings that form the basis for exploration and discussion in the next
chapter.
Table 10: Summary of research findings on role of scientists in regulatory process
& instruments
CHAPTER SUMMARY
Issues Findings
Involvement of scientists in GE work & These motivations and opportunities are linked to diverse
regulatory process spurred by diverse interests and values.
motivations & opportunities.
Tensions emanate during trials execution These are caused by varying perceptions of regulations &
related to regulations non compliance. attitude related factors.
Communicating GE science Poor public communication and biased reporting impacted by
many non technical factors like fear of misinterpretation and
interests.
Role of scientists in regulatory process & -The different activities were shaped by the four different
instruments regulatory phases. Role in the early phase received no
contestation but role in latter phases were characterised by
controversies and activism.
-Activities advanced within and around different relationships
were rhetorical and persuasive in nature towards influencing the
biosafety bill. These relationships were spurred by resources and
varying interests.
-Overall, scientists and their affiliated knowledge nodes have
been sources of different types of knowledge that has relatively
impacted policy and regulatory process.
-The influence of regulatory output is contested supported by
claims of policy safeguards raising questions about governance
and control, and how influence should be ana~ed.
These key findings relating to scientific practice present the scientific community
playing out different roles in different cultural realms, and perhaps unconsciously or
consciously, learning occurs through interactions, while knowledge is disseminated in
different ways. There is a complex interplay between scientific behaviour and the
associated roles, and the underpinning factors that seemingly direct practice and
outcome. This evidence-based complex scenario deserves a critical analysis to establish
the theoretical and policy ramifications which is the subject of the next chapter.
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Chapter Seven
7 Discussion
7.1 Introduction
Biotechnology innovation IS advancing in a relatively unprecedented pace that
challenges the evolution of the requisite structural, institutional, cultural and social
processes that are pertinent for a coordinated social and policy change (Tait et af.,
2006). Pertinent to this thesis are the institutional and cultural changes embodied in the
evolving biotechnology innovation system that illustrate features of Mode 2 knowledge
production terrain described by Gibbons and Nowotny and their colleagues. Biosafety
regulation, being one of the requisite institutional changes for management of
biotechnology knowledge is however bound up in the broader innovation system
transition. In this chapter, the cultural and institutional shifts impacted by the
biotechnology revolution in the context of scientific practice and regulatory practice,
and the implications for the emerging regulatory instruments are analysed.
The chapter is organised as follows: Firstly the perceptions of regulations and practice
are placed within the overall knowledge theme in which this thesis is grounded.
Secondly, specific issues that emerged in Chapters five and six are discussed in order to
develop an understanding of the perceptions of scientists on regulations and regulatory
practice, and their role in biosafety policy processes. This is followed by an analysis of
role and behaviour of scientists in the regulatory process including related tensions, in
the context of the evolving knowledge production terrain. The discussion ends with a
review of the role of the scientific community in the regulatory practice relative to the
influence of regulatory instruments.
203
7.2 Institutionalisation versus adaptation
Developments in the Kenyan modem biotechnology in agricultural innovations as
discussed in Chapter two have impacted major institutional changes at the technological
and policy level. It is also important to note that knowledge drives the purportedly
scientific and technical decision-making processes and is indeed a key resource shaping
the overall institutionalisation process.
The transdisciplinary nature of biotechnology innovation and related governance has
called for integration. This integration was however perceived by many interviewees to
have an economic connotation due to interests of the different knowledge
intermediaries. Moreover, the political economy of Kenyan biotechnology as externally
funded creates suspicion and distrust among players. Some interviewees felt this may
promote bias especially in dissemination of information from GE trials which would
purportedly promote interests of funding institutions, particularly on social matters
related to risk of biotechnology products. The distrust and suspicion views were shared
independently by various groups of interviewees irrespective of whether they are
practitioners, public or in policy arenas.
These issues are not new in the GMOs debate and reflect complex political, social and
economic challenges that characterise governance of modem biotechnology. As
extensively debated by proponents of governance theory (cfTait and Lyall, 2005; Lyall
et al., 2009a), they invariably expose the difficult terrain that characterise
institutionalisation of the new life sciences where diverse interests and values inevitably
drive the policy processes.
From the perspective of theories of knowledge, the involved dynamic
institutionalisation and adaptation by social actors portrays a redistribution of
knowledge from the innovation communities who comprise the research fraternity (who
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previously were perceived to be experts in their own right) and the technology
suppliers, to policy makers and public. It mimics the integrated mode of knowledge
generation and flow characterised by changing knowledge relations and the emergence
of new networks of knowledge users and producers (Gibbons et al., 1994; Nowotny et
al., 2001; Haas, 2004; Philips, 2007). This notwithstanding, these theories do not
explain vividly the behavioural changes that players experience simultaneously
alongside the linked institutional changes which are not confined to research arena as
implied by proponents of Mode 2. Interestingly, the players involved may even be
unconscious of the implications considering the shifting of perceptions by actors
prompted partly by the dynamic relationships and cumulative learning. This impacts the
ensuing knowledge use as discussed in the subsequent sections.
7.3 Perceptions of regulations and regulatory practice
Chapter five highlighted key issues which suggest that perceptions of interviewees
changed over time which can be linked to the four significant regulatory phases
discussed in Chapter two. The institutional dynamics involved have significantly shaped
the views of the interviewees about regulations and practice. This section is grounded in
this changing institutional context in an attempt to address the first research question:
the perspectives of scientists on implementation of biosafety regulations and reasons
behind the expressed views.
As demonstrated empirically in Chapter two, the development of a regulatory system
has been bounded up in the broader biotechnology innovation process. This distinction
makes it possible to relate the perceptions related to regulatory process to the broader
innovation process and scientific practice. This is because the twin processes of
biotechnology innovation and regulatory process are highly interlinked and iterative as
Fig 1 in Chapter one, section 1.1.3 illustrates.
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7.3.1 Contested risk assessment and decision-making processes
7.3.1.1 Challenges in decision-making process
The National Biosafety Committee (NBC) has been the interim institutional structure
(as a boundary organisation) through which regulations and decision-making processes
have been implemented. The interim structure has indeed facilitated biotechnology
deployment and establishment of a biosafety regulatory regime. However, this thesis
has brought to the fore certain inefficiencies inherent in this interim structure related to
institutional weaknesses and coordination of a transparent biosafety bill formulation.
The strength of any regulatory system would be determined based on legally binding
and clear regulatory standards (Maclean et al., 2002; Jaffe, 2006). Without undermining
the regulatory purpose that policy targets expected the regulations to articulate, without
clear regulations (at least prior to the Biosafety Act, 2009), the Kenyan regulatory
process was left to different interpretations and practices. It was therefore not a surprise
that many interviewees perceived the process to be inefficient.
Effective implementation of biosafety regulation is determined to a large extent by
institutional and capacity issues (Maclean et al., 2002; Traynor et al., 2002). Lack of
clarity of regulations brought about different conflicting approaches to risk assessment
and consequent decision-making processes. This challenged the scientific and technical
process advanced by the main regulatory instruments and desired by many interviewees.
This notwithstanding, the big question that is posed here relates to how the challenges
reported by interviewees impacted regulatory practice and with what implications for
scientific practice (this is discussed further on in the chapter).
7.3.1.2 Science based process versus value laden process
It is widely accepted that risk assessment procedures and consequent decision making in
regulation of GE activities should be based on sound science. However, accounts of
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scientists seem to put to doubt the objectivity of the decision-making process which
many interviewees repeatedly described as science-based or scientific. The regulatory
instruments that have since guided risk assessment also emphasise on science-based
process (RoK, 1998; RoK, 2009). The challenges and objectivity issues discussed here
relate to conflicts and tensions encountered in science policy debates (Newell, 2002). In
science-policy related activities that include use of scientific expertise, objectivity as
seen from a sound science perspective and transparency are highly constrained
(Levidow and Carr, 2007). The tensions that characterise the risk assessment (RA) and
decision making styles adopted by the NBC put the issue of "objective" decision-
making process into contestation in a manner similar to the case of European Food
Safety Authority (EFSA) illustrated by Levidow and Carr (2007). The deliberations of
EFSA, just like the NBC, are "officially" transparent and objective. However conflicts
and tensions have arisen due to difficulties experienced in an attempt to separate science
and policy since the two overlap significantly (Ibid,: 888).
7.3.1.3 Scientific versus social interpretations in decision-making processes
Contrasting arguments run through narratives of interviewees related to perceptions of
two related subjects: one, role of science in decision-making process and two,
representation and engagement in biosafety bill formulation. The "scientific"
interpretation of regulatory process emanates from the "objective science" approach to
regulations. In contrast, "social" interpretation seems to favour a broader view that
encourages integration of wider supposedly non-science considerations. These
interpretations, spread out across different groups of interviewees (scientists and non
scientists) reflecting diverse framings of GE technology and regulation resonate with
Hajer's (1995) conception of GMOs discourses. The scientific arguments emanating
from some pro-biotechnology coalition members reflect the "sound science", "science
based", "objective" and similar terms that protagonists use in their debates about GE
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science. On the other hand the frames like "subjective" and "biased" characterised the
positions or beliefs of those who hold a different perspective (mainly opponents).
The articulation of these arguments may be construed to mean that scientists may still
be trapped in their disciplinary based scientific thinking (Mode 1) where science was
perceived to be a neutral judge for the solution to policy problems. NBC was a perfect
sphere for deliberation of the social and scientific confrontations inherent in GE debate
where science-policy politics challenged the dominant and purportedly normal scientific
practice.
i. Understanding the social and scientific interpretations
Kenyan scientists interviewed in this study expressed desire to have the social and
science issues separate in biosafety regulation to enhance technology transfer and
regulations implementation. However, there was a clear distinction in the way the
interviewees interpreted the two concepts. When it means moving the science forward
(to products) the social must be given space as illustrated by the following remark from
a senior policy scientist:
"At the end of the day it depends on what you want as a country. Do you want to sit
back and hold on the science until you get the perfect [legal regulatory
environment] situation because these are trials? Science does not change, law or no
law; science remains fixed because it is something that is justified GE is a science
and existing regulations are science based. Biotechnology is a process that leads to
a product. There are no laws to protect the product of science, then there is a
problem because the products are going to be consumed and that is a decision you
cannot make with science alone. " (PRp-PS4, regulator & policy advisor, regulatory
agency, Feb. 2008)
Boundary work offers insights that can be drawn to interpret the contradictory
perceptions oscillating between social and science arguments. As Gieryn (1995:440)
contends, boundary work tends to separate science from non-science. This separation
conceptualises science and politics as two different social activities. In practice, this
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separation is problematic as exposed by the current study. Through the scientific
community engaging in boundary work, two objectives could be met. Firstly as experts,
they struggled between science and politics in an endeavour to uphold the cognitive
authority of science among scientists and outside this group (Gieryn, 1995:434-435).
Secondly, as policy makers, they used scientific knowledge to legitimise the regulations
(or regulatory process) to enhance objectivity and in the process re-configured the
scientific facts to balance the science and social concerns (Jasanoff, 2004b). One clear
reason for separating social from scientific in the Kenyan context was to legitimate the
regulatory process which proved to be problematic, at least for the innovation
communities like scientists.
Knorr-Cetina (1995:146) describes the origin of these artificial separations by noting
that "traditionally, social has been seen as external to the conduct of science." Jasanoff
(2004a:2) also debates the conflicts between these arguments using the "co-production"
framework192 and argues that scientists tend not to see the bigger picture, that any form
of knowledge is a product of social work. Perhaps what they fail to realise as affirmed
by Jasanoff and Knorr-Cetina is that, knowledge production involves "negotiation" and
"translation" of results that highlights the social character of that process. During
knowledge production scientists grapple with issues which they label as scientific and
non-scientific (Knorr-Cetina, 1995:154). Consequently the context and content of
scientific activities are continuously reconfigured and tacit agreements about what is
science and non science are negotiated to address controversies (CalIon, 1995:50-63).
ii. NBC as a boundary organisation
The NBC (as a government instrument overseeing boundary work) seems to have
played a big role in shaping views of scientists. Boundary organisations endeavour to
192 Co-production implies that "in broad areas of both present and past human activity, we gain explanatory power by
thinking of natural and social orders being produced together" (JasanotT, 2004a:2).
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draw an artificial line between scientific and political processes in terms of authority
and action through negotiation (Jasanoff, 1990; Guston, 2001). The work of NBC seems
to have concretized or reinforced the social and scientific arguments in practice. Firstly,
NBC derives its understanding of GE technology and biosafety from work of scientists.
This way, what scientists provide (e.g. for RA) may be construed to be scientific if it is
finally accepted for decision making by the NBC. If it is rejected, then it may be
categorised to be non-scientific (or social)."? Second, its practice relating to how it
conducts its business pertaining to regulation of GE technology confuses observers. It is
confusing and contradictory how the process can be based on sound science yet
decisions made are consensual.
Although the intention of the NBC is to bring harmony between science and politics, the
institutional weaknesses exposed frustrated scientists as it endeavoured to separate
social from science.!" For instance Mugo et al. (2005:1492), reacting to the
constraining and confusing nature of regulations, noted: "there have been cases of
conditions becoming stricter and non science based decisions influencing the process."
7.3.1.4 Conclusion with respect to contested processes
The issues reported here are not new but reinforce the controversies in governance of
environmental and the new life sciences (Miller, 2004; Lyall and Tait, 2005). However,
use of the concept of boundary organisation in analysing the effectiveness of
institutionalised structures and actors' practices (cf Kristjanson, 2008) enriches the
governance theories.
193This has implications for public policy in that the NBC selectively decides who, what and which evidence to
consider scientific for decision making purposes, making it possible to exclude particular views or sources in the
rocess. This can effect trust (scientists not trusting NBC and activists not trusting the scientists and government).
94lt may be concluded that this governance style adopted by NBC is confusing to actors and has implications for
perceptions because scientists tend to construct their images regarding what is social and scientific based on this.
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7.3.2 Prospects and risk perceptions in framing regulation and regulatory
processes
7.3.2.1 Technological prospects
One main argument expressed by all the scientist interviewees (except one from civil
society) is that biotechnology innovation can only achieve its potential to address
production constraints if supported by an effective regulatory regime. This being the
case, the sentiments about the nature of biosafety regulations and the institutional
structures to support implementation were based on this view.
These findings are not different from what others have reported regarding the history of
biotechnology research in Kenya. They point out the direct correlation between
agricultural biotechnology research and its governance (Ayele. et al., 2006; Harsh,
2005; Harsh, 2008; Mugo et al., 2005; Odame et al., 2002, 2003). GE technology was
the trigger for the existing regulatory regime. Odame et al. (2002, 2003) for instance
highlights how the Kenyan regulations were driven by technological pressure. It is
therefore not surprising that interpretation of regulations would relate to the historical
background. Thus, any held perception is likely to be interpreted in terms of whether
this technological pressure has been sustained, curtailed or enhanced.
Many scientists seemed to have formed an idealised stance about the direct and
seemingly uncontested prospect for GE technology to deliver solutions to agricultural
problems. According to Scoones (2002), it is not uncommon for scientists to take an
idealised stance regarding GE technology as a "magic bullet." This stance nevertheless
masks the broader social issues associated with biotechnology innovation as some
scholars have observed (Hisano, 2005; Scoones, 2002; Andanda, 2006). This stance is
concretised at the regional and international level. For instance, a FAO report of 2004
seems to support that GE technology may be explored and should be given a chance in
addressing food security challenges. Other regional policy initiatives also seem to
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support the same view (Juma and Serageldin, 2007). "Biotechnological determinism"
has been used to describe this technological mindset referring to a linear thinking that
assumes that production of knowledge leads to production of economic production
(Levidow, 2007; Jasanoff, 2002). It assumes that a technology "moves down a pre-set
path" (Harsh, 2008:48) and ultimately achieving global competitiveness (Levidow,
2007). This seemingly narrow thinking underplays the complex institutional issues
inherent in innovation systems that call for holistic thinking (Hall, 2005; Clark, et al.,
2003).
7.3.2.2 Risk based regulatory approach
Many interviewees were sceptical about OE technology and its safety. The regulatory
instruments in addition to the risk management measures imposed on the trials were
actually regulating potential risk to the environment. But different interpretations of risk
exposed the preferred regulatory approaches and decision-making processes.
Policy scientists, driven by fear linked to public accountability and stability of their
institutional careers preferred cautious but permissive regulations. Caution was to
safeguard against any unexpected risk that may be posed by the OE trials and
facilitation was to enhance research under confinement thus minimising chances of gene
escape (KEPHIS, 2004a). Balancing the two was achieved through drafting of
regulations that could only facilitate OE trials under confinement (RoK, 1998). This
early cautious approach to regulations reaffirms what other scholars have reported.
Sander (2007) for instance asserts that Kenya initially adopted a precautionary approach
to biosafety regulation due to lack of capacity and knowledge to institutionalise
biosafety and secure safety in modem biotechnology. Paarlberg (2001) concluded that,
Kenya's regulations were "precautionary" and restricted the entry of OM research
material. The current study reinforces these claims by identifying uncertainty and fear
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of the unknown associated with biotechnology as a contributing factor to the
precautionary position adopted.
In case of other countries' risk regulation approaches (cf EU precautionary approach),
caution would be aimed at addressing social conflicts related to risk uncertainty
(Levi dow et al., 1999). The uncertainty revealed in the Kenyan case was not directly
related to public safety, but rather uncertainty sparked by constrained freedom of
regulators from making independent regulatory decisions. This was linked to lack of
legal instruments that would guide RA and protect regulators irrespective of regulatory
decisions made. The following comment that has also been used in Chapter five, section
5.5.2.1 supports this analysis:
"The problem with regulations and the regulatory system in Africa which is still
developing. the individual person as the regulator has a problem because you
fear that if I allow this thing and something goes wrong, you will be the one to
be slaughtered. So the fear that you might get cheated and you do the wrong
thing and you lose your job and your children go hungry. " (RSIn-GP2, research
scientist, IRI, Dec. 2007)
This approach to regulation although risk based mimics the government's approach
(Tait et al., 2006) and the EU precautionary style which advances "it is better to be safe
than sorry" (Marchant, 2001:143). Indeed many interviewees consistently likened the
Kenyan regulatory decision-making process to Europe's precautionary regulation,
expressing their dissatisfaction with restrictive regulations that seemed to constrain GE
technology advancement beyond confinement.
The Kenyan style of regulatory decision-making process is not unexpected. From
global, regional and local context, regulation of GE technology has adopted a risk
approach (Cartagena Protocol, 2000; African Model Law; RoK, 1998, 2009; Andanda,
2006). But how these transnational and national contexts may have influenced the views
expressed by the scientists may not be apparent. This notwithstanding, the data suggest
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that the debates around product based and process based regulation (Tait and Levidow,
1992; Chataway, 1992; Jasanoff, 1995; Dunlop, 2000) had a major impact on
interviewees' perceptions of regulations. For instance, the pro-biotechnology
interviewees aligned themselves with product-based approach and tended to prefer risk
judgement based on quantifiable risk and sound science. Some policy scientists and non
scientists from civil society were however proactive and cautious and preferred
"government approach" with some form of regulatory control. This implies that risk is
value-laden, making biosafety regulation to be contested based on different
interpretations of risk.
7.3.3 Shifting perceptions of regulations and implementation
Framing of GE technology as a key agenda in the agricultural revolution has increased
the number of stakeholders in biotechnology innovation. At the early stages of the
regulatory process in Kenya, there were no major concerns in the way biotechnology
innovation was being governed. This may be associated with the purportedly few actors
and the limited knowledge in the supposedly new science and related biosafety. During
the technological and institutional transition from regulatory phase 1 to 4, the number of
actors proliferated, with the civil society becoming a central player in the governance
agenda in the latter regulatory phases. This increased the controversies with the framing
of regulations shifting from promises (benefits) approach advanced earlier towards
cautious (biosafety) approach. Framing of regulations in the context of prospects and
risk brought to the fore the economic and political context driving the construction of
views around regulatory process, exposing diverse values held by the scientific
community and other stakeholders.
It is possible for perceptions of actors to evolve and change with time alongside the
evolution of regulatory phases and technology development. Different reasons may be
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attributed to this. Firstly, using innovation systems thinking, perceptions of actors in a
dynamic system are not expected to remain static because of incremental learning that
takes place as actors interact in different ways. Consequently as actors become familiar
with both the technological and regulatory system, perceptions may also change based
on the way they are governed and how regulatory instruments impact upon the intended
outcome (Tait et al.• 2006). It emerged that the regulatory instruments were curtailing
knowledge generation and flow more generally. Some of the experiences revealed by
both practitioners and policy scientists indicate that certain aspects of the decision-
making process were very frustrating due to undefined or lack of clarity of existing
regulatory standards. The associated weaknesses seemed to emerge as the regulatory
regime matured from regulatory phase 1 towards phase 4 as actors experienced
regulatory constraints.
Further, scientists' regulatory preferences varied as the GE products moved from
containment, field trials and the anticipated commercialisation. This change in
perception along the product development continuum mimics the observation by
Chataway et al. (2006) involving policy makers and industry managers in the USA and
Europe. Based on different perceptions, these scholars could categorise different policy
instruments as enabling or constraining.
7.4 Role and behaviour of scientists in the regulatory process
In this section, reasons behind the actions taken by the scientific community as they
engaged in regulations formulation and regulatory practice are discussed in order to
address the following research question: how scientists shaped the evolution of the
regulatory process and instruments. The focus relates in particular to how risk
assessment information was managed, how regulatory decisions were made, how field
trials were managed, how information emanating from the field trials was handled, and
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finally how scientists engaged In the development of regulatory instruments,
particularly the biosafety bill.
7.4.1 Theoretical insights
To enhance the analysis, insights are drawn from theories of knowledge (e.g. Mode 1
and Mode 2 thinking). innovation systems (IS), policy coalitions and science policy
literature. The latter two concepts as described and applied by a number of researchers
augment the application of knowledge principles through the understanding of the role
of linkages in learning and knowledge dispersion. Policy coalitions, just like policy
networks explain how knowledge and diffusion are applied in policy processes through
influence achieved via interactions and negotiation (Lyall, 2007a; Sabatier, 2007). It
enriches the understanding of relationships building and interactions advanced in the IS
framework in which this thesis is grounded. Science policy and policy coalitions
concepts further add value to the analysis by grounding Mode 1 and 2 practice in the
political context under which biosafety regulation takes place.
7.4.2 Motivations for scientists and drivers of change in behavioural practice
Scientists' motivations for engaging in GE technology and related regulatory activities
coalesced around endogenous and exogenous motivations. The former reflect values
and interests that are personal. social and sometimes technical in nature (e.g. publishing
and fame). The latter is linked to contextual factors that confront the scientific
community (e.g. external funding for purportedly public research). These different
motivations albeit evoking the risk of conflict of interest, interplayed significantly to
influence the views and behaviour of scientists. Consequently, shifting social identities,
clear science policy roles and new forms of policy relationships were exposed.
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7.4.3 Scientists as experts in the regulatory process
Scientists in their capacity as experts played two key roles in implementation of
regulations, one as proactive agenda setters in matters of purportedly technical
biotechnology subject and two, as resources for actors in practice, government and
industry in the technical and non technical matters of biosafety policy. In articulating
these roles, they provided expertise as individuals or corporately within institutional
knowledge-based nodes (NOOs, government departments, research and academic
institutions, and professional and disciplinary groups). Provision of scientific expertise
is a role that all scientists are expected to be playing in uncertainty bound and complex
technical problems (Haas, 2004; Weingart, 1999; Jasanoff, 1990). Indeed, the
importance of scientific expertise in biotechnology regulation and environmental
policies has not been disputed (Scoones, 2002; Keeley and Scoones, 1999). However,
different challenges arise related to the way experts play out this role and which is
inadequately addressed by knowledge dynamics literature.
Gieryn (1995:440) and Haas (2004:572) point out that social and cultural factors may
constrain production of knowledge. For instance the different intermediary groups that
the scientific community belong to constrain independent thinking and policy actions.
This may imply that the knowledge generated from such knowledge nodes may be
subjective and has implications in its potential to misinform or manipulate science
policy processes. In the Kenyan context, experts seem to be coming from a few
institutions namely research institutions, regulatory agencies and academic institutions,
but who are connected to a wider stakeholder or intermediary groups outside the
government circles. This may not be surprising because capacity in both biotechnology
and biosafety is being developed and therefore experts serve multiple roles as OE
technology experts, biosafety experts, risk assessment reviewers and policy advisors.
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Most of the interviewees have served in multiple capacities in the science policy arena
at different times in their careers.
Multitasking demonstrated in Kenya with respect to expertise is common in the science
policy domain as Jasanoff (1990) and Rothstein et al. (1999) contend, referring to
regulatory systems in the USA and UK respectively. However, there seems to be a
problem in the way Kenya's expertise role is played out. It reflects an incomplete model
of expertise demanded by a socially desirable knowledge production atmosphere
(Nowotny, 2003). A complete model of expertise (that would produce knowledge that
meets the demand of an increasingly informed public) should be broader perhaps
coming from civil society who may be representing public or non-scientists. Nowotny
contends further that democratising expertise is problematic and tensions tend to
emerge. Perhaps what the scientific community (particularly the policy makers) seems
not to be aware of is the difference between scientific or technical expertise and the
broader expertise. This area needs to be addressed through appropriate institutional
policy and practice reforms (see Chapter 8).
7.4.4 Scientists behaviour reflecting shifting identities
Scientists had various obligations that they kept in mind as they endeavoured to
implement the regulations. They talked of meeting their basic personal scientific goals
as researchers in their various rights, meeting their organisational obligations as
employees, demonstrating the usefulness of GE especially through field trials, attracting
financial support for individual projects or organisations and responding to policy
demands. Consequently, several types of strategies were initiated and different
relationships forged to achieve these obligations and motivations.
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7.4.4.1 Diverse relationships during implementation of regulations
Researcher-patron relationship: The research terrain has changed with reduced
government support for research (most interviewees expressed displeasure with the
government regarding this) and this has made researchers seek resources elsewhere.
Some of these external sources of funds have been the biotechnology industry and
donor organisations. Consequently scientists have signed research contracts with the
biotechnology proponents within the increased Public Private Partnerships (PPPs) (see
also Ayele et al., 2006). Supposedly, easily available research funds became a
motivation for engaging in GE research as one interviewee argued:
"I found that most scientists hijacked the train from being conventional breeders
to biotechnology for one very unfortunate reason; the money. They jumped from
their normal research and it is like everybody wanted to be in the biotechnology
industry, there was money. As a scientist in your laboratory somewhere you may
be sitting there askingfor reagents for the last 2 months and then biotechnology
comes with money"( JO-NS6, journalist, local daily, Apr. 2008)
This kind of relationship is a global phenomenon and is expected because of reduced
funds for public research by respective governments (Waterton, 2005). What is perhaps
important is the outcome of this kind of relationship in terms of implication for what
would be considered socially desirable practice. Moreover, it is not unusual for
researchers to solicit collaborations in pursuit of non-technical gains. A recent study
involving Malawian social scientists revealed that Mode 2 researchers engage in
consultancies for economic gains and not necessarily to contribute to scholarship
through publications (Holland, 2009).
Researcher-policy-maker relationship: Alongside the modem biotechnology
programme, a regulatory regime was initiated by the government to support
biotechnology activities. Scientists in both policy and practice arenas became actively
involved as champions in the institutionalisation process. Another kind of unofficial
contract gradually emerged between scientists and government. Consciously or
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unconsciously. the scientists could influence policy as experts depending on the
dynamics of each of the evolving regulatory phases (see Chapter two. section 2.4).
Researcher-regulator relationships: Other contracts were prompted by the granting of
approval permits to conduct trials where scientists were obliged to comply with terms
and conditions of the approval permit (KEPHIS, 2005; NCST. 2006b). Two official
contracts consequently emerged (between NBC and the respective regulatory agencies
like KEPHIS and DVS). Through these contracts, specific shortcomings related to
institutional infrastructure were exposed which have implications for policy
implementation (see Chapter five).
Scientific community-public relationship: Another type of contract was gradually
conceived towards the later stages of the biosafety bill debate (phase 3), prompted by
the growing tension between pro-biotechnology groups and anti-bill coalition groups.
The scientists in policy and practice became increasingly aware that when designing
policies that have social concerns, they needed to think about the public and be
responsively accountable to them. This culminated into the launch of the National
Biotechnology Awareness Strategy (RoK, 2008b) as a platform for engaging the public
and other actors in biotechnology related matters.
Employer-employee relationships: All the contracts mentioned above are in addition to
the institutional or organisational contracts that the scientific communities get hooked to
by the virtue of being employees. These relationships are important because they open
up opportunities or space for production and diffusion of knowledge emanating from all
the other contracts as well as various knowledge-based nodes (e.g. adhoc coalitions and
technological groups).
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7.4.4.2 Shifting patterns of behaviour and regulatory roles
Scientists' identities consciously or unconsciously kept shifting m line with the
evolution of the regulatory system (through the four regulatory phases) as they tried to
accommodate the demands under each relationship described above. In phase 1, there
was no argument about the role of contemporary science and contemporary scientists in
guiding the regulatory process, even with the presence of donors, as Sander (2007)
contends. In the second phase, again the role was clear as scientist experts engaged
extensively in guiding the direction of the regulatory instruments with regards to
formulation (see also Harsh, 2005). There was a clear boundary between science and
policy, with occasional overlaps between institutional, policy, academic and technical
practices.
In the latter part of phase 2 and the entire phase 3, there was an evident merger between
science and policy, with the process becoming politicised as all players pursued what
they perceived to be a legal and desired regulatory regime. The government increasingly
relied upon the scientific experts to inform the regulatory policy in terms of resources
(scientific knowledge, finances and information). As the data suggest, scientists could
reflect on their behaviour and that of others (e.g. NGOs) during this transition. The
fourth phase has just commenced after the approval of the Biosafety Act, 2009, perhaps
opening up opportunities for engaging public practically and testing the implementation
of this particular regulatory instrument.
The experiences of scientists discussed here can be compared to studies that explain the
shifts in knowledge production dynamics (Gibbons et al., 1994; Nowotny et al., 2001).
Consequently, scientists try to find niches in the emerging cultural spaces of science
(Gieryn, 1995: 416) within a dynamic Mode 1 - Mode 2 continuum. From this
perspective, the overlaps between science, policy and public represents an empirical
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example of changing knowledge-based relationships. This has implications for scientific
practice. In trying to adapt to this challenging terrain, confronted by multiple
obligations, different identities are inevitably exposed as discussed in the earlier section.
These dynamics mimic the findings described by Waterton (2005) and Waterton et al.
(2001) about UK scientists engaged in boundary science policy related work. Waterton
(2005) argues that reduced government funding for research encouraged contract
research that demanded different accountabilities (public, home institutions,
government, regulator, funding institutions etc). This resulted in diverse forms of
science-policy relationships that supposedly shaped the different kinds of knowledge
produced by individual scientists, packaged to fit the requirements under each
relationship.
This is problematic and as pointed out by Jasanoff (2004b), under contract
arrangements, knowledge is "co-produced" and manipulated to fit different applications.
Waterton further argues:
..Variation in co-construction of the science-policy boundary in which scientists
playa part means that research questions, resulting knowledge and anticipated
outputs are always calibrated together with policy questions, policy knowledge
and policy understanding of what constitute acceptable outputs." (Waterton,
2005:439)
This shift in identities is also described by Gibbons et al. (1994), claiming that scientists
may adopt shifting social identities in research to attract funding. They argue that what
is needed to play this game is the ability to move back and forth between environments.
However, questions emerge as to how easily this can be navigated and what the
implications might be and it can be problematic as others have noted. For instance,
Guston (2001) alleges that, what these conflicting science policy knowledge production
efforts do is create tension and put a strain on the behaviour of scientists. Though
Guston does not explain the nature of this tension, it can be either negative or positive
for policy as illustrated by the current empirical case. This is because, as stated
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previously, there are different kinds of obligations (or accountabilities) with varying
interests demanded by each relationship (Waterton, 2005).
7.4.4.3 Implications for theory and practice
A Mode 2 research environment seems to be problematic for the scientific community
but it is unclear how actors should confront the ensuing strain. For instance, what Mode
2 practice fails to reveal in the regulatory context is the dynamism and activism
portrayed by actors (within the scientific community) in the pursuit of a desired
regulatory regime driven by particular motivations that could be value or interests
based. This activism is manifested corporately reflecting increased togetherness, with
principles different from those oftransdisciplinarity and integration. These principles as
understood in Mode 2 context may work perfectly under a research environment
towards technological development.
As others have noted (cf Jasanoff, 1987), this current research suggests that scientific
values (for example interests, scientific goals, protection of contract relationships) and
politics playa significant role in the learning dynamics experienced in a regulatory
context, perhaps more than a technological context. This is also consistent with the
claim by Murphy and Chataway (2005) that economic and social differences interplay
in the articulation of environmental policies. Although their focus is at international and
regional level, same issues intensify at domestic level as this research suggests, perhaps
more significantly. This may partly be supported by the seemingly close interconnection
between dynamics of knowledge production and use, and the stage of biotechnology
products development. In the early stage of product development (like in the case of
developing countries), efforts towards regulatory policy innovations may supersede
economic efforts although in the case of Kenya the two have co-evolved.l'" But that is
19' More research may be needed to generalise this claim.
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not to say that regulatory innovations and technological innovations are unrelated. On
the contrary, the two are iterative and highly dependant on cumulative learning of social
and institutional actors, and the relationships built around this, as implied by innovation
systems literature (see Chapter three, section 3.4.1).
Kenya's science and technology policy for a long time has been structured in such a
way that scientists pursued research as a public good (Odame et al., 2003). This may be
synonymous with Mode 1 research which indirectly impacted scientific practice and
consequently the regulatory practice. It was emerging that scientists were struggling to
conceptualise the new regulatory demands without putting much effort to change their
nonnative and rigid scientific thinking and behaviour. This suggests that some scientists
are still grappling with Mode 1 behaviour as Mode 2 knowledge production dynamics
confront them through biotechnology innovation. This may imply that the
biotechnology innovation system is a good platform for analysing Mode 2 principles as
alluded to by Odame et al. (2003). Similar struggles of identity and related practice in a
transdisciplinary setting was reported by Lenhard et al. (2006:345) who in their
empirical research on structural change in disciplines found that "old loyalties are
fiercely maintained while new identities are created". This observation is also shared by
Nowotny et al. (2003) who argue that scientific behaviour is modified to accommodate
the Mode 2 sciences and old normative practices continue to be experienced.
Perhaps this poses a fundamental question related to quality of knowledge "co-
produced" to suit a particular context. Context as implied by Mode 2 proponents tends
to take as given knowledge that is produced with users in mind such that at the end of
the day, it would be socially desirable. However, scholars advocating socially desirable
public participation, risk evaluation and risk communication models in the new life
sciences have warned against the decreasing credibility of scientific knowledge in
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informing environmental policies (cf Jasanoff, 1987, 2003). Reflexivity is what is
supposed to safeguard against this through what Nowotny et al. (2001) call re-
conceptualisation of knowledge. This again calls for learning in order to acquire "multi-
layered skills" that cater for critical reflexive capacity needed to engage with
divergently different interests and values (Lyall and Tait, 2005).
7.4.4.4 Lessons and conclusion with respect to shifting behaviour
On a positive note, what Mode 2 science seems to be doing in the Kenyan context is to
make scientists refocus their thinking towards a broader view of science. Firstly, the
need to protect knowledge (patents) has been emphasised, albeit a slow change. The
following quote from a university professor who at the time of field work was engaged
in science-policy work as a chair of the NBC explains the knowledge dynamics
occurring in Kenya:
..We scientists are not used to these elaborate [regulatory and patenting]
procedures. For example on the area of patenting, scientist see it as a bother.
Even now I have a letter saying please ensure you protect your research
findings. Because many of us find it as a bother, just to go to the Ministry of
trade to collect the patents applicationform andfilling it. One; Kenyan research
has always been public research whereby you are doing it for the public with no
expectation of reward from that. It is a culture because we have been doing
public research for the purpose of publishing and we do not see economic
returns from that. Kenya is not used to patenting of their research. Scientists are
used to public research for free. You are only thinking of publishing this nice
paper and get promoted. It is quantitative research rather than qualitative
research. Qualitative research is when you aim at getting a product and as me
here when I want to publish, I need three papers and I become a full professor;
that's it. Now we have to create awareness among research institutions because
the problem is that, they are not aware. Even in KARl, despite the fact they were
involved in all these GE processes, implementation [protection of research
findings] is difficult, they look like they have never heard of that. " (ATp-PS3,
technological & biosafety policy advisor, public university, Nov. 2007)
Secondly. engagement of scientists in the formulation of regulatory instruments,
(particularly the biosafety bill) that sparked public controversies made them re-think the
social implications of scientific practice and perhaps the resulting policies.
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Overall, what the current study seems to suggest is that a Mode 2 working environment
is too demanding for scientists (both in practice and policy) characterised by the
increased and dynamic pace in technological, institutional and regulatory policy
innovations. In trying to navigate their way through the unprecedented institutional
changes, the scientists have been challenged by many exogenous and endogenous
factors resulting in their devising coping strategies. The shifts in cultural practice
demonstrated empirically challenge Mode 2 principles which could not account for non-
technical factors that shape the behavioural practice linked to the regulatory practice.
Knowledge produced for the purpose of influencing the regulatory instruments could
also not be accounted for.
The dynamics occurring here can be partly explained through analysing scientists
holistically within the "communities of practice" or "epistemic communities" based on
the different roles they play within these groups as described elsewhere. The former as
advanced by Johnson (2007), although applied in the context of development, explains
the role of learning and knowledge production in a dynamic and often complex social
setting, particularly if conceptualised as "action learning spaces" (Johnson and Wilson,
2006). The conceptualisation of learning and knowledge production through the lens of
epistemic communities (Haas, 1992) on the other hand provides understanding of
scientific practice in a policy context. This concept is revisited further below as
learning, knowledge and policy influence are explored in the next section through the
lens of policy coalitions.
7.4.5 Influence of regulatory policy through policy coalitions
Biotechnology and biosafety arenas are important spaces where the heterogeneous
scientific community converged to consolidate support for their visions and views about
the regulatory process and policy. Within these spheres, they seem to have shared norms
and beliefs with regards to GE technology and desired regulations to a certain extent,
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thereby behaving like an epistemic community. However, there is a striking difference
in the way beliefs and values were shared in a regulatory context as described through
the lens of advocacy coalitions (AC).
7.4.5.1 Advocacy Coalitions Framework (ACF)
Efforts by both scientist and non scientist communities to influence regulatory policy,
particularly the biosafety bill occurred within informal advocacy coalitions. This
qualifies governance of biotechnology in Kenya as having elements of unstructured
procedures (llarsh, 2005). This deduction is derived from analysis of the regulatory
policy subsystem and its actors as it evolved for about 2 decades with increased tension
and conflict during end of regulatory phase 2 and entire phase 3. This tension is
anticipated to continue in phase 4 as the new Biosafety Act, 2009 enters the
implementation phase. This analysis is presented here using features of ACF (see
Chapter 3, section 3.4.4).
Kenyan regulatory policy subsystem scope and actors: The scope is defined by
innovations in modern biotechnology and actors implementing the various regulatory
instruments. The actors comprise government players, academics, researchers,
journalists, legal officers, farmers, consumers, media, NGOs in the biotechnology arena,
civil society among others (see Appendix 5). The heterogeneous group of scientific
community selected for this study form part of this scope.
Coalition members: Data identified two rival coalitions. The dominant one comprised
of a large group of scientists from the policy, practice and pro-biotechnology NGOS,
their respective institutions and some members of parliament. The minor coalition
comprised ofmcmbcrs from the civil society, media and some members of parliament.
227
Policy core beliefs: The interviewees were polarised in their preferences for a biosafety
bill. Some supported the bill due to its potential to enhance GE technology deployment
while others felt the bill would promote responsible science. Some members of civil
society supported the bill for its potential to enhance public protection through legal
controls while others were totally opposed to it. There were other differences in policy
beliefs expounded in details in Chapter five and perhaps which explain the
ambivalences in the nature of biosafety regulations different groups of scientists seemed
to detest or prefer (enabling, constraining, permissive, restrictive or cautious).
7.4.5.2 Analysis of Kenyan regulatory policy subsystem
The ACF predicts that membership of a coalition and policy core beliefs remain stable
and can be useful in identifying impediments to policy resolution in the formulation of
the biosafcty bill (Sabatier and Weible, 2007). Critical analysis of the regulatory policy
subsystem during the evolving regulatory phases exposes different groups with different
political interests who could negotiate core values and beliefs based on the concern or
contlict at hand (Sabatier, 1993). The biosafety bill conflict therefore separates different
coalitions based on the different core policy beliefs. In this particular case, the
legalisation of regulations through enactment of the bill for management of
biotechnology was the concern at hand.
Scientists both in the practice and policy arenas stood to gain from a regulatory policy
that would enhance their scientific and policy ethos (a view expressed by many
interviewees). As shown in Chapter six, there was a blurred boundary between pro-
biotechnology "scientists" and "policy makers" that qualified them to be proponents
especially in pursuing the temporary shared belief (bill for management of
biotechnology). Consequently they viewed the "non-scientific public" as non-supportive
of GE technology (resisting and fighting the biosafety bill was perceived to be a
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rejection of this technology). This consensual view of the bill portrayed by the scientific
community (though for different reasons) denotes a shared belief. Thus, as mentioned
previously, analysis of the data identified two competing coalitions" (opponents and
proponents of the biosafety bill). The opponents (civil society) presented a competing
counter coalition. The two coalitions influenced the regulatory policy subsystem in
various ways.
Use of resources:
The pro-bill coalition utilised resources in the following ways:
• The policy players happen to have legal authority to coordinate and direct the
policies placing them at an advantageous edge over the opponents. NeST for
instance directed the policy initiatives under the legal mandates of the Science
and Technology Act, (RoK, 1980 & 1982) and the interim biosafety regulations
(RoK, 1998).
• In knowledge intensive subject like biosafety, scientists in practice and Non
State Organisations (NSSINGOs), who happen to control scientific resources,
played a key role in provision of technical and scientific information. The Hand
Book for Policy Makers (2007) is evidence of a combined endeavour between
policy players, research scientists and NSS actors.
• Scientists affiliated to pro-biotechnology NOOs command substantive amounts
of finance directed towards policy, technical and biosafety research. They were
extensively linked to most policy and biotechnology fora, and activities
organised during the period under analysis (Appendices 5, 6, 7 & 9).
The anti-bill coalition on the other hand utilised resources in the following ways:
196 Stakeholders within a coalition are like-minded people who may include researchers, journalists, legal officers and
government officials. They share basic values and search for means to accomplish them. They also tend to over-
emphasise the influence of their opponents (Sabatier and Weible, 2007; Sabatier and Jenkins-Smith, 1993).
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• It commanded considerable amount of finances.'?" The increased media
reportage (see Appendix 9) may suggest increased finances and mobilisation
of a wide range of civil society actors, thus strengthening the coalition.
Initially the coalition had 7 members (Harsh, 2008) but the number grew to
12 (Action Aid, 2004) and later to over 30 as of 2008 (members of the
Kenya Biodiversity Coalition-KBioC).
• This coalition seemed to have public support through the orchestrated
activities of the established and popular members [e.g. Action Aid financing
their activities, Kenya Organic Farmers Association Network (KOAN)
representing organic farmers, Consumer Information Network (CIN)
representing consumers and Kenya Federation of Agricultural Producers
(KENFAP) representing farmers]. They therefore used the public as a
resource.
• Different members of this coalition had access to environmental groups198
and were also privileged to access "reliable" scientific information.l'"
A vailable venues: Venues are institutional arenas within which stakeholders have the
opportunity to influence policy-making (Weible, 2007:96). The pro-biosafety bill
coalition was active in various venues facilitated by the pro-biotechnology fraternity
and the government {conferences, workshops and government institutions like NCST,
KEPHIS, NBC and media}. Parliament was another venue in which both coalitions
actively engaged the parliamentarians. This is evidenced by two counter parallel bills
tabled in parliament by each of the coalitions (biosafety bill 2008 from the dominant
1971nterviews with NGOco-NS4 and NGOf-NS I indicate that at the early regulatory phases funds were limiting their
activities but later they were able to consolidate enough finances to counter pro-bill groups.
198During field work, interviewee NGOf-NS I disclosed that the KBioC coalition members had received training
from green peace officials on advocacy.
199One interviewee who is a molecular scientist offered valuable scientific advice to this coalition (he was that
important that an interview I had arranged with an official from one environmental NGO could not commence
without him being present). He was also purportedly linked to some scientific aspects of certain media reports
originating from the civil society through this coalition as disclosed by ajoumalist interviewee (JO-NS6).
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pro-bill coalition & the biotechnology and biosafety bill 2008 from members of the
minor biodiversity coalition). The court was another venue used by the anti-bill
coalition (a confidential document obtained during field work is proof of this litigation
act)_2ooThe public is another institutional venue, operationalised by the anti-bill
coalition through demonstrations to amass public and political support_2°1 The media
was another space used extensively by both groups (see Appendix 9).
7.4.5.3 Policy learning and influence
How was policy change achieved in the Kenya's regulatory policy subsystem? This
question is central to this thesis because the second research question sought to explore
how the scientific community may have influenced the development of regulatory
instruments. This section is discussed from that context. Three factors based on
Sabatier's framework can cause learning and belief change: external shock, policy
oriented learning and a hurting stalemate (Sabatier and Weible, 2007) and are explored
below in relation to Kenya.
An "external shock" is likely to change components of policy core beliefs. In the
Kenyan scenario, the over-emphasised potential of biotechnology applications to
address food insecurity impacted actors' re-conceptualisation of their stances towards,
for instance stringent regulations. This approach to regulation made pro-regulatory
policy advocacy coalition to argue for pro-innovation regulatory policy (permissive or
facilitative) in order to enhance economic competitiveness, presumably for the benefit
of the poor. The initiation of the biotechnology programme in early 1990's through the
sweet potato and rinderpest vaccine projects gave a new thrust to the hyped
200This was also corroborated by JO-NS7.
201 Interviews with RSln-GP2, NGOcs-NS3 and NGOco-NS5.
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biotechnology innovation and emerging regulatory policy subsystem that commenced
with the drafting of first regulations.202
The general elections towards the end of 2007 may be seen as another external political
shock. Most actors linked this shock to the premature halt of efforts by the pro-bill
coalition group to push for the enactment of the bill just before the parliament was
dissolved to pave way for the election campaigns.i'" Similarly, the dissolution of
parliament was seen as a "divine intervention from God" by the members of the anti-bill
coalition, which prevented approval of a purportedly flawed bill.204
Policy oriented learning may be analysed relative to the one and half decades that the
subsystem has been co-evolving alongside the biotechnology programme. During this
period. there has been an incremental accumulation of scientific and policy information.
Policy learning has presumably been gradual and incremental as the scientific
community engaged in biotechnology and biosafety activities and as they dealt with
challenges and conflicts during implementation of the interim regulations. Learning was
also enhanced through the heterogeneous knowledge-based nodes like the adhoc Kenya
Biosafety Coalition Network (KBC) fronted by the scientists and KEGCO or KBioC
groups fronted by the civil society. Influence of policy may be linked to the legalisation
of the biotechnology activities and the biosafety regulatory regime through the
enactment of Biosafety Act. The Act emerged and replaced the previously official "no
commercial GMOs" policy that many interviewees interpreted as ineffective, paving
way for a balanced policy approach to safety and development.
The policy learning impacted the shifting perspectives and beliefs of actors over time.
However. productive learning could have been constrained by possible instances where
2021ntcrviews with PRp-PS4. RSPu-PS8. TAN-NSS2. RSPu-PS7 and RSln-GP9.
20) Interviews with RSln-GP2. TAN-NSS2. TAR-NSSI and Blp-PS13.
2041ntcrvicws with NGOf-NS2. NGOco-NS4 and NGOf-NS I.
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actors may have despised or rejected conflicting or threatening information coming
from opposing groups. This would enhance a socially desirable balanced view making it
a legitimate process.
Hurting stalemate is a situation in which all parties involved in a dispute view
continuation of the status quo as unacceptable and run out of options and venues to
achieve their objectives (Sabatier and Weible, 2007). Two interpretations may be drawn
from the Kenyan case. Firstly, the anti-bill coalition may have succeeded in curtailing
the efforts of the pro-group in pushing for the enactment of the bill but this was only
temporarily. It may also have weakened the position of the pro-bill coalition and
perhaps strengthening opportunities for an "all-inclusive coalition" that could be
emerging in the post-bill or post-Act era. When a stalemate was experienced during
regulatory phase 3, various attempts to engage the opponents may be construed to be
consensus-based efforts towards dealing with the stalemete.i'" At the same time, the
BioAWARE was launched to integrate the voice of the public in the deployment of
GMOs (RoK, 2008b). Secondly, the bill was eventually promulgated into law on Feb.
2009 (RoK, 2009). This may be construed to be victory for the pro-bill coalition. The
Act is a product of a prolonged conflict between the pro-bill process group and the anti-
process group.
It is again too early to tell whether the coalitions will experience a hurting stalemate
during the implementation of the Act. Analysis of the policy subsystem makes it
possible to offer policy recommendations that may facilitate effective implementation of
the Act and related technology transfer (Chapter eight).
20' The opening remarks by interviewee ARBp-PS 16 from a public university who was moderating a stakeholders'
workshop between pro-bill and anti-bill groups appealed for both groups to work together towards a common agenda,
the deployment of biotechnology for economic usefulness (NeST, 2007).
233
7.4.5.4 Conclusion and implications with respect to policy coalitions
Using the principles of policy coalitions, the current study has empirically demonstrated
dynamism in advocacy coalitions formed around regulations implementation, and how
resources and belief systems interplay to influence policy learning and subsequent
policy change. These findings resonate with Weible's (2005, 2007) who demonstrated
how policy core beliefs and resources interplay in influencing formulation of a conflict
laden subsystem in USA {in Weible's case, the Marine Life Protection Act (MLPA)}.
Members within advocacy coalitions are able to adapt to challenges and opportunities
through learning in order to realise their goals. The intense coordination and
relationships building of like-minded players with respect to both coalitions (opponent
and proponent) supports the policy core belief concept that drives the sustainability of
advocacy coalitions as asserted by Sabatier and Weible. How the game was played out
defies the coalition principles related to policy learning, beliefs and consequent policy
change. Ilow is it possible then that policy scientists behaved more like an interest
group by interacting with actors of similar beliefs (with respect to the biosafety bill)
rather than with a mix of players representing all interests? Although this behaviour
supports advocacy coalition principles where government agencies can be members of
coalitions, shared beliefs fail to explain explicitly the dynamism of the policy learning
experienced particularly during regulatory phase 3.
The strategies used in the Kenyan subsystem exposed high level relationships building
and persuasion in an attempt to enlist members who could support their policy beliefs.
This persuasion is tantamount to influence, which is not given adequate space by AC
approach (this research study was not testing this theory). This however has both
positive and negative implications. Firstly from a positive view, this may have triggered
faster approval of biosafcty law perceived to have taken shorter period than other
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agricultural policies.i'"Approval of the Act has indeed opened up a new era for
technology transfer through deployment of products of GE technology, which may be
good for the country economically (perception held by many interviewees).
Secondly from a negative view, the approved regulatory policy may be perceived to be
lacking non-scientific or public input. For instance information (or knowledge) within
the pro-biosafety bill advocacy coalition was predominantly sought from allies within
the same coalition (policy makers relied upon researchers and NGO scientists) who
were members of the same coalition. This may impact the Biosafety Act
implementation, having not received wider public scrutiny or input.
7.5 Other tensions related to regulations and regulatory practice
Previous sections have shown that various challenges confronted scientists as they tried
to adapt to new ways of research and policy. In the process, two main tensions emerged
related to communication and regulatory compliance. This section analyses these
tensions in reference to various theoretical perspectives used in the entire chapter.
7.5.1 Poor and constrained communication
What is indisputable in the current study is the importance attached to value of
communication (about risk and GE technology) by many interviewees, at least to
change the negative public opinion. However, productive communication on the part of
scientists was constrained by fear of misinterpretation and exogenous pressures, hence
the biased reporting inclined towards benefits. This can be interpreted in various ways.
7.5.1.1 Exogenous pressures
Biased or impartial reporting was aggravated by pressures from different
accountabilities (for instance, donors require reporting to be done in particular way, the
206 Interview with TRTp-NSS3 when making a comparison with the seed policy.
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NBC require reporting to be tailored according to the GMOs application form; KEPHIS
requires monitoring and inspection reports in accordance with the compliance forms),
This exposes the strain of communication as scientists navigate the Mode 1 - Mode 2
research terrain discussed previously. A similar strain in reporting was experienced by
UK scientists as they tried to adapt to new research environment that supported contract
research (Waterton, 2005). Waterton observed that, scientists found it easier to produce
reports for fellow scientists since they are scientific reports as opposed to project and
policy reports. The latter are negotiated, thus, scientist become "co-producers" of
knowledge together with their "customers" (/bid,:439). If the customers reports are
difficult to write, what about public reports that have not been negotiated?
7.5.1.2 Challenges in risk communication
Fear of misinterpretation and misreporting, and distortion of scientific facts (by public
and activists) could also be explained by the uncertainty linked to GE technology and
perceived risks. Proponents of public participation theories have cautioned against
different repercussions of adopting a technical approach to risk regulation and
disregarding public in governance of risky innovations like biotechnology (cf Levidow,
2007). What scientists may not realise is the importance of risk communication
(amongst all stakeholders) as a key component of risk analysis and risk management
(Keese and Meek, 2006). According to Keese and Meek, based on their experiences in
the Australian GMOs regulatory practice, knowledge (information) sharing can have an
undue influence on the outcome of regulatory disputes.
7.5.2 Non-compliant regulatory practice
This practice may be interpreted in two ways. Firstly, the regulatory instruments were
weak in achieving the pro-innovation agenda and secondly, the policy targets have a
negative attitude towards regulation.
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7.5.2.1 Weak regulatory instruments
The instruments providing benchmark for regulations implementation were perceived to
be ineffective based on the agenda of the innovation communities. As earlier reported
regulatory instruments (particularly for field trials) were perceived to be restrictive,
bureaucratic and lacking clarity.
Constraining policy instruments can have negative impact on innovation based on mode
of operation as expressed by GE scientists in USA and Europe (Rabino, 1994). Through
this study, Rabino showed that strict government regulatory control results in increased
regulatory pressure, that reduces competitiveness (Ibid,:44). Others like Chataway et al.
(2006) through the accounts of industry managers and policy makers were able to
categorise biosafety regulations based on whether they are enabling or constraining in
achieving the intended purpose.
Besides delaying innovation, constraining or restrictive nature of regulations has other
ethical ramifications as this thesis shows. It demoralises researchers, impacting upon a
responsible and ethical regulatory practice, as expressed by an interviewee from an
international organisation:
"What this thing [bureaucracy] end up costing is, it makes scientists do things
on the back door. I am sure if you ever did a survey in this country you would
be so shocked at how much the scientists are doing and the regulators have no
idea that those things are happening. But when the system is bureaucratic the
scientists will not stop doing their science. If you think the regulators will be
hard on this, they just learn to loop around the regulation and continue doing
their thing because for them, they have to continue doing science and continue
publishing." (RSln-PS6, general health & safety advisor, IRI, Nov. 2007)
Based on this analysis, regulations may promote both innovative and unethical
behaviour, issues that all actors including regulators need to be aware of. On the other
hand, the government must factor these conflicting aspects into their policies and
enforcement mechanisms. Perhaps this is the reason why scholars in governance
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theories related to life sciences differentiate between the "government" and
"governance" approaches to regulation (Tait et al., 2006). The former aims at promoting
ethical behaviour (sometimes oblivious of implications), while the latter promotes
innovative policies based on evidence-based interests and values of multiple actors.
7.5.2.2 Attitude of scientists
Evidence from this study suggests that scientists in practice have a negative attitude
towards regulation and regulators. Irwin et al. (1997) in a study investigating
agrochemicals regulation in Britain observed similar negative attitude by scientists
towards regulation. In Kenya, this attitude is linked to the cumbersomeness in
complying with terms and conditions set out in the regulatory instruments. This
notwithstanding, what scientists do not seem to realise is that GE technology is highly
regulated as well as knowledge intensive, perhaps more than the basic research they are
used to. Irwin et al. (1997) argue in this respect that, regulatory compliance is a major
challenge for the institutions concerned as well as the individuals involved (emphasis
added). Regulatory practice is however different from normal basic academic practice.
As Jasanoff (1990: 80) asserts, in an academic environment, science is undertaken with
a view of advancing knowledge. On the other hand, regulatory practice is bounded by
exogenous pressures of "time, politics, directed towards closure, proprietary, subject to
a variety of types of review and undertaken with an aim of aiding policy-making". It is
also institutionally and culturally embedded (Irwin et al., 1997). These factors evoke
strain on the part of the scientists and may lead to accountability and transparency
compromises.
7.5.3 Conclusion with respect to emerging tensions
It was emerging that the Kenyan scientists are still grappling with the rapid
technological and institutional changes characteristic of Mode 2 and they are still
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holding Mode 1 values (pride, individualistic, optimistic thinking as described by the
interviewees). These values seem to affect the process of adaptation towards an
integrated behaviour, at least with respect to science communication and regulations
compliance.
With respect to transparency in communicating different aspects of GE science, the
increased demand for accountability and the informed public demand reflexivity on the
part of scientists. This is in line with the demands of Mode 2 research that call for
reflexive and socially desirable practice at least with regards to knowledge sharing and
dissemination (Nowotny et al., 2001).
With respect to regulatory practice, regulations or standards in Mode 1 research have
been just the basic good laboratory practice while in Mode 2 research, the additional
biosafety regulation demands accountability to a wider stakeholder (government,
regulator and public). However, as Rothstein et al. (1999) note, requisite regulatory
compliance comes with challenges like regulatory capacities. This could also work
against regulations implementation, hence impacting compliance negatively and
indirectly. In Kenya, capacity had been identified as a challenge in risk assessment and
decision-making processes.
Regulatory behaviour related to regulations compliance challenges what is expected
under Mode 1 and Mode 2 research scenarios. Behavioural change is inevitable towards
a compliant practice (on the part of practitioners) and enabling regulations (a role for the
policy scientists). This is a challenge since regulations are designed to address broader
societal issues (safety, quality, economic, technological). Perhaps this is the reason why
a number of scholars have emphasised rethinking of regulatory practices, towards a
"smart regulation" without undue strain to innovative practices as well as consideration
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of the local context under which the regulations are implemented (Tait et al., 2007; van
Zwanenberg et al., 2008).
7.6 Regulatory practice and influence of regulatory instruments
Data from this study suggest that the scientific community influenced the regulatory
regime trajectory. The influence was articulated through learning, and generation and
utilisation of knowledge as discussed in this chapter. But equally important are the
interests and values revealed empirically through the current study. Shared beliefs and
intense negotiation achieved through policy coalitions explained the activism portrayed
by the scientific community in the Kenyan regulatory policy subsystem. As discussed
above, resource was a driving force but perhaps what is clear is that the beliefs were
only shared for a particular purpose and agenda (lobbying for the enactment of the bill
that purportedly was in favour of the different interests of actors).
Influence can be interpreted from the perspective of use of expertise discussed
previously through selection of knowledge used to inform the decision-making
processes. Such form of expertise has been found to lack legitimacy based on its impact
on the outcome of science policy deliberations, for lacking wider public input (Levi dow
and Carr, 2007; Weingart, 1999). To legitimise the decision-making process, a
democratic expertise as Nowotny (2003) asserts, should involve a wider group of
experts outside the technical or scientific arena. This being the case, the Kenyan process
can be viewed largely as having excluded the wider stakeholder, particularly in the
formulation of the Biosafety Act. This is a positivist or narrow usage of knowledge that
some scholars have criticised arguing that it is politicised and assumes that expert
knowledge is objective and rational in guiding policy-making (Levidow, 2007;
Weingart, 1999).
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Despite these clear aspects of influence in terms of regulatory direction more generally,
critical analysis of the Biosafety Act seems to address many of the concerns raised by
interviewees. This may be viewed as positive influence of the content commensurate
with the concerns of the scientific community. However, there were other views that
any potential efforts to influence the outcome of the bill to accommodate unwarranted
interests were thwarted through various national regulatory and policy checks.
Notwithstanding, this is not to say that the regulatory instruments particularly the Act
(RoK, 2009) are acceptable regulatory documents.i'" Moreover, real test will occur
during phase 4 of the regulatory process in the actual implementation of the Act as
societal issues become real with the actual commercialisation of GE products.
7.7 Chapter conclusion and summary
Through insights and lessons drawn from the wide body of literature (science policy,
theories of knowledge and learning, innovation systems and policy coalitions), the
foregoing data analysis suggests that, the regulatory policy innovations occurring
alongside the overall biotechnology innovation system transition were somewhat
bounded up in the broader knowledge production dynamics associated with the latter.
As presented by proponents of Mode 2, knowledge production in a broad sense is
generally linked to institutional innovations. However, knowledge produced in the
regulatory context as illustrated in this thesis is relatively different in terms of
institutional and cultural aspects. It emanates from relationships built around
disciplinary, professional and policy knowledge-based groups. As much as it is
technical in nature, it reflects to an extent values and cultures of these groups. This
challenges application of most knowledge production theories with regards to
regulations implementation. Table (11) below summarises these challenges and
implications. and hccause this thesis does not stop at that, the implications are explored
207 Research should be done to establish this claim targeting a wider group of stakeholders outside the scientific
community.
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further in the next chapter with a view of providing some policy recommendations for
improving scientific and regulatory practice.
Table 11: Summary of interpretation of raised issues in the context of knowledge
dynamics
CHAPTER SUMMARY
Issues Interpretation Conclusion/implication
Divergent perceptions Historical background ofGE introduction in These expose a narrow approach to
of regulation & Kenya and the broad risk approaches to regulations implementation based
regulatory practice regulation support these views. on the imbalanced debate about
framed in terms ofGE benefits and risk.
prospects & related Scientific and social values held by With respect to regulatory policy
risk scientists in their heterogeneous knowledge- processes these distinctions reflect
based groups are exposed. different beliefs and values that
characterise different cultural
~_aces that scientists occupy.
Behaviour and role of -Scientific community proactively engaged -Policy coalitions complement
scientists in regulatory in regulatory activities as experts, a role Mode 2 in exploring the political
process & instruments presented by different learning and social factors that underpin the
opportunities and motivations at individual forms of knowledge produced in a
and corporate levels. regulatory and political context and
-The pursuit of desired regulatory regime the impact on policy change.
was articulated effectively within policy
coalitions & relationships built over the
years during technological revolution.
-Regulatory activities through different
types of knowledge produced directed the
regulatory trajectory.
Scientific & regulatory -The two are embedded in the broader -The ensuing requisite institutional
practice institutional and actors' shifts in cultural and behavioural changes cause
practices from Mode 1 to Mode 2 research, tensions and strain during
characterising a dynamic innovation system regulations implementation
in transition. reflected through shifting social
-Different behavioural features exposed identities.
during implementation of regulations -Mode 2 fails to capture sufficiently
triggered by different endogenous and shifts in cultural practices and the
exogenous pressures that accompany underpinning factors driving the
biotechnology innovation. involved actors. These factors
include nature of relationships,
values and interests.
242
Chapter Eight
8 Conclusions and recommendations
8.1 Introduction
This research project aimed at analysing, understanding, and describing practical
aspects of implementation of biosafety regulations in Kenya through the lens of the
scientific community. The thesis has identified the nature, content and form of
knowledge produced and used in regulatory context, and its impact on biosafety policy-
making. Further. it has sought to know what this dynamic of change in knowledge mean
for regulatory instruments and the broader biotechnology innovation system.
The general theoretical literature on governance of modern biotechnology and
specifically in the context of Africa is inconclusive on several vital questions within
knowledge production discourse (cfHarsh, 2005; Sander, 2007; Lyall et al., 2009a). To
explore this gap, this study set out to answer the following research questions:
1. What are the perspectives of scientists on the implementation of biosafety
regulations and why might they be holding these views?
2. Have the practices of scientists related to implementation of biosafety
regulations shaped the evolution of the regulatory process and if so how?
3. What is the implication of the scientific practice on the biotechnology
innovation policies and knowledge use?
The mam objective of this research was to explore how governance of modern
biotechnology through biosafety regulation may be improved for efficient deployment
for economic use.
To synthesise the empirical data generated in the process of tackling these questions,
this chapter is organised as follows: a summary of the findings is presented first,
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followed by a synthesis of the theoretical and policy implications. Following this,
practical policy recommendations and lessons are explored in the light of knowledge
use and how best regulations can be implemented for enhanced pro-biotechnology
innovation governance and deployment. The subsequent section explores suggestions
for further research, ushering in a discussion of limitations of this study. Lastly, the
chapter concludes with an epilogue.
8.2 Synthesis of empirical findings
The main empirical findings were theme specific as highlighted by each empirical
chapter. The ditTerent regulatory phases during the co-evolution of regulatory system
and the biotechnology innovation system are illustrated in Chapter two. This set the
background and the context for the study. The views of scientists on regulations and
regulatory practice are presented in Chapter five while the behaviour and role of the
scientific community in influencing the regulatory process is outlined in Chapter six. In
Chapter seven, the theoretical and empirical explanation of the data is undertaken.
Synthesis done in this section endeavours to show how the three research questions
were addressed and the conclusions that were drawn.
8.2.1 Perspectives of regulations and regulatory practice
In this sub-section, data synthesis is done to show whether and how this first research
question was tackled: the perspectives of scientists and the reasons behind the held
\.'iews.
Perceptions related to risk assessment (RA) and regulatory decision-making processes
brought to the fore weaknesses and strengths of the main regulatory instruments and
institutional structures. For instance, the instruments that guided biotechnology research
prior to Biosafcty Act (2009) were constraining both science in terms of progression
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and scientists in terms of scientific and regulatory freedom. Besides these institutional
weaknesses, this study identified non technical aspects that hampered the regulations
implementation process. These include values and interests that largely explained and
supported the reasons behind the perceptions of scientific community regarding nature
of regulatory instruments and practice. These social factors further explained many
regulatory actions undertaken by the scientific community towards achieving their
desired regulatory regime.
A general agreement that biotechnology innovation offers prospects for improved
agricultural production was a driver for scientists and accompanying institutional
changes. Thus, regulations were viewed in terms of providing space for technological
advancement. This reflects the interests and values the scientific community attach to
GE technology. This is consistent with the narrow view of the technology as an outright
solution to agricultural production constraints (Hisano, 2005) and is in line with the
historical developmental background upon which GMOs introduction in developing
countries is based {to address food production constraints (cf FAO, 2004)}. Further,
perceptions about risk placed the scientific community into proactive and reactive
groups reflecting the values they attach to risk. These stances are not dissimilar to
discourses about risk regulation discussed by various scholars and which are linked to
risk perceptions (cfTait and Levidow, 1992; Dunlop, 2000).
One unique feature about the current study is that the perceptions of scientists evolved
and changed over time along the different research stages and regulatory phases. This
was due to incremental learning and influence of different relationships built over time.
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8.2.2 Role of scientists in shaping of regulatory process & instruments
In this sub-section, implications of shifting perceptions and related practice IS
synthesised to show how the second research question has been addressed in this thesis:
how scientists shaped the evolution of the regulatory process and instruments.
Through individual based and institutionalised roles in the regulatory process, evidence
presented in this thesis shows that, the scientific community influenced the evolution of
the regulatory process. The study further suggests that scientists are not disinterested
actors in the regulatory instruments formulation process, and are inspired by different
motivations and interests. Perspectives related to the different activities they engaged in
based on different interpretations, reflect varying and shifting cultures ranging from
academic, research, practice, policy, economic or civic.
Scientists seized the opportunity to influence the regulatory process as experts
producing different kinds of knowledge and disseminating it in diverse ways. One way
they used this expertise is through persuasion of key players in regulatory
decisionmaking processes and enactment of the biosafety bill. This is however expected
in technically and politically charged biosafety regulatory policy process (Scoones,
2002; Newell, 2002). This notwithstanding, one distinct observation in this study is the
institutionalised nature of approach to regulatory process and particularly in the
formulation of the bill. A pro-bill group that comprised of both public and private
figures came together in their persuasion efforts to lobby for the enactment of the bill.
This has implications as discussed further below.
As much as the influence of outcome of the regulations was empirically demonstrated
driven by varying interests, some interviewees claimed that counter activities by
opponents, political controls and credibility of scientists minimised the potential
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influence of the content of the regulatory instruments and outcome of regulatory
decisions.
8.3 Theoretical and policy implications
Various implications for practice and policy are synthesised to support the third
research question: the implications of scientific practice for innovation policies and
knowledge use.
8.3.1 Theoretical contributions
8.3.1.1 Mode 2 and regulatory knowledge
The findings suggest that, the perspectives of the scientific community taking part in
this research are much more complex than can be explained by simple institutional
challenges that confront them as they implement regulations. This complexity is
reflected in the accompanying regulatory practice that reflects a subtle deviation from
the normative scientific practice. In addition to institutional dynamics reflected in Mode
2 knowledge production, implementation of regulations exposes cultural dynamics
characterised by changing behavioural patterns. This is revealed empirically as the
heterogeneous scientific community reacts and consequently adapts to new institutional
changes brought about by the reorganised role of knowledge in a changing multifaceted
and multiple actor biotechnology innovation and regulatory terrain. However as they
adapt, they exhibit particular behavioural practices that are commensurate with the
cultures of the disciplines, professions and knowledge groups they belong to. In
addition, relationships built over the years during professional progression provide a
means through which scientific behaviour is impacted. The ensuing shifting social
identities pose many questions that relate to the implications for biosafety regulatory
instruments and social accountability to the wider public.
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This has brought a new perspective of looking at knowledge production and use. From
this study, it can be concluded that knowledge produced in a regulatory context is value-
laden which is consistent with what other scholars have reported (Jasanoff, 1987, 2003;
Murphy and Chataway, 2005). It is also culturally embedded and depends on
relationships build around different cultural groups, particularly professional
relationships (Haas, 1992, 2004). These factors ultimately affect how it is eventually
used for policy and technological purpose.
As the literature suggests, the way Mode 2 thinking is currently applied at the
technological (research and development) innovations level tends to mask or generalise
the underlying and embedded aspects that are concerned with policy as part of
institutional and regulatory innovations. This study illuminates the shifts or changes in
regulatory behaviour portrayed by the scientific community as they adapt to different
accountabilities demanded by modem biotechnology. This actually calls for further
interrogation of knowledge flow and use, integration and relationships concepts in
Mode 2 research. This study has enhanced understanding of the important but under-
researched distinction between knowledge generated for technological or economic
innovations, and knowledge generated for policy innovations in a regulatory context.
Both types of knowledge are however important for spurring innovation capacity which
depends on productive learning, knowledge flow and use (Hall, 2005) as discussed
below.
8.3.1.2 Innovation systems (IS) and policy coalitions
There were advantages of approaching this study and the associated new knowledge
production terrain from an innovation systems standpoint. Innovation systems approach
is concerned with how knowledge flows between suppliers and receivers, and how this
is translated into useful knowledge through interactions (Clark, 2002). Thus, it pays
248
particular attention to learning which tends to be taken as given by Mode 2 approach,
which is concerned more with the institutional changes that accompany the knowledge
production dynamics (Gibbons et al., 1994). The two may therefore be complementary
in that they engage with systemic institutional issues. These issues are the ones which
were targeted by the current study for potential institutional (governance of
biotechnology) reforms. Since IS proposes a holistic view of changes within the
dynamic knowledge production terrain (whether technological, policy or regulatory
innovations), its concepts can be operationalised in recommending a meaningful
scientific/regulatory practice.
Innovation systems literature acknowledges the role of relationships in learning within a
system, especially one in a transition. Just like others have noted (cf Hanlin, 2006;
Chataway and Hanlin, 2008; Kristjanson et al., 2008), knowledge-flow and learning
from knowledge nodes and science-policy boundary organisations are important in
strengthening relationships. This study has demonstrated empirically the importance of
collective learning and working within a system which supposedly spurs innovative
capacity or development in line with other scholars' recommendations (cf Hall, 2005;
Johnson, 2007).
Evidence from this study has however challenged the IS concept by suggesting that
relationships or coalitions formed in a regulatory context may be counterproductive and
may work against the system. This is consistent with policy coalitions literature where
learning and consequent relationships building are largely driven by belief systems that
may exclude players who hold contradictory beliefs (Sabatier and Weible, 2007). Policy
coalitions have exposed the politics inherent in regulatory policy-making as well as the
underpinning factors that confound learning and relationships building. The context
under which learning occurs in a regulatory context may need to be reconsidered when
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researchers are analysing contentious innovation systems in the new life sciences and
environmental sciences. In this context, risk perceptions playa major role in influencing
the regulatory behaviour of actors and consequently the nature of knowledge that is
used in policy processes.
8.3.2 Regulatory policy and practice implications
As clearly demonstrated in Chapter three, section 3.2 and the entire thesis, this study is
grounded in the governance of the new life sciences scholarship. This section is
discussed in the context of how this current research has contributed to this scholarship.
8.3.2.1 Contribution to debates on governance in the new life sciences
This study has revealed the complex scenario under which regulatory actors articulate
the governance goal through regulation of biosafety. Beside the technical aspects that
confront them, this study has exposed the non technical factors that include social and
cultural factors which have to do with the actors' conceptualisation of different aspects
of biotechnology and regulation. It therefore exposed the context under which
regulatory decision-making processes are articulated by key scientist actors who are
supposed to be undertaking various steering roles of the governance agenda. In addition
to being driven by different values and interests, cultural practices of these actors tend
to shift based on different regulatory and technological contexts. This suggests a need to
re-contextualise the scientific community's role as regulatory experts and policy targets
in reconciling the contlict between government control and governance that
characterises new technologies.
With regards to governance of biotechnologies in Kenya, the practical meaning of
governance as moving away from the departmentalised and "do and don't" style of
implementing regulations which mimics government control, towards a well-thought-
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out integrated approach has not been understood. Governance according to Lyall and
Tait (2005:3) "attempts to set parameters of the system within which people and
institutions behave so that self regulation achieves the desired outcomes." This study
has re-enforced earlier calls for governance of biotechnology in Kenya and developing
countries in general to reconsider practical integration of actors and institutions in
decision-making processes if any meaningful gain from biotechnology is to be realised
(Harsh, 2005; Clark et al., 2005).
The findings around scientific practice have suggested the need for the scientific
community to be aware of the implications of their regulatory actions and decisions. For
instance, certain regulatory protocols may be challenging for implementers rather than
creating a conducive environment for learning and potential reflexivity. The latter is
inclined towards governance since it creates room for iterative adaptation and continued
learning (Stoker, 1998, cited in Lyall and Tait, 2005 :5). Further, the scientific
community within the different arenas and knowledge nodes they engage with needs to
develop the capacity to address the different multi-layered challenges in regulatory
decision-making processes. This is not easy and comes with not only the re-organisation
of institutional set-ups to accommodate more participative decision-making processes
(as the governance approach seems to suggest), but also with change of attitudes by the
individual social actors.
The normative grouping of the scientific community as one homogeneous group has
been challenged by this empirical study. It is emerging that different scientists exhibit
different behavioural practices based on different contexts. Some practices for example
reflect cultures of groups they find themselves in at different points of their careers.
Strategies will need to be designed to incorporate the heterogeneity of the scientists in
decision-making processes in order to improve the social desirability of the policy
outcomes. This is another way of overcoming the challenges embedded in the legitimate
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evidence-based decision making without undermining the role of evidence in the entire
process and the rightful role of stakeholders (Tait and Lyall, 2005).
One aspect taken for granted in debates on governance in the new life sciences is the
key role scientists playas knowledge drivers. This role is articulated vividly by scholars
in sociology of science (cf Jasanoff and Martello, 2004). This strand of scholarship
illuminates knowledge as a core output of scientists' interaction with innovations and
regulatory processes. The role of knowledge needs to complement debates around the
new modes of governance in biosciences that would lead to meaningful economic
development (Smith, 2009b). This points towards the importance of rethinking
knowledge management in the context of biosafety regulation in order to attain social
desirability of the resultant policies. Knowledge management is a responsibility of
•individual social actors as knowledge users or producers. By operationalising a
framework that married the innovation perspective and the knowledge perspective, this
thesis has shown how governance of the new life sciences serves as a perfect context in
which the two strands of literature conceptually augment each other.
8.3.2.2 Implementation of regulations
Kenya has been hailed as being a good example in the demonstration of how regulations
and innovation can co-evolve while informing each other at each stage. However,
analysis of experiences of the scientific community in the implementation of regulations
exposes various social and technical challenges that may work against such a model.
This empirical evidence seems to support a claim by Haas (2004) that it may be
disadvantageous to develop policies simultaneously alongside technological
development. This may be linked to the ensuing practice. For instance, evidence from
this study suggests that scientific disciplines, professional spaces and knowledge groups
in which the "seemingly homogeneous group" of biological scientists belong, instil
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cultural values that are consequently reflected in the ensuing scientific and regulatory
practices. This has implications on how these actors perceive policy and eventually how
they practice policy. This heterogeneity and the potential cultural bias should be
considered by policy makers when they engage scientists for policy-making and when
making policies that concern them (as implementers and social actors).
8.3.2.3 Regulations and the broader innovation goal
Biotechnology as a tool for innovation in developing countries has been emphasized
(Juma and Serageldin, 2007; FAO, 2004). Efforts to achieve the Millennium
Development Goals (MDGs) have targeted new innovations like biotechnology (Juma
and Lee, 2005). However, as evidence from this thesis points out, endeavours to achieve
this may be hampered by contextual factors related to cultural shifts discussed above,
that may need to be addressed. This notwithstanding, successful deployment of
biotechnology for improved agricultural production is believed to be reliant on effective
and conducive regulatory instruments (Bananuka, 2007; RoK, 2006a). This being the
case, theoretical science-policy boundary work need reconsideration in order to gain
better understanding of the impact of scientific and social factors in policy-making and
how this can be brought to bear on socially desirable and pro-innovation policies. This
study suggests that a balanced model that looks at the needs of the scientist actors on the
one hand, and those of the non-scientific players on the other needs to be developed in
the African context. This balance would deal with the complexities discussed head on in
order to confront the food security challenge productively.
In Kenya, the legal infrastructure that currently exists (Biotechnology Policy and
Biosafety Act) opens up new opportunities for GE technology towards playing a role in
attainment of recommendations of the MDGs (RoK, 2005b). This may be viewed as a
logical investment in agricultural innovation considering that the available arable land is
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hampered by increasing human population, decreasing agricultural production per unit
area due to erratic weather and reduced usage of farm inputs as well as diseases and
pests attack (RoK, 2005a, 2005b). However there is a real challenge ahead that entails
implementation of the Biosafety Act, testing of legitimacy of scientific knowledge,
testing of safety and usefulness of scientific products by farmers and testing of the
regulatory systems. Already the interviewees were sceptical about the unpreparedness
and inadequate capacity on the part of the government systems and public to enforce the
Biosafety Act. How then can these implementation problems be addressed to safeguard
against possible stalemate and rejection of GMOs by users which can be a big blow to
the government and the scientific community?
To address the regulatory challenges reported in the study, different experiences from
all actors can be harnessed to improve the regulatory regime at the same time spur
economic development (see section 8.3.3 below). Chataway et al. (2006) propose an
integrated approach to policy and governance that would embrace learnt experiences.
This approach "allows for an understanding of the impact of regulation that is more
nuanced and resource based" leading to profitable and socially acceptable regulatory
and innovation policies (lbid,:180-181).
The following theoretical insights and practical lessons offer some innovative thinking
recommendations on how this challenging task ahead may be re-conceptualised.
i. Towards effective learning and use of knowledge
This study has revealed the important role of knowledge in regulatory policy-making.
The problem in Kenya is that the source of knowledge seems to be one-sided, in that it
largely comes from scientific experts (who are mainly scientists and connected to
government). This one-sided practice has implications.
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In a complex science policy terrain with multiple factors working for or against
innovation and regulatory processes, the following question posed by Haas, (1992:1) is
very valid. Can policy makers or scientists themselves "identify national interests and
behave independently of pressures of social groups they nominally represent?" He
argues that, actors can learn new patterns of reasoning informed by a wider stakeholder
needs and interests. The general argument advanced here is that scientists can genuinely
play their part to influence positive change in policy-making through appropriate use of
knowledge and information (Haas, 1992:3). The scientific community has a major role
to play in this because they understand the complexities and uncertainties associated
with biotechnology better than the non-scientists and policy makers (Bradshaw and
Borchers, 2000). From an institutional point of view, the formulation and subsequent
review of regulatory policies should be open and transparent as suggested by some
interviewees. In addition, inclusion of a wide range of expertise that encompasses non-
technical professionals is a positive way to democratise the process (Nowotny, 2003).
This study further suggests a change of attitude of actors towards a socially responsible
process. The scientific community and policy makers, and those groups that claim to
represent the farmers and public must be honest with no hidden agenda (Ammann and
Ammann, 2004) while at the same time being reflexive towards integration of other
diverse views in policy-making process (Lyall et al., 2009c:261).
ii. Towards a productive public engagement
Scientists admitted that the introduction of biotechnology and subsequent policy process
was "hyped" and only realised the negative implications of this approach during the
formulation of the biosafety bill. However, there was a positive re-conceptualisation of
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the role of the publ ic which saw the birth and launch of the BioWARE initiative.i'" It is
this kind of public awareness and an all-stakeholders dialogue that must lie at the centre
of an effective regulatory process, which encourages the interrogation of scientific
claims, and ensures a more inclusive form of debate on issues pertaining to GE
technology and its potential to spur economical growth in the Kenyan agricultural
sector. This must be done on the premise that decisions on biotechnology regulation
cannot be done on the basis of sound science alone (Newell, 2002). This points towards
a responsive and accountable process hence a wider scope as well as a new agenda for
policy and practice in the post-Biosafety Act approval phase (Lyall, et al., 2009b).
There is now a legal framework where all players have been empowered (RoK, 2009). It
has mechanisms for public participation and education. The scientists can undertake
research while the public can demand proper public education. This platform can be
used constructively in engagement of all stakeholders in the GE products
implementation phase.
Although genuine public participation is important as a way to dialogue with public
regarding science, care should be taken to avoid "quantity of views" at the expense of
"quality and content" of what is brought to the table for discussion (Durodie, 2003).
Care also should be taken to ensure genuine representation. As others have noted (cf
Harsh, 2005), this research project reported increased proliferation of institutions
(NGOs, scientific, civil society) towards the last one decade purportedly representing
the interests of fanners and public in biotechnology governance. Durodie (2003: 87)
notes that these "self appointed voices of authority" tend to confuse the public dialogue
lOt During the BioWARE launch. the chief executive ofKENFAP (an association bringing fanners together) and the
Director of Agriculture arpealed for a radical and strategic attitude change in order to reverse the purportedly
scientific and industry led innovation approach. towards 8 process that recognises the need to take the users of the
tI.xhnology along (recorded speeches during BioWARE launch on Sep 2008 in Nairobi and analysis of the BioW ARE
strategy. RoK. 200llh).
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and it becomes difficult to know "who to believe." Harsh (2009) has empirically shown
that it is possible for NGOs to misrepresent the same people they purport to represent.
8.3.3 Lessons for practice
This section looks at insights that this study can draw from Kenya's one and half
decades of biotechnology and regulatory regime co-evolution in terms of practice. Three
distinct aspects are key in putting the lessons discussed here into context:
Dynamism: Biotechnology innovation is advancing at an unprecedented pace, perhaps
faster than the capacities of actors and institutions to adjust in order to accommodate the
requisite changes needed to foster innovation and responsive engagement of
stakeholders. including regulation (Tait et al., 2006:379). This has called for new styles
of governance as Lyall and Tait (2005) contend.
ltfultifaceted: The twin processes (biotech innovation and regulatory process) involve
many actors with each process being multifaceted. The policy and regulatory process
and the accompanying practice in life sciences in particular is perceived to be
problematic because of the different policy cultures that different actors exhibit at the
global and regional levels (Murphy and Chataway, 2005) and at national levels
including developing countries (Lyall et al., 2009a).
Complexities related 10 cultural shifts and practice: The entire biotechnology and
regulation revolution involves complex economic and institutional dynamics exhibiting
characteristics within a Mode 1 - Mode 2 knowledge production continuum. Actors
oscillate within this continuum with different technological and regulatory impacts. The
behavioural shifts tend to be prominent during regulations implementation with
different cultural identities impacting different demands and contributions that have
implications for the resultant regulatory instruments. It is very important to note that
these cultural dynamics are complex in nature, value-laden, interest driven, with varying
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expectations from peers and relationships. These shifts are sometimes encouraged by
the inadequate and specialised biotechnology-biosafety knowledge capacities needed to
move biosafety policy process forward. This may not be construed to be a bad thing
because within a dynamic and functional system operating from an innovation system
perspective, this may promote cumulative knowledge and learning. However, how
learning and knowledge are managed is important for practice.
A number of lessons can be drawn in relation to knowledge use and policy-making as
explored below.
8.3.3.1 Harnessing the positive aspects
The positive aspects of these cultural dynamics need to be harnessed. We cannot rule
out the important learning that has taken place in the last one and half decades both at
the institutional and individual levels, much of which is tacit. The government has to
look for ways of using this accumulated knowledge. One way it can do this is to
compile a list of experts who have been involved, and perhaps include and consider
them as official experts under the provisions of the Biosafety Clearing House (BCH).209
They would then be called upon from time to time in capacity building efforts at various
fora or public education campaigns. In addition to sensitising people about specific
technical subjects, they would also be requested to talk about their experiences in
biosafety regulatory process, providing a platform for meaningful deliberations that can
advance pro-poor and pro-innovation agenda.
8.3.3.2 Dealing with the negative aspects
It is possible that the cultural dynamics discussed above may have a negative impact on
final regulations and implementation. For instance, the scientific community's active
209 DCII is. mechanism ~t up by the Cartagena Protocol on Biosafety (2000) to facilitate the exchange of
information on living Modified Organisms (lMOs) and assist the Parties to better comply with their obligations
under the Protocol (www b:h.cM.jn!).
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participation in the regulatory process may have resulted into more of technical and
scientific knowledge informing the policy deliberations. This may have ignored some
other relevant knowledge which may enhance compliance with biosafety regulations.j'"
These possible negative aspects cannot be ignored and have to be factored into future
regulatory decision-making processes. How can this be done?
• The government has a major role to play by adopting a governance approach
through weighing and analysing the types of knowledge that inform the process.
The objective would be to ensure that socially desirable knowledge informs the
final policy outcome (Nowotny et al., 2001).
• The government needs to build and sustain technical capacities thereby have a
wide pool of experts in which to draw expertise from. It should also spread its
wings to other academic, non academic and research institutions to solicit
expertise not only for regulatory instruments, but also for overall risk assessment
and environmental safety reviews.
8.3.3.3 Reconceptualising policies formulation process
In addition to the above lessons, the significant cultural shifts demonstrated empirically
in the Kenyan case that accompany the biotechnology and biosafety revolution lead to a
compelling urge to reconsider how policy and regulatory formulation processes are
conceptualised and articulated. Regulatory practice, if it is to achieve greater effect in
reconciling the governance agenda of modem biotechnology on the one hand, and role
210 For instance local environment under which "refugia" may work if Bt maize is introduced into farmers' fields.
"Refugia" refers to fodders or cereal crops that foster the survival and reproduction of Bt-susceptible borers, hence
ensuring sustainahility (If the insect resistance trait of the transformed maize. For this to happen, "the refugia species
have to fit in with the fanners' cropping systems." (Margaret Mulaa, KARl scientist quoted in GENET a European
NGO on Gr:) accessed on Il'09ll9 at \\'\\'w.gcnc,ch/gcnct/2006!Jan. The farmers have better knowledge of their
farming systems that may W(lr\; better to ensure terms and conditions ofGMOs release are adhered to. This is good
for both researchers and the government \\ho want to sec technologies succeed, are adopted and sustained. It is also
good for regulilton "ha want to sec thai regulations arc complied with.
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of actors in providing evidence-based input into the process; it must factor into the
process this cultural shift.
This is not to denounce the economic and institutional changes in which this shift is
embodied, but rather to suggest that this becomes an additional consideration in policy
processes. Since this cultural shift is exhibited by actors spread out in different
institutions (academic, policy, NGOs, public), effective policy and regulatory processes
must first acknowledge its potential to influence policy directions. Consequently,
strategies should be devised that encourage a reflexive and responsive behaviour (Lyall,
et al., 2009c: 261). This may enrich how policies are implemented considering that
cultural practices in life sciences are linked to values and interests (Laurie et al., 2009).
This current research has just provided a pointer towards this direction.
8.4 Suggestions for further research
To generate productive policy and innovative strategies, there is need for more
empirical research to allow further assessment of local dimensions of regulations
implementation. Involving a wider group of actors beyond the scientific community and
outside the biosafety arena would add value to this process. Exploring the following
strategies may enhance the attainment of these goals.
• Empirically this study has shown that the institutionalisation of the
biotechnology system in Kenya involves both institutional and shifts in cultural
practice from Mode 1 to Mode 2. The latter is linked to the behavioural practices
of the scientific community as important actors in this process. It is however
unclear how particular values embedded in respective cultural spaces are upheld
as individuals move from one professional career to another or as players
oscillate within Mode 1 - Mode 2 continuum. It would be imperative therefore to
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explore to what extent cultural bias related to different disciplines and
professions in which scientific community belong to impact policy change.
• The heterogeneity of the scientific community may be advantageous in many
aspects as the current study suggests. However, research focusing on a
significant number of biological scientists from the seemingly non-practising
and non-policy institutes or civil society who may have contrasting views may
be crucial. This is definitely a target group that would yield considerable useful
and comparative data pertaining to scientists' perceptions and practice related to
controversial technologies in life sciences.
• This thesis employed an analytical framework that encompassed a mix of
concepts drawn from sociology of science and innovation systems literature. It
would be important to test this framework in different contexts (for instance in
another country) to enhance generalisation of the results.
8.5 Research limitations
Access to some interviewees who seemed to have opposing views was constrained by
the prevailing suspicion amongst proponents and opponents prompted by the biosafety
bill controversies. For instance, I managed to interview a molecular scientist from civil
society (presumably an opponent) but he refused to sign the consent form and also
demanded that I switch off the audio recorder at some point. He feared that his views
may be misinterpreted by fellow scientists (proponents).
The familiar research terrain discussed exhaustively in Chapter four may have had some
limitations in that participants may have unintentionally withheld some information,
assuming that I understood the context as they did. These limitations and other possible
negative validity issues were checked through triangulation as detailed in Chapter four.
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8.6 Chapter conclusion
This thesis has highlighted that investigating scientific practice in an institutional setup
provides crucial insights that can improve the productivity of the broader biotechnology
innovation system. Implementation of regulations as a subcomponent of the broader
biotechnology innovation system that has been undergoing revolution for about one and
half decades presented a dynamic "sub process" where both institutional and cultural
factors interplay to influence policy (regulatory policy). Analysis of this process
suggests that both institutional and cultural shifts occur, perhaps in the same magnitude
to direct the regulatory process. The latter is associated with shifts in scientific and
regulatory practice as the scientific community adapt to the new working environment
characteristic of biotechnology research.
The study has also made explicit the underpinning factors that characterise the process
of learning and relationships/coalitions building in the formulation of regulatory
policies. These factors range between belief systems, interests and values held by the
stakeholders who include not only the scientific community, but also the non-scientific
fraternity labelled as "opponents" in this study. The tensions that emanate in the process
expose the political nature of the wider biotechnology innovation system and its
governance.
Overall there have been incremental and unprecedented efforts to incorporate the
regulatory system and related institutions as part of the governance into the broader
biotechnology innovation system.i" This process has not been static for the last one and
half decade. This thesis confirms the complexity of establishing "effective" regulatory
instruments and that this process is underpinned by many perceptions and practice
related factors that only become vivid in an empirical study like this one. Theoretical
and policy implications have been explored, exposing strengths and weaknesses in the
211 Biotechnology innovation looked from a broad sense would reflect the non linear, complex and iterative
interrelationship between the three key components illustrated in Fig. 1 (Chapter one).
262
Kenyan system. The strengths need to be harnessed and weaknesses looked into,
towards a smart and productive regulation.
8.7 Epilogue
Having a flashback, and reflecting on where I began the journey, I can say the entire
PhD process has been both challenging but above all, transforming in terms of critical
approach to issues. It has been more than an academic journey. Coming from a
biological and positivist background, perhaps where critical perspectives may be
constrained by many factors like methodological issues, I can confidently say that I am
better placed to deal with social and policy related subjects, more generally.
But beside the personal and professional gams, this study set out to investigate
perceptions of the scientific community related to regulations and regulatory practice,
based on my pre-conceived ideas and perceptions that I had formed prior to the study. I
was later to discover that regulatory issues are complex, hampered by many factors that
have major implications for policy and practice, and the broader innovation policies. I
therefore approached this study with a reflexive mind, coming up with what I believe is
significant contribution to knowledge and policy. '
More significant is the post-PhD life. I believe all these attributes, skills and challenges
will continue to impact positively my contribution to the field of life sciences and
biosafety regulation, development studies, and the broader social and development
policies.
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Appendices
Appendix 1: Categorisation of participants based on interviews &
professional profiles
No. Participant Type of organisation Discipline/ description of Interview
codem professional role date
GE Practitioners (GP)
I RSPu-GPI Public research institute Molecular sciencelplant research 30/01/08
scientist
2 RSln-GP2 International research institute Plant breeding/plant research scientist 11/12/07
3 RSIn-GP3 International research institute Molecular sciencelplant research 17/03/08
scientist
4 RSPu-GP4 Public research institute Insect entomology/plant research 16/11/07
scientist
5 RSAc-GP5 Public university Molecular sciencelacademic & plant 11/12/07
research scientist
6 RSPo-GP6 Regional organisation for Medical biosciencelbiosafety & 1103/08
biotechnology research & biomedical research scientist
development and biosafety
capacity building.
7 RSPu-GP7 Public research institute Animal (veterinary) science/animal 11101/08
research scientist
8 RSPu-GP8 Public research institute Agriculture scienceljunior plant research 18/12/07
scientist
9 RSIn-GP9 International intermediary Ecology & environmental science/ 27/11107
organisation with links to plant research scientist
international & public research
institutes.
Policy Scientists (PS)
10 Blp-PSI Government institute for science Chemistry & hydrogeology/ biosafety 24/01108
and technology policy
II ARp-PS2 Ministry of Agriculture Plant pathology/agricultural & 14/01108
regulatory policy
12 ATp-PS3 Public university Mycologylacademic, technological & 23/11/07
biosafety policy
13 PRp-PS4 Regulatory agency Plant pathology/plant regulatory policy 12/02/08
14 ATBp-PS5 Public university Biochemistry/ academic, technological 22/11/07
& biosafety policy
15 RSIn-PS6 International research institute Micro-biologyl general health & safety 8/11/07
16 RSPu-PS7 Public research institute Plant scienceltechnological research & 27/11108
policy
17 RSPu-PS8 Public research institute Animal science/ technological research 25101108
& policy
18 ARp-PS9 Regulatory agency Veterinary Virologyl animal regulatory 30/10107
policy
19 PRp-PSIO Regulatory agency Plant pathologylplant regulatory and 09/01108
biosafcty policy
20 Blp-PSII Government institute for science Plant pathologylbiosafety policy 16/02/08
and technology
21 FSp-PSI2 Regulatory agency Food & nutrition science/food safety 02/1112007
policy
22 Blp-PS 13llJ Government institute for science Building economicslbiosafety policy 31110/07
- and technology23 ABp-PSI4 Ministry of Agriculture Agricultural scienceltechnological & 18/02/08
biosafety policy
24 ENp-PSI5 Regulatory agency Environmental science/environmental 28/03/08
212 Description of each participant varies based on anonymity requested. Some wanted institutions they work for
disguised. For abbreviations, see pages x-xi.
213 Not a biological scientist but his position as a key government biosafety policy advisor prompted his placement
in this category. His statements are analysed from only a policy perspective.
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policy
25 ARBp-PSI6 Public university Plant breeding/academics, plant 14/03/08
research scientist & biosafety policy
Non State Scientists (NSS)
26 TAR-NSSI International pro-biotechnology Biotechnology/technology advocacy & 4/02/08
NGO research
27 TAN-NSS2 International pro-biotechnology Environmental science/ technology 30/01/08
NGO advocacy
28 TRTp-NSS3 Local seed traders association Plant breeding/technological research & I5/IlI07
trade policy
29 TAN-NSS4 Regional pro-biotechnology NOO Agriculture science/ technology 31110/07
advocacy
30 EPA-NSS5 Environmental NOO (civil Molecular biology/environmental 24/01108
society) protection advocacy
31 TAD-NSS6 Pro-biotechnology donor agency Molecular biology/ technology 1102/08
advocacy ,
Non Biologist Scientists & Non Scientists (NS)
32 NOOf-NSI NGO (local organic farmers) Horticulture/environmental protection & 21/11107
farmers' rights advocacy
33 NGOf-NS2 NGO (local farmers & producers) Social science/ farmers' rights advocacy 5/11/07
34 NaOcs-NS3 Environmental NaO (civil Agriculture economics/civil society's 24/01108
society) rights advocacy
35 NOOco-NS4 NOO (consumers) Statistics/consumers' rights advocacy 21101108
36 NGOco-NS5 NOO (consumers) Food nutrition! consumers rights 21101108
advocacy
37 JO-NS6 Local daily newspaper Journalism! science editor 1104/08
38 JO-NS7 Local daily newspaper Journalism/ science editor 20/03/08
39 LABp-NS8 Attorney General's chambers Law & environmental science/ 23/01108
parliamentary counsel on biosafety
policy
40 LAEp-NS9 Regulatory agency Law/environmental policy 28/03/08
41 TAI-NSIO Biotechnology industry Food science/technology advocacy 21101108
42 TAD-NSli Pro-biotechnology donor agency Development policy/ technology 27/03/08
advocacy
Source: Secondary and mterview data
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Appendix 2: Interview sample guide
Policy group-(regulators, senior government officers, Legal officers, selected non
researchers who are NBC members)
Name ofInterviewee .
Date ofinterview Time Place .
PART 1: General information
a) Occupation: (To tick more than one if necessary)
Occupation (Tick) Institution Status/N ature of
Name interviewee=
Biotechnology researcher
Policy advisor
Field trials/GM regulator
Government official: Senior
Middle
Junior
Private sector/Industry official etc
NGO staff - International, regional or
multilateral
-Donor-capacity building
-Donor - funding
Media staff
Other (specify)
"'Nature/ status of the scientist/interviewee (to choose from this table)
Tick a~~ro~riate
Practising/bench scientists
Lab technician! greenhouse technician/field trial manager
Administrative scientist (Project coordinator, Principle investigator)
Institutional Biosafety Committee (IBC) member
National Biosafety Committee (NBC) member
Pro-GMOs activist
Anti-GMOs activist
Any other (Specify)
b) Project (Field Trial) .
c) DisciplinelProfession: (tick more than one if necessary)
Discipline Tick Institution Role
Molecular biologist
EntomologistlNematologist
Plant pathologist
Plant breeder
Tissue culture
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Bio-informatics
Biochemists
Botanists
Social scientists
-Sociologist
-Social economist
-Extension
-Other
Lab
technologists/Technician
Student
Other (specify)
d) Partners (list all for each project)
RolePartner
General Observations: (Detail minor happenings and interview setting).
PART 2: Questions guide on biosafety regulations and implementation
1. What is the view or position of your institution/ministry on GMO's?
2. What is your personal view about GM research and development? What is
your view about the field trials? Why do you hold this view?
3. What do you think of the biosafety regulations that are being used m
regulation of GM field trials?
a) Which one in particular do you think are useful? Do you think they
provide adequate guidance in the conduct of field trials in Kenya?
b) Do you think they are impacting upon GM research work in any way?
If yes, do you think this is compromising safety?
c) Did your institute/ministry participate in any way in the drafting
process? If yes, which role did it play? If no, why did it not participate?
In your view, should it have been involved? Why?
d) Were you involved in any way in the drafting process of any of the
legislation? If yes, in which capacity- as a scientist, as an individual or
representative of your institution? How were you involved? Any
comments on the drafting process?
e) The research scientists involved in this process, which role do you
think they played? Do you think this has an effect on GM research
work? What about the final regulatory instruments?
4. The essence of RA as well as accompanying regulations and related policies
that guide in RA is to minimise risk to the environment.
a) What does risk mean to you?
b) What do you think are biosafety risks in a field trial-Cf'T? (Risk to
biodiversity, cross pollination etc?)
c) How should judgement on risk be made? How should risk be
quantified?
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d) How should RA be conducted i) during the review of a eFT
application ii) during the trial - in the field? Do you think the
Regulations and Guidelines that exist provide adequate guidance
forRA?
e) Are measures being employed to address biosafety risk in the field
trials (Cf'Ts) adequate in your view? Ifno, why?
5. What is the role of the field trials in generating information on biosafety risk?
a) How is this data used by policy makers? Do you think it is useful?
Why?
b) How can the process of generating, compiling and reporting RA
information be made better for enhanced decision making by decision
makers at IBeINBe?
c) What role do you think the scientists/researchers who participate in RA
process play?
6. Having talked about various issues on biosafety regulations, in your view,
what are the factors affecting the regulations implementation in relation to GM
research work?
a) Among these factors, which one do you consider to be the most important?
Why?
7. Have you participated in monitoring and inspection of the field trials?
a) What concerns do you address during the M & I1what do you look for
in particular? What are your experiences? Are the trials being
conducted according to the regulations? If no, why?
b) How can this process (M &1) be made better?
c) What will be required to improve it the way you have described?
8. Do you think the views of your institute/ministry are represented in decisions
pertaining to GM field trials? If yes, how? If no, why do you think so? Do
you think it should be represented? Why? (Asked if necessary)
9. Some people believe that international donorslbiotechnology industry in
Kenya have had too much influence on biosafety policies in Kenya. Do you
hold the same view?
10. Some others believe that our research scientists have been compromised by
the international donorslbiotechnology industry. Do you hold the same view as
well?
11. Some people believe that scientists have influenced the biosafety regulations
development process (e.g. the biosafety bill) in favour of GM work. What is
your comment on this?
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Walton Hall
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Tel +44 (0) 1908653651
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dpp@open.ac.uk
www.openac.ul<
Ref: Y0231953
This is to confirm that Ann Njoki Kingiri is registered as a PhD research student. at Open University
in Millon Keynes. UK.
As part of her doctoral research. she is conducting a study on "Implementation of regulations
governing risk In modern crop biotechnology in Kenya".
I should be graleful for an~ assistance accorded to Ms Ann Kinglri to further her research work.
Yours faithfully.
I / • If)
r .I - , ....I' .1',., i ,~r
I. :/"TlJ:- /, .' ,'f ~'" '. i,..'/,\ .......-{:.~i.A,'-f i_,' . "L,r;' ..W v ,
I i t. i-\./\
\ ) "
Professor 'kazel Johnson
Head of Department
Development Policy and Practice
Faculty of Technology
Open University
Milton Keynes, UK
n.l't!Jopment Policy aDd Practice
Ttl:hn::Jlogy FaCI!Ity
Tbe Open Uni\'t:r;lit,
Walton Hall
~ll,~ IC..YNIiiSo ioIlC.'7 {V.""
285
>-
+I.-U\
Loo
OJ
>.-c:
::>
c:
OJc.o
OJ.c
I-
Faculty of Technology
Development Policy and Practice
The Open University
Walton Hall
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MK7 6AA, United Kingdom
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dpp@open.ac.uk
www.open.ac.uk
SUBJECT: CONSENT FORM
I am a research student currently undertaking doctorate studies at Open University, in UK.
My research intends to examine the different stakeholders' perspectives on biosafety
regulations and implementation in Kenya and consequently try to situate those perspectives in
a systemic understanding of biotechnology innovation in Kenya.
As part of my research work, I am asking for your consent to conduct an interview with you
and with your permission digitally record our discussion. This is mainly to help me remember
key aspects of our discussion. If you tell me of any aspect of our discussion that you wish to
remain private or confidential, I will not divulge it to anybody. If you wish that I destroy any
of the data that you provide, I will do so. If you decide to withdraw from participating in the
interview, you may do so at any point.
In reporting this research, I may describe our discussion and use short quotations from your
words without mentioning your name and without including any details that might identify
you. Otherwise in reporting the research, if I require to use any quotation that might identify
you, or use any excerpt from the audio recorder, I will honour your decision as provided
below.
My notes of our discussion and the full audio or software records will be held securely and
accessed only by myself.
Should you wish to discuss any aspect of your participation in this research, you can contact
my supervisors:
Professor Joanna Chataway
Innogen Research Centre, Open University
Walton Hall, Milton Keynes
MK76AA, UK
Tel. +44 (0) 1908655119
E-mail: J.C.Chataway@open.ac.uk
Dr. Seife Ayele
Technology Faculty, Open University
Milton Keynes MK7 6AA, UK
Tel. +44 (0)1908 655534
E-mail: s.ayele@open.ac.uk
Ann Njoki King'iri ...~""\Y
I agree to be recorded and interviewed as described above ~
I agree to be quoted L_j
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The Open University
Walton Hall
Milton Keynes
MK76AA
United Kingdom
Tel +44 (0) 1908 653 651
Fax +44 (0) 1908 654 825
dpp@open.ac.uk
www.open.ac.uk
Date: ..
SUBJECT: INVIT ATIONIINFORMA TION LETTER
I am a doctoral research student, at Open University in Milton Keynes, UK. As part of
my research, I am conducting a study on "Implementation of regulations governing
risk in modern crop biotechnology in Kenya". This study focuses on scientists'
perspectives on biosafety regulations and implementation with a hope of identifying
the regulatory challenges and opportunities that exist as they carry out their GM
research work. Consequently it is hoped that their views and experiences can be
harnessed to improve regulatory instruments and processes in Kenya.
Considering your role in crop biotechnology research and your experience in
regulation, I would be very grateful if you would kindly spare your time for an
interview at a time convenient for you.
I would like to state that this study is conducted independently and is not conducted
on behalf of any organisation or institution. It is sponsored by Open University,
Technology Faculty department which is hosting me currently for the period of the
study. All the information you provide during the interview will be treated as strictly
confidential. If you wish the data provided to be destroyed, that will be done. In
reporting this research, I will do it in such a way that you or your institution will not
be identified. If you wish to be quoted in any way, you may give an approval as
provided in the consent form.
I am fully aware that the interview will require your precious time, but this is the only
way I can interpret your worldview as narrated by you; based on your experience.
I thank you for your cooperation and hope to hear from you.
Yours sincerely,
Ann Njoki King'iri
287
00
00
NCl)Cl)
E
Cl)
.c....
~~c
.9
.<::
~
C.
Wo

-~._
Cj
e~
"0=~-~=e._-=-._-~=~
...o-CJC'G
C'G
'(j
o
f/)
..
In
~._
"0=~
Q..
Q..-e
eo
~c.
'C
CJ
Cl)
II)
c
..:- NOQ.fFJ
\.jlzC ,Vi:;:
0:: ...
fFJ
Z'N
~~...Z
.~
..c::eo
='8-s
8z
0;;
co
.~
E
co.~
.~
o
c
.9s
.~
o
~.~
t.! E
c ~
~.s
..
8.g
ce.-.....eo:.....
c
QJ
E
QJ-c..
E._
..
\C
~.-
"0
C
QJc..
c..-e
co.~
Cl)
E
~
c.
.5
.c.....~
<II
Cl)
.5
Cl)
'0.:;
o
Cl)
~.cc.
<II
01).5
'0
Cl)
Cl)
ec.
Cl)
.c.........o
...
Cl)-g
:= ....c
Cl)
E
'g
c
Cl)
-g
~
~o
'0c.c
2
c.o.c
<II~...
~
.....o
...c
Cl)
E
Eog
:::J
Co...
:::Jo
f!o...
CJcu
Cl)
>..
CJcue
Q.
I
000a-OI
a- 01- -
I
00 V"\
010
01 0-N
I
V"\oo
N
Cl)
o
CU.c
Q.
,-..
V)
oo
N
c-o.~
Z
~::=I---------------------------------------+~------------~~
0-o
o
N
Appendix 7: Major developments surrounding the formulation of the
biosafety bill 2008
Period Activity
The signing and ratification of Cartagena Protocol in 2000 and 2002 set various activities into motion.
Jul2002 Scientists and lawyers developed zero draft copies of the biotechnology policy and the
biosafety bill after a two weeks meeting.
Mar 2003 1st discussion of the zero drafts of the biotechnology policy and biosafety bill by
scientists and lawyers in a two-days meeting.
Apr 2003 I st stakeholders one week meeting to discuss the draft copies.
Aug2003 Two-days meeting with members of parliament to discuss the draft copies.
Nov 2003 One-week stakeholders meeting comprising of policy makers with majority being
members of parliament to sensitise them on biosafety bill.
May2004 A two-day study tour for parliamentary committees members to biotechnology
facilities in Kenya to assess the biotechnology and biosafety capacity as they debated
the bill in parliament.
Mar2005 One-week meeting of seventeen experts (scientists and lawyers) to review both the
policy and the bill.
Apr2006 Interested stakeholders discussed the revised draft policy documents to identify any
omissions for further input.
July 2006 Final reviewed documents presented to the Attorney General by the minister for
Science and Technology for perusal before being presented to the cabinet.
Sep 2006 The policy and the bill approved by the cabinet.
22 Jun 2007 The bill is published in the Kenya gazette to solicit public comments.
22 Jun-II Jul The period it remained in the public domain, significant number of public comments
2007 received.
July 2007 A half-day stakeholders meeting to discuss the bill and be sensitization on its
importance.
Aug2007 One-week meeting by a committee of experts (three lawyers and five scientists) to
review the comments from the public. The committee proposed a number of
technically sound amendments to the bill.
Oct 2007 -The biosafety bill, 2007 tabled in 9th Parliament by Minister for Education, Science
and Technology. It went through the l" and 2nd reading.
-Parliament was dissolved before the 3rd reading, hence further discussion ceased.
Feb 2008 NeST incorporated the proposed amendments to the biosafety bill, 2007 and
consequently requested the Attorney General to re-publish the then biosafety bill,
2008.
27Jun-I6 Bill published in the Kenya gazette and put in public domain for comments. No public
July 2008 comments were raised.
July 2008 Biosafety bill, 2008 tabled in the 10th parliament by the newly elected Minister for
Higher, Education Science and Technology.
Nov 27 2008 The bill passed the second reading and moved to the committee stage of the whole
parliamentary house.
9 Dec 2008 The bill passed after it was approved by the parliament.
12 Feb 2009 Presidential assent and finally bill became law. It was officially published in a special
issue of the Kenyan gazette in Feb. 2009 as Biosafety Act 2009.
Source: Primary and secondary sources [(Macharia, 2008; various documents detailed in Appendix 9;
PBS resource materials (www.pbs.org) & interviews]
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Appendix 8: Analysis of NBC members (between 1998-2008)
Institution (For abbreviations. see Traynor & Minutes of Proposed NBA
pages ix-x and Tables 2 & 3). Macharia, 2003 NBC
NCST ..J v ..J
KEPHIS v ..J v
ILRI v v -
Ministry of Agriculture (MOA) ..J v ..J
UON, Dept of Biological Sciences v ..J x
KENFAP/KNFU ..J v x
ABSF v v x
KIPI v ..J x
KEMRI ..J v x
MOPH&S (previously Ministry of Health) v ..J ..J
CIN ..J v x
STAK v V x
MOHE,S&T ..J ..J v
KEBS v v ..J
NEMA v ..J v
Plant Breeders Association of KenyalPBK x ..J x
Department of Veterinary ServiceslDVS x v v
Kenya Wildlife ServiceslKWS ..J x x
Biotechnology Trust Africa ..J x x
Kenyatta University v x x
Ministry of Trade & Industry ..J x x
AG's Chambers x x x
Ministry of finance - - ..J
PCPB x x x
Note: The table shows who have since' oined ~...J or exited (x) based on the new ro osed members ofJ () p p
the NBA as per the Biosafety Act, 2009; compared with Traynor and Macharia (2003) and some
minutes of a number of NBC meetings obtained for this study between 2007-2008. All the state
institutions not listed under the new Act will cease to be members. Instead, representation will be based
on expertise not confined to institutions as has been the case. The civil societies/public representation
will be based on who the Minister appoints (clause 6k).
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